

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
21 December 2000 (21.12.2000)

PCT

(10) International Publication Number
WO 00/77001 A1(51) International Patent Classification⁷: C07D 471/16,
A61K 31/437, 31/55, 31/407, A61P 25/00, C07D 487/16
// (C07D 471/16, 221:00, 209:00, 209:00) (C07D 471/16,
221:00, 221:00, 209:00) (C07D 471/16, 223:00, 221:00,
209:00)252 Apple Drive, Exton, PA 19341 (US). MCCLUNG,
Christopher, D.; 2129 Biddle Street, Wilmington, DE
19805 (US). CALVELLO, Emilie, J., B.; 18 North
Roberts Road, Bryn Mawr, PA 19010 (US). ZAWROTNY,
David, M.; 225 Laurence Drive, Moorestown, NJ 08057
(US).

(21) International Application Number: PCT/US00/16375

(22) International Filing Date: 15 June 2000 (15.06.2000)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
60/139,321 15 June 1999 (15.06.1999) US(74) Agent: LARSEN, Scott, K.; Du Pont Pharmaceuticals
Company, Legal Patent Records Center, 1007 Market
Street, Wilmington, DE 19898 (US).(81) Designated States (*national*): AU, BR, CA, CN, CZ, EE,
HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI,
SK, TR, UA, VN, ZA.(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).(71) Applicant: DU PONT PHARMACEUTICALS COM-
PANY [US/US]; 974 Centre Road, WR-1ST18, Wilming-
ton, DE 19807 (US).(72) Inventors: ROBICHAUD, Albert, J.; 120 Stonegate
Drive, Landenberg, PA 19350 (US). LEE, Taekyu;
110 Berry Drive, Wilmington, DE 19808 (US). DENG,
Wei; 1314 Copley Drive, Wilmington, DE 19803 (US).
MITCHELL, Ian, S.; Apartment #601, 201 South 25th
Street, Philadelphia, PA 19103 (US). CHEN, Wenting;

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES




(57) Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I): or pharmaceutically acceptable salt forms thereof, wherein R¹, R⁵, R^{6a}, R^{6b}, R⁷, R⁸, R⁹, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

TITLE

SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES.

FIELD OF THE INVENTION

5 The present invention is directed to certain novel compounds represented by structural Formula (I)



(I)

10 or pharmaceutically acceptable salt forms thereof, wherein R¹, R⁵, R^{6a}, R^{6b}, R⁷, R⁸, R⁹, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the

15 novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis,

20 schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

BACKGROUND OF THE INVENTION

25 There exists a substantial correlation for the relationship between 5-HT₂ receptor modulation and a variety of diseases and therapies. To date, three subtypes of the 5-HT₂ receptor class have been identified, 5-HT_{2A},

30 5-HT_{2B}, and 5-HT_{2C}. Prior to the early 1990's the 5-HT_{2C}

and 5-HT_{2A} receptors were referred to as 5-HT_{1C} and 5-HT₂, respectively.

The agonism or antagonism of 5-HT₂ receptors, either selectively or nonselectively, has been associated with the treatment of various central nervous system (CNS) disorders. Ligands possessing affinity for the 5-HT₂ receptors have been shown to have numerous physiological and behavioral effects (Trends in Pharmacological Sciences, 11, 181, 1990). In the recent past the contribution of serotonergic activity to the mode of action of antidepressant drugs has been well documented. Compounds that increase the overall basal tone of serotonin in the CNS have been successfully developed as antidepressants. The serotonin selective reuptake inhibitors (SSRI) function by increasing the amount of serotonin present in the nerve synapse. These breakthrough treatments, however, are not without side effects and suffer from delayed onset of action (Leonard, J. Clin. Psychiatry, 54(suppl), 3, 1993). Due to the mechanism of action of the SSRIs, they effect the activity of a number of serotonin receptor subtypes. This non-specific modulation of the serotonin family of receptors most likely plays a significant role in the side effect profile. In addition, these compounds often have a high affinity for a number of the serotonin receptors as well as a multitude of other monoamine neurotransmitters and nuisance receptors. Removing some of the receptor cross reactivity would allow for the examination and possible development of potent therapeutic ligands with an improved side effect profile.


There is ample evidence to support the role of selective 5-HT₂ receptor ligands in a number of disease therapies. Modulation of 5-HT₂ receptors has been associated with the treatment of schizophrenia and psychoses (Ugedo, L., et.al., Psychopharmacology, 98, 45, 1989). Mood, behavior and hallucinogenesis can be affected by 5-HT₂ receptors in the limbic system and cerebral

cortex. 5-HT₂ receptor modulation in the hypothalamus can influence appetite, thermoregulation, sleep, sexual behavior, motor activity, and neuroendocrine function (Hartig, P., et.al., Annals New York Academy of Science, 149, 159). There is also evidence indicating that 5-HT₂ receptors mediate hypoactivity, effect feeding in rats, and mediate penile erections (Pyschopharmacology, 101, 57, 1990).

Compounds exhibiting selectivity for the 5-HT_{2B} receptor are useful in treating conditions such as tachygastria, hypermotility associated with irritable bowel disorder, constipation, dyspepsia, and other peripherally mediated conditions.

5-HT_{2A} antagonists have been shown to be effective in the treatment of schizophrenia, anxiety, depression, and migraines (Koek, W., Neuroscience and Behavioral reviews, 16, 95, 1996). Aside from the beneficial antipsychotic effects, classical neuroleptic are frequently responsible for eliciting acute extrapyramidal side effects and neuroendocrine disturbances. These compounds generally possess significant dopamine D₂ receptor affinity (as well as other nuisance receptor affinity) which frequently is associated with extra pyramidal symptoms and tardive dyskinesia, thus detracting from their efficacy as front line treatments in schizophrenia and related disorders. Compounds possessing a more favorable selectivity profile would represent a possible improvement for the treatment of CNS disorders.


U.S. Patent Numbers 3,914,421; 4,013,652; 4,115,577; 4,183,936; and 4,238,607 disclose pyridopyrrolobenz-heterocycles of formula:



where X is O, S, S(=O), or SO₂; n is 0 or 1; R¹ is various carbon substituents, and Z is a monosubstituent of H, methyl, or chloro.

5

U.S. Patent Number 4,219,550 discloses pyridopyrrolo-benzheterocycles of formula:



where X is O or S; R¹ is C₁₋₄ alkyl or cyclopropyl; R² is H,
 10 CH₃, OCH₃, Cl, Br, F, or CF₃; and (A) is -CH₂-, -CH(CH₃)-,
 or -CH₂CH₂-.

SUMMARY OF THE INVENTION

One object of the present invention is to provide
 15 novel compounds which are useful as agonists or antagonists
 of 5-HT₂ receptors, more specifically 5-HT_{2A} and 5-HT_{2C}
 receptors, or pharmaceutically acceptable salts or prodrugs
 thereof.


It is another object of the present invention to
 20 provide pharmaceutical compositions comprising a
 pharmaceutically acceptable carrier and a therapeutically
 effective amount of at least one of the compounds of the
 present invention or a pharmaceutically acceptable salt or
 prodrug form thereof.

25 It is another object of the present invention to
 provide a method for treating central nervous system

disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep and sexual disorders, migraine and other conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

More specifically, the present invention provides a method for treating obesity anxiety, depression, or schizophrenia.

These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of Formula (I):




(I)

or pharmaceutically acceptable salt or prodrug forms thereof, wherein R¹, R⁵, R^{6a}, R^{6b}, R⁷, R⁸, R⁹, X, b, k, m, and n are defined below, are effective agonists or antagonists of 5-HT₂ receptors.

DETAILED DESCRIPTION OF THE EMBODIMENTS

Thus, in a first embodiment, the present invention provides a novel compound of Formula (I):



(I)

or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein:

5

b is a single bond or a double bond;

X is $-\text{CHR}^{10}-$, $-\text{C}(=\text{O})-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(=\text{O})-$, $-\text{S}(=\text{O})_2-$, $-\text{NR}^{10\text{A}}-$, $-\text{C}(=\text{O})\text{NR}^{10\text{A}}-$, or $-\text{NR}^{10\text{A}}\text{C}(=\text{O})-$;

10

R^1 is selected from

H,

$\text{C}(=\text{O})\text{R}^2$,

$\text{C}(=\text{O})\text{OR}^2$,

15

C_{1-8} alkyl,

C_{2-8} alkenyl,

C_{2-8} alkynyl,

C_{3-7} cycloalkyl,

C_{1-6} alkyl substituted with Z,

20

C_{2-6} alkenyl substituted with Z,

C_{2-6} alkynyl substituted with Z,

C_{3-6} cycloalkyl substituted with Z,

aryl substituted with Z,

5-6 membered heterocyclic ring system containing at

25

least one heteroatom selected from the group consisting of N, O, and S, said heterocyclic ring system substituted with Z;

C_{1-3} alkyl substituted with Y,

C_{2-3} alkenyl substituted with Y,

30

C_{2-3} alkynyl substituted with Y,

- C₁₋₆ alkyl substituted with 0-2 R²,
C₂₋₆ alkenyl substituted with 0-2 R²,
C₂₋₆ alkynyl substituted with 0-2 R²,
aryl substituted with 0-2 R², and
5 5-6 membered heterocyclic ring system containing at
least one heteroatom selected from the group
consisting of N, O, and S, said heterocyclic ring
system substituted with 0-2 R²;
- 10 Y is selected from
C₃₋₆ cycloalkyl substituted with Z,
aryl substituted with Z,
5-6 membered heterocyclic ring system containing at
least one heteroatom selected from the group
15 consisting of N, O, and S, said heterocyclic ring
system substituted with Z;
C₃₋₆ cycloalkyl substituted with -(C₁₋₃ alkyl)-Z,
aryl substituted with -(C₁₋₃ alkyl)-Z, and
5-6 membered heterocyclic ring system containing at
20 least one heteroatom selected from the group
consisting of N, O, and S, said heterocyclic ring
system substituted with -(C₁₋₃ alkyl)-Z;
- Z is selected from H,
25 -CH(OH)R²,
-C(ethylenedioxy)R²,
-OR²,
-SR²,
-NR²R³,
30 -C(O)R²,
-C(O)NR²R³,
-NR³C(O)R²,
-C(O)OR²,
-OC(O)R²,

- CH(=NR⁴)NR²R³,
-NHC(=NR⁴)NR²R³,
-S(O)R²,
-S(O)₂R²,
5 -S(O)₂NR²R³, and -NR³S(O)₂R²;

- R², at each occurrence, is independently selected from
C₁₋₄ alkyl,
C₂₋₄ alkenyl,
10 C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
phenyl substituted with 0-5 R⁴²;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
5-10 membered heterocyclic ring system containing from
15 1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;

- R³, at each occurrence, is independently selected from
20 H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

alternatively, R² and R³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R⁴)-;

- 25 R⁴, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

R⁵ is H or C₁₋₄ alkyl;

- 30 R^{6a} and R^{6b}, at each occurrence, are independently selected
from
H, -OH, -NR⁴⁶R⁴⁷, -CF₃, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄
alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl,
and

aryl substituted with 0-3 R⁴⁴;

R⁷ and R⁹, at each occurrence, are independently selected from

- 5 H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷,
C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy,
C₃₋₁₀ cycloalkyl, substituted with 0-2 R³³,
C₁₋₄ alkyl substituted with 0-2 R¹¹,
10 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
15 R³¹;

- OR¹², SR¹², NR¹²R¹³, C(O)R¹³, C(O)NR¹²R¹³, NR¹⁴C(O)R¹²,
C(O)OR¹², OC(O)R¹², OC(O)OR¹², CH(=NR¹⁴)NR¹²R¹³,
NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹², S(O)NR¹²R¹³,
20 S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², and NR¹⁴S(O)₂R¹²;

R⁸ is selected from

- H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂,
C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
25 C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy,
C₃₋₁₀ cycloalkyl, substituted with 0-2 R³³,
C₁₋₄ alkyl substituted with 0-2 R¹¹,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
30 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

OR¹², SR¹², NR¹²R¹³, C(O)R¹³, C(O)NR¹²R¹³, NR¹⁴C(O)R¹²,
C(O)OR¹², OC(O)R¹², OC(O)OR¹², CH(=NR¹⁴)NR¹²R¹³,
NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹², S(O)NR¹²R¹³,
5 S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², and NR¹⁴S(O)₂R¹²;

R¹⁰ is selected from H, -OH,
C₁₋₆ alkyl substituted with 0-1 R^{10B},
C₂₋₆ alkenyl substituted with 0-1 R^{10B},
10 C₂₋₆ alkynyl substituted with 0-1 R^{10B}, and
C₁₋₆ alkoxy;

R^{10A} is selected from H,
C₁₋₆ alkyl substituted with 0-1 R^{10B},
15 C₂₋₆ alkenyl substituted with 0-1 R^{10B},
C₂₋₆ alkynyl substituted with 0-1 R^{10B}, and
C₁₋₆ alkoxy;

R^{10B} is selected from
20 C₁₋₄ alkoxy,
C₃₋₆ cycloalkyl,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
phenyl substituted with 0-3 R³³, and
5-6 membered heterocyclic ring system containing 1, 2,
25 or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-2
R⁴⁴;

R¹¹ is selected from
30 H, halo, -CF₃, -CN, -NO₂,
C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
C₁₋₈ alkoxy, C₃₋₁₀ cycloalkyl,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,

aryl substituted with 0-5 R^{33} ,
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
5 R^{31} ;

OR^{12} , SR^{12} , $NR^{12}R^{13}$, $C(O)R^{13}$, $C(O)NR^{12}R^{13}$, $NR^{14}C(O)R^{12}$,
 $C(O)OR^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, $CH(=NR^{14})NR^{12}R^{13}$,
 $NHC(=NR^{14})NR^{12}R^{13}$, $S(O)R^{12}$, $S(O)_2R^{12}$, $S(O)NR^{12}R^{13}$,
10 $S(O)_2NR^{12}R^{13}$, $NR^{14}S(O)R^{12}$, and $NR^{14}S(O)_2R^{12}$;

R^{12} , at each occurrence, is independently selected from
 C_{1-4} alkyl,
 C_{2-4} alkenyl,
15 C_{2-4} alkynyl,
 C_{3-6} cycloalkyl,
phenyl substituted with 0-5 R^{33} ;
 C_{3-10} carbocyclic residue substituted with 0-3 R^{33} , and
5-10 membered heterocyclic ring system containing from
20 1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
 R^{31} ;

R^{13} , at each occurrence, is independently selected from
25 H, C_{1-4} alkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl;

alternatively, R^{12} and R^{13} join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R^{14})-;

30 R^{14} , at each occurrence, is independently selected from H
and C_{1-4} alkyl;

R^{31} , at each occurrence, is independently selected from
H, OH, halo, CF_3 , SO_2R^{45} , $NR^{46}R^{47}$, and C_{1-4} alkyl;

R³³, at each occurrence, is independently selected from
H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, C₁₋₆ alkyl,
C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₁₋₄
haloalkyl, C₁₋₄ haloalkyl-oxy-, C₁₋₄ alkyloxy-,
C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, and C₁₋₄ alkyl-
C(=O)NH-;

R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN;
C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴², and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;

R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶SO₂R⁴⁵, NR⁴⁶COR⁴⁵,
NR⁴⁶R⁴⁷, NO₂, CN, CH(=NH)NH₂, NHC(=NH)NH₂,
C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
C₃₋₆ cycloalkyl,
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴⁴, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;

R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;

R⁴⁴, at each occurrence, is independently selected from H, halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂, C₁₋₄ alkyl, and C₁₋₄ alkoxy;

5 R⁴⁵ is C₁₋₄ alkyl;

R⁴⁶, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

10 R⁴⁷, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

k is 1 or 2;

15 m is 0, 1, 2, or 3;

n is 0, 1, or 2;

provided when m is 0, then k is 1;

20

provided that when b is a double bond; n is 1 or 2; m is 1; k is 1; X is -O-, -S-, -S(=O)-, or -SO₂-; and the three substituents of R⁷, R⁸, and R⁹, consist of i) three hydrogens, ii) two hydrogens and one chloro, or iii) two

25 hydrogens and one methyl; then R¹ must contain the substituent Z or Y;

provided that when b is a double bond; n is 0 or 1; m is 1; k is 1; X is -CH₂-; and R¹ is hydrogen, C₁₋₆ alkyl or

30 benzyl; then one of R⁷, R⁸, and R⁹, must be other than hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy or trifluoromethyl;

provided that when b is a single bond; n is 1 or 2; m is 1; k is 1; X is O or S; and R¹ is C₁₋₄ alkyl or cyclopropyl, then R⁸ is a substituent other than H;

- 5 provided that when R⁶ or R^{6a} is NH₂, then X is not -CH(R¹⁰); and

provided that when n=0, then R⁶ or R^{6a} is not NH₂ or -OH.

- 10 In another embodiment of the present invention,

X is -CHR¹⁰-, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)₂-, -NH-, -C(=O)NH-, or -NHC(=O)-;

- 15 R¹ is selected from

H,

C(=O)R²,

C(=O)OR²,

C₁₋₈ alkyl,

- 20 C₂₋₈ alkenyl,

C₂₋₈ alkynyl,

C₃₋₇ cycloalkyl,

C₁₋₆ alkyl substituted with Z,

C₂₋₆ alkenyl substituted with Z,

- 25 C₂₋₆ alkynyl substituted with Z,

C₃₋₆ cycloalkyl substituted with Z,

aryl substituted with Z,

5-6 membered heterocyclic ring system containing at

least one heteroatom selected from the group

- 30 consisting of N, O, and S, said heterocyclic ring system substituted with Z;

C₁₋₃ alkyl substituted with Y,

C₂₋₃ alkenyl substituted with Y,

C₂₋₃ alkynyl substituted with Y,

- C₁₋₆ alkyl substituted with 0-2 R²,
C₂₋₆ alkenyl substituted with 0-2 R²,
C₂₋₆ alkynyl substituted with 0-2 R²,
aryl substituted with 0-2 R², and
5 5-6 membered heterocyclic ring system containing at least one heteroatom selected from the group consisting of N, O, and S, said heterocyclic ring system substituted with 0-2 R²;
- 10 Y is selected from
C₃₋₆ cycloalkyl substituted with Z,
aryl substituted with Z,
5-6 membered heterocyclic ring system containing at least one heteroatom selected from the group
15 consisting of N, O, and S, said heterocyclic ring system substituted with Z;
C₃₋₆ cycloalkyl substituted with -(C₁₋₃ alkyl)-Z,
aryl substituted with -(C₁₋₃ alkyl)-Z, and
5-6 membered heterocyclic ring system containing at least one heteroatom selected from the group
20 consisting of N, O, and S, said heterocyclic ring system substituted with -(C₁₋₃ alkyl)-Z;
- Z is selected from H,
25 -CH(OH)R²,
-C(ethylenedioxy)R²,
-OR²,
-SR²,
-NR²R³,
30 -C(O)R²,
-C(O)NR²R³,
-NR³C(O)R²,
-C(O)OR²,
-OC(O)R²,

- CH(=NR⁴)NR²R³,
-NHC(=NR⁴)NR²R³,
-S(O)R²,
-S(O)₂R²,
5 -S(O)₂NR²R³, and -NR³S(O)₂R²;

- R², at each occurrence, is independently selected from
halo,
C₁₋₃ haloalkyl,
10 C₁₋₄ alkyl,
C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
aryl substituted with 0-5 R⁴²;
15 C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;

- 20 R³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and
C₁₋₄ alkoxy;

- 25 alternatively, R² and R³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R⁴)-;

- R⁴, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

- 30 R⁵ is H or C₁₋₄ alkyl;

- R^{6a} and R^{6b}, at each occurrence, are independently selected
from

H, -OH, -NR⁴⁶R⁴⁷, -CF₃, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, and aryl substituted with 0-3 R⁴⁴;

5

R⁷ and R⁹, at each occurrence, are independently selected from

H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl, C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy, C₃₋₁₀ cycloalkyl substituted with 0-2 R³³, C₁₋₄ alkyl substituted with 0-2 R¹¹, C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, aryl substituted with 0-5 R³³, 5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R³¹;

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³, NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹², CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹², S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹², NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and NR¹²C(O)NHR¹⁵;

25

R⁸ is selected from

H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl, C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy, C₃₋₁₀ cycloalkyl substituted with 0-2 R³³, C₁₋₄ alkyl substituted with 0-2 R¹¹, C₂₋₄ alkenyl substituted with 0-2 R¹¹,

30

C₂₋₄ alkynyl substituted with 0-1 R¹¹,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
10 NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,
NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and
NR¹²C(O)NHR¹⁵;

15

R¹⁰ is selected from H, -OH,

C₁₋₆ alkyl substituted with 0-1 R^{10B},
C₂₋₆ alkenyl substituted with 0-1 R^{10B},
C₂₋₆ alkynyl substituted with 0-1 R^{10B}, and
20 C₁₋₆ alkoxy;

R^{10B} is selected from

C₁₋₄ alkoxy,
C₃₋₆ cycloalkyl,
25 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
phenyl substituted with 0-3 R³³, and
5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-2
30 R⁴⁴;

R¹¹ is selected from

H, halo, -CF₃, -CN, -NO₂,

- C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-4} haloalkyl,
 C_{1-8} alkoxy, C_{3-10} cycloalkyl,
 C_{3-10} carbocyclic residue substituted with 0-3 R^{33} ,
 aryl substituted with 0-5 R^{33} ,
 5 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 R^{31} ;
 10 OR^{12} , SR^{12} , $NR^{12}R^{13}$, $C(O)H$, $C(O)R^{12}$, $C(O)NR^{12}R^{13}$,
 $NR^{14}C(O)R^{12}$, $C(O)OR^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$,
 $CH(=NR^{14})NR^{12}R^{13}$, $NHC(=NR^{14})NR^{12}R^{13}$, $S(O)R^{12}$, $S(O)_2R^{12}$,
 $S(O)NR^{12}R^{13}$, $S(O)_2NR^{12}R^{13}$, $NR^{14}S(O)R^{12}$, $NR^{14}S(O)_2R^{12}$,
 $NR^{12}C(O)R^{15}$, $NR^{12}C(O)OR^{15}$, $NR^{12}S(O)_2R^{15}$, and
 15 $NR^{12}C(O)NHR^{15}$;

- R^{12} , at each occurrence, is independently selected from
 C_{1-4} alkyl substituted with 0-1 R^{12a} ,
 C_{2-4} alkenyl substituted with 0-1 R^{12a} ,
 20 C_{2-4} alkynyl substituted with 0-1 R^{12a} ,
 C_{3-6} cycloalkyl substituted with 0-3 R^{33} ,
 phenyl substituted with 0-5 R^{33} ;
 C_{3-10} carbocyclic residue substituted with 0-3 R^{33} , and
 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
 25 consisting of N, O, and S substituted with 0-3
 R^{31} ;

- R^{12a} , at each occurrence, is independently selected from
 30 phenyl substituted with 0-5 R^{33} ;
 C_{3-10} carbocyclic residue substituted with 0-3 R^{33} , and
 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group

consisting of N, O, and S substituted with 0-3
R³¹;

5 R¹³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

alternatively, R¹² and R¹³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R¹⁴)-;

10 alternatively, R¹² and R¹³ when attached to N may be
combined to form a 9- or 10-membered bicyclic
heterocyclic ring system containing from 1-3
heteroatoms selected from the group consisting of N,
O, and S, wherein said bicyclic heterocyclic ring
15 system is unsaturated or partially saturated, wherein
said bicyclic heterocyclic ring system is substituted
with 0-3 R¹⁶;

20 R¹⁴, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

R¹⁵, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

25 R¹⁶, at each occurrence, is independently selected from
H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,
C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,
C₁₋₃ haloalkyl-oxy-, and C₁₋₃ alkyloxy-;

30 R³¹, at each occurrence, is independently selected from
H, OH, halo, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, and C₁₋₄ alkyl;

R³³, at each occurrence, is independently selected from
H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,

C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,
C₃₋₆ cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyl-oxy-,
C₁₋₄ alkyloxy-,
C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, C₁₋₄ alkyl-C(=O)NH-,
5 C₁₋₄ alkyl-OC(=O)-,
C₁₋₄ alkyl-C(=O)O-, C₃₋₆ cycloalkyl-oxy-, C₃₋₆
cycloalkylmethyl-oxy-;
C₁₋₆ alkyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy; and
10 C₂₋₆ alkenyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy;

R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, =O;
15 C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴², and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
20 consisting of N, O, and S substituted with 0-3
R⁴⁴;

R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, SOR⁴⁵, SR⁴⁵, NR⁴⁶SO₂R⁴⁵,
25 NR⁴⁶COR⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, CH(=NH)NH₂,
NHC(=NH)NH₂,
C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
C₃₋₆ cycloalkyl,
C₁₋₄ alkyl substituted with 0-1 R⁴³,
30 aryl substituted with 0-3 R⁴⁴, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group

consisting of N, O, and S substituted with 0-3
R⁴⁴;

R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;

5

R⁴⁴, at each occurrence, is independently selected from H,
halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂,
C₁₋₄ alkyl, and C₁₋₄ alkoxy;

10 R⁴⁵ is C₁₋₄ alkyl;

R⁴⁶, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

15 R⁴⁷, at each occurrence, is independently selected from H,
C₁₋₄ alkyl, -C(=O)NH(C₁₋₄ alkyl), -SO₂(C₁₋₄ alkyl),
-C(=O)O(C₁₋₄ alkyl), -C(=O)(C₁₋₄ alkyl), and -C(=O)H;

k is 1 or 2;

20 m is 0, 1, or 2;

n is 0, 1, 2, or 3;

provided when m is 0 or 1 then k is 1 or 2;

provided when m is 2 then k is 1;

25

provided that when b is a double bond; n is 0 or 1; m is 1;
k is 1; X is -CH₂-; and R¹ is hydrogen, C₁₋₆ alkyl or
benzyl; then one of R⁷, R⁸, and R⁹, must be other than
hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy or trifluoromethyl;

30

provided that when R⁶ or R^{6a} is NH₂, then X is not -CH(R¹⁰);
and

provided that when n=0, then R⁶ or R^{6a} is not NH₂ or -OH.

[2] In a preferred embodiment of the present invention,

5

X is $-\text{CHR}^{10}-$ or $-\text{C}(=\text{O})-$;

R^1 is selected from

H,

10

$\text{C}(=\text{O})\text{R}^2$,

$\text{C}(=\text{O})\text{OR}^2$,

C_{1-8} alkyl,

C_{2-8} alkenyl,

C_{2-8} alkynyl,

15

C_{3-7} cycloalkyl,

C_{1-6} alkyl substituted with Z,

C_{2-6} alkenyl substituted with Z,

C_{2-6} alkynyl substituted with Z,

C_{3-6} cycloalkyl substituted with Z,

20

aryl substituted with Z,

5-6 membered heterocyclic ring system containing at least one heteroatom selected from the group consisting of N, O, and S, said heterocyclic ring system substituted with Z;

25

C_{1-3} alkyl substituted with Y,

C_{2-3} alkenyl substituted with Y,

C_{2-3} alkynyl substituted with Y,

C_{1-6} alkyl substituted with 0-2 R^2 ,

C_{2-6} alkenyl substituted with 0-2 R^2 ,

30

C_{2-6} alkynyl substituted with 0-2 R^2 ,

aryl substituted with 0-2 R^2 , and

5-6 membered heterocyclic ring system containing at least one heteroatom selected from the group

consisting of N, O, and S, said heterocyclic ring system substituted with 0-2 R²;

Y is selected from

- 5 C₃₋₆ cycloalkyl substituted with Z,
aryl substituted with Z,
5-6 membered heterocyclic ring system containing at least one heteroatom selected from the group consisting of N, O, and S, said heterocyclic ring system substituted with Z;
10 C₃₋₆ cycloalkyl substituted with -(C₁₋₃ alkyl)-Z,
aryl substituted with -(C₁₋₃ alkyl)-Z, and
5-6 membered heterocyclic ring system containing at least one heteroatom selected from the group consisting of N, O, and S, said heterocyclic ring system substituted with -(C₁₋₃ alkyl)-Z;
15

Z is selected from H,

- CH(OH)R²,
20 -C(ethylenedioxy)R²,
-OR²,
-SR²,
-NR²R³,
-C(O)R²,
25 -C(O)NR²R³,
-NR³C(O)R²,
-C(O)OR²,
-OC(O)R²,
-CH(=NR⁴)NR²R³,
30 -NHC(=NR⁴)NR²R³,
-S(O)R²,
-S(O)₂R²,
-S(O)₂NR²R³, and -NR³S(O)₂R²;

- R², at each occurrence, is independently selected from
halo,
C₁₋₃ haloalkyl,
C₁₋₄ alkyl,
5 C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
aryl substituted with 0-5 R⁴²;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
10 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;
- 15 R³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and
C₁₋₄ alkoxy;
- alternatively, R² and R³ join to form a 5- or 6-membered
20 ring optionally substituted with -O- or -N(R⁴)-;
- R⁴, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;
- 25 R⁵ is H or C₁₋₄ alkyl;
- R^{6a} and R^{6b}, at each occurrence, are independently selected
from
H, -OH, -NR⁴⁶R⁴⁷, -CF₃, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄
30 alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl,
and
aryl substituted with 0-3 R⁴⁴;

- R⁷ and R⁹, at each occurrence, are independently selected from
- H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷,
C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
5 C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy,
C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
C₁₋₄ alkyl substituted with 0-2 R¹¹,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
10 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;
- 15 OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,
NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and
20 NR¹²C(O)NHR¹⁵;

- R⁸ is selected from
- H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂,
C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
25 C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy,
C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
C₁₋₄ alkyl substituted with 0-2 R¹¹,
C₂₋₄ alkenyl substituted with 0-2 R¹¹,
C₂₋₄ alkynyl substituted with 0-1 R¹¹,
30 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group

consisting of N, O, and S substituted with 0-3
R³¹;

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
5 NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,
NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and
NR¹²C(O)NHR¹⁵;

10

R¹⁰ is selected from H, -OH,

C₁₋₆ alkyl substituted with 0-1 R^{10B},

C₂₋₆ alkenyl substituted with 0-1 R^{10B},

C₂₋₆ alkynyl substituted with 0-1 R^{10B}, and

15

C₁₋₆ alkoxy;

R^{10B} is selected from

C₁₋₄ alkoxy,

C₃₋₆ cycloalkyl,

20

C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,

phenyl substituted with 0-3 R³³, and

5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group

consisting of N, O, and S substituted with 0-2

25

R⁴⁴;

R¹¹ is selected from

H, halo, -CF₃, -CN, -NO₂,

C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,

30

C₁₋₈ alkoxy, C₃₋₁₀ cycloalkyl,

C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,

aryl substituted with 0-5 R³³,

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

5

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,
10 NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and
NR¹²C(O)NHR¹⁵;

R¹², at each occurrence, is independently selected from
C₁₋₄ alkyl substituted with 0-1 R^{12a},
15 C₂₋₄ alkenyl substituted with 0-1 R^{12a},
C₂₋₄ alkynyl substituted with 0-1 R^{12a},
C₃₋₆ cycloalkyl substituted with 0-3 R³³,
phenyl substituted with 0-5 R³³;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
20 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

25 R^{12a}, at each occurrence, is independently selected from
phenyl substituted with 0-5 R³³;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
30 consisting of N, O, and S substituted with 0-3
R³¹;

R¹³, at each occurrence, is independently selected from

H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

alternatively, R¹² and R¹³ join to form a 5- or 6-membered ring optionally substituted with -O- or -N(R¹⁴)-;

5

alternatively, R¹² and R¹³ when attached to N may be combined to form a 9- or 10-membered bicyclic heterocyclic ring system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S, wherein said bicyclic heterocyclic ring system is unsaturated or partially saturated, wherein said bicyclic heterocyclic ring system is substituted with 0-3 R¹⁶;

10

15 R¹⁴, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

R¹⁵, at each occurrence, is independently selected from H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

20

R¹⁶, at each occurrence, is independently selected from H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ haloalkyl-oxy-, and C₁₋₃ alkyloxy-;

25

R³¹, at each occurrence, is independently selected from H, OH, halo, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, and C₁₋₄ alkyl;

30

R³³, at each occurrence, is independently selected from H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyl-oxy-, C₁₋₄ alkyloxy-,

- C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, C₁₋₄ alkyl-C(=O)NH-,
C₁₋₄ alkyl-OC(=O)-,
C₁₋₄ alkyl-C(=O)O-, C₃₋₆ cycloalkyl-oxy-, C₃₋₆
cycloalkylmethyl-oxy-;
- 5 C₁₋₆ alkyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy; and
C₂₋₆ alkenyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy;
- 10 R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, =O;
C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴², and
- 15 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;
- 20 R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, SO₂R⁴⁵, SR⁴⁵, NR⁴⁶SO₂R⁴⁵,
NR⁴⁶COR⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, CH(=NH)NH₂,
NHC(=NH)NH₂,
C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
25 C₃₋₆ cycloalkyl,
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴⁴, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
30 consisting of N, O, and S substituted with 0-3
R⁴⁴;

R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;

R⁴⁴, at each occurrence, is independently selected from H, halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂, C₁₋₄ alkyl, and C₁₋₄ alkoxy;

5 R⁴⁵ is C₁₋₄ alkyl;

R⁴⁶, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

10 R⁴⁷, at each occurrence, is independently selected from H, C₁₋₄ alkyl, -C(=O)NH(C₁₋₄ alkyl), -SO₂(C₁₋₄ alkyl), -C(=O)O(C₁₋₄ alkyl), -C(=O)(C₁₋₄ alkyl), and -C(=O)H;

k is 1 or 2;

15 m is 0, 1, or 2;

n is 0, 1, 2, or 3;

provided when m is 0 or 1 then k is 1 or 2;

provided when m is 2 then k is 1;

20

provided that when b is a double bond; n is 0 or 1; m is 1; k is 1; X is -CH₂-; and R¹ is hydrogen, C₁₋₆ alkyl or benzyl; then one of R⁷, R⁸, and R⁹, must be other than hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy or trifluoromethyl;

25

provided that when R⁶ or R^{6a} is NH₂, then X is not -CH(R¹⁰); and

provided that when n=0, then R⁶ or R^{6a} is not NH₂ or -OH.

30

[3] In a further preferred embodiment of the present invention,

X is -CHR¹⁰- or -C(=O)-;

R¹ is selected from

- H,
- C(=O)R²,
- 5 C(=O)OR²,
- C₁₋₈ alkyl,
- C₂₋₈ alkenyl,
- C₂₋₈ alkynyl,
- C₃₋₇ cycloalkyl,
- 10 C₁₋₆ alkyl substituted with 0-2 R²,
- C₂₋₆ alkenyl substituted with 0-2 R²,
- C₂₋₆ alkynyl substituted with 0-2 R²,
- aryl substituted with 0-2 R², and
- 5-6 membered heterocyclic ring system containing at
- 15 least one heteroatom selected from the group
- consisting of N, O, and S, said heterocyclic ring
- system substituted with 0-2 R²;

R², at each occurrence, is independently selected from

- 20 F, Cl, CH₂F, CHF₂, CF₃,
- C₁₋₄ alkyl,
- C₂₋₄ alkenyl,
- C₂₋₄ alkynyl,
- C₃₋₆ cycloalkyl,
- 25 phenyl substituted with 0-5 R⁴²;
- C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
- 5-10 membered heterocyclic ring system containing from
- 1-4 heteroatoms selected from the group
- consisting of N, O, and S substituted with 0-3
- 30 R⁴¹;

R⁵ is H, methyl, ethyl, propyl, or butyl;

R^{6a} is selected from

H, -OH, -NR⁴⁶R⁴⁷, -CF₃,

C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, and
aryl substituted with 0-3 R⁴⁴;

5 R^{6b} is H;

R⁷ and R⁹, at each occurrence, are independently selected
from

H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷,

10 C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy,

C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,

C₁₋₄ alkyl substituted with 0-2 R¹¹,

C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,

15 aryl substituted with 0-5 R³³,

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

20

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,

NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,

CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,

S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,

25 NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and

NR¹²C(O)NHR¹⁵;

R⁸ is selected from

H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂,

30 C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy,

C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,

C₁₋₄ alkyl substituted with 0-2 R¹¹,

- C₂₋₄ alkenyl substituted with 0-2 R¹¹,
C₂₋₄ alkynyl substituted with 0-1 R¹¹,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;
- 10 OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,
NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and
15 NR¹²C(O)NHR¹⁵;

- R¹⁰ is selected from H, -OH,
C₁₋₆ alkyl substituted with 0-1 R^{10B},
C₂₋₆ alkenyl substituted with 0-1 R^{10B},
20 C₂₋₆ alkynyl substituted with 0-1 R^{10B}, and
C₁₋₆ alkoxy;

- R^{10B} is selected from
C₁₋₄ alkoxy,
25 C₃₋₆ cycloalkyl,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
phenyl substituted with 0-3 R³³, and
5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
30 consisting of N, O, and S substituted with 0-2
R⁴⁴;

R¹¹ is selected from

- H, halo, -CF₃, -CN, -NO₂,
 C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
 C₁₋₈ alkoxy, C₃₋₁₀ cycloalkyl,
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
 5 aryl substituted with 0-5 R³³,
 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 R³¹;
- 10 OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
 NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
 CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
 S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,
 15 NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and
 NR¹²C(O)NHR¹⁵;
- R¹², at each occurrence, is independently selected from
 C₁₋₄ alkyl substituted with 0-1 R^{12a},
 20 C₂₋₄ alkenyl substituted with 0-1 R^{12a},
 C₂₋₄ alkynyl substituted with 0-1 R^{12a},
 C₃₋₆ cycloalkyl substituted with 0-3 R³³,
 phenyl substituted with 0-5 R³³;
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
 25 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 R³¹;
- 30 R^{12a}, at each occurrence, is independently selected from
 phenyl substituted with 0-5 R³³;
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

5

R¹³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

10 alternatively, R¹² and R¹³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R¹⁴)-;

alternatively, R¹² and R¹³ when attached to N may be
combined to form a 9- or 10-membered bicyclic
15 heterocyclic ring system containing from 1-3
heteroatoms selected from the group consisting of N,
O, and S, wherein said bicyclic heterocyclic ring
system is unsaturated or partially saturated, wherein
said bicyclic heterocyclic ring system is substituted
20 with 0-3 R¹⁶;

R¹⁴, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

25 R¹⁵, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

R¹⁶, at each occurrence, is independently selected from
H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,
30 C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,
C₁₋₃ haloalkyl-oxy-, and C₁₋₃ alkyloxy-;

R³¹, at each occurrence, is independently selected from
H, OH, halo, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, and C₁₋₄ alkyl;

- R³³, at each occurrence, is independently selected from
H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,
C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,
5 C₃₋₆ cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyl-oxy-,
C₁₋₄ alkyloxy-,
C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, C₁₋₄ alkyl-C(=O)NH-,
C₁₋₄ alkyl-OC(=O)-,
C₁₋₄ alkyl-C(=O)O-, C₃₋₆ cycloalkyl-oxy-, C₃₋₆
10 cycloalkylmethyl-oxy-;
C₁₋₆ alkyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy; and
C₂₋₆ alkenyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy;
15
- R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN;
C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl
C₁₋₄ alkyl substituted with 0-1 R⁴³,
20 aryl substituted with 0-3 R⁴², and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;
25
- R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
CH(=NH)NH₂, NHC(=NH)NH₂,
C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
30 C₃₋₆ cycloalkyl,
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴⁴, and

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;

5

R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;

R⁴⁴, at each occurrence, is independently selected from H,
halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂,
10 C₁₋₄ alkyl, and C₁₋₄ alkoxy;

R⁴⁵ is C₁₋₄ alkyl;

R⁴⁶, at each occurrence, is independently selected from H
15 and C₁₋₄ alkyl;

R⁴⁷, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

20 k is 1 or 2;

m is 0, 1, or 2; and

n is 0, 1, 2, or 3.
25

[4] In a more preferred embodiment of the present
invention,

X is -CHR¹⁰-;
30

R¹ is selected from
H,
C(=O)R²,
C(=O)OR²,

- C₁₋₆ alkyl,
C₂₋₆ alkenyl,
C₂₋₆ alkynyl,
C₃₋₆ cycloalkyl,
5 C₁₋₄ alkyl substituted with 0-2 R²,
C₂₋₄ alkenyl substituted with 0-2 R², and
C₂₋₄ alkynyl substituted with 0-2 R²;

- R², at each occurrence, is independently selected from
10 C₁₋₄ alkyl,
C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
phenyl substituted with 0-5 R⁴²;
15 C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;

- 20 R⁵ is H, methyl, ethyl, propyl, or butyl;

R^{6a} is selected independently from
H, -OH, -NR⁴⁶R⁴⁷, -CF₃, C₁₋₃ alkyl, and C₁₋₃ alkoxy;

- 25 R^{6b} is H;

- R⁷ and R⁹, at each occurrence, are independently selected
from
30 H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷,
C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,
C₁₋₆ alkoxy, (C₁₋₄ haloalkyl)oxy,
C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,

- C₁₋₄ alkyl substituted with 0-2 R¹¹,
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
 aryl substituted with 0-5 R³³,
 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 R³¹;
- OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
 NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
 CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹²,
 S(O)₂R¹², S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹²,
 and NR¹⁴S(O)₂R¹²;
- R⁸ is selected from
 H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂,
 C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,
 C₁₋₆ alkoxy, (C₁₋₄ haloalkyl)oxy,
 C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
 C₁₋₄ alkyl substituted with 0-2 R¹¹,
 C₂₋₄ alkenyl substituted with 0-2 R¹¹,
 C₂₋₄ alkynyl substituted with 0-1 R¹¹,
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
 aryl substituted with 0-5 R³³,
 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 R³¹;
- OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
 NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
 CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
 S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,

$\text{NR}^{12}\text{C}(\text{O})\text{R}^{15}$, $\text{NR}^{12}\text{C}(\text{O})\text{OR}^{15}$, $\text{NR}^{12}\text{S}(\text{O})_2\text{R}^{15}$, and
 $\text{NR}^{12}\text{C}(\text{O})\text{NHR}^{15}$;

R^{10} is selected from H, -OH,

- 5 C_{1-6} alkyl substituted with 0-1 $\text{R}^{10\text{B}}$,
 C_{2-6} alkenyl substituted with 0-1 $\text{R}^{10\text{B}}$,
 C_{2-6} alkynyl substituted with 0-1 $\text{R}^{10\text{B}}$, and
 C_{1-6} alkoxy;

10 $\text{R}^{10\text{B}}$ is selected from

C_{1-4} alkoxy,
 C_{3-6} cycloalkyl,
 C_{3-10} carbocyclic residue substituted with 0-3 R^{33} ,
 phenyl substituted with 0-3 R^{33} , and

- 15 5-6 membered heterocyclic ring system containing 1, 2,
 or 3 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-2
 R^{44} ;

20 R^{11} is selected from

 H, halo, $-\text{CF}_3$, $-\text{CN}$, $-\text{NO}_2$, C_{1-6} alkyl,
 C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} haloalkyl, C_{1-6} alkoxy,
 C_{3-10} cycloalkyl,

- C_{3-10} carbocyclic residue substituted with 0-3 R^{33} ,
25 aryl substituted with 0-5 R^{33} ,
 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 R^{31} ;

30

OR^{12} , SR^{12} , $\text{NR}^{12}\text{R}^{13}$, $\text{C}(\text{O})\text{H}$, $\text{C}(\text{O})\text{R}^{12}$, $\text{C}(\text{O})\text{NR}^{12}\text{R}^{13}$,
 $\text{NR}^{14}\text{C}(\text{O})\text{R}^{12}$, $\text{C}(\text{O})\text{OR}^{12}$, $\text{OC}(\text{O})\text{R}^{12}$, $\text{OC}(\text{O})\text{OR}^{12}$,
 $\text{CH}(=\text{NR}^{14})\text{NR}^{12}\text{R}^{13}$, $\text{NHC}(=\text{NR}^{14})\text{NR}^{12}\text{R}^{13}$, $\text{S}(\text{O})\text{R}^{12}$,

$S(O)_2R^{12}$, $S(O)NR^{12}R^{13}$, $S(O)_2NR^{12}R^{13}$, $NR^{14}S(O)R^{12}$,
and $NR^{14}S(O)_2R^{12}$;

R^{12} , at each occurrence, is independently selected from
5 C_{1-4} alkyl substituted with 0-1 R^{12a} ,
 C_{2-4} alkenyl substituted with 0-1 R^{12a} ,
 C_{2-4} alkynyl substituted with 0-1 R^{12a} ,
 C_{3-6} cycloalkyl substituted with 0-3 R^{33} ,
phenyl substituted with 0-5 R^{33} ;
10 C_{3-10} carbocyclic residue substituted with 0-3 R^{33} , and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
 R^{31} ;

15 R^{12a} , at each occurrence, is independently selected from
phenyl substituted with 0-5 R^{33} ;
 C_{3-10} carbocyclic residue substituted with 0-3 R^{33} , and
5-10 membered heterocyclic ring system containing from
20 1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
 R^{31} ;

R^{13} , at each occurrence, is independently selected from
25 H, C_{1-4} alkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl;

alternatively, R^{12} and R^{13} join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R^{14})-;

30 alternatively, R^{12} and R^{13} when attached to N may be
combined to form a 9- or 10-membered bicyclic
heterocyclic ring system containing from 1-3
heteroatoms selected from the group consisting of N,
O, and S, wherein said bicyclic heterocyclic ring

system is unsaturated or partially saturated, wherein said bicyclic heterocyclic ring system is substituted with 0-3 R¹⁶;

5 R¹⁴, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;

R¹⁵, at each occurrence, is independently selected from H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

10

R¹⁶, at each occurrence, is independently selected from H, OH, F, Cl, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, and trifluoromethoxy;

15

R³¹, at each occurrence, is independently selected from H, OH, halo, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, and C₁₋₄ alkyl;

20 R³³, at each occurrence, is independently selected from H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyl-oxy-, C₁₋₄ alkyloxy-, C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, C₁₋₄ alkyl-C(=O)NH-,
25 C₁₋₄ alkyl-OC(=O)-, C₁₋₄ alkyl-C(=O)O-, C₃₋₆ cycloalkyl-oxy-, C₃₋₆ cycloalkylmethyl-oxy-;
C₁₋₆ alkyl substituted with OH, methoxy, ethoxy, propoxy, or butoxy; and
30 C₂₋₆ alkenyl substituted with OH, methoxy, ethoxy, propoxy, or butoxy;

R⁴¹, at each occurrence, is independently selected from H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,

C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴², and
5 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;

R⁴², at each occurrence, is independently selected from
10 H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
CH(=NH)NH₂, NHC(=NH)NH₂,
C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
C₃₋₆ cycloalkyl,
C₁₋₄ alkyl substituted with 0-1 R⁴³,
15 aryl substituted with 0-3 R⁴⁴, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;

20 R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;

R⁴⁴, at each occurrence, is independently selected from H,
halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂,
25 C₁₋₄ alkyl, and C₁₋₄ alkoxy;

R⁴⁵ is C₁₋₄ alkyl;

R⁴⁶, at each occurrence, is independently selected from H
30 and C₁₋₄ alkyl;

R⁴⁷, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

k is 1 or 2;

m is 0 or 1; and

5 n is 0, 1 or 2.

[5] In an even more preferred embodiment of the present invention,

10 X is $-\text{CH}_2-$;

R^1 is selected from

H,

C_{1-4} alkyl,

15 C_{2-4} alkenyl,

C_{2-4} alkynyl,

C_{3-4} cycloalkyl,

C_{1-3} alkyl substituted with 0-1 R^2 ,

C_{2-3} alkenyl substituted with 0-1 R^2 , and

20 C_{2-3} alkynyl substituted with 0-1 R^2 ;

R^2 , at each occurrence, is independently selected from

C_{1-4} alkyl,

C_{2-4} alkenyl,

25 C_{2-4} alkynyl,

C_{3-6} cycloalkyl,

phenyl substituted with 0-5 R^{42} ;

C_{3-6} carbocyclic residue substituted with 0-3 R^{41} , and

5-6 membered heterocyclic ring system containing 1, 2,

30 or 3 heteroatoms selected from the group

consisting of N, O, and S substituted with 0-3

R^{41} ;

R^5 is H, methyl, ethyl, propyl, or butyl;

R^{6a} is H, methyl, ethyl, methoxy, -OH, or -CF₃;

R^{6b} is H;

5

R⁷ and R⁹, at each occurrence, are independently selected from

H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷,

C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,

10 C₁₋₄ alkoxy, (C₁₋₄ haloalkyl)oxy,

C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,

C₁₋₄ alkyl substituted with 0-2 R¹¹,

C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,

aryl substituted with 0-5 R³³, and

15 5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

20 R⁸ is selected from

H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂,

C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,

C₁₋₄ alkoxy, (C₁₋₄ haloalkyl)oxy,

C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,

25 C₁₋₄ alkyl substituted with 0-2 R¹¹,

C₂₋₄ alkenyl substituted with 0-2 R¹¹,

C₂₋₄ alkynyl substituted with 0-1 R¹¹,

C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,

aryl substituted with 0-5 R³³,

30 5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

OR¹², SR¹², NR¹²R¹³, NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵,
NR¹²S(O)₂R¹⁵, and NR¹²C(O)NHR¹⁵;

R¹¹ is selected from

- 5 H, halo, -CF₃, -CN, -NO₂,
 C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,
 C₁₋₄ alkoxy, (C₁₋₄ haloalkyl)oxy,
 C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
10 aryl substituted with 0-5 R³³, and
 5-6 membered heterocyclic ring system containing 1, 2,
 or 3 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 R³¹;

15

R¹², at each occurrence, is independently selected from

- C₁₋₄ alkyl substituted with 0-1 R^{12a},
 C₂₋₄ alkenyl substituted with 0-1 R^{12a},
 C₂₋₄ alkynyl substituted with 0-1 R^{12a},
20 C₃₋₆ cycloalkyl substituted with 0-3 R³³,
 phenyl substituted with 0-5 R³³;
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
25 consisting of N, O, and S substituted with 0-3
 R³¹;

R^{12a}, at each occurrence, is independently selected from
phenyl substituted with 0-5 R³³;

- 30 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group

consisting of N, O, and S substituted with 0-3
R³¹;

5 R¹³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

alternatively, R¹² and R¹³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R¹⁴)-;

10 alternatively, R¹² and R¹³ when attached to N may be
combined to form a 9- or 10-membered bicyclic
heterocyclic ring system containing from 1-3
heteroatoms selected from the group consisting of one
N, two N, three N, one N one O, and one N one S;
15 wherein said bicyclic heterocyclic ring system is
unsaturated or partially saturated, wherein said
bicyclic heterocyclic ring system is substituted with
0-2 R¹⁶;

20 R¹⁴, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

R¹⁵, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

25

R¹⁶, at each occurrence, is independently selected from
H, OH, F, Cl, CN, NO₂, methyl, ethyl, methoxy, ethoxy,
trifluoromethyl, and trifluoromethoxy;

30 R³¹, at each occurrence, is independently selected from
H, OH, halo, CF₃, methyl, ethyl, and propyl;

R³³, at each occurrence, is independently selected from
H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,

C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,
C₃₋₆ cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyl-oxy-,
C₁₋₄ alkyloxy-,
C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, C₁₋₄ alkyl-C(=O)NH-,
5 C₁₋₄ alkyl-OC(=O)-,
C₁₋₄ alkyl-C(=O)O-, C₃₋₆ cycloalkyl-oxy-, C₃₋₆
cycloalkylmethyl-oxy-;
C₁₋₆ alkyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy; and
10 C₂₋₆ alkenyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy;

R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
15 C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₃ alkoxy, C₁₋₃ haloalkyl,
and C₁₋₃ alkyl;

R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
20 CH(=NH)NH₂, NHC(=NH)NH₂,
C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₃ alkoxy, C₁₋₃ haloalkyl,
C₃₋₆ cycloalkyl, and C₁₋₃ alkyl;

R⁴³ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
25 phenyl, or pyridyl, each substituted with 0-3 R⁴⁴;

R⁴⁴, at each occurrence, is independently selected from H,
halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂,
methyl, ethyl, propyl, butyl, methoxy, ethoxy,
30 propoxy, and butoxy;

R⁴⁵ is methyl, ethyl, propyl, or butyl;

R⁴⁶, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

5 R⁴⁷, at each occurrence, is independently selected from
from H, methyl, ethyl, propyl, and butyl;

k is 1;

m is 1; and

10

n is 0, 1 or 2.

[6] In an even more preferred embodiment of the
present invention,

15

X is -CH₂-;

R¹ is selected from

20 H,
C₁₋₄ alkyl,
C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₄ cycloalkyl,
C₁₋₃ alkyl substituted with 0-1 R²,
25 C₂₋₃ alkenyl substituted with 0-1 R², and
C₂₋₃ alkynyl substituted with 0-1 R²;

R², at each occurrence, is independently selected from

30 C₁₋₄ alkyl,
C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
phenyl substituted with 0-5 R⁴²;
C₃₋₆ carbocyclic residue substituted with 0-3 R⁴¹, and

5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;

5

R⁵ is H, methyl, ethyl, propyl, or butyl;

R^{6a} is H, methyl, ethyl, methoxy, -OH, or -CF₃;

10 R^{6b} is H;

R⁷ and R⁹, at each occurrence, are independently selected
from

H, F, Cl, -CH₃, -OCH₃, -CF₃, -OCF₃, -CN, and -NO₂,

15

R⁸ is selected from

H, F, Cl, Br, -CF₃, -OCF₃, -OH, -CN, -NO₂,

C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,

C₁₋₄ alkoxy, (C₁₋₄ haloalkyl)oxy,

20

C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,

C₁₋₄ alkyl substituted with 0-2 R¹¹,

C₂₋₄ alkenyl substituted with 0-2 R¹¹,

C₂₋₄ alkynyl substituted with 0-1 R¹¹,

C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,

25

aryl substituted with 0-5 R³³,

5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

30

OR¹², SR¹², NR¹²R¹³, NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵,
NR¹²S(O)₂R¹⁵, and NR¹²C(O)NHR¹⁵;

R¹¹ is selected from

H, halo, -CF₃, -CN, -NO₂,

- C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,
C₁₋₄ alkoxy, (C₁₋₄ haloalkyl)oxy,
C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
5 aryl substituted with 0-5 R³³, and
5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;
- 10 R¹², at each occurrence, is independently selected from
C₁₋₄ alkyl substituted with 0-1 R^{12a},
C₂₋₄ alkenyl substituted with 0-1 R^{12a},
C₂₋₄ alkynyl substituted with 0-1 R^{12a},
15 C₃₋₆ cycloalkyl substituted with 0-3 R³³,
phenyl substituted with 0-5 R³³;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
20 consisting of N, O, and S substituted with 0-3
R³¹;
- R^{12a}, at each occurrence, is independently selected from
phenyl substituted with 0-5 R³³;
- 25 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;
- 30 R¹³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

alternatively, R¹² and R¹³ join to form a 5- or 6-membered ring optionally substituted with -O- or -N(R¹⁴)-;

alternatively, R¹² and R¹³ when attached to N may be
5 combined to form a 9- or 10-membered bicyclic heterocyclic ring system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S; wherein said bicyclic heterocyclic ring system is selected from indolyl, indolinyl, indazolyl,
10 benzimidazolyl, benzimidazolinyl, benztriazolyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, and dioxobenzthiazolyl; wherein said bicyclic heterocyclic ring system is substituted with 0-1 R¹⁶;

15 R¹⁴, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;

R¹⁵, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;

20

R¹⁶, at each occurrence, is independently selected from H, OH, F, Cl, CN, NO₂, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, and trifluoromethoxy;

25 R³¹, at each occurrence, is independently selected from H, OH, halo, CF₃, methyl, ethyl, and propyl;

R³³, at each occurrence, is independently selected from H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,
30 C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyl-oxy-, C₁₋₄ alkyloxy-, C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, C₁₋₄ alkyl-C(=O)NH-, C₁₋₄ alkyl-OC(=O)-,

- C₁₋₄ alkyl-C(=O)O-, C₃₋₆ cycloalkyl-oxy-, C₃₋₆ cycloalkylmethyl-oxy-;
C₁₋₆ alkyl substituted with OH, methoxy, ethoxy, propoxy, or butoxy; and
5 C₂₋₆ alkenyl substituted with OH, methoxy, ethoxy, propoxy, or butoxy;
- R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
10 C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₃ alkoxy, C₁₋₃ haloalkyl, and C₁₋₃ alkyl;
- R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
15 CH(=NH)NH₂, NHC(=NH)NH₂, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₃ alkoxy, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkyl;
- R⁴³ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
20 phenyl, or pyridyl, each substituted with 0-3 R⁴⁴;
- R⁴⁴, at each occurrence, is independently selected from H, halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂, methyl, ethyl, propyl, butyl, methoxy, ethoxy,
25 propoxy, and butoxy;
- R⁴⁵ is methyl, ethyl, propyl, or butyl;
- R⁴⁶, at each occurrence, is independently selected from H,
30 methyl, ethyl, propyl, and butyl;
- R⁴⁷, at each occurrence, is independently selected from
from H, methyl, ethyl, propyl, and butyl;

k is 1;

m is 1; and

5 n is 0, 1 or 2.

[7] In an even further more preferred embodiment of the present invention,

10 X is -CH₂-;

R¹ is selected from H,

C₁₋₅ alkyl substituted with 0-1 R²,

C₂₋₅ alkenyl substituted with 0-1 R², and

15 C₂₋₃ alkynyl substituted with 0-1 R²;

R² is C₃₋₆ cycloalkyl;

R⁵ is H, methyl, ethyl, or propyl;

20

R^{6a} is H, methyl, or ethyl;

R^{6b} is H;

25 R⁷ and R⁹, at each occurrence, are independently selected from

H, F, Cl, -CH₃, -OCH₃, -CF₃, -OCF₃, -CN, and -NO₂,

R⁸ is selected from

30 methyl substituted with R¹¹;

ethenyl substituted with R¹¹;

OR¹², SR¹², NR¹²R¹³, NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵,

NR¹²S(O)₂R¹⁵, and NR¹²C(O)NHR¹⁵;

- R¹¹ is selected from
- phenyl- substituted with 0-5 fluoro;
 - 2-(H₃CCH₂C(=O))-phenyl- substituted with R³³;
 - 2-(H₃CC(=O))-phenyl- substituted with R³³;
 - 5 2-(HC(=O))-phenyl- substituted with R³³;
 - 2-(H₃CCH(OH))-phenyl- substituted with R³³;
 - 2-(H₃CCH₂CH(OH))-phenyl- substituted with R³³;
 - 2-(HOCH₂)-phenyl- substituted with R³³;
 - 2-(HOCH₂CH₂)-phenyl- substituted with R³³;
 - 10 2-(H₃COCH₂)-phenyl- substituted with R³³;
 - 2-(H₃COCH₂CH₂)-phenyl- substituted with R³³;
 - 2-(H₃CCH(OMe))-phenyl- substituted with R³³;
 - 2-(H₃COC(=O))-phenyl- substituted with R³³;
 - 2-(HOCH₂CH=CH)-phenyl- substituted with R³³;
 - 15 2-((MeOC(=O)CH=CH)-phenyl- substituted with R³³;
 - 2-(methyl)-phenyl- substituted with R³³;
 - 2-(ethyl)-phenyl- substituted with R³³;
 - 2-(i-propyl)-phenyl- substituted with R³³;
 - 2-(F₃C)-phenyl- substituted with R³³;
 - 20 2-(NC)-phenyl- substituted with R³³;
 - 2-(H₃CO)-phenyl- substituted with R³³;
 - 2-(fluoro)-phenyl- substituted with R³³;
 - 2-(chloro)-phenyl- substituted with R³³;
 - 3-(NC)-phenyl- substituted with R³³;
 - 25 3-(H₃CO)-phenyl- substituted with R³³;
 - 3-(fluoro)-phenyl- substituted with R³³;
 - 3-(chloro)-phenyl- substituted with R³³;
 - 4-(NC)-phenyl- substituted with R³³;
 - 4-(fluoro)-phenyl- substituted with R³³;
 - 30 4-(chloro)-phenyl- substituted with R³³;
 - 4-(H₃CS)-phenyl- substituted with R³³;
 - 4-(H₃CO)-phenyl- substituted with R³³;

- 4-(ethoxy)-phenyl- substituted with R^{33} ;
- 4-(i-propoxy)-phenyl- substituted with R^{33} ;
- 4-(i-butoxy)-phenyl- substituted with R^{33} ;
- 4-($H_3CCH_2CH_2C(=O)$)-phenyl- substituted with R^{33} ;
- 5 4-((H_3C) $_2$ CHC(=O))-phenyl- substituted with R^{33} ;
- 4-($H_3CCH_2C(=O)$)-phenyl- substituted with R^{33} ;
- 4-($H_3CC(=O)$)-phenyl- substituted with R^{33} ;
- 4-($H_3CCH_2CH_2CH(OH)$)-phenyl- substituted with R^{33} ;
- 4-((H_3C) $_2$ CHCH(OH))-phenyl- substituted with R^{33} ;
- 10 4-($H_3CCH_2CH(OH)$)-phenyl- substituted with R^{33} ;
- 4-($H_3CCH(OH)$)-phenyl- substituted with R^{33} ;
- 4-(cyclopropyloxy)-phenyl- substituted with R^{33} ;
- 4-(cyclobutyloxy)-phenyl- substituted with R^{33} ; and
- 4-(cyclopentyloxy)-phenyl- substituted with R^{33} ;

15

R^{12} is selected from

- phenyl- substituted with 0-5 fluoro;
- 2-($H_3CCH_2C(=O)$)-phenyl- substituted with R^{33} ;
- 2-($H_3CC(=O)$)-phenyl- substituted with R^{33} ;
- 20 2-(HC(=O))-phenyl- substituted with R^{33} ;
- 2-($H_3CCH(OH)$)-phenyl- substituted with R^{33} ;
- 2-($H_3CCH_2CH(OH)$)-phenyl- substituted with R^{33} ;
- 2-(HOCH $_2$)-phenyl- substituted with R^{33} ;
- 2-(HOCH $_2$ CH $_2$)-phenyl- substituted with R^{33} ;
- 25 2-(H_3COCH_2)-phenyl- substituted with R^{33} ;
- 2-($H_3COCH_2CH_2$)-phenyl- substituted with R^{33} ;
- 2-($H_3CCH(OMe)$)-phenyl- substituted with R^{33} ;
- 2-($H_3COC(=O)$)-phenyl- substituted with R^{33} ;
- 2-(HOCH $_2$ CH=CH)-phenyl- substituted with R^{33} ;
- 30 2-((MeOC=O)CH=CH)-phenyl- substituted with R^{33} ;
- 2-(methyl)-phenyl- substituted with R^{33} ;
- 2-(ethyl)-phenyl- substituted with R^{33} ;

- 2-(i-propyl)-phenyl- substituted with R^{33} ;
2-(F₃C)-phenyl- substituted with R^{33} ;
2-(NC)-phenyl- substituted with R^{33} ;
2-(H₃CO)-phenyl- substituted with R^{33} ;
5 2-(fluoro)-phenyl- substituted with R^{33} ;
2-(chloro)-phenyl- substituted with R^{33} ;
3-(NC)-phenyl- substituted with R^{33} ;
3-(H₃CO)-phenyl- substituted with R^{33} ;
3-(fluoro)-phenyl- substituted with R^{33} ;
10 3-(chloro)-phenyl- substituted with R^{33} ;
4-(NC)-phenyl- substituted with R^{33} ;
4-(fluoro)-phenyl- substituted with R^{33} ;
4-(chloro)-phenyl- substituted with R^{33} ;
4-(H₃CS)-phenyl- substituted with R^{33} ;
15 4-(H₃CO)-phenyl- substituted with R^{33} ;
4-(ethoxy)-phenyl- substituted with R^{33} ;
4-(i-propoxy)-phenyl- substituted with R^{33} ;
4-(i-butoxy)-phenyl- substituted with R^{33} ;
4-(H₃CCH₂CH₂C(=O))-phenyl- substituted with R^{33} ;
20 4-((H₃C)₂CHC(=O))-phenyl- substituted with R^{33} ;
4-(H₃CCH₂C(=O))-phenyl- substituted with R^{33} ;
4-(H₃CC(=O))-phenyl- substituted with R^{33} ;
4-(H₃CCH₂CH₂CH(OH))-phenyl- substituted with R^{33} ;
4-((H₃C)₂CHCH(OH))-phenyl- substituted with R^{33} ;
25 4-(H₃CCH₂CH(OH))-phenyl- substituted with R^{33} ;
4-(H₃CCH(OH))-phenyl- substituted with R^{33} ;
4-(cyclopropyloxy)-phenyl- substituted with R^{33} ;
4-(cyclobutyloxy)-phenyl- substituted with R^{33} ; and
4-(cyclopentyloxy)-phenyl- substituted with R^{33} ;
30
- R^{13} is H, methyl, or ethyl;

alternatively, R¹² and R¹³ join to form a 5- or 6-membered ring selected from pyrrolyl, pyrrolidinyl, imidazolyl, piperidinyl, piperiziny, methylpiperiziny, and morpholinyl;

5

alternatively, R¹² and R¹³ when attached to N may be combined to form a 9- or 10-membered bicyclic heterocyclic ring system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S; wherein said bicyclic heterocyclic ring system is selected from indolyl, indolinyl, indazolyl, benzimidazolyl, benzimidazolinyl, benztriazolyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, and dioxobenzthiazolyl; wherein said bicyclic heterocyclic ring system is substituted with 0-1 R¹⁶;

10

15

R¹⁵ is H, methyl, ethyl, propyl, or butyl;

R¹⁶, at each occurrence, is independently selected from H, OH, F, Cl, CN, NO₂, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, and trifluoromethoxy;

20

25

R³³, at each occurrence, is independently selected from H, F, Cl, -CH₃, -OCH₃, -CF₃, -OCF₃, -CN, and -NO₂;


k is 1;

m is 1; and

30

n is 1 or 2.

[8] In an even more preferred embodiment of the present invention, the compound of Formula (I) is selected from Formula (I-a):



(I-a)

wherein:

b is a single bond or a double bond;

X is $-\text{CH}_2-$, $-\text{CH}(\text{OH})-$, or $-\text{C}(=\text{O})-$;

R^1 is selected from

hydrogen, methyl, ethyl, n-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, n-hexyl, 2-propyl, 2-butyl, 2-pentyl, 2-hexyl, 2-methylpropyl, 2-methylbutyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, 3-methylbutyl, 4-methylpentyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl,

2-propenyl, 2-methyl-2-propenyl, trans-2-butenyl, 3-methyl-butenyl, 3-butenyl, trans-2-pentenyl, cis-2-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 3,3-dichloro-2-propenyl, trans-3-phenyl-2-propenyl,

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl,

benzyl, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl,
2,5-dimethylbenzyl, 2,4-dimethylbenzyl, 3,5-
dimethylbenzyl,
2,4,6-trimethyl-benzyl, 3-methoxy-benzyl, 3,5-dimethoxy-
5 benzyl, pentafluorobenzyl, 2-phenylethyl, 1-phenyl-2-
propyl, 4-phenylbutyl, 4-phenylbenzyl, 2-phenylbenzyl,

(2,3-dimethoxy-phenyl)C(=O)-, (2,5-dimethoxy-
phenyl)C(=O)-, (3,4-dimethoxy-phenyl)C(=O)-,
10 (3,5-dimethoxy-phenyl)C(=O)-, cyclopropyl-C(=O)-,
isopropyl-C(=O)-, ethyl-CO₂-, propyl-CO₂-, t-butyl-CO₂-,
2,6-dimethoxy-benzyl, 2,4-dimethoxy-benzyl,
2,4,6-trimethoxy-benzyl, 2,3-dimethoxy-benzyl,
2,4,5-trimethoxy-benzyl, 2,3,4-trimethoxy-benzyl,
15 3,4-dimethoxy-benzyl, 3,4,5-trimethoxy-benzyl,
(4-fluoro-phenyl)ethyl,

-CH=CH₂, -CH₂-CH=CH₂, -CH=CH-CH₃, -C≡CH, -C≡C-CH₃, and
-CH₂-C≡CH;

20

R⁷, R⁸, and R⁹, at each occurrence, are independently
selected from

hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl,
propyl, isopropyl, butyl, t-butyl, nitro,
25 trifluoromethyl, methoxy, ethoxy, isopropoxy,
trifluoromethoxy, phenyl,

methylC(=O)-, ethylC(=O)-, propylC(=O)-, isopropylC(=O)-,
butylC(=O)-, phenylC(=O)-,

30

methylCO₂-, ethylCO₂-, propylCO₂-, isopropylCO₂-,
butylCO₂-, phenylCO₂-,

dimethylamino-S(=O)-, diethylamino-S(=O)-,

dipropylamino-S(=O)-, di-isopropylamino-S(=O)-,
dibutylamino-S(=O)-, diphenylamino-S(=O)-,

5 dimethylamino-SO₂-, diethylamino-SO₂-, dipropylamino-SO₂-
, di-isopropylamino-SO₂-, dibutylamino-SO₂-,
diphenylamino-SO₂-,

10 dimethylamino-C(=O)-, diethylamino-C(=O)-,
dipropylamino-C(=O)-, di-isopropylamino-C(=O)-,
dibutylamino-C(=O)-, diphenylamino-C(=O)-,

15 2-chlorophenyl, 2-fluorophenyl, 2-bromophenyl, 2-
cyanophenyl, 2-methylphenyl, 2-trifluoromethylphenyl,
2-methoxyphenyl, 2-trifluoromethoxyphenyl,

3-chlorophenyl, 3-fluorophenyl, 3-bromophenyl,
3-cyanophenyl, 3-methylphenyl, 3-ethylphenyl,
3-propylphenyl, 3-isopropylphenyl, 3-butylphenyl,
3-trifluoromethylphenyl, 3-methoxyphenyl,
20 3-isopropoxyphenyl, 3-trifluoromethoxyphenyl,
3-thiomethoxyphenyl,

4-chlorophenyl, 4-fluorophenyl, 4-bromophenyl,
4-cyanophenyl, 4-methylphenyl, 4-ethylphenyl,
25 4-propylphenyl, 4-isopropylphenyl, 4-butylphenyl,
4-trifluoromethylphenyl, 4-methoxyphenyl,
4-isopropoxyphenyl, 4-trifluoromethoxyphenyl,
4-thiomethoxyphenyl,

30 2,3-dichlorophenyl, 2,3-difluorophenyl, 2,3-
dimethylphenyl,
2,3-ditrifluoromethylphenyl, 2,3-dimethoxyphenyl,
2,3-ditrifluoromethoxyphenyl,

- 2,4-dichlorophenyl, 2,4-difluorophenyl, 2,4-dimethylphenyl,
2,4-ditrifluoromethylphenyl, 2,4-dimethoxyphenyl,
2,4-ditrifluoromethoxyphenyl,
- 5 2,5-dichlorophenyl, 2,5-difluorophenyl, 2,5-dimethylphenyl,
2,5-ditrifluoromethylphenyl, 2,5-dimethoxyphenyl,
2,5-ditrifluoromethoxyphenyl,
- 10 2,6-dichlorophenyl, 2,6-difluorophenyl, 2,6-dimethylphenyl,
2,6-ditrifluoromethylphenyl, 2,6-dimethoxyphenyl,
2,6-ditrifluoromethoxyphenyl,
- 15 3,4-dichlorophenyl, 3,4-difluorophenyl, 3,4-dimethylphenyl,
3,4-ditrifluoromethylphenyl, 3,4-dimethoxyphenyl,
3,4-ditrifluoromethoxyphenyl,
- 20 2,4,6-trichlorophenyl, 2,4,6-trifluorophenyl,
2,4,6-trimethylphenyl, 2,4,6-tritrifluoromethylphenyl,
2,4,6-trimethoxyphenyl, 2,4,6-tritrifluoromethoxyphenyl,
- 25 2-chloro-4-CF₃-phenyl, 2-fluoro-3-chloro-phenyl,
2-chloro-4-CF₃-phenyl, 2-chloro-4-methoxy-phenyl,
2-methoxy-4-isopropyl-phenyl, 2-CF₃-4-methoxy-phenyl,
2-methyl-4-methoxy-5-fluoro-phenyl,
2-methyl-4-methoxy-phenyl, 2-chloro-4-CF₃O-phenyl,
- 30 2,4,5-trimethyl-phenyl, 2-methyl-4-chloro-phenyl,

methyl-C(=O)NH-, ethyl-C(=O)NH-, propyl-C(=O)NH-,
isopropyl-C(=O)NH-, butyl-C(=O)NH-, phenyl-C(=O)NH-,
- 35 4-acetylphenyl, 3-acetamidophenyl, 4-pyridyl, 2-furanyl,

- 2-thiophenyl, 2-naphthyl;
- 2-Me-5-F-phenyl, 2-F-5-Me-phenyl, 2-MeO-5-F-phenyl,
 2-Me-3-Cl-phenyl, 3-NO₂-phenyl, 2-NO₂-phenyl,
 5 2-Cl-3-Me-phenyl, 2-Me-4-EtO-phenyl, 2-Me-4-F-phenyl,
 2-Cl-6-F-phenyl, 2-Cl-4-(CHF₂)O-phenyl,
 2,4-diMeO-6-F-phenyl, 2-CF₃-6-F-phenyl,
 2-MeS-phenyl, 2,6-diCl-4-MeO-phenyl,
 2,3,4-triF-phenyl, 2,6-diF-4-Cl-phenyl,
 10 2,3,4,6-tetraF-phenyl, 2,3,4,5,6-pentaF-phenyl,
 2-CF₃-4-EtO-phenyl, 2-CF₃-4-iPrO-phenyl,
 2-CF₃-4-Cl-phenyl, 2-CF₃-4-F-phenyl, 2-Cl-4-EtO-phenyl,
 2-Cl-4-iPrO-phenyl, 2-Et-4-MeO-phenyl,
 2-CHO-4-MeO-phenyl, 2-CH(OH)Me-4-MeO-phenyl,
 15 2-CH(OMe)Me-4-MeO-phenyl, 2-C(=O)Me-4-MeO-phenyl,
 2-CH₂(OH)-4-MeO-phenyl, 2-CH₂(OMe)-4-MeO-phenyl,
 2-CH(OH)Et-4-MeO-phenyl, 2-C(=O)Et-4-MeO-phenyl,
 (Z)-2-CH=CHCO₂Me-4-MeO-phenyl,
 2-CH₂CH₂CO₂Me-4-MeO-phenyl,
 20 (Z)-2-CH=CHCH₂(OH)-4-MeO-phenyl,
 (E)-2-CH=CHCO₂Me-4-MeO-phenyl,
 (E)-2-CH=CHCH₂(OH)-4-MeO-phenyl,
 2-CH₂CH₂OMe-4-MeO-phenyl,
 2-F-4-MeO-phenyl, 2-Cl-4-F-phenyl,
 25 (2-Cl-phenyl)-CH=CH-, (3-Cl-phenyl)-CH=CH-,
 (2,6-diF-phenyl)-CH=CH-, -CH₂CH=CH₂,
 phenyl-CH=CH-, (2-Me-4-MeO-phenyl)-CH=CH-,
 cyclohexyl, cyclopentyl, cyclohexylmethyl,
 -CH₂CH₂CO₂Et, -(CH₂)₃CO₂Et, -(CH₂)₄CO₂Et,
 30 benzyl, 2-F-benzyl, 3-F-benzyl, 4-F-benzyl,
 3-MeO-benzyl, 3-OH-benzyl, 2-MeO-benzyl,
 2-OH-benzyl, 2-CO₂Me-3-MeO-phenyl,
 2-Me-4-CN-phenyl, 2-Me-3-CN-phenyl, 2-CF₃-4-CN-phenyl,
 3-CHO-phenyl, 3-CH₂(OH)-phenyl, 3-CH₂(OMe)-phenyl,


3-CH₂(NMe₂)-phenyl, 3-CN-4-F-phenyl,
 3-CONH₂-4-F-phenyl, 2-CH₂(NH₂)-4-MeO-phenyl-,
 phenyl-NH-, (4-F-phenyl)-NH-, (2,4-diCl-phenyl)-NH-,
 phenyl-C(=O)NH-, benzyl-NH-, (2-Me-4-MeO-phenyl)-NH-,
 5 (2-F-4-MeO-phenyl)-NH-, (2-Me-4-F-phenyl)-NH-,
 phenyl-S-, -NMe₂, 1-pyrrolidinyl, and
 -N(tosylate)₂,

provided that two of R⁷, R⁸, and R⁹, are independently
 10 selected from hydrogen, fluoro, chloro, bromo, cyano,
 methyl, ethyl, propyl, isopropyl, butyl, t-butyl, nitro,
 trifluoromethyl, methoxy, ethoxy, isopropoxy, and
 trifluoromethoxy;

15 m is 1; and

n is 0, 1 or 2.

[9] In another even more preferred embodiment of the
 20 present invention, the compound of Formula (I) is selected
 from Formula (V):



(V)

25 wherein:

b is a single bond, wherein the bridge hydrogens are in a
 cis position;

30 R¹ is selected from
 hydrogen, methyl, ethyl, n-propyl, n-butyl, s-butyl,

t-butyl, n-pentyl, n-hexyl, 2-propyl, 2-butyl, 2-pentyl,
2-hexyl, 2-methylpropyl, 2-methylbutyl, 2-methylpentyl,
2-ethylbutyl, 3-methylpentyl, 3-methylbutyl,
4-methylpentyl, 2-fluoroethyl, 2,2-difluoroethyl,
5 2,2,2-trifluoroethyl, 2-propenyl, 2-methyl-2-propenyl,
trans-2-butenyl, 3-methyl-butenyl, 3-butenyl,
trans-2-pentenyl, cis-2-pentenyl, 4-pentenyl,
4-methyl-3-pentenyl, 3,3-dichloro-2-propenyl,
trans-3-phenyl-2-propenyl, cyclopropyl, cyclobutyl,
10 cyclopentyl, cyclohexyl, cyclopropylmethyl,
cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl,
-CH=CH₂, -CH₂-CH=CH₂, -CH=CH-CH₃, -C≡CH, -C≡C-CH₃,
and -CH₂-C≡CH;

15 R⁷ and R⁹, at each occurrence, are independently selected
from hydrogen, fluoro, methyl, trifluoromethyl, and
methoxy;

R⁸ is selected from

20 hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl,
propyl, isopropyl, butyl, t-butyl, nitro,
trifluoromethyl, methoxy, ethoxy, isopropoxy,
trifluoromethoxy, phenyl,

25 methylC(=O)-, ethylC(=O)-, propylC(=O)-, isopropylC(=O)-,
butylC(=O)-, phenylC(=O)-,

methylCO₂-, ethylCO₂-, propylCO₂-, isopropylCO₂-,
butylCO₂-, phenylCO₂-,

30

dimethylamino-S(=O)-, diethylamino-S(=O)-,
dipropylamino-S(=O)-, di-isopropylamino-S(=O)-,
dibutylamino-S(=O)-, diphenylamino-S(=O)-,

- dimethylamino-SO₂-, diethylamino-SO₂-, dipropylamino-SO₂-
, di-isopropylamino-SO₂-, dibutylamino-SO₂-,
diphenylamino-SO₂-,
- 5 dimethylamino-C(=O)-, diethylamino-C(=O)-,
dipropylamino-C(=O)-, di-isopropylamino-C(=O)-,
dibutylamino-C(=O)-, diphenylamino-C(=O)-,
- 10 2-chlorophenyl, 2-fluorophenyl, 2-bromophenyl, 2-
cyanophenyl, 2-methylphenyl, 2-trifluoromethylphenyl,
2-methoxyphenyl, 2-trifluoromethoxyphenyl,
- 15 3-chlorophenyl, 3-fluorophenyl, 3-bromophenyl,
3-cyanophenyl, 3-methylphenyl, 3-ethylphenyl,
3-propylphenyl, 3-isopropylphenyl, 3-butylphenyl,
3-trifluoromethylphenyl, 3-methoxyphenyl,
3-isopropoxyphenyl, 3-trifluoromethoxyphenyl,
3-thiomethoxyphenyl,
- 20 4-chlorophenyl, 4-fluorophenyl, 4-bromophenyl,
4-cyanophenyl, 4-methylphenyl, 4-ethylphenyl,
4-propylphenyl, 4-isopropylphenyl, 4-butylphenyl,
4-trifluoromethylphenyl, 4-methoxyphenyl,
4-isopropoxyphenyl, 4-trifluoromethoxyphenyl,
- 25 4-thiomethoxyphenyl,
- 2,3-dichlorophenyl, 2,3-difluorophenyl, 2,3-
dimethylphenyl,
2,3-ditrifluoromethylphenyl, 2,3-dimethoxyphenyl,
- 30 2,3-ditrifluoromethoxyphenyl,
- 2,4-dichlorophenyl, 2,4-difluorophenyl, 2,4-
dimethylphenyl,
2,4-ditrifluoromethylphenyl, 2,4-dimethoxyphenyl,
- 35 2,4-ditrifluoromethoxyphenyl,

2,5-dichlorophenyl, 2,5-difluorophenyl, 2,5-dimethylphenyl,
2,5-ditrifluoromethylphenyl, 2,5-dimethoxyphenyl,
5 2,5-ditrifluoromethoxyphenyl,

2,6-dichlorophenyl, 2,6-difluorophenyl, 2,6-dimethylphenyl,
2,6-ditrifluoromethylphenyl, 2,6-dimethoxyphenyl,
10 2,6-ditrifluoromethoxyphenyl,

3,4-dichlorophenyl, 3,4-difluorophenyl, 3,4-dimethylphenyl,
3,4-ditrifluoromethylphenyl, 3,4-dimethoxyphenyl,
15 3,4-ditrifluoromethoxyphenyl,

2,4,6-trichlorophenyl, 2,4,6-trifluorophenyl,
2,4,6-trimethylphenyl, 2,4,6-tritrifluoromethylphenyl,
2,4,6-trimethoxyphenyl, 2,4,6-tritrifluoromethoxyphenyl,
20
2-chloro-4-CF₃-phenyl, 2-fluoro-3-chloro-phenyl,
2-chloro-4-CF₃-phenyl, 2-chloro-4-methoxy-phenyl,
2-methoxy-4-isopropyl-phenyl, 2-CF₃-4-methoxy-phenyl,
2-methyl-4-methoxy-5-fluoro-phenyl,
25 2-methyl-4-methoxy-phenyl, 2-chloro-4-CF₃O-phenyl,
2,4,5-trimethyl-phenyl, 2-methyl-4-chloro-phenyl,

methyl-C(=O)NH-, ethyl-C(=O)NH-, propyl-C(=O)NH-,
isopropyl-C(=O)NH-, butyl-C(=O)NH-, phenyl-C(=O)NH-,
30
4-acetylphenyl, 3-acetamidophenyl, 4-pyridyl, 2-furanyl,
2-thiophenyl, 2-naphthyl;

2-Me-5-F-phenyl, 2-F-5-Me-phenyl, 2-MeO-5-F-phenyl,
35 2-Me-3-Cl-phenyl, 3-NO₂-phenyl, 2-NO₂-phenyl,

- 2-Cl-3-Me-phenyl, 2-Me-4-EtO-phenyl, 2-Me-4-F-phenyl,
 2-Cl-6-F-phenyl, 2-Cl-4-(CHF₂)O-phenyl,
 2,4-diMeO-6-F-phenyl, 2-CF₃-6-F-phenyl,
 2-MeS-phenyl, 2,6-diCl-4-MeO-phenyl,
 5 2,3,4-triF-phenyl, 2,6-diF-4-Cl-phenyl,
 2,3,4,6-tetraF-phenyl, 2,3,4,5,6-pentaF-phenyl,
 2-CF₃-4-EtO-phenyl, 2-CF₃-4-iPrO-phenyl,
 2-CF₃-4-Cl-phenyl, 2-CF₃-4-F-phenyl, 2-Cl-4-EtO-phenyl,
 2-Cl-4-iPrO-phenyl, 2-Et-4-MeO-phenyl,
 10 2-CHO-4-MeO-phenyl, 2-CH(OH)Me-4-MeO-phenyl,
 2-CH(OMe)Me-4-MeO-phenyl, 2-C(=O)Me-4-MeO-phenyl,
 2-CH₂(OH)-4-MeO-phenyl, 2-CH₂(OMe)-4-MeO-phenyl,
 2-CH(OH)Et-4-MeO-phenyl, 2-C(=O)Et-4-MeO-phenyl,
 (Z)-2-CH=CHCO₂Me-4-MeO-phenyl,
 15 2-CH₂CH₂CO₂Me-4-MeO-phenyl,
 (Z)-2-CH=CHCH₂(OH)-4-MeO-phenyl,
 (E)-2-CH=CHCO₂Me-4-MeO-phenyl,
 (E)-2-CH=CHCH₂(OH)-4-MeO-phenyl,
 2-CH₂CH₂OMe-4-MeO-phenyl,
 20 2-F-4-MeO-phenyl, 2-Cl-4-F-phenyl,
 (2-Cl-phenyl)-CH=CH-, (3-Cl-phenyl)-CH=CH-,
 (2,6-diF-phenyl)-CH=CH-, -CH₂CH=CH₂,
 phenyl-CH=CH-, (2-Me-4-MeO-phenyl)-CH=CH-,
 cyclohexyl, cyclopentyl, cyclohexylmethyl,
 25 -CH₂CH₂CO₂Et, -(CH₂)₃CO₂Et, -(CH₂)₄CO₂Et,
 benzyl, 2-F-benzyl, 3-F-benzyl, 4-F-benzyl,
 3-MeO-benzyl, 3-OH-benzyl, 2-MeO-benzyl,
 2-OH-benzyl, 2-CO₂Me-3-MeO-phenyl,
 2-Me-4-CN-phenyl, 2-Me-3-CN-phenyl, 2-CF₃-4-CN-phenyl,
 30 3-CHO-phenyl, 3-CH₂(OH)-phenyl, 3-CH₂(OMe)-phenyl,
 3-CH₂(NMe₂)-phenyl, 3-CN-4-F-phenyl,
 3-CONH₂-4-F-phenyl, 2-CH₂(NH₂)-4-MeO-phenyl-,
 phenyl-NH-, (4-F-phenyl)-NH-, (2,4-diCl-phenyl)-NH-,
 phenyl-C(=O)NH-, benzyl-NH-, (2-Me-4-MeO-phenyl)-NH-,

(2-F-4-MeO-phenyl)-NH-, (2-Me-4-F-phenyl)-NH-,
phenyl-S-, -NMe₂, 1-pyrrolidinyl, and
-N(tosylate)₂; and

5 n is 0, 1 or 2.

[10] In another preferred embodiment of the present
invention,

10 X is -CHR¹⁰- or -C(=O)-;

R¹ is selected from

- C₁₋₆ alkyl substituted with Z,
- C₂₋₆ alkenyl substituted with Z,
- 15 C₂₋₆ alkynyl substituted with Z,
- C₃₋₆ cycloalkyl substituted with Z,
- aryl substituted with Z,
- 5-6 membered heterocyclic ring system containing at
least one heteroatom selected from the group
consisting of N, O, and S, said heterocyclic ring
20 system substituted with Z;
- C₁₋₆ alkyl substituted with 0-2 R²,
- C₂₋₆ alkenyl substituted with 0-2 R²,
- C₂₋₆ alkynyl substituted with 0-2 R²,
- 25 aryl substituted with 0-2 R², and
- 5-6 membered heterocyclic ring system containing at
least one heteroatom selected from the group
consisting of N, O, and S, said heterocyclic ring
system substituted with 0-2 R²;

30

Z is selected from H,

- CH(OH)R²,
- C(ethylenedioxy)R²,
- OR²,

-SR²,
-NR²R³,
-C(O)R²,
-C(O)NR²R³,
5 -NR³C(O)R²,
-C(O)OR²,
-OC(O)R²,
-CH(=NR⁴)NR²R³,
-NHC(=NR⁴)NR²R³,
10 -S(O)R²,
-S(O)₂R²,
-S(O)₂NR²R³, and -NR³S(O)₂R²;

R², at each occurrence, is independently selected from
15 C₁₋₄ alkyl,
C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
aryl substituted with 0-5 R⁴²;
20 C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;

25 R³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and
C₁₋₄ alkoxy;

30 alternatively, R² and R³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R⁴)-;

R⁴, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

R⁵ is H, methyl, ethyl, propyl, or butyl;

R^{6a} is selected from

- 5 H, -OH, -NR⁴⁶R⁴⁷, -CF₃,
 C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₄
 haloalkyl, C₃₋₆ cycloalkyl, and
 aryl substituted with 0-3 R⁴⁴;

- 10 R^{6b} is H;

R⁷, R⁸, and R⁹, at each occurrence, are independently
selected from

- H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷,
15 C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
 C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy,
 C₁₋₄ alkyl substituted with 0-2 R¹¹,
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
 aryl substituted with 0-5 R³³,
20 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 R³¹;

- 25 OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
 NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
 CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
 S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,
 NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and
30 NR¹²C(O)NHR¹⁵;

R¹⁰ is selected from H, -OH,

 C₁₋₆ alkyl substituted with 0-1 R^{10B},

C₂₋₆ alkenyl substituted with 0-1 R^{10B},
C₂₋₆ alkynyl substituted with 0-1 R^{10B}, and
C₁₋₆ alkoxy;

- 5 R^{10B} is selected from
C₁₋₄ alkoxy,
C₃₋₆ cycloalkyl,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
phenyl substituted with 0-3 R³³, and
10 5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-2
R⁴⁴;
- 15 R¹¹ is selected from
H, halo, -CF₃, -CN, -NO₂,
C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
C₁₋₈ alkoxy, C₃₋₁₀ cycloalkyl,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
20 aryl substituted with 0-5 R³³,
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;
- 25
OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹²,
S(O)₂R¹², S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹²,
30 and NR¹⁴S(O)₂R¹²;

R¹², at each occurrence, is independently selected from
C₁₋₄ alkyl,

- C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
phenyl substituted with 0-5 R³³;
5 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;
- 10 R¹³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;
- alternatively, R¹² and R¹³ join to form a 5- or 6-membered
15 ring optionally substituted with -O- or -N(R¹⁴)-;
- R¹⁴, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;
- 20 R³¹, at each occurrence, is independently selected from
H, OH, halo, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, methyl, ethyl, and
propyl;
- R³³, at each occurrence, is independently selected from
25 H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷,
C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, C₃₋₅ cycloalkyl,
C₁₋₃ haloalkyl, C₁₋₃ haloalkyl-oxy-, C₁₋₃ alkyloxy-
, C₁₋₃ alkylthio-, C₁₋₃ alkyl-C(=O)-, and C₁₋₃
alkyl-C(=O)NH-;
- 30 R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, =O,
C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl
C₁₋₄ alkyl substituted with 0-1 R⁴³,

aryl substituted with 0-3 R⁴², and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
5 R⁴⁴;

R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, SR⁴⁵, NR⁴⁶R⁴⁷, OR⁴⁸,
NO₂, CN, CH(=NH)NH₂, NHC(=NH)NH₂,
10 C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
C₃₋₆ cycloalkyl,
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴⁴, and
5-10 membered heterocyclic ring system containing from
15 1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;

R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;
20

R⁴⁴, at each occurrence, is independently selected from H,
halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂,
C₁₋₄ alkyl, and C₁₋₄ alkoxy;

25 R⁴⁵ is C₁₋₄ alkyl;

R⁴⁶, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

30 R⁴⁷, at each occurrence, is independently selected from H,
C₁₋₄ alkyl, -C(=O)NH(C₁₋₄ alkyl), -SO₂(C₁₋₄ alkyl),
-SO₂(phenyl), -C(=O)O(C₁₋₄ alkyl), -C(=O)(C₁₋₄ alkyl),
and -C(=O)H;

R⁴⁸, at each occurrence, is independently selected from H,
C₁₋₄ alkyl, -C(=O)NH(C₁₋₄ alkyl), -C(=O)O(C₁₋₄ alkyl),
-C(=O)(C₁₋₄ alkyl), and -C(=O)H;

5 k is 1 or 2;

m is 0, 1, or 2; and

n is 0, 1 or 2.

10

[11] In a further preferred embodiment of the present invention,

X is -CHR¹⁰- or -C(=O)-;

15

R¹ is selected from

C₂₋₅ alkyl substituted with Z,

C₂₋₅ alkenyl substituted with Z,

C₂₋₅ alkynyl substituted with Z,

20

C₃₋₆ cycloalkyl substituted with Z,

aryl substituted with Z,

5-6 membered heterocyclic ring system containing at
least one heteroatom selected from the group
consisting of N, O, and S, said heterocyclic ring
system substituted with Z;

25

C₁₋₅ alkyl substituted with 0-2 R²,

C₂₋₅ alkenyl substituted with 0-2 R², and

C₂₋₅ alkynyl substituted with 0-2 R²;

30 Z is selected from H,

-CH(OH)R²,

-C(ethylenedioxy)R²,

-OR²,

-SR²,

- NR²R³,
-C(O)R²,
-C(O)NR²R³,
-NR³C(O)R²,
5 -C(O)OR²,
-OC(O)R²,
-CH(=NR⁴)NR²R³,
-NHC(=NR⁴)NR²R³,
-S(O)R²,
10 -S(O)₂R²,
-S(O)₂NR²R³, and -NR³S(O)₂R²;

- R², at each occurrence, is independently selected from
C₁₋₄ alkyl,
15 C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
aryl substituted with 0-5 R⁴²;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
20 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;

- 25 R³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and
C₁₋₄ alkoxy;

- alternatively, R² and R³ join to form a 5- or 6-membered
30 ring optionally substituted with -O- or -N(R⁴)-;

R⁴, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

R⁵ is H, methyl, or ethyl;

R^{6a} is selected from

- H, -OH, -NR⁴⁶R⁴⁷, -CF₃,
5 C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₄
haloalkyl, and C₃₋₆ cycloalkyl;

R^{6b} is H;

- 10 R⁷, R⁸, and R⁹, at each occurrence, are independently
selected from
H, halo, -CF₃, -OCF₃, -OH, -OCH₃, -CN, -NO₂, -NR⁴⁶R⁴⁷,
C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl,
C₁₋₆ alkoxy, (C₁₋₄ haloalkyl)oxy,
15 C₁₋₄ alkyl substituted with 0-2 R¹¹,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
20 consisting of N, O, and S substituted with 0-3
R³¹;

- OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², CH(=NR¹⁴)NR¹²R¹³,
25 NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹², S(O)₂NR¹²R¹³,
NR¹⁴S(O)₂R¹², NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹², NR¹²C(O)R¹⁵,
NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and NR¹²C(O)NHR¹⁵;

- R¹⁰ is selected from H, -OH, C₁₋₆ alkyl, C₁₋₄ alkoxy, and
30 C₁₋₂ alkyl substituted with 0-1 R^{10B};

R^{10B} is C₃₋₆ cycloalkyl or

phenyl substituted with 0-3 R³³;

R¹¹ is selected from

H, halo, -CF₃, -OCF₃, -OH, -OCH₃, -CN, -NO₂, -NR⁴⁶R⁴⁷,
C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl,
5 C₁₋₆ alkoxy, (C₁₋₄ haloalkyl)oxy,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
10 consisting of N, O, and S substituted with 0-3
R³¹;

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², CH(=NR¹⁴)NR¹²R¹³,
15 NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹², S(O)₂NR¹²R¹³,
and NR¹⁴S(O)₂R¹²;

R¹², at each occurrence, is independently selected from
C₁₋₄ alkyl,
20 C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
phenyl substituted with 0-5 R³³;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
25 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

30 R¹³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

alternatively, R¹² and R¹³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R¹⁴)-;

R¹⁴, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

5 R³¹, at each occurrence, is independently selected from H, OH, halo, CF₃, methyl, and ethyl;

R³³, at each occurrence, is independently selected from H, OH, halo, CN, NO₂, CF₃, methyl, and ethyl;

10

R⁴¹, at each occurrence, is independently selected from H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, =O, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ alkyl substituted with 0-1 R⁴³,
15 aryl substituted with 0-3 R⁴², and 5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R⁴⁴;

20

R⁴², at each occurrence, is independently selected from H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, SR⁴⁵, NR⁴⁶R⁴⁷, OR⁴⁸, NO₂, CN, CH(=NH)NH₂, NHC(=NH)NH₂, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl,
25 C₁₋₄ alkyl substituted with 0-1 R⁴³, aryl substituted with 0-3 R⁴⁴, and 5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group
30 consisting of N, O, and S substituted with 0-3 R⁴⁴;

R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;

R⁴⁴, at each occurrence, is independently selected from H, halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂, C₁₋₄ alkyl, and C₁₋₄ alkoxy;

5 R⁴⁵ is C₁₋₄ alkyl;

R⁴⁶, at each occurrence, is independently selected from H and C₁₋₃ alkyl;

10 R⁴⁷, at each occurrence, is independently selected from H, C₁₋₄ alkyl, -C(=O)NH(C₁₋₄ alkyl), -SO₂(C₁₋₄ alkyl), -SO₂(phenyl), -C(=O)O(C₁₋₄ alkyl), -C(=O)(C₁₋₄ alkyl), and -C(=O)H;

15 R⁴⁸, at each occurrence, is independently selected from H, C₁₋₄ alkyl, -C(=O)NH(C₁₋₄ alkyl), -C(=O)O(C₁₋₄ alkyl), -C(=O)(C₁₋₄ alkyl), and -C(=O)H;

k is 1 or 2;

20

m is 0, 1, 2; and

n is 0, 1 or 2.

25 [12] In a more preferred embodiment of the present invention,

X is -CH₂-;

30 R¹ is selected from

C₂₋₄ alkyl substituted with Z,
C₂₋₄ alkenyl substituted with Z,
C₂₋₄ alkynyl substituted with Z,
C₃₋₆ cycloalkyl substituted with Z,

aryl substituted with Z,
5-6 membered heterocyclic ring system containing at
least one heteroatom selected from the group
consisting of N, O, and S, said heterocyclic ring
5 system substituted with Z;
C₂₋₄ alkyl substituted with 0-2 R², and
C₂₋₄ alkenyl substituted with 0-2 R²;

Z is selected from H,
10 -CH(OH)R²,
-C(ethylenedioxy)R²,
-OR²,
-SR²,
-NR²R³,
15 -C(O)R²,
-C(O)NR²R³,
-NR³C(O)R²,
-C(O)OR²,
-S(O)R²,
20 -S(O)₂R²,
-S(O)₂NR²R³, and -NR³S(O)₂R²;

R², at each occurrence, is independently selected from
phenyl substituted with 0-5 R⁴²;
25 C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;

30 R³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and
C₁₋₄ alkoxy;

alternatively, R² and R³ join to form a 5- or 6-membered ring optionally substituted with -O- or -N(R⁴)-;

5 R⁴, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;

R⁵ is H;

10 R^{6a} is selected from H, -OH, -CF₃, methyl, ethyl, propyl, butyl, methoxy, and, ethoxy;

R^{6b} is H;

15 R⁷, R⁸, and R⁹, at each occurrence, are independently selected from
H, halo, -CF₃, -OCF₃, -OH, -OCH₃, -CN, -NO₂,
C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, (C₁₋₃
haloalkyl)oxy, and
C₁₋₄ alkyl substituted with 0-2 R¹¹;

20

R¹¹ is selected from
H, halo, -CF₃, -OCF₃, -OH, -OCH₃, -CN, -NO₂,
C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, and (C₁₋₃
haloalkyl)oxy;

25

R³³, at each occurrence, is independently selected from
H, OH, halo, CF₃, and methyl;

30 R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, =O,
C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴², and

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;

5

R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, SR⁴⁵, NR⁴⁶R⁴⁷, OR⁴⁸,
NO₂, CN, CH(=NH)NH₂, NHC(=NH)NH₂,

10

C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
C₃₋₆ cycloalkyl,

C₁₋₄ alkyl substituted with 0-1 R⁴³,

aryl substituted with 0-3 R⁴⁴, and

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;

15

R⁴³ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
phenyl, or pyridyl, each substituted with 0-3 R⁴⁴;

20

R⁴⁴, at each occurrence, is independently selected from H,
halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂,
methyl, ethyl, propyl, butyl, methoxy, ethoxy,
propoxy, and butoxy;

25

R⁴⁵ is methyl, ethyl, propyl, or butyl;

R⁴⁶, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

30

R⁴⁷, at each occurrence, is independently selected from
H, methyl, ethyl, n-propyl, i-propyl, n-butyl,
i-butyl, -C(=O)NH(methyl), -C(=O)NH(ethyl),
-SO₂(methyl), -SO₂(ethyl), -SO₂(phenyl),

-C(=O)O(methyl), -C(=O)O(ethyl), -C(=O)(methyl),
-C(=O)(ethyl), and -C(=O)H;

5 R⁴⁸, at each occurrence, is independently selected from
H, methyl, ethyl, n-propyl, i-propyl, -
C(=O)NH(methyl), -C(=O)NH(ethyl), -C(=O)O(methyl), -
C(=O)O(ethyl), -C(=O)(methyl), -C(=O)(ethyl), and -
C(=O)H;

10 k is 1;

m is 0, 1, or 2; and

n is 0, 1 or 2.

15

[13] In another more preferred embodiment of the present
invention,

X is -CH₂-;

20

R¹ is selected from

ethyl substituted with Z,
propyl substituted with Z,
butyl substituted with Z,
25 propenyl substituted with Z,
butenyl substituted with Z,
ethyl substituted with R²,
propyl substituted with R²,
butyl substituted with R²,
30 propenyl substituted with R², and
butenyl substituted with R²;

Z is selected from H,

-CH(OH)R²,
35 -OR²,

-SR²,
-NR²R³,
-C(O)R²,
-C(O)NR²R³,
5 -NR³C(O)R²,
-C(O)OR²,
-S(O)R²,
-S(O)₂R²,
-S(O)₂NR²R³, and -NR³S(O)₂R²;

10

R², at each occurrence, is independently selected from
phenyl substituted with 0-3 R⁴²;
naphthyl substituted with 0-3 R⁴²;
cyclopropyl substituted with 0-3 R⁴¹;
15 cyclobutyl substituted with 0-3 R⁴¹;
cyclopentyl substituted with 0-3 R⁴¹;
cyclohexyl substituted with 0-3 R⁴¹;
pyridyl substituted with 0-3 R⁴¹;
indolyl substituted with 0-3 R⁴¹;
20 indolinyl substituted with 0-3 R⁴¹;
benzimidazolyl substituted with 0-3 R⁴¹;
benzotriazolyl substituted with 0-3 R⁴¹;
benzothienyl substituted with 0-3 R⁴¹;
benzofuranyl substituted with 0-3 R⁴¹;
25 phthalimid-1-yl substituted with 0-3 R⁴¹;
inden-2-yl substituted with 0-3 R⁴¹;
2,3-dihydro-1H-inden-2-yl substituted with 0-3 R⁴¹;
indazolyl substituted with 0-3 R⁴¹;
tetrahydroquinolinyl substituted with 0-3 R⁴¹; and
30 tetrahydro-isoquinolinyl substituted with 0-3 R⁴¹;

R³, at each occurrence, is independently selected from

H, methyl, and ethyl;

R⁵ is H;

5 R^{6a} is selected from H, -OH, methyl, and methoxy;

R^{6b} is H;

10 R⁷, R⁸, and R⁹, at each occurrence, are independently
selected from H, F, Cl, methyl, ethyl, methoxy, -CF₃,
and -OCF₃;

15 R⁴¹, at each occurrence, is independently selected from
H, F, Cl, Br, OH, CF₃, NO₂, CN, =O, methyl, ethyl,
propyl, butyl, methoxy, and ethoxy;

20 R⁴², at each occurrence, is independently selected from
H, F, Cl, Br, OH, CF₃, SO₂R⁴⁵, SR⁴⁵, NR⁴⁶R⁴⁷, OR⁴⁸, NO₂,
CN, =O, methyl, ethyl, propyl, butyl, methoxy, and
ethoxy;

R⁴⁵ is methyl, ethyl, propyl, or butyl;

25 R⁴⁶, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

30 R⁴⁷, at each occurrence, is independently selected from
H, methyl, ethyl, n-propyl, i-propyl, n-butyl,
i-butyl, -C(=O)NH(methyl), -C(=O)NH(ethyl),
-SO₂(methyl), -SO₂(ethyl), -SO₂(phenyl),
-C(=O)O(methyl), -C(=O)O(ethyl), -C(=O)(methyl),
-C(=O)(ethyl), and -C(=O)H;

R⁴⁸, at each occurrence, is independently selected from

H, methyl, ethyl, n-propyl, i-propyl, -
 C(=O)NH(methyl), -C(=O)NH(ethyl), -C(=O)O(methyl), -
 C(=O)O(ethyl), -C(=O)(methyl), -C(=O)(ethyl), and -
 C(=O)H;

5


k is 1;

m is 0, 1, or 2; and

10 n is 0, 1 or 2.

[14] In an even more preferred embodiment of the
 present invention, the compound of Formula (I) is selected
 from Formula (I-a):

15



20 wherein:

b is a single bond or a double bond;

X is -CH₂-, CH(OH)-, or -C(=O)-

25

R¹ is selected from




- (CH₂)₃C(=O) (4-fluoro-phenyl),
- (CH₂)₃C(=O) (4-bromo-phenyl),
- (CH₂)₃C(=O) (4-methyl-phenyl),
- 30 - (CH₂)₃C(=O) (4-methoxy-phenyl),
- (CH₂)₃C(=O) (4-(3,4-dichloro-phenyl)phenyl),
- (CH₂)₃C(=O) (3-methyl-4-fluoro-phenyl),

- (CH₂)₃C(=O) (2,3-dimethoxy-phenyl),
- (CH₂)₃C(=O) (phenyl),
- (CH₂)₃C(=O) (4-chloro-phenyl),
- (CH₂)₃C(=O) (3-methyl-phenyl),
- 5 - (CH₂)₃C(=O) (4-t-butyl-phenyl),
- (CH₂)₃C(=O) (3,4-difluoro-phenyl),
- (CH₂)₃C(=O) (2-methoxy-5-fluoro-phenyl),
- (CH₂)₃C(=O) (4-fluoro-1-naphthyl),
- (CH₂)₃C(=O) (benzyl),
- 10 - (CH₂)₃C(=O) (4-pyridyl),
- (CH₂)₃C(=O) (3-pyridyl),
- (CH₂)₃CH(OH) (4-fluoro-phenyl),
- (CH₂)₃CH(OH) (4-pyridyl),
- (CH₂)₃CH(OH) (2,3-dimethoxy-phenyl),
- 15 - (CH₂)₃S(3-fluoro-phenyl),
- (CH₂)₃S(4-fluoro-phenyl),
- (CH₂)₃S(=O) (4-fluoro-phenyl),
- (CH₂)₃SO₂ (3-fluoro-phenyl),
- (CH₂)₃SO₂ (4-fluoro-phenyl),
- 20 - (CH₂)₃O(4-fluoro-phenyl),
- (CH₂)₃O(phenyl),
- (CH₂)₃O(3-pyridyl),
- (CH₂)₃O(4-pyridyl),
- (CH₂)₃O(2-NH₂-phenyl),
- 25 - (CH₂)₃O(2-NH₂-5-F-phenyl),
- (CH₂)₃O(2-NH₂-4-F-phenyl),
- (CH₂)₃O(2-NH₂-3-F-phenyl),
- (CH₂)₃O(2-NH₂-4-Cl-phenyl),
- (CH₂)₃O(2-NH₂-4-OH-phenyl),
- 30 - (CH₂)₃O(2-NH₂-4-Br-phenyl),
- (CH₂)₃O(2-NHC(=O)Me-4-F-phenyl),
- (CH₂)₃O(2-NHC(=O)Me-phenyl),
- (CH₂)₃NH(4-fluoro-phenyl),

- (CH₂)₃N(methyl)(4-fluoro-phenyl),
- (CH₂)₃CO₂(ethyl),
- (CH₂)₃C(=O)N(methyl)(methoxy),
- (CH₂)₃C(=O)NH(4-fluoro-phenyl),
- 5 - (CH₂)₂NHC(=O)(phenyl),
- (CH₂)₂NMeC(=O)(phenyl),
- (CH₂)₂NHC(=O)(2-fluoro-phenyl),
- (CH₂)₂NMeC(=O)(2-fluoro-phenyl),
- (CH₂)₂NHC(=O)(4-fluoro-phenyl),
- 10 - (CH₂)₂NMeC(=O)(4-fluoro-phenyl),
- (CH₂)₂NHC(=O)(2,4-difluoro-phenyl),
- (CH₂)₂NMeC(=O)(2,4-difluoro-phenyl),
- (CH₂)₃(3-indolyl),
- (CH₂)₃(1-methyl-3-indolyl),
- 15 - (CH₂)₃(1-indolyl),
- (CH₂)₃(1-indolinyl),
- (CH₂)₃(1-benzimidazolyl),
- (CH₂)₃(1H-1,2,3-benzotriazol-1-yl),
- (CH₂)₃(1H-1,2,3-benzotriazol-2-yl),
- 20 - (CH₂)₂(1H-1,2,3-benzotriazol-1-yl),
- (CH₂)₂(1H-1,2,3-benzotriazol-2-yl),
- (CH₂)₃(3,4 dihydro-1(2H)-quinolinyl),
- (CH₂)₂C(=O)(4-fluoro-phenyl),
- (CH₂)₂C(=O)NH(4-fluoro-phenyl),
- 25 -CH₂CH₂(3-indolyl),
- CH₂CH₂(1-phthalimidyl),
- (CH₂)₄C(=O)N(methyl)(methoxy),
- (CH₂)₄CO₂(ethyl),
- (CH₂)₄C(=O)(phenyl),
- 30 - (CH₂)₄(cyclohexyl),
- (CH₂)₃CH(phenyl)₂,
- CH₂CH₂CH=C(phenyl)₂,
- CH₂CH₂CH=CMe(4-F-phenyl),

- (CH₂)₃CH(4-fluoro-phenyl)₂,
- CH₂CH₂CH=C(4-fluoro-phenyl)₂,
- (CH₂)₂(2,3-dihydro-1H-inden-2-yl),
- (CH₂)₃C(=O)(2-NH₂-phenyl),
- 5 - (CH₂)₃C(=O)(2-NH₂-5-F-phenyl),
- (CH₂)₃C(=O)(2-NH₂-4-F-phenyl),
- (CH₂)₃C(=O)(2-NH₂-3-F-phenyl),
- (CH₂)₃C(=O)(2-NH₂-4-Cl-phenyl),
- (CH₂)₃C(=O)(2-NH₂-4-OH-phenyl),
- 10 - (CH₂)₃C(=O)(2-NH₂-4-Br-phenyl),
- (CH₂)₃(1H-indazol-3-yl),
- (CH₂)₃(5-F-1H-indazol-3-yl),
- (CH₂)₃(7-F-1H-indazol-3-yl),
- (CH₂)₃(6-Cl-1H-indazol-3-yl),
- 15 - (CH₂)₃(6-Br-1H-indazol-3-yl),
- (CH₂)₃C(=O)(2-NHMe-phenyl),
- (CH₂)₃(1-benzothien-3-yl),
- (CH₂)₃(6-F-1H-indol-1-yl),
- (CH₂)₃(5-F-1H-indol-1-yl),
- 20 - (CH₂)₃(6-F-2,3-dihydro-1H-indol-1-yl),
- (CH₂)₃(5-F-2,3-dihydro-1H-indol-1-yl),
- (CH₂)₃(6-F-1H-indol-3-yl),
- (CH₂)₃(5-F-1H-indol-3-yl),
- (CH₂)₃(5-F-1H-indol-3-yl),
- 25 - (CH₂)₃(9H-purin-9-yl),
- (CH₂)₃(7H-purin-7-yl),
- (CH₂)₃(6-F-1H-indazol-3-yl),
- (CH₂)₃C(=O)(2-NHSO₂Me-4-F-phenyl),
- (CH₂)₃C(=O)(2-NHC(=O)Me-4-F-phenyl),
- 30 - (CH₂)₃C(=O)(2-NHC(=O)Me-phenyl),
- (CH₂)₃C(=O)(2-NHCO₂Et-4-F-phenyl),
- (CH₂)₃C(=O)(2-NHC(=O)NH₂-4-F-phenyl),
- (CH₂)₃C(=O)(2-NHCHO-4-F-phenyl),

- (CH₂)₃C(=O) (2-OH-4-F-phenyl) ,
 - (CH₂)₃C(=O) (2-MeS-4-F-phenyl) ,
 - (CH₂)₃C(=O) (2-NHSO₂Me-4-F-phenyl) ,
 - (CH₂)₂C(Me)CO₂Me ,
 5 - (CH₂)₂C(Me)CH(OH) (4-F-phenyl)₂ ,
 - (CH₂)₂C(Me)CH(OH) (4-Cl-phenyl)₂ ,
 - (CH₂)₂C(Me)C(=O) (4-F-phenyl) ,
 - (CH₂)₂C(Me)C(=O) (2-MeO-4-F-phenyl) ,
 - (CH₂)₂C(Me)C(=O) (3-Me-4-F-phenyl) ,
 10 - (CH₂)₂C(Me)C(=O) (2-Me-phenyl) ,
 - (CH₂)₂C(Me)C(=O)phenyl ,



- R⁷, R⁸, and R⁹, at each occurrence, are independently
 20 selected from
 hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl,
 propyl, isopropyl, butyl, t-butyl, nitro,
 trifluoromethyl, methoxy, ethoxy, isopropoxy,
 trifluoromethoxy, phenyl, benzyl,

25

HC(=O)-, methylC(=O)-, ethylC(=O)-, propylC(=O)-,
isopropylC(=O)-, n-butylC(=O)-, isobutylC(=O)-,
secbutylC(=O)-, tertbutylC(=O)-, phenylC(=O)-,

5 methylC(=O)NH-, ethylC(=O)NH -, propylC(=O)NH-,
isopropylC(=O)NH-, n-butylC(=O)NH-, isobutylC(=O)NH-,
secbutylC(=O)NH-, tertbutylC(=O)NH-, phenylC(=O)NH-,

methyldamino-, ethyldamino-, propyldamino-, isopropyldamino-,
10 n-butylamino-, isobutylamino-, secbutylamino-,
tertbutylamino-, phenylamino-,

provided that two of substituents R⁷, R⁸, and R⁹, are
independently selected from hydrogen, fluoro, chloro,
15 bromo, cyano, methyl, ethyl, propyl, isopropyl, butyl, t-
butyl, nitro, trifluoromethyl, methoxy, ethoxy,
isopropoxy, and trifluoromethoxy;


k is 1 or 2;

20

m is 1 or 2; and

n is 0, 1 or 2.

25 [15] In another even more preferred embodiment of the
present invention, the compound of Formula (I) is selected
from Formula (V-a):



30

wherein:

b is a single bond, wherein the bridge hydrogens are in a cis position;

5

R¹ is selected from




- (CH₂)₃C(=O) (4-fluoro-phenyl),
- (CH₂)₃C(=O) (4-bromo-phenyl),
- (CH₂)₃C(=O) (4-methyl-phenyl),
- 10 - (CH₂)₃C(=O) (4-methoxy-phenyl),
- (CH₂)₃C(=O) (4-(3,4-dichloro-phenyl)phenyl),
- (CH₂)₃C(=O) (3-methyl-4-fluoro-phenyl),
- (CH₂)₃C(=O) (2,3-dimethoxy-phenyl),
- (CH₂)₃C(=O) (phenyl),
- 15 - (CH₂)₃C(=O) (4-chloro-phenyl),
- (CH₂)₃C(=O) (3-methyl-phenyl),
- (CH₂)₃C(=O) (4-t-butyl-phenyl),
- (CH₂)₃C(=O) (3,4-difluoro-phenyl),
- (CH₂)₃C(=O) (2-methoxy-5-fluoro-phenyl),
- 20 - (CH₂)₃C(=O) (4-fluoro-1-naphthyl),
- (CH₂)₃C(=O) (benzyl),
- (CH₂)₃C(=O) (4-pyridyl),
- (CH₂)₃C(=O) (3-pyridyl),
- (CH₂)₃CH(OH) (4-fluoro-phenyl),
- 25 - (CH₂)₃CH(OH) (4-pyridyl),
- (CH₂)₃CH(OH) (2,3-dimethoxy-phenyl),
- (CH₂)₃S(3-fluoro-phenyl),
- (CH₂)₃S(4-fluoro-phenyl),
- (CH₂)₃S(=O) (4-fluoro-phenyl),
- 30 - (CH₂)₃SO₂ (3-fluoro-phenyl),
- (CH₂)₃SO₂ (4-fluoro-phenyl),
- (CH₂)₃O(4-fluoro-phenyl),
- (CH₂)₃O(phenyl) ,

- (CH₂)₃NH(4-fluoro-phenyl),
- (CH₂)₃N(methyl)(4-fluoro-phenyl),
- (CH₂)₃CO₂(ethyl),
- (CH₂)₃C(=O)N(methyl)(methoxy),
- 5 - (CH₂)₃C(=O)NH(4-fluoro-phenyl),
- (CH₂)₂NHC(=O)(phenyl),
- (CH₂)₂NMeC(=O)(phenyl),
- (CH₂)₂NHC(=O)(2-fluoro-phenyl),
- (CH₂)₂NMeC(=O)(2-fluoro-phenyl),
- 10 - (CH₂)₂NHC(=O)(4-fluoro-phenyl),
- (CH₂)₂NMeC(=O)(4-fluoro-phenyl),
- (CH₂)₂NHC(=O)(2,4-difluoro-phenyl),
- (CH₂)₂NMeC(=O)(2,4-difluoro-phenyl),
- (CH₂)₃(3-indolyl),
- 15 - (CH₂)₃(1-methyl-3-indolyl),
- (CH₂)₃(1-indolyl),
- (CH₂)₃(1-indoliny),
- (CH₂)₃(1-benzimidazolyl),
- (CH₂)₃(1H-1,2,3-benzotriazol-1-yl),
- 20 - (CH₂)₃(1H-1,2,3-benzotriazol-2-yl),
- (CH₂)₂(1H-1,2,3-benzotriazol-1-yl),
- (CH₂)₂(1H-1,2,3-benzotriazol-2-yl),
- (CH₂)₃(3,4 dihydro-1(2H)-quinoliny),
- (CH₂)₂C(=O)(4-fluoro-phenyl),
- 25 - (CH₂)₂C(=O)NH(4-fluoro-phenyl),
- CH₂CH₂(3-indolyl),
- CH₂CH₂(1-phthalimidyl),
- (CH₂)₄C(=O)N(methyl)(methoxy),
- (CH₂)₄CO₂(ethyl),
- 30 - (CH₂)₄C(=O)(phenyl),
- (CH₂)₄(cyclohexyl),
- (CH₂)₃CH(phenyl)₂,
- CH₂CH₂CH=C(phenyl)₂,

- CH₂CH₂CH=CMe(4-F-phenyl),
- (CH₂)₃CH(4-fluoro-phenyl)₂,
- CH₂CH₂CH=C(4-fluoro-phenyl)₂,
- (CH₂)₂(2,3-dihydro-1H-inden-2-yl),
- 5 -(CH₂)₃C(=O)(2-NH₂-phenyl),
- (CH₂)₃C(=O)(2-NH₂-5-F-phenyl),
- (CH₂)₃C(=O)(2-NH₂-4-F-phenyl),
- (CH₂)₃C(=O)(2-NH₂-3-F-phenyl),
- (CH₂)₃C(=O)(2-NH₂-4-Cl-phenyl),
- 10 -(CH₂)₃C(=O)(2-NH₂-4-OH-phenyl),
- (CH₂)₃C(=O)(2-NH₂-4-Br-phenyl),
- (CH₂)₃(1H-indazol-3-yl),
- (CH₂)₃(5-F-1H-indazol-3-yl),
- (CH₂)₃(7-F-1H-indazol-3-yl),
- 15 -(CH₂)₃(6-Cl-1H-indazol-3-yl),
- (CH₂)₃(6-Br-1H-indazol-3-yl),
- (CH₂)₃C(=O)(2-NHMe-phenyl),
- (CH₂)₃(1-benzothien-3-yl),
- (CH₂)₃(6-F-1H-indol-1-yl),
- 20 -(CH₂)₃(5-F-1H-indol-1-yl),
- (CH₂)₃(6-F-2,3-dihydro-1H-indol-1-yl),
- (CH₂)₃(5-F-2,3-dihydro-1H-indol-1-yl),
- (CH₂)₃(6-F-1H-indol-3-yl),
- (CH₂)₃(5-F-1H-indol-3-yl),
- 25 -(CH₂)₃(5-F-1H-indol-3-yl),
- (CH₂)₃(9H-purin-9-yl),
- (CH₂)₃(7H-purin-7-yl),
- (CH₂)₃(6-F-1H-indazol-3-yl),
- (CH₂)₃C(=O)(2-NHSO₂Me-4-F-phenyl),
- 30 -(CH₂)₃C(=O)(2-NHC(=O)Me-4-F-phenyl),
- (CH₂)₃C(=O)(2-NHC(=O)Me-4-F-phenyl),
- (CH₂)₃C(=O)(2-NHCO₂Et-4-F-phenyl),
- (CH₂)₃C(=O)(2-NHC(=O)NH₂Et-4-F-phenyl),

- (CH₂)₃C(=O) (2-NHCHO-4-F-phenyl),
- (CH₂)₃C(=O) (2-OH-4-F-phenyl),
- (CH₂)₃C(=O) (2-MeS-4-F-phenyl),
- (CH₂)₃C(=O) (2-NHSO₂Me-4-F-phenyl),
- 5 - (CH₂)₂C(Me)CO₂Me,
- (CH₂)₂C(Me)CH(OH) (4-F-phenyl)₂,
- (CH₂)₂C(Me)CH(OH) (4-Cl-phenyl)₂,
- (CH₂)₂C(Me)C(=O) (4-F-phenyl),
- (CH₂)₂C(Me)C(=O) (2-MeO-4-F-phenyl),
- 10 - (CH₂)₂C(Me)C(=O) (3-Me-4-F-phenyl),
- (CH₂)₂C(Me)C(=O) (2-Me-phenyl),
- (CH₂)₂C(Me)C(=O)phenyl,

15



- 20 R⁷, R⁸, and R⁹, at each occurrence, are independently selected from hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, nitro, trifluoromethyl, methoxy, ethoxy, isopropoxy, trifluoromethoxy, methylC(=O)-, ethylC(=O)-, propylC(=O)-, isopropylC(=O)-, methylC(=O)NH-, ethylC(=O)NH-, propylC(=O)NH-, isopropylC(=O)NH-,
- 25

methylamino-, ethylamino-, propylamino-, and
isopropylamino-,

provided that two of substituents R⁷, R⁸, and R⁹, are
5 independently selected from hydrogen, fluoro, chloro,
methyl, trifluoromethyl, methoxy, and trifluoromethoxy;

m is 1 or 2; and

10 n is 0, 1 or 2.

In an even further more preferred embodiment of the
present invention, are compounds of Formula (I) selected
from Table 1.

15

In an even further more preferred embodiment of the
present invention, are compounds of Formula (I) selected
from Table 2.

20 In an even further more preferred embodiment of the
present invention, are compounds of Formula (I) selected
from Table 3.

In a second embodiment, the present invention provides
25 a pharmaceutical composition comprising a compound of
Formula (I) and a pharmaceutically acceptable carrier.

In a third embodiment, the present invention provides
a method for the treatment a central nervous system
30 disorder comprising administering to a host in need of such
treatment a therapeutically effective amount of a compound
of Formula (I), or a pharmaceutically acceptable salt
thereof, wherein the compound is a 5HT_{2a} antagonist or a
5HT_{2c} agonist.

35

In a preferred embodiment the compound is a 5HT2a antagonist.

5 In another preferred embodiment the compound is a 5HT2c agonist.

In a more preferred embodiment the present invention provides a method for the treatment central nervous system disorders including obesity, anxiety, depression,
10 psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility comprising administering to a host in need of such
15 treatment a therapeutically effective amount of a compound of Formula (I).

In a further preferred embodiment the central nervous system disorder comprises obesity.
20

In another further preferred embodiment the central nervous system disorder comprises schizophrenia.

In another further preferred embodiment the central nervous system disorder comprises depression.
25

In another further preferred embodiment the central nervous system disorder comprises anxiety.

30 In a fourth embodiment the present invention provides novel compounds of Formula (I) or pharmaceutically acceptable salt forms thereof for use in therapy.


In a fifth embodiment the present invention provides
35 the use of novel compounds of Formula (I) or pharmaceutically acceptable salt forms thereof for the

manufacture of a medicament for the treatment of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders.


DEFINITIONS

10 The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by
15 resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and
20 trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific
25 stereochemistry or isomeric form is specifically indicated.

 The numbering of the tetracyclic ring-system present in the compounds of Formula (I), as defined by nomenclature known to one skilled in the art, is shown for two examples in Formula (I'), when k is 1, m is 1, and n is 1; and in
30 Formula (I''), when k is 1, m is 1, and n is 2:



(I')



(I'')

The tetracyclic ring-system present in compounds of Formula (I) occur as "cis" or "trans" isomers when the carbon-carbon bond b in Formula (I) is a single bond. As such, the terms "cis" and "trans", in conjunction with the tetracyclic ring structure, refer to the configuration of hydrogen atoms on carbon atoms 7a and 11a in Formula (I') or, for example, on carbon atoms 8a and 12a in Formula (I''), above. When both hydrogens are on the same side of the mean plane determined by the octahydro tetracyclic moiety then the configuration is designated "cis", if not, the configuration is designated "trans". It is understood that the above example is for demonstrative purposes only and not intended to limit the scope of the tetracyclic ring-system present in compounds of Formula (I). As such, it is understood that one skilled in the art of organic chemistry can apply the above numbering system to other values of k, m, and n in the scope of compounds of Formula (I) to determine the appropriate numbering. Additional Examples of the numbering of the tetracyclic ring-system are further provided below in the synthetic Examples. Lastly, it is understood that the use of "cis" or "trans" in the identification of the tetracyclic ring-system is not meant to construe the configuration of any other cis or trans geometric isomer in the molecule, for example, cis or trans butene.

The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that

the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.

5 When any variable (e.g., R^2) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R^2 , then
10 said group may optionally be substituted with up to two R^2 groups and R^2 at each occurrence is selected independently from the definition of R^2 . Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

15 When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such
20 substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein, "alkyl" or "alkylene" is intended to
25 include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; for example, " C_1 - C_6 alkyl" denotes alkyl having 1 to 6 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl,
30 n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, n-hexyl, 2-methylbutyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl.

"Alkenyl" or "alkenylene" is intended to include hydrocarbon chains of either a straight or branched
35 configuration having the specified number of carbon atoms

and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain. Examples of alkenyl include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, 4-methyl-3-pentenyl, and the like.

"Alkynyl" or "alkynylene" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more carbon-carbon triple bonds which may occur in any stable point along the chain, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like.

"Cycloalkyl" is intended to include saturated ring groups, having the specified number of carbon atoms. For example, "C₃-C₆ cycloalkyl" denotes such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

"Alkoxy" or "alkyloxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy. Similarly, "alkylthio" is represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge.

"Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like.

"Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example -C_vF_w where v = 1 to 3

and $w = 1$ to $(2v+1)$). Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl.

5 As used herein, "carbocycle" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7- to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to,
10 cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).

15 As used herein, the term "heterocycle" or "heterocyclic ring" is intended to mean a stable 5- to 7-membered monocyclic or bicyclic or 7- to 14-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic), and which consists
20 of carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally
25 be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If
30 specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the
35 heterocycle is not more than 1.

Examples of heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinoliziny, 6H-1,2,5-thiadiazinyl, acridinyl, 5 azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, b-carbolinyl, chromanyl, 10 chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, imidazolopyridinyl, 1H-indazolyl, indolenyl, indolinyl, indoliziny, indolyl, isatinoyl, 15 isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolopyridinyl, isoxazolyl, isoxazolopyridinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 20 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolopyridinyl, oxazolidinylperimidinyl, oxindolyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, 25 piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolopyridinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, 30 quinolinyl, 4H-quinoliziny, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, 35 thiazolopyridinyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl,

1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl,
1,3,4-triazolyl, and xanthenyl. Preferred heterocycles
include, but are not limited to, pyridinyl, furanyl,
thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl,
5 imidazolyl, indolyl, benzimidazolyl, 1H-indazolyl,
oxazolidinyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl,
oxindolyl, benzoxazolyl, benzthiazolyl, benzisothiazolyl,
isatinoyl, isoxazolopyridinyl, isothiazolopyridinyl,
thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl,
10 and pyrazolopyridinyl. Preferred 5 to 6 membered
heterocycles include, but are not limited to, pyridinyl,
furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl,
piperazinyl, imidazolyl, and oxazolidinyl. Also included
are fused ring and spiro compounds containing, for example,
15 the above heterocycles.

As used herein, the term "bicyclic heterocyclic ring
system" is intended to mean a stable 9- to 10-membered
bicyclic heterocyclic ring formed from the substituent
NR¹²R¹³, which is partially unsaturated or unsaturated
20 (aromatic), and which consists of carbon atoms, a nitrogen
atom, and 1 or 2 additional heteroatoms independently
selected from the group consisting of N, O and S. The
additional nitrogen or sulfur heteroatoms may optionally be
oxidized. The heterocyclic ring is attached to its pendant
25 group by the nitrogen atom of the group NR¹²R¹³ and for
which results in a stable structure. The heterocyclic
rings described herein may be substituted on carbon or on a
nitrogen atom if the resulting compound is stable. If
specifically noted, a nitrogen in the heterocycle may
30 optionally be quaternized. It is preferred that when the
total number of S and O atoms in the heterocycle exceeds 1,
then these heteroatoms are not adjacent to one another. It
is preferred that the total number of S and O atoms in the
heterocycle is not more than 1. The term "bicyclic
35 heterocyclic ring system" is intended to be a subset of the
term "heterocyclic ring system". Preferred examples of a 9-

to 10- membered bicyclic heterocyclic ring system are
benzimidazolyl, benzimidazoliny, benzoxazoliny,
dihydrobenzthiazolyl, dihydrodioxobenzthiazolyl,
benzisoxazoliny, 1*H*-indazolyl, indolyl, indoliny,
5 isoindoliny, tetrahydro-isoquinoliny, tetrahydro-
quinoliny, and benzotriazolyl.

Additionally, a subclass of preferred heterocycles are
heterocycles which function as an isostere of a cyclic but
10 non-heterocyclic substituent such as -CH₂-C(=O)-phenyl.
Preferred examples of such heterocycles include, but are
not limited to, benzimidazolyl, benzofuranyl,
benzothiophenyl, benzoxazolyl, benzthiazolyl,
benzisoxazolyl, furanyl, imidazoliny, 1*H*-indazolyl,
15 indoliny, isoindoliny, isoquinoliny, oxazolyl,
piperidinyl, pyrazinyl, pyridinyl, pyrimidinyl, quinoliny,
thiazolyl, thiophenyl, and 1,2,3-triazolyl.

As used herein, the term "aryl", or aromatic residue,
is intended to mean an aromatic moiety containing the
20 specified number of carbon atoms, such as phenyl, pyridinyl
and naphthyl.

The phrase "pharmaceutically acceptable" is employed
herein to refer to those compounds, materials,
compositions, and/or dosage forms which are, within the
25 scope of sound medical judgment, suitable for use in
contact with the tissues of human beings and animals
without excessive toxicity, irritation, allergic response,
or other problem or complication, commensurate with a
reasonable benefit/risk ratio.

30 As used herein, "pharmaceutically acceptable salts"
refer to derivatives of the disclosed compounds wherein the
parent compound is modified by making acid or base salts
thereof. Examples of pharmaceutically acceptable salts
include, but are not limited to, mineral or organic acid
35 salts of basic residues such as amines; alkali or organic
salts of acidic residues such as carboxylic acids; and the

like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such
5 conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic,
10 tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

15 The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a
20 stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in *Remington's Pharmaceutical*
25 *Sciences*, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

"Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug
30 according to formula (I) *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of a compound of formula (I) are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine
35 manipulation or *in vivo*, to the parent compound. Prodrugs include compounds of formula (I) wherein a hydroxy, amino,

or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of
5 prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of Formula (I), and the like.

"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive
10 isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

SYNTHESIS

Throughout the details of the invention, the following abbreviations are used with the following meanings:

5 Reagents:

MCPBA	m-chloroperoxybenzoic acid
DIBAL	diisobutyl aluminum hydride
Et ₃ N	triethylamine
TFA	trifluoroacetic acid
10 LAH	lithium aluminum hydride
NBS	N-bromo succinimide
Red-Al	Sodium bis(2-methoxyethoxy)aluminum hydride
Pd ₂ dba ₃	Tris(dibenzylideneacetone)dipalladium(0)
ACE-Cl	2-chloroethylchloroformate

15

Solvents:

THF	tetrahydrofuran
MeOH	methanol
EtOH	ethanol
20 EtOAc	ethyl acetate
HOAc	acetic acid
DMF	dimethyl formamide
DMSO	dimethyl sulfoxide
DME	dimethoxyethane
25 Et ₂ O	diethylether
iPrOH	isopropanol
MEK	methyl ethyl ketone

Others:

30 Ar	aryl
Ph	phenyl
Me	methyl
Et	ethyl
NMR	nuclear magnetic resonance
35 MHz	megahertz

	BOC	tert-butoxycarbonyl
	CBZ	benzyloxycarbonyl
	Bn	benzyl
	Bu	butyl
5	Pr	propyl
	cat.	catalytic
	mL	milliliter
	nM	nanometer
	ppm	part per million
10	mmol	millimole
	mg	milligram
	g	gram
	kg	kilogram
	TLC	thin layer chromatography
15	HPLC	high pressure liquid chromatography
	RPM	revolutions per minute
	rt	room temperature
	aq.	aqueous
	sat.	saturated

20

The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference.

The novel compounds of this invention may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below,

it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.

The preparation of compounds of Formula (I) of the present invention may be carried out in a convergent or sequential synthetic manner. Detailed synthetic preparations of the compounds of Formula (I) are shown in the following reaction schemes. The skills required in preparation and purification of the compounds of Formula (I) and the intermediates leading to these compounds are known to those in the art. Purification procedures include, but are not limited to, normal or reverse phase chromatography, crystallization, and distillation.

Several methods for the preparation of the compounds of the present invention are illustrated in the schemes and examples shown below. The substitutions are as described and defined above.

Compounds of Formula (I) of this invention may be prepared as shown in Scheme 1. Thus, preparation of an aryl hydrazine (III) is accomplished, for example, by treatment of a corresponding substituted aniline (II) with NaNO_2 followed by reduction of the N-nitroso intermediate with a reducing agent such as LAH or zinc and an organic acid, such as acetic acid or trifluoroacetic acid at low temperature. Assembly of the core tetracyclic intermediate indole (V) is accomplished by Fischer indole cyclization of


the aryl hydrazine and a suitably substituted ketone (i.e. (IV)) by methods described by, but not limited to, R.J. Sundberg, "Indoles, Best Synthetic Methods" 1996, Academic Press, San Diego, CA. For example, treatment of the aryl hydrazine (III) as the free base or the corresponding mineral acid salt with the ketone (IV) ($R^1 = H, Bn, CBZ, CO_2Et$, etc) in an alcoholic solvent in the presence of mineral acid affords the indoles (V) as the free bases (after treatment with aq. NaOH). Reduction of the indoles to the corresponding cis or trans substituted dihydroindoles is accomplished by, for example, treatment with hydrogen in the presence of a catalyst such as platinum oxide or palladium on carbon, or with a metal such as zinc and a mineral acid such as hydrochloric acid, or with sodium and liquid ammonia, or with borane-amine complex such as borane-triethylamine in tetrahydrofuran, or preferably by treatment with $NaCNBH_3$ in an acid such as acetic or trifluoroacetic acid.

The corresponding enantiomers can be isolated by separation of the racemic mixture of (I) on a chiral stationary phase column utilizing normal or reverse phase HPLC techniques, the details of which are described in the examples. Alternatively, a diastereomeric mixture of (I) can be prepared by treatment of (I, $R^1 = H$) with an appropriate chiral acid (or suitably activated derivative), for example dibenzoyl tartrate or the like (see, for example, Kinbara, K., et. al., *J. Chem. Soc., Perkin Trans. 2*, 1996, 2615; and Tomori, H., et. al., *Bull. Chem. Soc. Jpn.*, 1996, 3581). The diastereomers would then be separated by traditional techniques (i.e. silica chromatography, crystallization, HPLC, etc) followed by removal of the chiral auxiliary to afford enantiomerically pure (I).

In the cases where the carboline nitrogen has been protected (VI) (i.e. $R^1 = Boc, Bn, CBZ, CO_2R$), it may be

removed under a variety of conditions as described in Greene, T.W., Wuts, P.G.W., "Protective Groups in Organic Synthesis, 2nd Edition", John Wiley and Sons, Inc., New York, pages 309-405, 1991. The free secondary amine could then be alkylated, for example, by treatment with a suitably substituted alkyl halide (R^1Cl , or R^1I) and a base to afford additional compounds of type (I), as described, for example, by Glennon, R.A., et. al., *Med. Chem. Res.*, 1996, 197.

10


SCHEME 1

Alternatively, compounds of Formula (I) can be prepared as described in Scheme 2. Treatment of an ortho

halonitrobenzene compound (VII) with a nucleophilic alkyl halide ($X = OH, SH, NHR, (VIII)$) (as described by Kharasch, N., Langford, R.B., *J. Org. Chem.*, **1963**, 1903) and a suitable base followed by subsequent reduction of the corresponding nitroaryl derivative to the aniline (IX). The reduction may be accomplished with a variety of reducing agents, for example, LAH, $SnCl_2$, $NaBH_4$, N_2H_4 , etc. or with hydrogen in the presence of a suitable catalyst, such as palladium on carbon, or platinum oxide, etc., (see Hudlicky, M., "Reductions in Organic Chemistry", Ellis Horwood, Ltd., Chichester, UK, **1984**). Formation of the aryl hydrazine (X) may be accomplished as described previously in Scheme 1 or more directly by treatment of the aniline (IX) with aq. hydrochloric acid, stannous chloride and $NaNO_2$ at room temperature (see, Buck, J.S., Ide, W.S., *Org. Syn., Coll. Vol.*, **2**, **1943**, 130). This primary aryl hydrazine (X) can then be cyclized under Fischer indole cyclization conditions as detailed above for compound (V), to afford the indole (XI) as the corresponding salt. Upon treatment of the indole (XI) with a base such potassium hydroxide or potassium t-butoxide in a solvent such as DME or THF affords the tetracyclic indole intermediates (V). These indoles can also be reduced to the corresponding cis or trans indolines (I) as described previously in Scheme 1.

25


SCHEME 2



Still another related route to compounds of Formula (I) is shown in Scheme 3. Initiating the synthesis with a nitrobenzene derivative such as (XII), this approach allows for a variety of derivatization. More highly substituted nitrobenzenes can be obtained by traditional synthetic manipulation (*i.e.* aromatic substitution) and are known by those in the art (see Larock, R.C., *Comprehensive Organic Transformations*, VCH Publishers, New York, 1989).

Treatment of nitrobenzene derivative with a reducing agent such as LAH, etc., as described previously (see Hudlicky, et. al.), affords the corresponding aniline intermediate. Subsequent formation of the hydrazine followed by Fischer indole cyclization with a suitably functionalized ketone as described above (*i.e.* Scheme 1, (III) to (V)) affords the

g-carboline indole (XIII). At this point the fused ring may be appended by condensation of a haloalkyl carboxylic acid or a related activated carboxylic acid (i.e. acid chloride, mixed anhydride, etc.) such as (XIV). Reduction of the resultant heterocyclic carbonyl may be effected with various reducing agents, for example, sodium borohydride, diisobutyl aluminum hydride and the like (see Larock, R.C., *Comprehensive Organic Transformations*, VCH Publishers, New York, 1989 and/or Hudlicky, M., "Reductions in Organic Chemistry", Ellis Horwood, Ltd., Chichester, UK, 1984) to afford the tetracyclic indoles (V). Further reduction of the indole (V) to the indolines (I) is as described previously in Scheme 1.


SCHEME 3

15

Preparation of the aniline precursors (II) to the Fischer indole cyclizations is shown in Scheme 4. Treatment of a suitably ortho-functionalized aniline (XVI) with a chloroalkyl carboxylic acid or ester (or equivalent substrate, i.e. acrylic acid, acryloyl chloride, etc.) and concomitant condensation, followed by reduction of the

resultant heterocyclic carbonyl with a reducing agent such as LAH, DIBAL, or Red-Al affords the fused heterocyclic benzene derivatives (II). More diverse intermediates of (II) may be obtained by formation of the ortho substituted aniline from the corresponding ortho substituted nitobenzenes and concomitant reduction of the nitro moiety as described above. Furthermore, aromatic substitution of the fluoro (or other halo derived nitrobenzene) functionality of (XV) for an oxygen, or sulphur moiety is accomplished, for example, by treatment of (XV) with a nucleophile, such as sodium sulfide or an alcohol, followed by formation of the requisite thiophenol or phenol, respectively, using standard techniques known by those in the art (see Larock, R.C., *Comprehensive Organic Transformations*, VCH Publishers, New York, 1989, page 481). Reduction of the nitro as before affords the substituted anilines (XVI).

SCHEME 4




20

An alternate approach to the substituted fused anilines (II) is shown in Scheme 5. Treatment of the phenol ($X = OH$), thiophenol ($X = SH$), or other nucleophilically aromatic substituted derivative (XVII) with, for example, a haloalkyl carboxylic acid (or equivalent activated haloalkylcarboxylic acid, (i.e. acid halide, mixed anhydride, acrylic acid, acryloyl chloride, etc.), affords the derivative (XVIII) which when treated under Friedel-Crafts acylation conditions (see Ed. G.A.

25

Olah, "Friedel-Crafts and Related Reactions", J. Wiley and Sons, New York, 1964, Vol 3, Pts 1 and 2 or Chem. Rev., 1955, 229, or Olah, G.A., "Friedel-Crafts Chemistry", Wiley Interscience, New York, 1973, for varying conditions and protocols), i.e. strong Lewis acids (AlCl_3 , FeCl_3 , etc.), affords the cyclic alkylphenones (XIX). Incorporation of the nitrogen functionality can be accomplished in several ways. For example, Schmidt rearrangement (as described by Smith, P.A.S., *J. Am. Chem. Soc.*, 1948, 320) is effected by treatment of the carbonyl derivative (XIX) with NaN_3 and methanesulfonic acid to afford the bicyclic lactam (XX). Alternatively, this transformation may be carried out under Hoffmann rearrangement protocol (see, for example, Dike, S.Y., et. al., *Bioorg. Med. Chem. Lett.*, 1991, 383), by initial formation of the oxime derivative of (XXI) by treatment with hydroxylamine hydrochloride. Subsequent rearrangement to the lactam is efficiently accomplished by heating in polyphosphoric acid to afford the lactam (XX). Reduction of the lactam (XX) can be accomplished with a variety of reducing agents, for example, DIBAL, Red-Al and the like to afford the aniline (II).

SCHEME 5




The preparation of compounds of Formula (I) with additional diversity of functionalization of the aromatic A ring of the tetracycle is shown in Scheme 6 and Scheme 7 and described here. Due to the nature of the synthetic route of Scheme 1 to derivatives of Formula (I), compounds with halogen substituents on the A-ring are difficult to prepare. However, bromination of the indolines (I, R⁸ = H) when the amine is protected, for example, with the Boc or CBZ protecting groups, with, for example, NBS in DMF affords the R⁸ brominated derivatives (XXII). These activated aryl derivatives (XXII) act as excellent counterparts for a number of important synthetic transformations.

For example, biaryl coupling is accomplished under Suzuki coupling protocol. For a review and leading references of palladium catalyzed cross coupling reactions,

see Miyaura, N., Suzuki, A., *Chem. Rev.*, **1995**, 2457. One such procedure entails treatment of the aryl bromide (XXII) with a functionalized aryl boronic acid (XXIII) in the presence of a catalytic Pd(0) species, such as Pd(PPh₃)₄, Pd(PPh₃)₂Cl₂, Pd(OAc)₂, Pd₂(dba)₃ and a suitable ligand such as PPh₃, AsPh₃, etc., or other such Pd(0) catalyst, and a base such as Na₂CO₃ or Et₃N in a suitable solvent such as DMF, toluene, THF, DME or the like, to afford the indolines (XXIV). Alternatively formation of the indole boronic acid from the bromine derivative (XXII) (i.e. (I, R⁸ = B(OH)₂)) would allow for greater diversity in the subsequent coupling of this indole boronic acid with commercially available haloaromatic derivatives in a similar Suzuki coupling strategy as described above to afford the indolines (XXIV).


SCHEME 6



Similarly biaryl coupling of the bromine derivatives (XXV), readily obtained by the synthetic sequence exemplified in Scheme 2, (starting with the suitably functionalized bromo nitrobenzenes (II)), is shown in

Scheme 7. This approach allows for the preparation of biaryl indoles as well as the corresponding indoline derivatives. Protection of the amine functionality must be carried out if $R^1 = H$ (see Greene et.al for protections of amines). This is readily accomplished, for example, by treatment of bromo derivatives (XXV) with $(Boc)_2O$ in aqueous sodium hydroxide and dioxane. Subsequent Suzuki coupling with a variety of aryl boronic acids is carried out as described above in Scheme 6, to afford the biaryl adducts (XXVI). This protocol is amenable to R^7 , R^8 , and R^9 bromide, iodide, triflates, and/or diazo derivatives (see Miyaura, N., Suzuki, A., *Chem. Rev.*, 1995, 2457, for a review of aryl couplings).

SCHEME 7




15

Furthermore and as an extension of this approach to a rapid preparation of a large array of biaryl indole and indoline derivatives, these bromide derivatives (XXV) can be bound to a solid support and the Suzuki couplings can be carried out on solid support (see XXVIII) as illustrated in Scheme 8. Towards that end treatment of indoline (XXV) with TFA in CH_2Cl_2 , to remove the Boc protecting group, followed extraction from aqueous base provides the free amine (XXXVII). The free amine can be loaded onto a suitable solid support such as (XXVIII) using conditions

25

well known to those skilled in the art. Thus, p-nitrophenylchloroformate Wang resin (XXVIII) which can be obtained commercially from sources such as Novabiochem, Inc. is swollen in a suitable solvent such as N-methyl pyrrolidinone and treated with 1.5 equiv. of amine to afford the functionalized resin (XXIX). Suzuki couplings are then carried out in array format by treatment of resins (XXIX) with a suitable palladium source such as $\text{Pd}(\text{PPh}_3)_4$ or $\text{Pd}(\text{dppf})\text{Cl}_2$ and a suitable base such as 2M aqueous K_2CO_3 or Na_2CO_3 or triethylamine with an excess (typically 5 equivalents) of an aryl boronic acid (procedures for solid-phase Suzuki and other palladium couplings are well-known by those in the art, see for instance L.A. Thompson and J.A. Ellman, *Chem. Rev.* 1996, 96, (1), 555-600). The coupling may be repeated to ensure complete conversion to the desired coupled product. Cleavage from the solid support by treatment with TFA affords the corresponding indoles and indolines (XXX) as their TFA salts.


SCHEME 8




In addition, there exists a wide range of procedures and protocols for functionalizing haloaromatics, aryl diazonium and aryl triflate compounds. These procedures are well known by those in the art and described, for example, by Stanforth, S.P., *Tetrahedron*, **1998**, 263; Buchwald, S.L., et. al., *J. Am. Chem. Soc.*, **1998**, 9722; Stille, J.K., et. al., *J. Am. Chem. Soc.*, **1984**, 7500. Among these procedures are biaryl couplings, alkylations, acylations, aminations, and amidations. The power of palladium catalyzed functionalization of aromatic cores has been explored in depth in the last decade. An excellent review of this field can be found in J. Tsuji, "Palladium Reagents and Catalysts, Innovations in Organic Synthesis", J. Wiley and Sons, New York, **1995**.

One such method to prepare compounds of Formula (I) with substituted R^1 sidechains in a more direct manner is shown in Scheme 9. Alkylation of the indole or indoline derivatives (I, $R^1 = H$) with a haloalkyl ester, such as $ClCH_2(CH_2)_pCO_2Me$, in the presence of NaI or KI and a base such as K_2CO_3 , Na_2CO_3 or the like, in dioxane or THF or other such solvent while heating (see Glennon, R.A., et al., *Med. Chem. Res.*, **1996**, 197) affords the R^1 alkylated esters. Subsequent formation of the activated amides (XXXI) is accomplished by treatment of the ester with N,O-dimethylhydroxylamine hydrochloride and a Lewis acid such as trimethylaluminum or triethylaluminum in toluene (see, for example, Golec, J.M.C., et al., *Tetrahedron*, **1994**, 809) at $0^\circ C$. Treatment of the amide (XXXI) with a variety of organometallic agents, such as Grignard reagents $R^{1a}MgBr$, alkyl and aryl lithium reagents etc. (see Sibi, M.P., et al., *Tetrahedron Lett.*, **1992**, 1941; and more generally House, H.O., *Modern Synthetic Reactions*, W.A. Benjamin, Inc., Menlo Park, CA., **1972**), in a suitable solvent such as THF, ether, etc. at low temperatures affords the substituted ketones (XXXII).

SCHEME 9



Preparation of compounds of Formula (I) where $m=0$, $k = 1$ is outlined in Scheme 10 and described here. Fischer indole cyclization of the previously described hydrazine (III) with a known protected 2,3-dioxopyrrolidine (Carlson, E.H., et. al., *J. Org. Chem.*, **1956**, 1087) under a variety of typical cyclization conditions affords the tetracyclic indole (XXXIII). The reduction may be accomplished with a variety of reducing agents, for example, LAH, DIBAL, etc., to yield the pyrole fused indole (XXXIV). This derivative can then be deprotected and subsequently alkylated as described previously (see Greene, T.W., Wuts, P.G.W., "Protective Groups in Organic Synthesis, 2nd Edition", John Wiley and Sons, Inc., New York, **1991**, and Scheme 1), to give the R^1 alkylated indole analogs (XXXV). Alternatively, reduction of the indole to the indoline, as described previously (see Scheme 1), followed by deprotection of the benzyl group to give (XXXVI) and alkylation gives access to the corresponding R^1 alkylated indoline derivatives (XXXVII). All the previously described methods to functionalize the aromatic ring, and to afford derivatives of varying R^1 sidechains are applicable to these cores.

SCHEME 10**EXAMPLES**

- 5 Chemical abbreviations used in the Examples are defined above. The detailed processes for preparing the compounds of Formula (I) are illustrated by the following Examples. It is, however, understood that this invention is not limited to the specific details of these examples.
- 10 The Examples as set forth below are intended to demonstrate the scope of the invention but are not intended to limit the scope of the invention. Proton nuclear magnetic resonance spectra (1H NMR) were measured in chloroform-d

(CDCl₃) unless otherwise specified and the peaks are reported in parts per million (ppm) downfield from tetramethylsilane (TMS). The coupling patterns are reported as follows: s, singlet; d, doublet; dd, doublet of
5 doublets; t, triplet; q, quartet; m, multiplet; bs, broad singlet; bm, broad multiplet.

EXAMPLE 1

4,5,7,8,9,10-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole
10 hydrochloride

A mixture of 1-amino-2,3-dihydroindole (1.0 g, 5.9 mmol), piperidone hydrochloride monohydrate (0.91 g, 5.9 mmol) and isopropanol (29 mL) was brought to reflux for 4
15 hours. The resulting brown solid was filtered and washed with cold diethylether (20 mL) and dried under vacuum, affording the title compound (1.01 g, 74%). ¹H NMR (CD₃OD, 300 MHz) δ 7.15 (d, 1H, J = 7.7 Hz), 6.85-6.96 (m, 2H), 4.39-4.50 (m, 4H), 3.75 (t, 2H, J = 7.3 Hz), 3.57 (t, 2H, J
20 = 6.2 Hz), 3.15 (t, 2H, J = 6.2 Hz) ppm.

EXAMPLE 2

9-cyclopropyl-4,5,7,8,9,10-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole hydrochloride
25

The title compound was prepared by substituting cyclopropylpiperidone for the monohydrate piperidone hydrochloride by the procedure of Example 1 in 64%. ¹H NMR (DMSO, 300 MHz) δ 7.16 (d, 1H, J = 7.3), 7.85-7.93 (m,
30 2H), 4.6 (d, 1H, J = 6.6), 4.38-4.48 (m, 3H), 3.72-3.85 (m, 1H), 3.7 (t, 2H, J = 7 Hz), 3.58-3.62 (m, 1H), 3.0-3.18 (m, 3H), 1.07-1.12 (m, 2H), 0.83-0.9 (m, 2H) ppm.

EXAMPLE 3

(±)-cis-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole

5 4,5,7,8,9,10-Hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole from Example 1 (0.50 g, 2.14 mmol) was stirred under N₂ in TFA (15.5 mL) at 0° C for 10 minutes. NaBH₄ (0.44 g, 6.4 mmol) was added slowly keeping the temperature below 2° C. The reaction was allowed to warm to room
10 temperature and stirred overnight. Ice chips were then added and the reaction basified to pH 12 with 50% aqueous NaOH. The aqueous layer was then extracted with CHCl₃ (3 x 20 mL). The combined extracts were washed with brine, H₂O and dried (Na₂SO₄) and evaporated affording the title
15 compound (0.42 g, 100%). ¹H NMR (CDCl₃, 300 MHz) δ 6.94 (d, 1H, J = 7.7 Hz), 6.88 (d, 1H, J = 6.9 Hz), 6.63 (t, 7.3, 1H, J = 7.3 Hz), 3.64 (dt, 1H, J = 8.0, 1.5 Hz), 3.29-3.5 (m, 2H), 3.05-3.29 (m, 3H), 3.03 (dd, 1H, J = 11.7, 3.6 Hz), 2.72-3.02 (m, 2H), 1.66-1.90 (m, 2H) ppm.

20

EXAMPLE 16

5,6,8,9,10,11-hexahydro-4H-pyrido[3',4':4,5] pyrrolo[3,2,1-ij]quinoline

25 Step A:

 1,2,3,4-Tetrahydroquinoline (2.12 g, 15.9 mmol) was dissolved in AcOH (30mL) and water (10 mL). The solution was cooled to 0°C. An aqueous solution of NaNO₂ (1.20g, 17.5 mmol in 3 mL water) was added dropwise. The reaction
30 was warmed to RT and stirred 2 hrs. Water (20mL) and EtOAc (20mL) were added. The layers were separated and the aqueous phase was extracted (2 x 20 mL) with EtOAc. The combined organic layers were washed with brine, dried, and concentrated to afford a crude orange oil (2.62g). The
35 product was purified by column chromatography (20-40%

EtOAc/hexane) to afford 1-nitroso-1,2,3,4-tetrahydroquinoline (2.48g, 96%) as a yellow oil. ^1H NMR (CDCl₃, 300MHz) δ 8.07 (d, 1H, J = 8.1 Hz), 7.21-7.34 (m, 3 H), 3.91 (t, 2H, J = 6.2 Hz), 3.81 (t, 2H, J = 6.2 Hz),
5 1.97-2.05 (m, 2H) ppm.

Step B:

1-Nitroso-1,2,3,4-tetrahydroquinoline (1.51 g, 9.0 mmol) was dissolved in THF. The solution was cooled to
10 0°C. 1M LAH in THF (9 mL, 9.0 mmol) was added dropwise. The reaction was allowed to warm to RT and was stirred over night. The reaction was cooled to 0 °C and was quenched with 20 mL a saturated aqueous Rochelle salt solution (20 mL). The suspension was stirred for 2 h and the layers
15 were separated. The aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried, and concentrated to afford an orange solid (1.26g). The crude product was purified by column chromatography (20-0% hexane/CH₂Cl₂) to afford 1,2,3,4-
20 tetrahydroquinoylamine (1.02g, 76%) as a yellow solid. ^1H NMR (CDCl₃, 300MHz) δ 7.09-7.18 (m, 2H), 6.97 (dd, 1H, J = 0.7 Hz, 7.3 Hz), 6.68-6.74 (m, 1H), 3.64 (m, 2H), 3.31 (t, 2H, J = 6.0 Hz), 2.77 (t, 2H, J = 6.6 Hz), 2.02-2.11 (m, 2H) ppm.

25

Step C:

1,2,3,4-Tetrahydroquinoylamine (0.925 g, 6.25 mmol) and 4-piperidone monohydrate hydrochloride (0.960g, 6.25 mmol) were dissolved in EtOH (15mL). Conc. HCl (0.52 mL,
30 6.25 mmol) was added. The reaction was refluxed for 3 hrs and then cooled to RT. The precipitate was collected by vacuum filtration. The residue was washed with 5 mL of EtOH, to afford the title compound (1.32g, 85%) as a pure, white powder. ^1H NMR (CD₃OD, 300MHz) δ 7.22 (d, 1H, J = 8.1
35 Hz), 6.92-6.97 (m, 1H), 6.86 (d, 1H, J = 7.2 Hz), 4.87 (s,

2H), 4.05 (t, 2H, J = 6.0Hz), 3.61 (t, 2H, J = 6.0Hz), 3.14 (t, 2H, J = 6.0Hz), 2.94 (t, 2H, J = 6.3 Hz), 2.16-2.24 (m, 2H) ppm.

5

EXAMPLE 17

(±)-cis-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

5,6,8,9,10,11-Hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (2.84g, 11.4 mmol) was dissolved in TFA (35 mL). The reaction was cooled to 0°C. NaCNBH₃ (2.15 g, 34.27 mmol) was added in small portions over 30 min, keeping the temperature less than 5°C. The reaction was stirred at 0°C for 2 h. Ice was added to the reaction flask, and the reaction was basified with 50% NaOH until pH=14. Water (20 mL) was added to dissolve the precipitate. The reaction was extracted with CHCl₃ (3 x 20 mL). The combined organic layers were washed with brine, dried, and concentrated to afford the title compound (1.67 g, 68%) as a pale-brown, amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 6.80-7.00 (m, 2H), 6.55-6.6.70 (m, 1H), 3.20-3.40 (m, 2H), 2.95-3.20 (m, 2H), 2.75-2.95 (m, 2H), 2.50-2.75 (m, 4H), 2.00-2.20 (m, 2H), 1.85-2.00 (m, 1H), 1.70-1.85 (m, 1H) ppm.

25

EXAMPLE 37

(±)-cis-9-(cyclopropylcarbonyl)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole

(±)-cis-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole from Example 3 (0.050 g, 0.25 mmol) was dissolved in CH₂Cl₂ (5 mL) with Et₃N (0.75 mL) and cooled to 0°C. The cyclopropanecarbonyl chloride (0.026 g, 0.26 mmol) was then added dropwise. The solution was stirred at 0°C for 1 h and then warmed to room temperature

and stirred for 1 h. The reaction mixture was partitioned between water and CHCl_3 (3 x 15 mL) and the layers separated. The aqueous layer was extracted with CHCl_3 . The combined organics were washed with brine, H_2O and dried (5) (Na_2SO_4) and evaporated affording a light yellow liquid which was further purified by preparatory silica gel TLC (5% $\text{MeOH}/\text{CH}_2\text{Cl}_2$). The title compound was isolated as a clear colorless liquid (0.042g, 65%). ^1H NMR (CD_3OD , 300 MHz) δ 7.22-7.58 (m, 3H), 4.62-4.75 (m, 1H), 3.85-4.30 (m, 10 5H), 3.55-3.62 (m, 2H), 1.9-2.18 (m, 3H), 0.75-0.9 (m, 4H) ppm.

EXAMPLE 38

(±)-cis-9-isobutyryl-4,5,6a,7,8,9,10,10a-
15 octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole

The title compound was prepared by substituting isobutyrylchloride for cyclopropanecarbonyl chloride by the procedure of Example 37 in 53% yield. ^1H NMR (CD_3OD , 300
20 MHz) δ 6.85-6.95 (m, 2H), 6.6 (t, 1H, $J = 7.3$), 4.48 (dd, 0.5 H, $J = 8.4$, 4.0 Hz), 4.21 (br d, 0.5 H, $J = 13.2$ Hz), 4.05 (dd, 0.5 H, $J = 11.7$, 4 Hz), 3.85 (br d, 0.5 H, $J = 13.9$ Hz), 3.47-3.7 (m, 2H), 3.18-3.45 (m, 4H), 2.85-3.18 (m, 3H), 2.72-2.85 (m, 1H), 1.75-2.05 (m, 2H), 1.15 (t, 3H,
25 $J = 6.5$ Hz), 1.05 (t, 3H, $J = 6.9$ Hz) ppm.

EXAMPLE 89

tert-butyl (±)-cis-2-(2-chlorophenyl)-4,5,7,8,10,10a-
hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-
30 carboxylate

Step A:

(±)-cis-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-
b]pyrrolo[3,2,1-hi]indole (387 mg, 1.93 mmol) was dissolved
35 in CHCl_3 (8 mL). BOC_2O (464 mg, 2.13 mmol) was added. The

reaction was stirred at RT 18 h. 1M aqueous NaOH (10 mL) was added. The biphasic mixture was stirred 10 min, and the layers were separated. The aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic layers were
5 washed with brine, dried, and concentrated to afford an amorphous white solid (820 mg). The crude product was purified by column chromatography (0-10% MeOH/CH₂Cl₂) to afford *tert*-butyl (±)-*cis*-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-
10 carboxylate (596 mg, 100%) as an amorphous white solid. ¹H NMR (CDCl₃, 300MHz) δ 6.97 (d, 1H, J = 7.3 Hz), 6.93 (d, 1H, J = 7.3 Hz), 6.60-6.75 (m, 1H), 3.75-3.90 (m, 1H), 3.50-3.72 (m, 1H), 3.05-3.48 (m, 5H), 2.70-2.90 (m, 1H), 1.70-1.90 (m, 2H) ppm. MS (CI, NH₃): 301 (base, M+H)

15

Step B:

To a solution of *tert*-butyl (±)-*cis*-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate (0.576 g, 1.92 mmol) in DMF (4 mL) at 0 °C,
20 freshly recrystallized NBS (0.375 g, 2.1 mmol) was added as a solution in DMF (4 mL). The reaction was stirred at 0 °C for 20 min, after which it was warmed to RT. The reaction was stirred at RT for 0.5 h. Water (10 mL) and EtOAc (10 mL) were added. The layers were separated, and the aqueous
25 phase was extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and dried. Concentration afforded a crude brown oil. The crude product was purified by column chromatography (MeOH/CH₂Cl₂). *Tert*-butyl (±)-*cis*-2-bromo-4,5,7,8,10,10a-
30 hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate (550 mg, 75%) was isolated as a brown amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.06 (s, 1H), 7.02 (s, 1H), 3.70-3.90 (m, 1H), 3.50-3.70 (m, 1H), 3.00-3.45 (m,

6H), 2.70-2.90 (m, 2H), 1.70-1.90 (m, 2H), 1.48 (s, 9H) ppm.

Step C:

5 *Tert*-butyl (\pm)-*cis*-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate (87.5 mg, 0.23 mmol) was dissolved in benzene (4 mL). 2M sodium carbonate (0.4 mL) added. 2-Chlorophenylboronic acid (71.9 mg, 0.46 mmol) was added, followed by Pd(PPh₃)₂Cl₂ (8.1 mg, 0.0115 mmol). The reaction was evacuated and kept under a nitrogen atmosphere. The suspension was refluxed for 18 h and then cooled to RT. The reaction was concentrated in vacuo, after which water (10 mL) and EtOAc (10 mL) were added. The layers were separated and the aqueous phase was extracted with EtOAc (2 x 10 mL). The organic layers were washed with brine (2 x 10 mL), dried, and concentrated to afford a crude brown amorphous solid (110.9mg). The residue was purified by column chromatography (20-40% EtOAc/Hexane) to afford the title compound (62mg, 66%) as a white amorphous solid. MS (CI, NH₃): 411 (base, M+H).

EXAMPLE 90

tert-butyl (\pm)-*cis*-2-(2,4-dichlorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate

The title compound (55.9mg, 50%) was prepared by the method of Example 89 Step C from *tert*-butyl (\pm)-*cis*-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate (94mg, 0.25 mmol) and 2,4-dichlorophenylboronic acid (95 mg, 0.5 mmol) as a white amorphous solid. MS (CI, NH₃): 445 (base, M+H).

EXAMPLE 91

tert-butyl (±)-cis-2-(3,4-dichlorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate

5

Tert-butyl (±)-cis-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate (135 mg, 0.30 mmol) was dissolved in DME (4 mL). 2M sodium carbonate (0.75 mL) was added. 3,4-Dichlorophenylboronic acid (114 mg, 0.60 mmol) was added, followed by Pd₂(dba)₃ (15 mg, .015 mmol). PPh₃ (16 mg, 0.06 mmol) was added. The reaction flask was degassed and kept under a nitrogen atmosphere. The suspension was refluxed for 18 h cooled to RT. The reaction was concentrated in vacuo, after which water (10 mL) and EtOAc (10 mL) were added. The layers were separated and the aqueous phase was extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine (2 x 10 mL), dried, and concentrated to afford a crude brown amorphous solid (214 mg). The residue was purified by column chromatography (20-40% EtOAc/Hexane) to afford the title compound (120 mg, 90%) as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.55 (d, 1H, J = 1.5 Hz), 7.41 (d, 1H, J = 8.4 Hz), 7.30 (dd, 1H, J = 1.8 Hz, 8.4 Hz), 7.26 (s, 1H), 7.13 (s, 1H), 3.75-3.90 (m, 1H), 3.60-3.70 (m, 1H), 3.10-3.50 (m, 7H), 2.80-3.00 (m, 1H), 1.70-1.90 (m, 2H), 1.48 (s, 9H) ppm. MS (CI, NH₃): 445 (base, M+H).

25

EXAMPLE 92

tert-butyl (±)-cis-2-(2,3-dichlorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate

The title compound was prepared by the method of Example 90 from tert-butyl (±)-cis-2-bromo-4,5,7,8,10,10a-

35

hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6*aH*)-
carboxylate (124 mg, 0.27 mmol) and corresponding 2,3-
dichlorophenylboronic acid (104 mg, 0.54 mmol), to afford
after chromatographic purification the title compound (157
5 mg, 99%) as a white amorphous solid. ¹H NMR (CDCl₃, 300
MHz) δ 7.30-7.40 (m, 1H), 7.20 (s, 1H), 7.18 (d, 1H, J =
3.6 Hz), 6.99 (s, 1H), 6.94 (s, 1H), 3.80-3.90 (m, 1H),
3.60-3.80 (m, 1H), 3.10-3.50 (m, 7H), 2.80-3.00 (m, 1H),
1.70-1.90 (m, 2H), 1.47 (s, 9H) ppm. MS (CI, NH₃): 445
10 (base, M+H).

EXAMPLE 93

tert-butyl (±)-*cis*-2-[2-chloro-4-(trifluoromethyl)phenyl]-
4,5,7,8,10,10*a*-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-
15 *hi*]indole-9(6*aH*)-carboxylate

The title compound was prepared by the method of
Example 90 from *tert*-butyl (±)-*cis*-2-bromo-4,5,7,8,10,10*a*-
hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6*aH*)-
20 carboxylate (136 mg, 0.30 mmol) and corresponding 2-
chloro-4-trifluoromethylphenylboronic acid (128mg, 0.60
mmol), to afford after chromatographic purification the
title compound (160 mg, 99%) as a white amorphous solid. ¹H
NMR (CDCl₃, 300 MHz) δ 7.70 (br, 1H), 7.51 (dd, 1H, J = 1.1
25 Hz, 8.0 Hz), 7.42 (d, 1H, J = 8.0 Hz), 7.03 (s, 1H), 6.99
(s, 1H), 3.80-3.90 (m, 1H), 3.60-3.80 (m, 1H), 3.10-3.50
(m, 7H), 2.80-3.00 (m, 1H), 1.70-1.90 (m, 2H), 1.48 (s, 9H)
ppm. MS (CI, NH₃): 479 (base, M+H).

30

EXAMPLE 94

tert-butyl (±)-*cis*-2-(2-chloro-4-methoxyphenyl)-
4,5,7,8,10,10*a*-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-
hi]indole-9(6*aH*)-carboxylate

The title compound was prepared by the method of Example 90 from *tert*-butyl (\pm)-*cis*-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate (121 mg, 0.27 mmol) and corresponding 2-chloro-4-methoxyphenylboronic acid (100 mg, 0.54 mmol), to afford after chromatographic purification the title compound (141 mg, 68%) as a white amorphous solid. ^1H NMR (CDCl_3 , 300 MHz) δ 7.21 (d, 1H, $J = 8.4$ Hz), 6.94-6.99 (m, 3H), 6.82 (dd, 1H, $J = 2.9$ Hz, 8.8 Hz), 3.75-4.00 (m, 7H), 3.60-3.70 (m, 1H), 3.10-3.50 (m, 7H), 2.80-3.00 (m, 1H), 1.70-1.90 (m, 2H), 1.48 (s, 9H) ppm. MS (CI, NH_3): 441 (base, $\text{M}+\text{H}$).

EXAMPLE 95

tert-butyl (\pm)-*cis*-2-(5-isopropyl-2-methoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate

The title compound was prepared by the method of Example 90 from *tert*-butyl (\pm)-*cis*-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate (127 mg, 0.28 mmol) and corresponding 4-isopropyl-2-methoxyphenylboronic acid (109 mg, 0.56 mmol), to afford after chromatographic purification the title compound (58.4 mg, 46%) as a white amorphous solid. ^1H NMR (CDCl_3 , 300 MHz) δ 7.00-7.20 (m, 4H), 6.87 (d, 1H, $J = 8.4$ Hz), 3.85-4.0 (m, 1H), 3.79 (s, 3H), 3.60-3.75 (m, 1H), 3.10-3.50 (m, 6H), 2.70-3.00 (m, 2H), 1.70-1.90 (m, 2H), 1.48 (s, 9H), 1.25 (d, 6 H, $J = 7.0$ Hz) ppm. MS (CI, NH_3): 449 (base, $\text{M}+\text{H}$).

EXAMPLE 96

tert-butyl (\pm)-*cis*-2-(3-fluorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate

The title compound was prepared by the method of Example 90 *tert*-butyl (\pm)-*cis*-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate (125 mg, 0.28 mmol) and corresponding 3-fluorophenylboronic acid (77 mg, 0.56 mmol), to afford after chromatographic purification the title compound (48 mg, 44%) as a white amorphous solid. ^1H NMR (CDCl_3 , 300 MHz) δ 7.20-7.40 (m, 2H), 7.10-7.20 (m, 3H), 6.80-7.00 (m, 1H), 3.80-3.90 (m, 1H), 3.60-3.80 (m, 1H), 3.10-3.50 (m, 7H), 2.80-3.00 (m, 1H), 1.70-1.90 (m, 2H), 1.48 (s, 9H) ppm. MS (CI, NH_3): 395 (base, $\text{M}+\text{H}$).

EXAMPLE 97

tert-butyl (\pm)-*cis*-2-(2,4-dimethoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate

The title compound was prepared by the method of Example 90 from *tert*-butyl (\pm)-*cis*-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate (143 mg, 0.32 mmol) and corresponding 2,4-dimethoxyphenylboronic acid (115 mg, 0.63 mmol), to afford after chromatographic purification the title compound (92 mg, 66%) as a white amorphous solid. ^1H NMR (CDCl_3 , 300 MHz) δ 7.15-7.18 (m, 1H), 7.08 (s, 1H), 7.04 (s, 1H), 6.40-6.60 (m, 2H), 3.75-4.00 (m, 7H), 3.60-3.70 (m, 1H), 3.00-3.50 (m, 7H), 2.70-2.90 (m, 1H), 1.70-1.90 (m, 2H), 1.48 (s, 9H) ppm. MS (CI, NH_3): 437 (base, $\text{M}+\text{H}$).

EXAMPLE 98

(\pm)-*cis*-2-(2-chlorophenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole

Tert-butyl (\pm)-*cis*-2-(2-chlorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-

carboxylate (45.1 mg, 0.11 mmol) was dissolved in 20% TFA in methylene chloride (4mL) and was stirred at RT for 2 h. The reaction was solution was cooled to 0 °C and basified with 1M NaOH until pH > 14. The layers were separated.

5 The aqueous phase was extracted the methylene chloride (2 x 10 ml). The organic layers were washed with brine and dried. Concentration afforded the title compound (29.3 mg, 86%) as a pale yellow amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.42 (dd, 1H, J = 1.4, 7.3 Hz), 7.16-7.33 (m, 3H),
10 7.02 (s, 1H), 6.96 (s, 1H), 3.69 (dt, 1H, J = 1.4, 8.1 Hz), 3.15-3.50 (m, 5H), 3.06 (dt, 1H, J = 3.2, 12.3 Hz), 2.82-2.97 (m, 3H), 1.78-1.93 (m, 2H) ppm. MS (CI, NH₃): 311 (base, M+H).

15

EXAMPLE 99

(±)-*cis*-2-(2,4-dichlorophenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole

The title compound was prepared by the method of
20 Example 98 from *tert*-butyl (±)-*cis*-2-(2,4-dichlorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate (44.3 mg, 0.99mmol) to afford the title compound (35mg, 100%) as a pale yellow amorphous solid. The enantiomers of (±)-*cis*-2-(2,4-dichlorophenyl)-
25 4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole were separated by preparative HPLC on a chiracel OD column using isocratic 6% IPA/hexane as the eluent. ¹H NMR (CDCl₃, 300 MHz) δ 7.44 (s, 1H), 7.23-7.26 (m, 2H),
6.97 (s, 1H), 6.92 (s, 1H), 3.70 (dt, 1H, J = 1.4, 8.0 Hz),
30 3.15-3.50 (m, 5H), 3.06 (dt, 1H, J = 3.3, 11.3 Hz), 2.77-2.96 (m, 3H), 1.76-1.93 (m, 2H) ppm. MS (CI, NH₃): 345 (base, M+H).

EXAMPLE 100

(±)-*cis*-2-(3,4-dichlorophenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole

5 The title compound was prepared by the method of
Example 98 from *tert*-butyl (±)-*cis*-2-(3,4-dichlorophenyl)-
4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-
hi]indole-9(6aH)-carboxylate (110 mg, 0.25mmol) to afford
the title compound (71mg, 82%) as a pale yellow amorphous
10 solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.57 (d, 1H, J = 2.2 Hz),
7.41 (d, 1H, J = 8.4 Hz), 7.30 (dd, 1H, J = 1.8, 8.1 Hz),
7.13 (s, 1H), 7.07 (s, 1H), 3.70 (dt, 1H, J = 1.8, 7.6 Hz),
3.15-3.50 (m, 5H), 3.04 (dt, 1H, J = 3.6, 12.4 Hz), 2.83-
2.95 (m, 3H), 1.76-1.92 (m, 2H) ppm. MS (CI, NH₃): 345
15 (base, M+H).

EXAMPLE 101

(±)-*cis*-2-(2,3-dichlorophenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole

20 The title compound was prepared by the method of
Example 98 from *tert*-butyl (±)-*cis*-2-(2,3-dichlorophenyl)-
4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-
hi]indole-9(6aH)-carboxylate (128 mg, 0.29 mmol) to afford
the title compound (99mg, 100%) as a pale yellow amorphous
25 solid. The enantiomers were separated by preparative HPLC on
a chiracel OD column using isocratic 6% IPA/hexane as the
eluent. ¹H NMR (CDCl₃, 300 MHz) δ 7.38 (dd, 1H, J = 2.6,
7.3 Hz), 7.14-7.23 (m, 2H), 7.02 (s, 1H), 6.98 (s, 1H),
30 6.92 (s, 1H), 3.70 (dt, 1H, J = 1.8, 8.1 Hz), 3.15-3.50 (m,
5H), 3.05 (dt, 1H, J = 3.3, 12.2 Hz), 2.85-2.95 (m, 3H),
1.73-1.93 (m, 2H) ppm. MS (CI, NH₃): 345 (base, M+H).

EXAMPLE 102

(±)-cis-2-[2-chloro-4-(trifluoromethyl)phenyl]-
4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-
hi]indole

5

The title compound was prepared by the method of
Example 98 tert-butyl (±)-cis-2-[2,-chloro-4-
(trifluoromethyl)phenyl]-4,5,7,8,10,10a-
hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-
10 carboxylate (80 mg, 0.17 mmol) to afford the title compound
(65.3 mg, 100%) as a pale yellow amorphous solid. The
enantiomers were separated by preparative HPLC on a
chiracel OD column using isocratic 3% IPA/hexane as the
eluent. ¹H NMR (CDCl₃, 300 MHz) δ 7.69 (s, 1H), 7.51 (d,
15 1H, J = 8.1Hz), 7.42 (d, 1H, J = 8.0 Hz), 7.02 (s, 1H),
6.96 (s, 1H), 3.68-3.73 (m, 1H), 3.16-3.50 (m, 5H), 2.85-
3.09 (m, 4H), 1.75-1.93 (m, 2H) ppm. MS (CI, NH₃): 379
(base, M+H).

20

EXAMPLE 103

(±)-cis-2-(2-chloro-4-methoxyphenyl)-4,5,6a,7,8,9,10,10a-
octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole

The title compound was prepared by the method of
25 Example 98 from tert-butyl (±)-cis-2-(2-chloro-4-
methoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-
b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate (60 mg, 0.14
mmol) to afford the title compound (50.4 mg, 100%) as a
pale yellow amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.22
30 (d, 1H, J = 8.8Hz), 6.95-7.00 (m, 2H), 7.02 (s, 1H), 6.92
(s, 1H), 6.81 (dd, 1H, J = 2.7, 8.5 Hz), 3.82 (s, 3H), 3.69
(dt, 1H, J = 1.4, 7.7 Hz), 3.13-3.50 (m, 5H), 3.00-3.10
(dt, 1H, J = 3.3, 11.7 Hz), 2.84-2.94 (m, 3H), 1.74-1.92
(m, 2H) ppm. MS (CI, NH₃): 341 (base, M+H).

35

EXAMPLE 104

(±)-*cis*-2-(4-isopropyl-2-methoxyphenyl)-
4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole

5

The title compound was prepared by the method of
Example 98 from *tert*-butyl (±)-*cis*-2-(4-isopropyl-2-
methoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-
b]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate (52 mg, 0.12
10 mmol) to afford the title compound (42 mg, 100%) as a pale
yellow amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.07-7.14
(m, 4H), 6.88 (d, 1H, J = 8.4 Hz), 3.79 (s, 3H), 3.68 (dt,
1H, J = 1.4, 8.0 Hz), 3.14-3.50 (m, 5H), 3.05 (dt, 1H, J =
3.3, 12.1 Hz), 2.79-2.94 (m, 3H), 1.60-1.93 (m, 3H), 1.25
15 (d, 6H, J = 6.9 Hz) ppm. MS (CI, NH₃): 349 (base, M+H).

EXAMPLE 105

(±)-*cis*-2-(3-fluorophenyl)-4,5,6a,7,8,9,10,10a-
octahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole

20

The title compound was prepared by the method of
Example 98 from *tert*-butyl (±)-*cis*-2-(3-fluorophenyl)-
4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-
hi]indole-9(6aH)-carboxylate (39.5 mg, 0.10 mmol) to afford
25 the title compound (35.4 mg, 90%) as a pale yellow
amorphous solid. The enantiomers were separated by
preparative HPLC on a chiracel OD column using isocratic 5%
IPA/hexane as the eluent. ¹H NMR (CDCl₃, 300 MHz) δ 7.19-
7.35 (m, 3H), 7.16 (s, 1H), 7.11 (s, 1H), 6.89-6.96 (m,
30 1H), 3.69 (dt, 1H, J = 1.8, 8.0 Hz), 3.15-3.50 (m, 5H),
3.04 (dt, 1H, J = 3.3, 12.1 Hz), 2.83-2.95 (m, 3H), 1.76-
1.92 (m, 2H) ppm. MS (CI, NH₃): 295 (base, M+H).

EXAMPLE 106

(±)-cis-2-(2,4-dimethoxyphenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole

5 The title compound was prepared by the method of Example 98 from tert-butyl (±)-cis-2-(2,4-dimethoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate (85.0 mg, 0.19 mmol) to afford the title compound (55.0 mg, 86%) as a pale yellow
10 amorphous solid. The enantiomers were separated by preparative HPLC on a chiracel OD column using isocratic 8% IPA/hexane as the eluent. ¹H NMR (CDCl₃, 300 MHz) δ 7.17 (dd, 1H, J = 1.4, 6.9 Hz), 7.06 (s, 1H), 7.01 (s, 1H), 6.50-6.60 (m, 2H), 3.84 (s, 3H), 3.79 (s, 3H), 3.67 (dt, 1H, J = 1.5, 7.7 Hz), 3.12-3.49 (m, 5H), 3.05 (dt, 1H, J = 3.3, 12.1 Hz), 2.78-2.98 (m, 3H), 1.73-1.91 (m, 2H) ppm. MS (CI, NH₃): 337 (base, M+H).

EXAMPLE 107

20 tert-butyl (±)-cis-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate

 (±)-Cis-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline, from Example
25 17 (1.67 g, 7.79 mmol) was dissolved in dioxane (16 mL) and 1M NaOH (8 mL). The reaction was cooled to 0°C. BOC₂O (1.87 g, 8.57 mmol) was added. The reaction was stirred at RT 18 hrs. EtOAc (10 mL) was added and the biphasic
30 mixture was stirred for 10 min. the layers were separated. The aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine, dried, and concentrated to afford an amorphous white solid (2.30 g). The crude product was purified by column
35 chromatography (20-40% EtOAc/hexane) to afford the title

compound (2.17 g, 69%) as an amorphous white solid. ¹H NMR (CDCl₃, 300MHz) δ 6.93 (d, 1H, J = 7.3 Hz), 6.86 (d, 1H, J = 7.3 Hz), 6.61-6.66 (m, 1H), 3.65-3.80 (m, 1H), 3.30-3.50 (m, 1H), 3.10-3.31 (m, 3H), 2.70 (t, 2H, J = 6.6 Hz), 2.50-2.65 (m, 1H), 2.00-2.20 (m, 2H), 1.75-1.90 (m, 2H) ppm. MS (CI, NH₃): 315 (base, M+H)

EXAMPLE 108

tert-butyl (±)-cis-2-bromo-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate

The title compound (0.81g, 35%) was prepared by the method of Example 89 Step B using tert-butyl (±)-cis-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (1.85g) as an amorphous white solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.01 (s, 1H), 6.98 (s, 1H), 3.50-3.70 (m, 1H), 3.30-3.50 (m, 1H), 3.00-3.30 (m, 5H), 2.50-2.70 (m, 3H), 2.00-2.30 (m, 2H), 1.70-1.90 (m, 2H), 1.48 (s, 9H) ppm.

EXAMPLE 109

tert-butyl (±)-cis-2-(2,3-dichlorophenyl)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate

Tert-butyl (±)-cis-2-bromo-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (110 mg, 0.28 mmol) was dissolved in DME (4 mL). 2M aqueous sodium carbonate (0.75 ml) was added. 2,3-Dichlorophenylboronic acid (107 mg, 0.56 mmol) was added, followed by Pd₂(dba)₃ (14.5 mg, .014 mmol). P(Ph)₃ (14.7 mg, 0.056 mmol) was added. The reaction flask was degassed and kept under a nitrogen atmosphere. The suspension was

refluxed for 18 h cooled to rt. The reaction was concentrated in vacuo, after which water (10 mL) and EtOAc (10 mL) were added. The layers were separated and the aqueous phase was extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine (2 x 10 mL), dried, and concentrated to afford a crude brown amorphous solid (162 mg). The residue was purified by column chromatography (20-0% hexane/CH₂Cl₂) to afford the title compound (96.8 mg, 75%) as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.61-7.94 (m, 1H), 7.20 (s, 1 H), 7.18 (d, 1H, 3.3 Hz), 7.00 (s, 1H), 6.93 (s, 1H), 3.70-3.74 (m, 1H), 3.45-60 (m, 1H), 3.15-3.35 (m, 4H), 2.65-2.80 (m, 4H), 2.10-2.20 (m, 2H), 1.80-2.00 (m, 2H), 1.46 (s, 9H) ppm.

15

EXAMPLE 110

tert-butyl (±)-*cis*-2-(3,4-dichlorophenyl)-5,6,8,9,11,11a-hexahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7*aH*)-carboxylate

20

The title compound was prepared by the method of Example 109 from *tert*-butyl (±)-*cis*-2-bromo-5,6,8,9,11,11a-hexahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7*aH*)-carboxylate (101.7 mg, 0.26 mmol) and 3,4-dichlorophenylboronic acid (97 mg, 0.52 mmol), after chromatographic purification (91.6 mg, 77%) as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.57 (d, 1H, J = 1.8 Hz), 7.42 (d, 1 H, J = 8.4 Hz), 7.31 (dd, 1H, J = 2.2, 8.4 Hz), 7.12 (bs, 1H), 7.07 (bs, 1H), 3.62-3.75 (m, 1H), 3.48-60 (m, 1H), 3.15-3.35 (m, 4H), 2.65-2.80 (m, 4H), 2.10-2.20 (m, 2H), 1.85-2.00 (m, 2H), 1.46 (s, 9H) ppm.

30

EXAMPLE 111

tert-butyl (±)-cis-2-[2-chloro-4-(trifluoromethyl)phenyl]-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate

5

The title compound was prepared by the method of Example 109 from tert-butyl (±)cis-2-bromo-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (63 mg, 0.16 mmol) and 2-chloro-4-(trifluoromethyl)phenylboronic acid (69 mg, 0.32 mmol), after chromatographic purification (35.9 mg, 46%) as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.69 (s, 1H), 7.51 (bd, 1 H, J = 8.0 Hz), 7.42 (d, 1H, J = 8.1 Hz), 7.04 (s, 1H), 6.97 (s, 1H), 3.60-3.75 (m, 1H), 3.48-60 (m, 1H), 3.15-3.35 (m, 4H), 2.65-2.80 (m, 4H), 2.10-2.20 (m, 2H), 1.85-2.00 (m, 2H), 1.46 (s, 9H) ppm. MS (CI, NH₃): 493 (base, M+H).

15

EXAMPLE 112

(±)-cis-2-(2,3-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

20

Tert-butyl (±)-cis-2-(2,3-dichlorophenyl)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (55 mg, 0.12 mmol) was dissolved in 20% TFA in methylene chloride (4mL) and was stirred at RT for 2 h. The reaction was solution was cooled to 0 °C and basified with 1M NaOH until pH > 14. The layers were separated. The aqueous phase was extracted the methylene chloride (2 x 10 ml). The organic layers were washed with brine and dried. Concentration afforded the title compound (43 mg, 100%) as a pale yellow amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.37 (dd, 1H, J = 2.6, 7.3 Hz), 7.15-7.23 (m, 2 H), 6.97 (s, 1H), 6.92 (s, 1H), 3.43-

25

30

3.46 (m, 1H), 3.31 (dt, 1H, J = 4.4, 10.2), 3.03-3.11 (m, 2H), 2.81-2.94 (m, 2H), 2.60-2.80 (m, 4H), 2.11-2.20 (m, 2H), 1.89-1.98 (m, 1H), 1.74-1.85 (m, 1H) ppm. MS (CI, NH₃): 359 (base, M+H).

5

Example 113

(±)-cis-2-(3,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

10 The title compound (72.6 mg, 100%) was prepared by the method of Example 112 from tert-butyl (±)-cis-2-(3,4-dichlorophenyl)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (90 mg, 0.20 mmol) as pale yellow amorphous
15 solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.58 (d, 1H, J = 2.2 Hz), 7.41 (d, 1 H, J = 8.4 Hz), 7.32 (dd, 1H, J = 2.2, 8.4 Hz), 7.09 (s, 1H), 7.07 (s, 1H), 3.34-3.46 (m, 1H), 3.31 (dt, 1H, J = 4.4, 10.7 Hz), 3.03-3.13 (m, 2H), 2.83-2.92 (m, 2H), 2.61-2.78 (m, 4H), 2.10-2.19 (m, 2H), 1.74-1.91 (m,
20 2H) ppm. MS (CI, NH₃): 359 (base, M+H).

EXAMPLE 114

(±)-cis-2-[2-chloro-4-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline
25

The title compound (21 mg, 90%) was prepared by the method of Example 112 from tert-butyl (±)-cis-2-(3,4-dichlorophenyl)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (28.5 mg, 0.06 mmol) as a pale yellow amorphous solid. The enantiomers of the title compound were separated by preparative HPLC on a Chiracel OD column using isocratic 6% IPA/hexane as the eluent. ¹H NMR (CDCl₃, 300 MHz) δ 7.46
30

(s, 1H), 7.69 (s, 1H), 7.49 (d, 1H, J = 8.0 Hz), 7.43 (d, 1H, J = 8.08 Hz), 7.02 (s, 1H), 6.96 (s, 1H), 3.45-3.50 (m, 1H), 3.32 (dt, 1H, J = 4.4, 10.3 Hz), 3.01-3.12 (m, 2H), 2.84-2.89 (m, 2H), 2.64-2.81 (m, 4H), 2.11-2.23 (m, 2H), 1.90-1.98 (m, 1H), 175-1.86 (m, 1H) ppm. MS (CI, NH₃): 393 (base, M+H).

EXAMPLE 189

4-((±)-cis-2-(2-chlorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indol-9(6aH)-yl)-1-(4-fluorophenyl)-1-butanone

(±)-Cis-2-(2-chlorophenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole (26.4mg, 0.085 mmol) 0.7 ml of MEK. KI (14 mg, 0.085 mmol) and K₂CO₃ (22 mg, 0.26 mmol), and 4-chloro-4'-fluorobutyrophenone (22.2 mg, 0.11 mmol) were added. The suspension was refluxed for 48 h and then cooled to rt. The suspension was filtered and the residue was washed with CH₂Cl₂ (5ml). The solution was concentrated in vacuo. The residue was purified by column chromatography (10% MeOH-CH₂Cl₂) to afford the title compound (18.8 mg, 47%) as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 8.00-8.04 (m, 2 H), 7.41 (dd, 1H, J = 1.5, 7.3 Hz), 7.30 (dd, 1H, J = 1.8, 7.3 Hz), 7.10-7.20 (m, 4H), 7.01 (s, 1H), 6.96 (s, 1H), 3.68 (bt, 1H, J = 6.6 Hz), 3.30-3.50 (m, 2H), 3.10-3.30 (m, 2H), 2.92-3.08 (m, 3H), 2.60-2.92 (m, 2H), 2.38-2.58 (m, 3H), 2.27 (t, 1H, J = 11.3 Hz), 1.70-2.05 (m, 4H) ppm. MS (CI, NH₃): 475 (base, M+H).

EXAMPLE 190

4-((±)-cis-2-(2,4-dichlorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indol-9(6aH)-yl)-1-(4-fluorophenyl)-1-butanone

The title compound (36 mg, 37%) was prepared by the method of Example 189 from (±)-cis-2-(2,4-dichlorophenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole (65.8 mg, 0.19 mmol), 4-chloro-4'-fluorobutyrophenone (50.0 mg, 0.25 mmol), KI (31.5 mg, 0.19 mmol), and K₂CO₃ (50.0 mg, 0.57 mmol) after chromatographic purification as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.90-7.95 (m, 2 H), 7.37 (s, 1H), 7.16 (s, 2H), 7.03 (t, 2H, J = 8.8 Hz), 6.91 (s, 1H), 6.85 (s, 1H), 3.49 (bt, 1H, J = 8.0 Hz), 3.25-3.45 (m, 2H), 3.02-3.22 (m, 2H), 2.90-3.02 (m, 3H), 2.50-2.88 (m, 2H), 2.10-2.45 (m, 4H), 1.70-2.00 (m, 4H) ppm. MS (CI, NH₃): 509 (base, M+H).

EXAMPLE 191

4-((±)-cis-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]qionolin-10(7aH)-yl)-1-(4-fluorophenyl)-1-butanone

The title compound (19.1 mg, 56%) was prepared by the method of Example 189 from (±)-cis-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]qionoline (30.0 mg, 0.09 mmol), 4-chloro-4'-fluorobutyrophenone (23.0 mg, 0.12 mmol), KI (15.0 mg, 0.09 mmol), and K₂CO₃ (37.0 mg, 0.27 mmol) after chromatographic purification as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.91-7.96 (m, 2 H), 7.01-7.19 (m, 2H), 6.82 (d, 1H, J = 12.1 Hz), 6.80 (d, 1H, J = 11.7 Hz), 2.98-3.25 (m, 3H), 2.94 (t, 2H, J = 6.9 Hz), 2.80-2.85 (m, 1H), 2.55-2.75 (m, 3H), 2.20-2.55 (m, 4H), 1.80-2.18 (m, 7H) ppm. MS (ESI): 379 (base, M+H).

EXAMPLE 265

4-((±)-cis-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indol-9(6aH)-yl)-1-(4-fluorophenyl)-1-butanone

A mixture of (\pm)-*cis*-4,5,6a,7,8,9,10,10a-octahydropyrido[4.3-*b*]pyrrolo[3,2,1-*hi*] indole (2.8 g, 14 mmol), 4-chloro-4'-fluorobutyrophenone (4.21 g, 21 mmol),
5 triethylamine (3 mL), KI (3.48 g, 21 mmol), dioxane (25 mL), and toluene (25 mL) was stirred and refluxed for 15 h under an atmosphere of nitrogen and then evaporated under reduced pressure to remove the volatiles. The residue was trituated with a small volume of dichloromethane and
10 decanted from the insoluble material. The process was repeated two more times and the combined dichloromethane solution was added to 0.5N solution of hydrogen chloride in ether (200 mL). The salt that separated was filtered off, washed with ether, dissolved immediately in a minimum
15 quantity of water and the solution extracted with ether. The ether extract was discarded and aqueous layer basified with 10% aqueous sodium hydroxide. The resulting mixture was extracted with dichloro- methane (2X) and the extract dried over magnesium sulfate and stripped of the solvent
20 under reduced pressure to yield the title compound (3.3 g, 65%) as a highly viscous light brown liquid. ^1H NMR (CDCl₃, 300 MHz) δ 1.70-1.80 (m, 2H), 1.80-2.02 (m, 2H), 2.19 (t, J = 10.9 Hz, 1H), 2.30-2.52 (m, 3H), 2.62-2.72 (m, 1H), 2.72-2.85 (m, 1H), 2.99 (t, J = 7.0 Hz, 2H), 3.02-3.20
25 (m, 2H), 3.25-3.42 (m, 2H), 3.59-3.65 (m, 1H), 6.85 (s, 1H), 6.90 (s, 1H), 7.01 (t, J = 7.0 Hz, 2H), 7.98-8.03 (m, 2H) ppm. MS (CI): 365 (M+H⁺).

EXAMPLE 274

30 (6a*S*,10a*R*)-2-(2-fluoro-4-methoxyphenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole

Step A:

Tert-butyl (6aS,10aR)-2-(2-fluoro-4-methoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate (116mg, 55%) was prepared by the method of Example 89 step C from tert-butyl (6aS,10aR)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate (189mg, 0.5 mmol) and 2-fluoro-4-methoxyphenylboronic acid (158mg, 1.0 mmol).

Step B:

The title compound was prepared by the method of Example 98 from tert-butyl (6aS,10aR)-2-(2-fluoro-4-methoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate to afford the title compound (82mg, 93%). ¹H NMR (CDCl₃, 300 MHz) δ 7.24-7.30 (m, 1H), 7.08 (s, 1H), 7.02 (s, 1H), 6.65-6.73 (m, 2H), 3.81 (s, 3H), 3.66-3.71 (m, 1H), 3.32-3.49 (m, 3H), 3.01-3.30 (m, 4H), 2.82-2.97 (m, 2H), 2.25 (bs, 1H), 1.79-1.93 (m, 2H) ppm. MS - ESI: 325 [MH]⁺.

EXAMPLE 275

tert-butyl (6aS,10aR)-2-[4-ethoxy-2-(trifluoromethyl)phenyl]-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate

Tert-butyl (6aS,10aR)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)carboxylate (189mg, 0.5 mmol) was dissolved in DME (7.8 mL). Ba(OH)₂ 8H₂O (236.6mg, 0.75mmol) in H₂O (2.6 mL) was added. 4-ethoxy-2-trifluoromethylphenyl boronic acid (140mg, 0.6 mmol) was added followed by Pd(PPh₃)₄ (12mg, 0.01 mmol). The reaction flask was degassed and refluxed under a nitrogen atmosphere for 18 hrs. After cooling to RT, the reaction was concentrated in vacuo. Water (10 mL) and EtOAc (10 mL) were added. The layers were separated and the aqueous phase was extracted with EtOAc (2 x 10 mL).

The combined organic layer was washed with brine (2 x 10 mL), dried over MgSO₄ and concentrated in vacuo and after chromatographic purification (30% EtOAc/Hexane) to afford the title compound (140mg, 57%). ¹H NMR (CDCl₃, 300 MHz) δ

5 7.20 (d, 2H, J = 5.9 Hz), 7.19 (s, 1H), 7.01 (dd, 1H, J = 6.2, 2.2 Hz), 6.85 (s, 1H), 6.81 (s, 1H), 4.05-4.10 (m, 3H), 3.82-3.94 (m, 1H), 3.64-3.68 (m, 1H), 3.22-3.44 (m, 4H), 2.84-3.10 (m, 3H), 1.80-1.90 (m, 2H), 1.42-1.47 (m, 12H) ppm. MS - ApCI: 489 [M+H⁺].

10

EXAMPLE 276

(6aS,10aR)-2-[4-ethoxy-2-(trifluoromethyl)phenyl]-4,5,6a,7,8,9,10,10a-octahydropyrido [4,3-b]pyrrolo[3,2,1-hi]indole

15

The title compound was prepared by the method of Example 98 from tert-butyl (6aS,10aR)-2-[4-ethoxy-2-(trifluoromethyl)phenyl]-4,5,7,8,10,10a-hexahydropyrido [4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate to afford

20 the title compound (97mg, 87%). ¹H NMR (CDCl₃, 300 MHz) δ 7.17 (d, 1H, J = 8.1Hz), 7.12 (d, 1H, J = 2.9Hz), 6.93 (dd, 1H, J = 8.4, 2.6Hz), 6.77 (s, 1H), 6.71 (s, 1H), 4.00 (q, 2H, J = 6.9Hz), 3.61 (t, 1H, J = 8.0Hz), 2.93-3.41 (m, 6H), 2.75-2.86 (m, 3H), 1.62-1.97 (m, 3H), 1.37 (t, 3H, J =

25 6.9Hz) ppm. MS - ApCI: 389 [M+H⁺].

EXAMPLE 277

tert-butyl (6aS,10aR)-2-(4-chloro-2-fluorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate

30

The title compound was prepared by the method of Example 89 step C from tert-butyl (6aS,10aR)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH) carboxylate (189mg, 0.5 mmol) and

35

corresponding 4-chloro-2-fluorophenyl boronic acid (175mg, 1.0 mmol) to afford after chromatographic purification the title compound (128mg, 60%). ¹H NMR (CDCl₃, 300 MHz) δ 7.28-7.29 (m, 1H), 7.05-7.15 (m, 4H), 3.6-4.2 (m, 3H), 2.80-3.50 (m, 7H), 1.80-1.90 (m, 2H), 1.48 (s, 9H) ppm. MS - ApCI: 429 [M+H⁺].

EXAMPLE 278

(6aS,10aR)-2-(4-chloro-2-fluorophenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido [4,3-b]pyrrolo[3,2,1-hi]indole

The title compound was prepared by the method of Example 98 from tert-butyl (6aS,10aR)-2-(4-chloro-2-fluorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate to afford the title compound (66mg, 67%). ¹H NMR (CDCl₃, 300 MHz) δ 7.29-7.35 (m, 1H), 6.99-7.15 (m, 4H), 3.60-3.80 (m, 1H), 2.80-3.50 (m, 9H), 1.70-1.95 (m, 2H), 1.62 (bs, 1H) ppm. MS - ApCI: 329 [M+H⁺].

EXAMPLE 279

tert-butyl (6aS,10aR)-2-[4-isopropoxy-2-(trifluoromethyl)phenyl]-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate

The title compound was prepared by the method of Example 89 step C from tert-butyl (6aS,10aR)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH) carboxylate (189mg, 0.5 mmol) and 4-isopropoxy-2-(trifluoromethyl)phenylboronic acid (248mg, 1.0 mmol) to afford after chromatographic purification the title compound (186mg, 74%). ¹H NMR (CDCl₃, 300 MHz) δ 7.11-7.18 (m, 2H), 6.90-6.94 (m, 1H), 6.78 (s, 1H), 6.74 (s,

1H), 4.50-4.54 (m, 1H), 3.75-3.85 (m, 1H), 3.59-3.70 (m, 1H), 2.79-3.40 (m, 8H), 1.74-1.84 (m, 2H), 1.40 (s, 9H), 1.21 (d, 6H, J = 5.9Hz) ppm. MS - ApCI: 503 [M+H⁺].

5

EXAMPLE 280

(6aS,10aR)-2-[4-isopropoxy-2-(trifluoromethyl)phenyl]-4,5,6a,7,8,9,10,10a-octahydropyrido [4,3-b]pyrrolo[3,2,1-hi]indole

10

The title compound was prepared by the method of Example 98 from tert-butyl (6aS,10aR)-2-[4-isopropoxy-2-(trifluoromethyl)phenyl]-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate to afford the title compound (96mg, 65%). ¹H

15

NMR (CDCl₃, 300 MHz) δ 7.14 (d, 1H, J = 8.4Hz), 7.10 (d, 1H, J = 2.5Hz), 6.90 (dd, 1H, J = 2.6, 8.4Hz), 6.75 (s, 1H), 6.69 (s, 1H), 4.46-4.54 (m, 1H), 3.56-3.62 (m, 1H), 2.91-3.39 (m, 6H), 2.73-2.83 (m, 3H), 1.64-1.82 (m, 3H), 1.46 (d, 6H, J = 5.8Hz) ppm. MS - ApCI: 403 [M+H⁺].

20

EXAMPLE 281

tert-butyl (6aS,10aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate

25

The title compound was prepared by the method of Example 89 step C from tert-butyl (6aS,10aR)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH) carboxylate (189mg, 0.5 mmol) and 4-methoxy-2-(trifluoromethyl)phenylboronic acid (248mg, 1.0 mmol) to afford after chromatographic purification the title compound (196mg, 83%). ¹H NMR (CDCl₃, 300 MHz) δ 7.21-7.26 (m, 2H), 7.01-7.05 (m, 1H), 6.86 (s, 1H), 6.82 (s, 1H), 3.90-4.30 (m, 3H), 3.86 (s, 3H), 3.3.64-3.75 (m, 1H),

35

3.25-3.50 (m, 4H), 3.05-3.12 (m, 1H), 2.85-2.95 (m, 1H),
1.80-1.90 (m, 2H), 1.47 (s, 9H) ppm. MS - ApCI: 475 [M+H⁺].

EXAMPLE 282

5 (6aS,10aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-
4,5,6a,7,8,9,10,10a-octahydropyrido [4,3-b]pyrrolo[3,2,1-
hi]indole

The title compound was prepared by the method of Example 98
10 from tert-butyl (6aS,10aR)-2-[4-methoxy-2-
(trifluoromethyl)phenyl]-4,5,7,8,10,10a-
hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-
carboxylate to afford the title compound (94mg, 61%). ¹H
NMR (CDCl₃, 300 MHz) δ 7.20-7.25 (m, 2H), 7.02 (dd, 1H, J =
15 8.6, 2.5Hz), 6.85 (s, 1H), 6.77 (m, 1H), 3.86 (s, 1H),
3.64-3.74 (m, 1H), 3.26-3.48 (m, 3H), 3.02-3.24 (m, 3H),
2.82-2.98 (m, 3H), 1.74-1.96 (m, 3H) ppm. MS - ApCI: 375
[M+H⁺].

20

EXAMPLE 283

tert-butyl (6aS,10aR)-2-phenyl-4,5,7,8,10,10a-
hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-
carboxylate

25 The title compound was prepared by the method of
Example 89 step C from tert-butyl (6aS,10aR)-2-bromo-
4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-
hi]indole-9(6aH) carboxylate (189mg, 0.5 mmol) and
phenylboronic acid (122mg, 1.0 mmol) to afford after
30 chromatographic purification the title compound (74mg,
20%). ¹H NMR (CDCl₃, 300 MHz) δ 7.49 (d, 2H, J = 7.7Hz),
7.34-7.40 (m, 2H), 7.25-7.30 (m, 1H), 7.20 (s, 1H), 7.15
(s, 1H), 3.85-3.95 (m, 1H), 3.68-3.70 (m, 1H), 3.24-3.52
(m, 4H), 2.84-3.22 (m, 4H), 1.82-1.94 (m, 2H), 1.49 (s, 9H)
35 ppm. MS - ApCI: 377 [M+H⁺].

EXAMPLE 284

(6a*S*,10a*R*)-2-phenyl-4,5,6a,7,8,9,10,10a-octahydropyrido
[4,3-*b*]pyrrolo[3,2,1-*hi*]indole

5

The title compound was prepared by the method of
Example 98 from *tert*-butyl (6a*S*,10a*R*)-2-phenyl-
4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-
hi]indole-9(6a*H*)-carboxylate to afford the title compound
10 (35mg, 64%). ¹H NMR (CDCl₃, 300 MHz) δ 7.49 (d, 2H, J =
7.7 Hz), 7.34-7.40 (m, 2H), 7.22-7.27 (m, 1H), 7.19 (s,
1H), 7.13 (s, 1H), 3.68-3.73 (m, 1H), 2.98-3.56 (m, 6H),
2.82-2.96 (m, 3H), 1.70-1.96 (m, 2H), 1.63 (bs, 1H) ppm. MS
- ApCI: 277 [M+H⁺].

15

EXAMPLE 285

tert-butyl (6a*S*,10a*R*)-2-(2-methylphenyl)-4,5,7,8,10,10a-
hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-
carboxylate

20

The title compound was prepared by the method of
Example 89 step C from *tert*-butyl (6a*S*,10a*R*)-2-bromo-
4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-
hi]indole-9(6a*H*) carboxylate (189mg, 0.5 mmol) and 2-
25 methylphenylboronic acid (136mg, 1.0 mmol) to afford after
chromatographic purification the title compound (90mg,
46%). ¹H NMR (CDCl₃, 300 MHz) δ 7.11-7.18 (m, 4H), 6.82 (s,
1H), 6.77 (s, 1H), 3.86-4.30 (m, 2H), 3.58-3.64 (m, 1H),
2.76-3.42 (m, 7H), 2.20 (s, 3H), 1.70-1.85 (m, 2H), 1.40
30 (s, 9H) ppm. MS - ApCI: 391 [M+H⁺].

EXAMPLE 286

(6a*S*,10a*R*)-2-(2-methylphenyl)-4,5,6a,7,8,9,10,10a-
octahydropyrido [4,3-*b*]pyrrolo[3,2,1-*hi*]indole

35

The title compound was prepared by the method of Example 98 from *tert*-butyl (6a*S*,10a*R*)-2-(2-methylphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-carboxylate to afford the title compound

5 (52mg, 78%). ¹H NMR (CDCl₃, 300 MHz) δ 7.09-7.18 (m, 4H), 6.80 (s, 1H), 6.74 (s, 1H), 3.59-3.65 (m, 1H), 2.93-3.42 (m, 6H), 2.74-2.87 (m, 3H), 2.20 (s, 3H), 1.66-1.85 (m, 2H), 1.51 (bs, 1H) ppm. MS - ApCI: 291 [M+H⁺].

10

EXAMPLE 287

tert-butyl (6a*S*,10a*R*)-2-[2-(trifluoromethyl)phenyl]-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-carboxylate

15

The title compound was prepared by the method of Example 89 step C from *tert*-butyl (6a*S*,10a*R*)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*) carboxylate (189mg, 0.5 mmol) and 2-(trifluoromethyl)phenylboronic acid (190mg, 1.0 mmol) to afford after chromatographic purification the title

20

compound (175mg, 79%). ¹H NMR (CDCl₃, 300 MHz) δ 7.69 (d, 1H, J = 7.7Hz), 7.50 (dd, 1H, J = 7.3, 7.7Hz), 7.40 (dd, 1H, J = 7.7, 7.3Hz), 7.31 (d, 1H, J = 7.3Hz), 6.89 (s, 1H), 6.85 (s, 1H), 3.82-4.30 (m, 2H), 3.66-3.71 (m, 1H), 2.88-3.50 (m, 7H), 1.80-1.90 (m, 2H), 1.47 (s, 9H) ppm. MS - ApCI: 445 [M+H⁺].

25

EXAMPLE 288

(6a*S*,10a*R*)-2-[2-(trifluoromethyl)phenyl]-

30

4,5,6a,7,8,9,10,10a-octahydropyrido [4,3-*b*]pyrrolo[3,2,1-*hi*]indole

The title compound was prepared by the method of Example 98 from *tert*-butyl (6a*S*,10a*R*)-2-[2-

35

(trifluoromethyl)phenyl]-4,5,7,8,10,10a-

hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-
carboxylate to afford the title compound (92mg, 68%). ¹H
NMR (CDCl₃, 300 MHz) δ 7.71 (d, 1H, J = 7.6Hz), 7.51 (dd,
1H, J = 6.9, 7.4Hz), 7.33-7.42 (m, 2H), 6.89 (s, 1H), 6.83
5 (s, 1H), 3.68-3.73 (m, 1H), 3.03-3.48 (m, 7H), 2.83-2.99
(m, 3H), 1.74-1.94 (m, 2H), 1.59 (bs, 1H) ppm. MS - ApCI:
345 [M+H⁺].

EXAMPLE 289

10 tert-butyl (6a*S*,10a*R*)-2-(3,4-dimethoxyphenyl)-
4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-
hi]indole-9(6a*H*)-carboxylate

The title compound was prepared by the method of
15 Example 89 step C from tert-butyl (6a*S*,10a*R*)-2-bromo-
4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-
hi]indole-9(6a*H*) carboxylate (189mg, 0.5 mmol) and
corresponding 3,4-dimethoxyphenyl boronic acid (182mg, 1.0
mmol) to afford after chromatographic purification the
20 title compound (92mg, 42%). ¹H NMR (CDCl₃, 300 MHz) δ 7.15
(s, 1H), 7.11 (s, 1H), 7.01-7.04 (m, 2H), 6.89 (d, 1H, J =
8.0Hz), 4.02-4.10 (m, 1H), 3.92 (d, 6H, J = 8.1Hz), 3.64-
3.78 (m, 1H), 2.82-3.52 (m, 8H), 1.82-1.90 (m, 2H), 1.49
(s, 9H) ppm. MS - ApCI: 437 [M+H⁺].

25

EXAMPLE 290

(6a*S*,10a*R*)-2-(3,4-dimethoxyphenyl)-4,5,6a,7,8,9,10,10a-
octahydropyrido [4,3-*b*]pyrrolo[3,2,1-*hi*]indole

30 The title compound was prepared by the method of
Example 98 from tert-butyl (6a*S*,10a*R*)-2-(3,4-
dimethoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-
b]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-carboxylate to afford the
title compound (52mg, 73%). ¹H NMR (CDCl₃, 300 MHz) δ 7.16
35 (s, 1H), 7.10 (s, 1H), 7.03-7.06 (m, 2H), 6.91(d, 1H, J =

8.8Hz), 3.93 (d, 6H, J = 8.1Hz), 3.69-3.75 (m, 1H), 2.83-3.52 (m, 9H), 1.74-1.94 (m, 3H) ppm. MS - ApCI: 337 [M+H⁺].

5

EXAMPLE 291

tert-butyl (6aS,10aR)-2-(2,5-dichlorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate

10

The title compound was prepared by the method of Example 89 step C from tert-butyl (6aS,10aR)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH) carboxylate (189mg, 0.5 mmol) and 2,5-dichlorophenylboronic acid (191mg, 1.0 mmol) to afford after chromatographic purification the title compound (105mg, 47%). ¹H NMR (CDCl₃, 300 MHz) δ 7.30-7.36 (m, 2H), 7.15-7.19 (m, 1H), 7.01 (s, 1H), 3.82-4.22 (m, 2H), 3.82-3.96 (m, 1H), 2.82-3.52 (m, 7H), 1.82-1.90 (m, 2H), 1.48 (s, 9H) ppm. MS - ApCI: 445 [M+H⁺].

20

EXAMPLE 292

(6aS,10aR)-2-(2,5-dichlorophenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido [4,3-b]pyrrolo[3,2,1-hi]indole

25

The title compound was prepared by the method of Example 98 from tert-butyl (6aS,10aR)-2-(2,5-dichlorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate to afford the title compound (60mg, 74%). ¹H NMR (CDCl₃, 300 MHz) δ 7.18-7.28 (m, 2H), 7.08 (dd, 1H, J = 2.6, 8.4Hz), 6.92 (s, 1H), 6.86 (s, 1H), 3.59-3.64 (m, 1H), 3.06-3.41 (m, 6H), 2.74-3.01 (m, 3H), 1.64-1.83 (m, 2H), 1.48 (bs, 1H) ppm. MS - ApCI: 345 [M+H⁺].

35

EXAMPLE 293

tert-butyl (6aS,10aR)-2-(3,5-dichlorophenyl)-
4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-
hi]indole-9(6aH)-carboxylate

5 The title compound was prepared by the method of
Example 89 step C from tert-butyl (6aS,10aR)-2-bromo-
4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-
hi]indole-9(6aH) carboxylate (189mg, 0.5 mmol) and 3,5-
dichlorophenylboronic acid (191mg, 1.0 mmol) to afford
10 after chromatographic purification the title compound
(85mg, 38%). ¹H NMR (CDCl₃, 300 MHz) δ 7.35 (s, 2H), 7.21-
7.23 (m, 1H), 7.13 (s, 1H), 7.10 (s, 1H), 3.82-4.22 (m,
2H), 3.65-3.75 (m, 1H), 2.84-3.52 (m, 7H), 1.80-1.90 (m,
2H), 1.49 (s, 9H) ppm. MS - ApCI: 445 [M+H⁺].

15

EXAMPLE 294

(6aS,10aR)-2-(3,5-dichlorophenyl)-4,5,6a,7,8,9,10,10a-
octahydropyrido [4,3-b]pyrrolo[3,2,1-hi]indole

20 The title compound was prepared by the method of
Example 98 from tert-butyl (6aS,10aR)-2-(3,5-
dichlorophenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-
b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate to afford the
title compound (60mg, 74%). ¹H NMR (CDCl₃, 300 MHz) δ 7.27
25 (d, 2H, J = 1.9Hz), 7.12-7.14 (m, 1H), 7.05 (s, 1H), 6.99
(s, 1H), 3.59-3.65 (m, 1H), 3.00-3.41 (m, 5H), 2.91-2.99
(m, 1H), 2.74-2.89 (m, 3H), 1.65-1.83 (m, 2H), 1.49 (bs,
1H) ppm. MS - ApCI: 345 [M+H⁺].

30

EXAMPLE 295

tert-butyl (6aS,10aR)-2-(2-isopropyl-4-methoxyphenyl)-
4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-
hi]indole-9(6aH)-carboxylate

The title compound was prepared by the method of Example 89 step C from *tert*-butyl (6a*S*,10a*R*)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*) carboxylate (189mg, 0.5 mmol) and corresponding 2-isopropyl-4-methoxyphenyl boronic acid (178mg, 1.0 mmol) to afford after chromatographic purification the title compound (152mg, 68%). ¹H NMR (CDCl₃, 300 MHz) δ 7.09 (d, 1H, J = 8.4Hz), 6.88 (d, 1H, J = 2.5 Hz), 6.83 (s, 1H), 6.78 (s, 1H), 6.72 (dd, 1H, J = 8.4, 2.9Hz), 3.80-4.20 (m, 2H), 3.84 (s, 3H), 3.74-3.78 (m, 1H), 3.05-3.50 (m, 7H), 2.84-2.98 (m, 1H), 1.82-1.94 (m, 2H), 1.48 (s, 9H), 1.12-1.17 (m, 6H) ppm. MS - ApCI: 449 [M+H⁺].

15

EXAMPLE 296

(6a*S*,10a*R*)-2-(2-isopropyl-4-methoxyphenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido [4,3-*b*]pyrrolo[3,2,1-*hi*]indole

20

The title compound was prepared by the method of Example 98 from *tert*-butyl (6a*S*,10a*R*)-2-(2-isopropyl-4-methoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-carboxylate to afford the title compound (88mg, 75%). ¹H NMR (CDCl₃, 300 MHz) δ 7.10 (d, 1H, J = 8.0Hz), 6.87 (d, 1H, J = 3.0Hz), 6.81 (s, 1H), 6.70-6.75 (m, 2H), 3.84 (s, 3H), 3.67-3.73 (m, 1H), 3.01-3.50 (m, 7H), 2.82-2.94 (m, 3H), 1.73-1.93 (m, 2H), 1.67 (bs, 1H), 1.14 (m, 6H) ppm. MS - ApCI: 349 [M+H⁺].

25

EXAMPLE 297

tert-butyl (6a*S*,10a*R*)-2-(5-fluoro-4-methoxy-2-methylphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-carboxylate

The title compound was prepared by the method of Example 89 step C from *tert*-butyl (6a*S*,10a*R*)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*) carboxylate (189mg, 0.5 mmol) and
5 corresponding 5-fluoro-4-methoxy-2-methylphenyl boronic acid (184mg, 1.0 mmol) to afford after chromatographic purification the title compound (130mg, 60%). ¹H NMR (CDCl₃, 300 MHz) δ 6.94 (d, 1H, J = 12.5Hz), 6.84 (s, 1H), 6.79-6.82 (m, 2H), 4.02-4.22 (m, 1H), 3.90 (s, 3H), 3.82-
10 3.92 (m, 1H), 3.64-3.74 (m, 1H), 3.24-3.54 (m, 4H), 2.86-3.22 (m, 3H), 2.22 (s, 3H), 1.82-1.94 (m, 2H), 1.48 (s, 9H) ppm. MS - ApCI: 439 [M+H⁺].

EXAMPLE 298

15 (6a*S*,10a*R*)-2-(5-fluoro-4-methoxy-2-methylphenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido [4,3-*b*]pyrrolo[3,2,1-*hi*]indole

The title compound was prepared by the method of
20 Example 98 from *tert*-butyl (6a*S*,10a*R*)-2-(5-fluoro-4-methoxy-2-methylphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-carboxylate to afford the title compound (85mg, 85%). ¹H NMR (CDCl₃, 300 MHz) δ 6.93 (d, 1H, J = 13.1Hz), 6.77-6.82 (m, 3H), 3.90 (s, 3H), 3.66-
25 3.72 (m, 1H), 3.01-3.49 (m, 6H), 2.81-2.94 (m, 3H), 2.23 (s, 3H), 1.69-1.93 (m, 3H) ppm. MS - ApCI: 339 [M+H⁺].

EXAMPLE 299

tert-butyl (6a*S*,10a*R*)-2-(4-methoxy-2-methylphenyl)-
30 4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-carboxylate

The title compound was prepared by the method of Example 89 step C from *tert*-butyl (6a*S*,10a*R*)-2-bromo-
35 4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-

hi]indole-9(6aH) carboxylate (189mg, 0.5 mmol) and 4-methoxy-2-methylphenylboronic acid (166mg, 1.0 mmol) to afford after chromatographic purification the title compound (105mg, 50%). ¹H NMR (CDCl₃, 300 MHz) δ 7.04 (d, 1H, J = 8.5Hz), 6.65-6.79 (m, 4H), 3.75-4.22 (m, 2H), 3.74 (s, 3H), 3.58-3.68 (m, 1H), 3.18-3.42 (m, 4H), 2.76-3.16 (m, 3H), 2.17 (s, 3H), 1.70-1.84 (m, 2H), 1.40 (s, 9H) ppm. MS - ApCI: 421 [M+H⁺].

10

EXAMPLE 300

(6aS,10aR)-2-(4-methoxy-2-methylphenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido [4,3-b]pyrrolo[3,2,1-hi]indole

15

The title compound was prepared by the method of Example 98 from tert-butyl (6aS,10aR)-2-(4-methoxy-2-methylphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate to afford the title compound (50mg, 63%). ¹H NMR (CDCl₃, 300 MHz) δ 7.14 (d, 1H, J = 8.5Hz), 6.85 (s, 1H), 6.73-6.79 (m, 3H), 3.82 (s, 3H), 3.67-3.69 (m, 1H), 3.02-3.50 (m, 6H), 2.82-2.94 (m, 3H), 2.26 (s, 3H), 1.73-1.93 (m, 2H), 1.63 (bs, 1H) ppm. MS - ApCI: 321 [M+H⁺].

20

25

EXAMPLE 301

tert-butyl (6aS,10aR)-2-(2-chloro-4-methoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate

30

The title compound was prepared by the method of Example 89 step C from tert-butyl (6aS,10aR)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH) carboxylate (189mg, 0.5 mmol) and 2-chloro-4-methoxyphenylboronic acid (187mg, 1.0 mmol) to afford after chromatographic purification the title

35

compound (133mg, 60%). ¹H NMR (CDCl₃, 300 MHz) δ 7.23 (d, 1H, J = 8.8Hz), 7.01 (s, 2H), 6.97 (s, 1H), 6.84 (dd, 1H, J = 8.5, 2.6Hz), 3.84-4.24 (m, 2H), 3.84 (s, 3H), 3.68-3.74 (m, 1H), 3.24-3.54 (m, 4H), 2.86-3.26 (m, 3H), 1.84-1.8 (m, 2H), 1.49 (s, 9H) ppm. MS - ApCI: 441 [M+H⁺].

EXAMPLE 302

(6aS,10aR)-2-(2-chloro-4-methoxyphenyl)-
4,5,6a,7,8,9,10,10a-octahydropyrido [4,3-*b*]pyrrolo[3,2,1-
10 *hi*]indole

The title compound was prepared by the method of
Example 98 from *tert*-butyl (6aS,10aR)-2-(2-chloro-4-
methoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-
15 *b*]pyrrolo[3,2,1-*hi*]indole-9(6aH)-carboxylate to afford the
title compound (66mg, 64%). ¹H NMR (CDCl₃, 300 MHz) δ 7.24
(d, 1H, J = 8.4Hz), 7.00-7.01 (m, 2H), 6.94 (s, 1H), 6.83
(dd, 1H, J = 8.7, 2.6Hz), 3.84 (s, 3H), 3.68-3.74 (m, 1H),
3.02-3.51 (m, 6H), 2.85-2.95 (m, 3H), 1.76-1.93 (m, 2H),
20 1.63 (bs, 1H) ppm. MS - ApCI: 341 [M+H⁺].

EXAMPLE 303

tert-butyl (6aS,10aR)-2-(3-chloro-2-methylphenyl)-
4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-
25 *hi*]indole-9(6aH)-carboxylate

The title compound was prepared by the method of
Example 89 step C from *tert*-butyl (6aS,10aR)-2-bromo-
4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-
30 *hi*]indole-9(6aH) carboxylate (189mg, 0.5 mmol) and 3-
chloro-2-methylphenylboronic acid (140mg, 1.0 mmol) to
afford after chromatographic purification the title
compound (99mg, 47%). ¹H NMR (CDCl₃, 300 MHz) δ 7.28-7.31
(m, 1H), 7.10 (d, 2H, J = 4.4Hz), 6.85 (s, 1H), 6.81 (s,
35 1H), 3.82-4.24 (m, 2H), 3.64-3.74 (m, 1H), 3.24-3.54 (m,

4H), 2.86-3.26 (m, 3H), 1.86 (s, 3H), 1.84-1.89 (m, 2H),
1.48 (s, 9H) ppm. MS - ApCI: 425 [M+H⁺].

EXAMPLE 304

5 (6aS,10aR)-2-(3-chloro-2-methylphenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido [4,3-b]pyrrolo[3,2,1-hi]indole

The title compound was prepared by the method of Example 98 from tert-butyl (6aS,10aR)-2-(3-chloro-2-methylphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate to afford the title compound (48mg, 63%). ¹H NMR (CDCl₃, 300 MHz) δ 7.27-7.30 (m, 1H), 7.07-7.13 (m, 2H), 6.83 (s, 1H), 6.78 (s, 1H), 3.67-3.73 (m, 1H), 3.01-3.50 (m, 6H), 2.83-2.94 (m, 15 3H), 2.29 (s, 3H), 1.75-1.93 (m, 2H), 1.62 (bs, 1H) ppm. MS - ApCI: 325 [M+H⁺].

EXAMPLE 305

2-[(6aS,10aR)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]-2-yl]-5-methoxybenzaldehyde
20

Step A:

To a solution of tert-butyl (6aS, 10aR)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-carboxylate (0.600 g, 1.59 mmol) in DME
25 (35 mL) was added 2-formyl-4-methoxybenzeneboronic acid (0.344 g, 1.91 mmol), tetrakis(triphenylphosphine)palladium(0) (0.110 g), barium hydroxide octahydrate (0.753 g, 2.39 mmol), and H₂O (10
30 mL). The combined mixture was refluxed for 20 h. Once at room temperature, the mixture was taken up in H₂O (300 mL) and extracted with EtOAc (3 x 100 mL). The combined extracts were dried over MgSO₄ and stripped of solvent under reduced pressure. Purification by normal phase HPLC
35 using 25% EtOAc in hexanes afforded 0.280 g (41%) of tert-

butyl (6a*S*,10a*R*)-2-(2-formyl-4-methoxyphenyl)-
4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-carboxylate.

5 **Step B:**

A solution of *tert*-butyl (6a*S*,10a*R*)-2-(2-formyl-4-methoxyphenyl)-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-carboxylate (0.066 g, 0.15 mmol) in CH₂Cl₂ (5 mL) was treated with TFA (2 mL) and
10 stirred at room temperature for 18 h in a closed vial. The solution was basified with 1*N* NaOH (50 mL) and extracted with CH₂Cl₂ (3 x 25 mL). The combined extracts were dried over Na₂SO₄, and stripped of the solvent under reduced pressure to yield 0.042 g (82%) of 2-[(6a*S*,10a*R*)-
15 4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]-2-yl]-5-methoxybenzaldehyde as a foam. ¹H NMR (CDCl₃, 300 MHz) δ 7.45 (d, 1H), 7.35 (d, 1H), 7.16 (dd, 1H), 6.92 (d, 1H), 6.86 (d, 1H), 3.88 (s, 1H), 3.74 (td, 1H), 3.51-3.24 (m, 3H), 3.23-3.00 (m, 2H), 2.98-2.83 (m, 1H), 2.00-
20 1.92 (m, 2H). MS (CI): 337 (M+H⁺).

EXAMPLE 306

(6a*S*,10a*R*)-2-(2,6-dichlorophenyl)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole
25

The title compound was prepared by Example 305, Step A, from *tert*-butyl(6a*S*, 10a*R*)-2-bromo-4,5,7,8,10,10a-hexahydropyrido[4,3-*b*]pyrrolo[3,2,1-*hi*]indole-9(6a*H*)-carboxylate and the corresponding 2,6-
30 dichlorobenzeneboronic acid followed by hydrolysis of the resultant BOC protected amine adduct by the procedure of Example 305, Step B. ¹H NMR (CDCl₃, 300 MHz) δ 7.38 (dd, 2H), 7.15 (t, 1H), 6.80 (d, 1H), 6.73 (d, 1H), 3.69 (td, 1H), 3.57-3.30(m, 3H), 3.28-3.00 (m, 3H), 3.00-2.83 (m, 3H), 2.20 (bs, 2H), 2.00-1.81 (m, 2H). MS (CI): 346 (M+H⁺).
35

EXAMPLE 307

N-[4-[(6aS,10aR)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-
b]pyrrolo[3,2,1-hi]indol-2-yl]-3-(trifluoromethyl)phenyl]-
5 N-methylamine

The title compound was prepared by Example 305, Step
A, from tert-butyl(6aS, 10aR)-2-bromo-4,5,7,8,10,10a-
hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-
10 carboxylate and the corresponding 2-
(trifluoromethyl)benzeneboronic acid followed by hydrolysis
of the resultant BOC protected amine adduct by the
procedure of Example 305, Step B. ¹H NMR (CDCl₃, 300 MHz) δ
7.09 (d, 1H), 6.76 (dd, 2H), 6.70 (dd, 1H), 6.63 (dd, 2H),
15 3.80 (bs, 1H), 3.60 (t, 1H), 3.41-2.96 (m, 5H), 2.95-2.73
(m, 4H), 2.10 (bs, 2H), 1.98-1.75 (m, 2H). MS (CI): 374
(M+H⁺).

EXAMPLE 308

20 4-[(6aS,10aR)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-
b]pyrrolo[3,2,1-hi]indol-2-yl]-3-
(trifluoromethyl)phenylamine

The title compound was prepared by Example 305, Step
25 A, from tert-butyl(6aS,10aR)-2-bromo-4,5,7,8,10,10a-
hexahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indole-9(6aH)-
carboxylate and the corresponding 2-
(trifluoromethyl)benzeneboronic acid followed by hydrolysis
of the resultant BOC protected amine adduct by the
30 procedure of Example 305, Step B. ¹H NMR (CDCl₃, 300 MHz) δ
7.03 (d, 1H), 6.90 (d, 1H), 6.79-6.70 (m, 3H), 3.78 (bs,
1H), 3.60 (t, 1H), 3.41-3.18 (m, 2H), 3.17-2.79 (m, 5H),
2.27 (bs, 2H), 1.90-1.80 (m, 2H). MS (CI): 360 (M+H⁺).

EXAMPLE 309

1-(2-[(6aS,10aR)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indol-2-yl]-5-methoxyphenyl)ethanol

5 To a solution of 2-[(6aS,10aR)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]-2-yl]-5-methoxybenzaldehyde (0.156 g, 0.47 mmol) from Example 305 in freshly distilled THF (8 mL) at -78°C was added 3.0 M methylmagnesiumbromide in diethylether (0.88 mL, 2.65 mmol). The reaction was stirred at room temperature for 18 h under a nitrogen atmosphere. The reaction mixture was quenched with aqueous ammonium chloride (20 mL) and extracted with EtOAc (3 x 10 mL). The combined extracts were dried over Na₂SO₄ and evaporated to dryness under reduced pressure to yield a 60% mixture of product and 40% starting material. Purification by reverse phase HPLC using a gradient of 0-100% water, acetonitrile with 0.1% TFA afforded 0.024 g (15%) of 1-(2-[(6aS,10aR)-4,5,6a,7,8,9,10,10a-octahydropyrido[4,3-b]pyrrolo[3,2,1-hi]indol-2-yl]-5-methoxyphenyl)ethanol after generation of the free base. ¹H NMR (CDCl₃, 300 MHz) δ 7.18 (d, 1H), 7.13 (dd, 1H), 6.80 (dd, 2H), 6.77 (d, 1H), 5.03-4.96 (m, 1H), 3.85 (s, 3H), 3.68 (dt, 1H), 3.51-3.39 (m, 1H), 3.36-3.28 (m, 2H), 3.21-3.00 (m, 3H), 2.98-2.80 (m, 3H), 2.00-1.78 (m, 2H), 1.19 (q, 3H). MS (CI): 351 (M+H⁺).

EXAMPLE 310

(±)-cis-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole

30

Step A:

Sodium azide (1.95 g, 30 mmol) was added in small portions to a solution of 3,4-dihydro-1(2H)-naphthalenone (2.92 g, 20 mmol) in CH₃SO₃H (50 mL) at 0°C. The mixture was stirred at 0°C for 15 min, 1hr at room temperature,

35

poured into ice (400 mL), basified until pH > 8 with 1N NaOH at 0°C and extracted with ether (3 × 100 mL). The combined organic layer was dried (MgSO₄), concentrated in vacuo and flash column chromatography (EtOAc:hexane / 1:1) gave 1,3,4,5-tetrahydro-2H-1-benzazepin-2-one (2.71 g, 85%) as a white solid. ¹H NMR (CDCl₃, 300 MHz) δ 2.18-2.32 (m, 2H), 2.36 (t, J = 7.1 Hz, 2H), 2.80 (t, J = 7.6 Hz, 2H), 6.99 (d, J = 8.1 Hz, 1H), 7.13 (td, J = 7.6, 1.5 Hz, 1H), 7.22 (d, J = 7.0 Hz, 2H), 8.10 (br, 1H) ppm.

10

Step B:

A solution of 1,3,4,5-tetrahydro-2H-1-benzazepin-2-one (2.71 g, 16.7 mmol) in THF (40 mL) was added dropwise to a suspension of LAH (1.27 g, 33.4 mmol) in ether (150 mL) at room temperature. The mixture was refluxed for 16h. Saturated Rochelle's salt solution (15 mL) was added to the mixture cooled with an ice-water bath. The mixture was stirred for 2hrs and the two layers were separated. The aqueous layer was extracted with ether (2 × 25 mL). The combined organic layer was dried (Na₂SO₄), concentrated in vacuo and flash column chromatography (EtOAc:hexane / 3:7) gave 2,3,4,5-tetrahydro-1H-1-benzazepine (2.40 g, 98%) as a yellow liquid. ¹H NMR (CDCl₃, 300 MHz) δ 1.58-1.70 (m, 2H), 1.72-1.86 (m, 2H), 2.72-2.82 (m, 2H), 3.00-3.10 (m, 2H), 3.78 (br, 1H), 6.74 (dd, J = 1.1, 7.7 Hz, 1H), 6.82 (td, J = 7.3, 1.1 Hz, 1H), 7.04 (td, J = 7.5, 1.5 Hz, 1H), 7.11 (d, J = 7.4 Hz, 1H) ppm.

Step C:

A solution of sodium nitrite (1.35 g, 19.6 mmol) in water (4.0 mL) was added dropwise to a solution of 2,3,4,5-tetrahydro-1H-1-benzazepine (2.40 g, 16.3 mmol) in AcOH (10 mL) at 0-10°C. The mixture was stirred at 5°C for 10 min, room temperature for 1 h and extracted with CH₂Cl₂ (3 × 20 mL). The organic layer was dried (MgSO₄), concentrated in

35

vacuo and flash column chromatography (EtOAc:hexane / 1:9) gave 1-nitroso-2,3,4,5-tetrahydro-1H-1-benzazepine (2.60 g, 91%) as a brown liquid. ^1H NMR (CDCl_3 , 300 MHz) δ 1.70-1.85 (m, 4H), 2.70-2.82 (m, 2H), 3.92 (br, 2H), 7.25-7.32 (m, 1H), 7.32-7.40 (m, 2H), 7.40-7.48 (m, 1H) ppm.

Step D:

A solution of 1-nitroso-2,3,4,5-tetrahydro-1H-1-benzazepine (2.60 g, 14.7 mmol) in THF (40 mL) was added dropwise under N_2 to a suspension of LAH (0.56 g, 14.7 mmol) in THF (10 mL) cooled with an ice-bath such that the temperature did not rise above 15°C . The mixture was stirred at room temperature for 1 h, quenched with saturated Rochelle's salt solution (15 mL) and extracted with ether (3×20 mL). The organic layer was dried (Na_2SO_4), concentrated in vacuo and flash column chromatography (EtOAc:hexane / 1:4) gave 2,3,4,5-tetrahydro-1H-1-benzazepin-amine (1.63 g, 68%) as a light yellow solid. ^1H NMR (CDCl_3 , 300 MHz) δ 1.50-1.72 (m, 2H), 1.78-1.92 (m, 2H), 2.70-2.82 (m, 2H), 3.180-3.22 (m, 2H), 3.78 (br, 2H), 6.91 (td, $J = 7.3, 1.5$ Hz, 1H), 7.10 (dd, $J = 1.1, 7.4$ Hz, 1H), 7.21 (td, $J = 8.0, 1.4$ Hz, 1H), 7.28 (dd, $J = 1.4, 8.0$ Hz, 1H) ppm.

Step E:

A mixture of 4-piperidone monohydrate HCl (1.54 g, 10 mmol) and 2,3,4,5-tetrahydro-1H-1-benzazepin-amine (1.62 g, 10 mmol) in IPA (50 mL) was refluxed for 2 h and cooled to room temperature. Concentrated HCl (0.82 mL, 10 mmol) was added and the resultant mixture was refluxed for 3 hrs before being cooled to room temperature. The solid was filtered, rinsed with cold IPA (2×20 mL) and concentrated in vacuo. 4,5,6,7,9,10,11,12-Octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole hydrochloride (1.88 g, 71%) was obtained as a pink solid. 4,5,6,7,9,10,11,12-

Octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole hydrochloride (20 mg, 0.076 mmol) in water (1.0 mL) was basified with 1N NaOH until pH > 14 and extracted with CHCl₃ (3 × 10 mL).

The combined organic layer was washed with brine (10 mL),
5 dried (MgSO₄) and concentrated *in vacuo*.

4,5,6,7,9,10,11,12-Octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole (16 mg, 95%) was obtained as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.83 (br, 1H), 2.00-2.20 (m, 4H), 2.72 (t, J = 5.7 Hz, 2H), 3.05-3.20 (m, 2H), 3.25 (t, J = 5.6
10 Hz, 2H), 3.92-4.02 (m, 2H), 4.05 (t, J = 1.6 Hz, 2H), 6.92 (d, J = 6.3 Hz, 1H), 6.98 (t, J = 7.4 Hz, 1H), 7.25 (dd, J = 1.0, 7.4 Hz, 1H) ppm.

Step F:

15 NaCNBH₃ (0.94 g, 15 mmol) was added in small portions to a solution of 4,5,6,7,9,10,11,12-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole hydrochloride (1.32 g, 5.0 mmol) in TFA (15 mL) at 0 °C. After stirring at room temperature for 2 h, the mixture was carefully treated with 6 N HCl (10
20 mL) and refluxed for 1 h. The mixture was basified with 50% NaOH and extracted with CH₂Cl₂ (3 × 20 mL). The organic layer was dried (MgSO₄) and concentrated *in vacuo*. The title compound (1.0 g, 89%) was obtained as a yellow oil.
¹H NMR (CDCl₃, 300 MHz) δ 1.48-1.68 (m, 1H), 1.68-2.10 (m,
25 7H), 2.42-2.72 (m, 3H), 2.80-3.00 (m, 3H), 3.05 (dd, J = 6.3, 12.4 Hz, 1H), 3.12-3.55 (m, 2H), 6.69 (t, J = 7.4 Hz, 1H), 6.92 (dd, J = 2.5, 7.4 Hz, 2H) ppm.

EXAMPLE 311

30 tert-butyl (±)-*cis*-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8aH)-carboxylate

1 N NaOH (10 mL) was added to a solution of (±)-*cis*-
35 4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-

hi]pyrido[4,3-*b*]indole (1.00 g, 4.37 mmol) and di-*tert*-butyl dicarbonate (1.05 g, 4.8 mmol) in 1,4-dioxane (20 mL) and the mixture was stirred for 2 h at room temperature. The solvent was concentrated in *vacuo* and EtOAc (30 mL) was
5 added. The solution was washed with brine (30 mL), dried (MgSO₄), concentrated in *vacuo* and flash column chromatography (EtOAc:hexane / 1:4) gave the title compound (1.2 g, 83%) as a white solid.

10

EXAMPLE 312

(8a*S*,12a*R*)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole

Step A:

15 *Tert*-Butyl (8a*S*,12a*R*)-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate was obtained from (±)-*tert*-butyl *cis*-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate by using preparative HPLC on a
20 Chiracel® OD column (2% IPA in hexane).

Step B:

Tert-Butyl (8a*S*,12a*R*)-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-
25 carboxylate (0.24 g, 0.73 mmol) was stirred in 20% TFA in CH₂Cl₂ (10 mL) at room temperature for 2 h before the solution was basified with saturated NH₄OH until pH > 10. The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (3 × 20 mL). The combined organic
30 layer was washed with brine (20 mL), dried (MgSO₄) and concentrated in *vacuo*. The title compound (0.16 g, 94%) was obtained as a white foam. ¹H NMR was identical to (±)-*cis*-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole of Example 310.

35

EXAMPLE 313

(8aR,12aS)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole

5 Step A:

Tert-butyl (8aR,12aS)-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate was obtained from (±)-tert-butyl cis-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate by using preparative HPLC on a Chiracel® OD column (2% IPA in hexane).

Step B:

The title compound (0.063 g, 98%) was prepared by the
15 general method of Example 312, step B from tert-butyl (8aR,12aS)-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.092 g, 0.28 mmol) as a white foam. ¹H NMR was identical to (±)-cis-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole of Example 310.
20

EXAMPLE 314

tert-butyl (8aS,12aR)-2-bromo-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-
25 carboxylate

A solution of NBS (0.29 g, 1.6 mmol) in DMF (2.0 mL) was added dropwise to a solution of tert-butyl (8aS,12aR)-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]-indole-11(8aH)-carboxylate (0.53 g, 1.6 mmol) in DMF
30 (3.0 mL) at 0 °C. The mixture was stirred at 0 °C for 15 min and room temperature for 0.5 h before poured into water (10 mL). The milky mixture was extracted with EtOAc (3 × 10 mL) and the extract was dried (MgSO₄), concentrated in
35 vacuo and flash column chromatography (EtOAc:hexane / 1:4) gave the title compound (0.58 g, 89%) as a white solid.

EXAMPLE 315

(8a*S*,12a*R*)-2-(2,4-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
5 *hi*]pyrido[4,3-*b*]indole

Step A:

A mixture of *tert*-butyl (8a*S*,12a*R*)-2-bromo-
4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-
10 *b*]indole-11(8a*H*)-carboxylate (0.20 g, 0.50 mmol), 2,4-
dichlorophenylboronic acid (0.19 g, 1.0 mmol), Ba(OH)₂·8H₂O
(0.32 g, 1.0 mmol), Pd₂(dba)₃ (7.5 mg, 0.0075 mmol) and PPh₃
(5.24 mg, 0.02 mmol) in DME (10 mL) and water (2.5 mL) was
degassed and refluxed for 18 h and cooled to room
15 temperature. The mixture was concentrated *in vacuo* and
EtOAc (20 mL) was added. The solution was washed with
saturated Na₂CO₃ (2 × 10 mL), dried (Na₂SO₄), concentrated
in vacuo and flash column chromatography (EtOAc:hexane /
1:9) gave *tert*-butyl (8a*S*,12a*R*)-2-(2,4-dichlorophenyl)-
20 4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.16 g, 66%) as
a white foam.

Step B:

25 The title compound (0.087 g, 77%) was prepared by the
general method of Example 312, step B from *tert*-butyl
(8a*S*,12a*R*)-2-(2,4-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.14 g, 0.30
30 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70
(m, 1H), 1.70-1.90 (m, 2H), 1.90-2.10 (m, 4H), 2.48-2.80
(m, 3H), 2.80-3.00 (m, 3H), 3.04 (dd, J = 6.3, 12.4 Hz,
1H), 3.10-3.25 (m, 1H), 3.25-3.42 (m, 2H), 6.96 (s, 1H),
7.00 (s, 1H), 7.20-7.30 (m, 2H), 7.44 (d, J = 1.1 Hz, 1H)
35 ppm.

EXAMPLE 316

(8aS,12aR)-2-(2,3-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
5 hi]pyrido[4,3-b]indole

Step A:

Tert-butyl (8aS,12aR)-2-(2,3-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
10 hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.14 g, 59%)
was prepared by the general method of Example 89, step C
from tert-butyl (8aS,12aR)-2-bromo-4,5,6,7,9,10,12,12a-
octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-
carboxylate (0.20 g, 0.50 mmol), 2,3-dichlorophenyl boronic
15 acid (0.19 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol),
Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam.

Step B:

The title compound (0.10 g, 92%) was prepared by the
20 general method of Example 312, step B from tert-butyl
(8aS,12aR)-2-(2,3-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.14 g, 0.30
mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70
25 (m, 1H), 1.70-1.92 (m, 2H), 1.92-2.08 (m, 3H), 2.15-2.80
(m, 4H), 2.80-3.00 (m, 3H), 3.05 (dd, J = 6.3, 12.4 Hz,
1H), 3.10-3.34 (m, 2H), 3.34-3.42 (m, 1H), 6.96 (d, J = 1.6
Hz, 1H), 7.00 (d, J = 1.6 Hz, 1H), 7.12-7.25 (m, 2H), 7.38
(dd, J = 2.4, 7.2 Hz, 1H) ppm. MS (ESI): 373 (base, M+H).

30

EXAMPLE 317

(8aS,12aR)-2-(3,4-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole

35

Step A:

Tert-butyl (8aS,12aR)-2-(3,4-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.070 g, 30%)
5 was prepared by the general method of Example 89, step C
from tert-butyl (8aS,12aR)-2-bromo-4,5,6,7,9,10,12,12a-
octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-
carboxylate (0.20 g, 0.50 mmol), 3,4-dichlorophenyl boronic
acid (0.19 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol),
10 Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam.

Step B:

The title compound (0.040 g, 72%) was prepared by the
general method of Example 312, step B from tert-butyl
15 (8aS,12aR)-2-(3,4-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.070 g, 0.15
mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70
(m, 1H), 1.70-1.92 (m, 2H), 1.92-2.10 (m, 3H), 2.23 (br,
20 1H), 2.48-2.80 (m, 3H), 2.80-3.00 (m, 3H), 3.06 (dd, J =
6.3, 12.4 Hz, 1H), 3.14-3.25 (m, 1H), 3.25-3.40 (m, 2H),
7.11 (s, 2H), 7.35 (dd, J = 2.2, 8.4 Hz, 1H), 7.42 (d, J =
8.4 Hz, 1H), 7.61 (d, J = 2.2 Hz, 1H) ppm.

EXAMPLE 318

(8aS,12aR)-2-(3,5-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole

Step A:

Tert-butyl (8aS,12aR)-2-(3,5-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.13 g, 55%)
was prepared by the general method of Example 89, step C
35 from tert-butyl (8aS,12aR)-2-bromo-4,5,6,7,9,10,12,12a-

octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-
carboxylate (0.20 g, 0.50 mmol), 3,5-dichlorophenyl boronic
acid (0.19 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol),
Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI):
5 473 (base, M+H).

Step B:

The title compound (0.10 g, 92%) was prepared by the
general method of Example 312, step B from *tert*-butyl
10 (8a*S*,12a*R*)-2-(3,5-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.14 g, 0.30
mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70
(m, 1H), 1.70-1.90 (m, 2H), 1.90-2.15 (m, 5H), 2.48-65 (m,
15 2H), 2.65-2.80 (m, 1H), 2.82-2.90 (m, 2H), 3.07 (dd, J =
6.3, 12.4 Hz, 1H), 3.12-3.26 (m, 1H), 3.26-3.40 (m, 2H),
7.10 (s, 2H), 7.22 (t, J = 1.8 Hz, 2H), 7.39 (d, J = 1.8
Hz, 2H) ppm. MS (ESI): 373 (base, M+H).

20 **EXAMPLE 319**

(8a*S*,12a*R*)-2-(2,5-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole

25 **Step A:**

A mixture of *tert*-butyl (8a*S*,12a*R*)-2-bromo-
4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-
b]indole-11(8a*H*)-carboxylate (0.10 g, 0.25 mmol), 2,5-
dichlorophenyl boronic acid (0.10 g, 0.50 mmol) and Ba(OH)₂
30 (0.17 M, 3.0 mL, 0.51 mmol) in DME (15 mL) was degassed at
40-50 °C before Pd(PPh₃)₄ (12 mg, 0.010 mmol) was added.
The mixture was degassed again as described before and
refluxed for 16 h. The mixture was concentrated in *vacuo*
and EtOAc (20 mL) was added. The solution was washed with
35 saturated Na₂CO₃ (2 × 10 mL), dried (Na₂SO₄), concentrated

in vacuo and flash column chromatography (EtOAc:hexane /
1:9) gave *tert*-butyl (8a*S*,12a*R*)-2-(2,5-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.098 g, 83%)
5 as a white foam. MS (ESI): 473 (base, M+H).

Step B:

The title compound (0.077 g, 100%) was prepared by the
general method of Example 312, step B from *tert*-butyl
10 (8a*S*,12a*R*)-2-(2,5-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.098 g, 0.21
mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70
(m, 2H), 1.70-1.90 (m, 2H), 1.90-2.10 (m, 3H), 2.48-2.80
15 (m, 3H), 2.85-3.00 (m, 3H), 3.08 (dd, J = 6.3, 12.4 Hz,
1H), 3.15-3.35 (m, 2H), 3.35-3.44 (m, 1H), 6.98 (s, 1H),
7.02 (s, 1H), 7.18 (dd, J = 2.6, 8.6 Hz, 1H), 7.32 (d, J =
2.6 Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H) ppm. MS (ESI): 373
(base, M+H).

20

EXAMPLE 320

(8a*S*,12a*R*)-2-(2,6-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole

25

Step A:

A mixture of *tert*-butyl (8a*S*,12a*R*)-2-bromo-
4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-
b]indole-11(8a*H*)-carboxylate (0.10 g, 0.25 mmol), 2,6-
30 dichlorophenylboronic acid (0.10 g, 0.50 mmol),
Pd(dppf)₂Cl₂ (10 mg, 0.012 mmol) and TEA (1.0 mL, 7.2 mmol)
in DME (15 mL) was degassed at 40-50 °C and refluxed for 32
h. The mixture was concentrated in vacuo and EtOAc (20 mL)
was added. The solution was washed with saturated Na₂CO₃
35 (2 × 10 mL), dried (Na₂SO₄) and concentrated in vacuo.

Normal phase HPLC (5% EtOAc in hexane) gave *tert*-butyl
(8a*S*,12a*R*)-2-(2,6-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.030 g, 26%)
5 as a white foam. MS (ESI): 473 (base, M+H).

Step B:

The title compound (0.025 g, 100%) was prepared by the
general method of Example 312, step B from *tert*-butyl
10 (8a*S*,12a*R*)-2-(2,6-dichlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.030 g, 0.060
mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70
(m, 1H), 1.70-1.88 (m, 2H), 1.88-2.10 (m, 3H), 2.48-2.80
15 (m, 4H), 2.82-3.00 (m, 3H), 3.06 (dd, J = 6.3, 12.4 Hz,
1H), 3.15-3.38 (m, 2H), 3.38-3.44 (m, 1H), 6.79 (s, 2H),
7.14 (t, J = 8.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H) ppm. MS
(ESI): 373 (base, M+H).

20

EXAMPLE 321

(8a*S*,12a*R*)-2-(2-chlorophenyl)-4,5,6,7,8a,9,10,11,12,12a-
decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole

Step A:

25

Tert-butyl (8a*S*,12a*R*)-2-(2-chlorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.15 g, 67%)
was prepared by the general method of Example 89, step C
from *tert*-butyl (8a*S*,12a*R*)-2-bromo-4,5,6,7,9,10,12,12a-
30 octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-
carboxylate (0.20 g, 0.50 mmol), 2-chlorophenylboronic acid
(0.16 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃
(2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 439
(base, M+H).

35

Step B:

The title compound (0.087 g, 77%) was prepared by the general method of Example 312, step B from tert-butyl (8a*S*,12a*R*)-2-(2-chlorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.15 g, 0.33 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 1H), 1.70-2.10 (m, 5H), 2.48-2.78 (m, 3H), 2.88-3.02 (m, 3H), 3.10 (dd, *J* = 6.3, 12.4 Hz, 1H), 3.20-3.35 (m, 2H), 3.35-3.42 (m, 1H), 3.63 (br, 1H), 7.01 (s, 1H), 7.05 (s, 1H), 7.15-7.35 (m, 3H), 7.43 (dd, *J* = 1.7, 7.5 Hz, 1H) ppm. MS (ESI): 339 (base, M+H).

EXAMPLE 322

(8a*S*,12a*R*)-2-(3-chlorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole

Step A:

Tert-butyl (8a*S*,12a*R*)-2-(3-chlorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.12 g, 55%) was prepared by the general method of Example 89, step C from tert-butyl (8a*S*,12a*R*)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.20 g, 0.50 mmol), 3-chlorophenylboronic acid (0.16 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 439 (base, M+H).

Step B:

The title compound (0.045 g, 100%) was prepared by the general method of Example 312, step B from tert-butyl (8a*S*,12a*R*)-2-(3-chlorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.058 g, 0.13 mmol) as a white foam. ¹H NMR

(CDCl₃, 300 MHz) δ 1.43 (br, 1H), 1.50-1.70 (m, 1H), 1.70-2.10 (m, 5H), 2.40-2.80 (m, 3H), 2.80-3.00 (m, 3H), 3.08 (dd, J = 6.3, 12.4 Hz, 1H), 3.10-3.42 (m, 3H), 7.14 (s, 2H), 7.21 (d, J = 7.5 Hz, 1H), 7.30 (t, J = 7.8 Hz, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.52 (s, 1H) ppm. MS (ESI): 339 (base, M+H).

EXAMPLE 323

(8aS,12aR)-2-(4-chlorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole

Step A:

Tert-butyl (8aS,12aR)-2-(4-chlorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.11 g, 50%) was prepared by the general method of Example 89, step C from tert-butyl (8aS,12aR)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.20 g, 0.50 mmol), 4-chlorophenylboronic acid (0.16 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 439 (base, M+H).

Step B:

The title compound (0.084 g, 99%) was prepared by the general method of Example 312, step B from tert-butyl (8aS,12aR)-2-(4-chlorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.11 g, 0.25 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 1H), 1.70-2.10 (m, 5H), 2.48-2.80 (m, 3H), 2.80-3.05 (m, 4H), 3.12 (dd, J = 6.3, 12.4 Hz, 1H), 3.20-3.42 (m, 3H), 7.14 (s, 2H), 7.36 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H) ppm. MS (ESI): 339 (base, M+H).

EXAMPLE 324

(±)-cis-2-(2,6-difluorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole

5 Step A:

Tert-butyl (±)-2-(2,6-difluorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.045 g, 21%) was prepared by the general method of Example 320, step A from tert-butyl (±)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.20 g, 0.50 mmol), 2,6-difluorophenylboronic acid (0.32 g, 2.0 mmol), Pd(dppf)₂Cl₂ (24 mg, 0.030 mmol), TEA (1.6 mL, 11 mmol) as a white foam.

15

Step B:

The title compound (0.017 g, 49%) was prepared by the general method of Example 312, step B from tert-butyl (8aS,12aR)-2-(2,6-difluorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.045 g, 0.10 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 1H), 1.70-2.10 (m, 5H), 2.50-2.80 (m, 3H), 2.80-3.05 (m, 3H), 3.05-3.20 (m, 2H), 3.20-3.35 (m, 2H), 3.35-3.42 (m, 1H), 6.94 (t, J = 8.1 Hz, 2H), 7.04 (s, 2H), 7.15-7.22 (m, 1H) ppm.

25

EXAMPLE 325

(8aS,12aR)-2-(2,6-difluorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole

30

Step A:

Tert-butyl (8aS,12aR)-2-(2,6-difluorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-

35

hi]pyrido[4,3-*b*]indole-11(8*aH*)-carboxylate (0.040 g, 18%)
was prepared by the general method of Example 320, step A
from *tert*-butyl (8*aS*, 11*aR*)-2-bromo-4,5,6,7,9,10,12,12*a*-
octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8*aH*)-
5 carboxylate (0.20 g, 0.50 mmol), 2,6-difluorophenylboronic
acid (0.32 g, 2.0 mmol), Pd(dppf)₂Cl₂ (24 mg, 0.030 mmol),
TEA (1.6 mL, 11 mmol) as a white foam.

Step B:

10 The title compound (9.0 mg, 29%) was prepared by the
general method of Example 312, step B from *tert*-butyl
(8*aS*, 12*aR*)-2-(2,6-difluorophenyl)-
4,5,6,7,8*a*,9,10,11,12,12*a*-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8*aH*)-carboxylate (0.040 g, 0.091
15 mmol) as a white foam. ¹H NMR was identical to that of (±)-
cis-2-(2,6-difluorophenyl)-4,5,6,7,8*a*,9,10,11,12,12*a*-
decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole

EXAMPLE 326

20 (8*aS*, 12*aR*)-2-(2,3-difluorophenyl)-
4,5,6,7,8*a*,9,10,11,12,12*a*-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole

Step A:

25 *Tert*-butyl (8*aS*, 12*aR*)-2-(2,3-difluorophenyl)-
4,5,6,7,8*a*,9,10,11,12,12*a*-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8*aH*)-carboxylate (0.069 g, 63%)
was prepared by the general method of Example 319, step A
from *tert*-butyl (8*aS*, 12*aR*)-2-bromo-4,5,6,7,9,10,12,12*a*-
30 octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8*aH*)-
carboxylate (0.10 g, 0.25 mmol), 2,3-difluorophenylboronic
acid (0.080 g, 0.5 mmol), Pd(PPh₃)₄ (12 mg, 0.010 mmol),
and Ba(OH)₂ (0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS
(ESI): 441 (base, M+H).

35

Step B:

The title compound (0.053 g, 100%) was prepared by the general method of Example 312, step B from tert-butyl (8a*S*,12a*R*)-2-(2,3-difluorophenyl)-
5 4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.069 g, 0.16 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 1H), -1.70-2.10 (m, 5H), 2.48-2.80 (m, 3H), 2.85-3.02 (m, 3H), 3.12 (dd, *J* = 6.3, 12.4 Hz, 1H), 3.20-3.60 (m,
10 4H), 7.00-7.22 (m, 5H) ppm. MS (ESI): 341 (base, M+H).

EXAMPLE 327

(8a*S*,12a*R*)-2-(3,4-difluorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
15 hi]pyrido[4,3-*b*]indole

Step A:

Tert-butyl (8a*S*,12a*R*)-2-(3,4-difluorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
20 hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.078 g, 71%)
was prepared by the general method of Example 319, step A
from tert-butyl (8a*S*,12a*R*)-2-bromo-4,5,6,7,9,10,12,12a-
octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-
carboxylate (0.10 g, 0.25 mmol), 3,4-difluorophenylboronic
25 acid (0.080 g, 0.50 mmol), Pd(PPh₃)₄ (12 mg, 0.010 mmol),
and Ba(OH)₂ (0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS
(ESI): 441 (base, M+H).

Step B:

30 The title compound (0.055 g, 92%) was prepared by the
general method of Example 312, step B from tert-butyl
(8a*S*,12a*R*)-2-(3,4-difluorophenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.078 g, 0.18
35 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70

(m, 1H), 1.70-2.12 (m, 5H), 2.50-2.80 (m, 3H), 2.92-3.05 (m, 3H), 3.14 (dd, J = 6.3, 12.4 Hz, 1H), 3.22-3.42 (m, 3H), 3.49 (s, 1H), 7.05-7.40 (m, 5H) ppm. MS (ESI): 341 (base, M+H).

5

EXAMPLE 328

(8aS,12aR)-2-(3-fluorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole

10 **Step A:**

Tert-butyl (8aS,12aR)-2-(3-fluorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.13 g, 62%) was prepared by the general method of Example 89, step C from tert-butyl (8aS,12aR)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.20 g, 0.50 mmol), 3-fluorophenylboronic acid (0.14 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 423 (base, M+H).

20

Step B:

The title compound (0.025 g, 93%) was prepared by the general method of Example 312, step B from tert-butyl (8aS,12aR)-2-(3-fluorophenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.035 g, 0.083 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 1H), 1.70-2.17 (m, 6H), 2.48-2.82 (m, 3H), 2.82-3.05 (m, 3H), 3.08 (dd, J = 6.3, 12.4 Hz, 1H), 3.15-3.40 (m, 3H), 6.88-6.96 (m, 1H), 7.15 (s, 2H), 7.18-7.26 (m, 1H), 7.28-7.35 (m, 2H) ppm. MS (ESI): 323 (base, M+H).

30

EXAMPLE 329

(8aS,12aR)-2-[2-chloro-4-(trifluoromethyl)phenyl]-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole

5

Step A:

Tert-butyl (8aS,12aR)-2-[2-chloro-4-
(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-
decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8aH)-
10 carboxylate (0.21 g, 82%) was prepared by the general
method of Example 89, step C from *tert*-butyl (8aS,12aR)-2-
bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8aH)-carboxylate (0.20 g, 0.50
mmol), 2-chloro-4-(trifluoromethyl)phenylboronic acid (0.22
15 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0
M, 1.0 mL, 2.0 mmol) as a white foam.

Step B:

The title compound (0.15 g, 87%) was prepared by the
20 general method of Example 312, step B from *tert*-butyl
(8aS,12aR)-2-[2-chloro-4-(trifluoromethyl)phenyl]-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-*b*]indole-11(8aH)-carboxylate (0.21 g, 0.41
mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70
25 (m, 1H), 1.70-1.90 (m, 2H), 1.90-2.20 (m, 4H), 2.48-2.80
(m, 3H), 2.80-3.00 (m, 3H), 3.05 (dd, J = 6.3, 12.4 Hz,
1H), 3.10-3.25 (m, 1H), 3.25-3.36 (m, 1H), 3.36-3.45 (m,
1H), 7.00 (d, J = 1.5 Hz, 1H), 7.05 (d, J = 1.5 Hz, 1H),
7.44 (d, J = 8.1 Hz, 1H), 7.51 (dd, J = 1.1, 8.1 Hz, 1H),
30 7.70 (s, 1H) ppm.

EXAMPLE 330

(8aS,12aR)-2-(2-chloro-4-methoxyphenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
35 *hi*]pyrido[4,3-*b*]indole

Step A:

Tert-butyl (8a*S*,12a*R*)-2-(2-chloro-4-methoxyphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.15 g, 64%) was prepared by the general method of Example 89, step C from *tert-butyl* (8a*S*,12a*R*)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.20 g, 0.50 mmol), 2-chloro-4-methoxyphenylboronic acid (0.19 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam.

Step B:

The title compound (0.12 g, 97%) was prepared by the general method of Example 312, step B from *tert-butyl* (8a*S*,12a*R*)-2-(2-chloro-4-methoxyphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.15 g, 0.32 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 1H), 1.70-1.85 (m, 2H), 1.90-2.10 (m, 3H), 2.10-2.30 (m, 2H), 2.48-2.72 (m, 3H), 2.88-3.00 (m, 1H), 3.08-3.40 (m, 4H), 3.48-3.58 (m, 1H), 3.81 (s, 3H), 6.82 (dd, J = 2.4, 8.4 Hz, 1H), 6.92-7.05 (m, 3H), 7.19 (d, J = 8.4 Hz, 1H) ppm.

EXAMPLE 331

(8a*S*,12a*R*)-2-(2-fluoro-4-methoxyphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole

Step A:

Tert-butyl (8a*S*,12a*R*)-2-(2-fluoro-4-methoxyphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.16 g, 69%)

was prepared by the general method of Example 89, step C from tert-butyl (8aS,12aR)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.20 g, 0.50 mmol), 2-fluoro-4-methoxyphenylboronic acid (0.17 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 453 (base, M+H).

Step B:

The title compound (0.11 g, 94%) was prepared by the general method of Example 312, step B from tert-butyl (8aS,12aR)-2-(2-fluoro-4-methoxyphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.15 g, 0.34 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 1H), 1.70-1.90 (m, 2H), 1.90-2.10 (m, 3H), 2.50-2.80 (m, 3H), 2.80-3.00 (m, 3H), 3.05 (dd, J = 6.3, 12.4 Hz, 1H), 3.10-3.25 (m, 1H), 3.25-3.40 (m, 2H), 3.82 (s, 3H), 6.64-6.76 (m, 2H), 7.07 (s, 1H), 7.08 (s, 1H), 7.31 (t, J = 8.8 Hz, 1H) ppm. MS (ESI): 353 (base, M+H).

EXAMPLE 332

(8aS,12aR)-2-(4-methoxy-2-methylphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole

Step A:

Tert-butyl (8aS,12aR)-2-(4-methoxy-2-methylphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.095 g, 42%) was prepared by the general method of Example 89, step C from tert-butyl (8aS,12aR)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.20 g, 0.50 mmol), 4-methoxy-2-methylphenyl boronic acid (0.17 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025

mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 449 (base, M+H).

Step B:

5 The title compound (0.071 g, 96%) was prepared by the general method of Example 312, step B from tert-butyl (8a*S*,12a*R*)-2-(4-methoxy-2-methylphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.095 g, 0.21 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 1H), 1.70-1.92 (m, 2H), 1.92-2.10 (m, 3H), 2.28 (s, 3H), 2.45-2.60 (m, 3H), 2.62-2.78 (m, 1H), 2.85-2.98 (m, 3H), 3.08 (dd, J = 6.3, 12.4 Hz, 1H), 3.12-3.40 (m, 3H), 3.82 (s, 3H), 6.70-6.80 (m, 3H), 6.84 (s, 1H), 6.85 (s, 1H), 7.14 (d, J = 8.4 Hz, 1H) ppm. MS (ESI): 349 (base, M+H).

EXAMPLE 333

(8a*S*,12a*R*)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole

Step A:

25 Tert-butyl (8a*S*,12a*R*)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.20 g, 78%) was prepared by the general method of Example 89, step C from tert-butyl (8a*S*,12a*R*)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.20 g, 0.50 mmol), 4-methoxy-2-(trifluoromethyl)phenylboronic acid (0.22 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 503 (base, M+H).

35

Step B:

The title compound (0.13 g, 84%) was prepared by the general method of Example 312, step B from *tert*-butyl (8a*S*,12a*R*)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.20 g, 0.39 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 1H), 1.70-1.90 (m, 2H), 1.90-2.10 (m, 4H), 2.45-2.62 (m, 2H), 2.62-2.75 (m, 1H), 2.80-2.95 (m, 3H), 3.08 (dd, J = 6.3, 12.4 Hz, 1H), 3.08-3.20 (m, 1H), 3.25-3.40 (m, 2H), 3.86 (s, 3H), 6.83 (s, 1H), 6.85 (s, 1H), 7.03 (dd, J = 2.2, 8.4 Hz, 1H), 7.18-7.25 (m, 2H) ppm. MS (ESI): 403 (base, M+H).

15

EXAMPLE 334

(8a*S*,12a*R*)-2-[2-(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole

20 **Step A:**

Tert-butyl (8a*S*,12a*R*)-2-[2-(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.15 g, 61%) was prepared by the general method of Example 89, step C from *tert*-butyl (8a*S*,12a*R*)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.20 g, 0.50 mmol), 2-(trifluoromethyl)phenylboronic acid (0.19 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 473 (base, M+H).

30

Step B:

The title compound (0.11 g, 96%) was prepared by the general method of Example 312, step B from *tert*-butyl (8a*S*,12a*R*)-2-[2-(trifluoromethyl)phenyl]-

35

4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.15 g, 0.31
mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70
(m, 1H), 1.70-1.92 (m, 2H), 1.92-2.25 (m, 3H), 2.45-2.65
5 (m, 2H), 2.65-2.80 (m, 1H), 2.80-3.00 (m, 4H), 3.08 (dd, J
= 6.3, 12.4 Hz, 1H), 3.12-3.25 (m, 1H), 3.25-3.42 (m, 2H),
6.88 (s, 1H), 6.90 (s, 1H), 7.30-7.45 (m, 2H), 7.52 (t, J =
7.3 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H) ppm. MS (ESI): 373
(base, M+H).

10

EXAMPLE 335

(8aS,12aR)-2-[4-isopropoxy-2-(trifluoromethyl)phenyl]-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole

15

Step A:

Tert-butyl (8aS,12aR)-2-[4-isopropoxy-2-
(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-
decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-
20 carboxylate (0.17 g, 63%) was prepared by the general
method of Example 89, step C from tert-butyl (8aS,12aR)-2-
bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.20 g, 0.50
mmol), 4-isopropoxy-2-(trifluoromethyl)phenylboronic acid
25 (0.18 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃
(2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 531
(base, M+H).

Step B:

30 The title compound (0.14 g, 100%) was prepared by the
general method of Example 312, step B from tert-butyl
(8aS,12aR)-2-[4-isopropoxy-2-(trifluoromethyl)phenyl]-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.17 g, 0.32
35 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70

(m, 1H), 1.39 (d, J = 6.0 Hz, 6H), 1.70-2.10 (m, 5H), 2.45-2.78 (m, 3H), 2.85-3.00 (m, 3H), 3.00-3.10 (m, 1H), 3.12-3.32 (m, 4H), 4.62 (p, J = 6.0 Hz, 1H), 6.86 (s, 1H), 6.87 (s, 1H), 6.98-7.08 (m, 1H), 7.18-7.26 (m, 2H) ppm. MS (ESI): 431 (base, M+H).

EXAMPLE 336

(8aS,12aR)-2-[2,4-bis(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole

Step A:

Tert-butyl (8aS,12aR)-2-[2,4-bis(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.047 g, 17%) was prepared by the general method of Example 319, step A from tert-butyl (8aS,12aR)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.20 g, 0.50 mmol), 2,4-bis(trifluoromethyl)phenylboronic acid (0.26 g, 1.0 mmol), Pd(PPh₃)₄ (12 mg, 0.010 mmol), and Ba(OH)₂ (2 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 541 (base, M+H).

Step B:

The title compound (0.038 g, 100%) was prepared by the general method of Example 312, step B from tert-butyl (8aS,12aR)-2-[2,4-bis(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.047 g, 0.087 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.40-1.80 (m, 3H), 1.80-2.30 (m, 5H), 2.30-2.72 (m, 3H), 2.72-3.00 (m, 1H), 3.00-3.50 (m, 5H), 6.83 (s, 1H), 6.84 (s, 1H), 7.36 (d, J = 8.3 Hz, 1H), 7.69 (d, J = 8.3 Hz, 1H), 7.87 (s, 1H) ppm. MS (ESI): 441 (base, M+H).

EXAMPLE 337

(8aS,12aR)-2-[4-fluoro-2-(trifluoromethyl)phenyl]-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
5 hi]pyrido[4,3-b]indole

Step A:

Tert-butyl (8aS,12aR)-2-[4-fluoro-2-
(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-
10 decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-
carboxylate (0.10 g, 84%) was prepared by the general
method of Example 319, step A from tert-butyl (8aS,12aR)-2-
bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.10 g, 0.25
15 mmol), 4-fluoro-2-(trifluoromethyl)phenylboronic acid (0.10
g, 0.50 mmol), Pd(PPh₃)₄ (12 mg, 0.010 mmol), and Ba(OH)₂
(0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS (ESI): 491
(base, M+H).

Step B:

The title compound (0.042 g, 52%) was prepared by the
general method of Example 312, step B from tert-butyl
(8aS,12aR)-2-[4-fluoro-2-(trifluoromethyl)phenyl]-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
25 hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.10 g, 0.21
mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70
(m, 1H), 1.70-2.10 (m, 5H), 2.48-2.65 (m, 2H), 2.65-2.80
(m, 1H), 2.85-3.20 (m, 4H), 3.20-3.42 (m, 4H), 7.10 (s,
2H), 7.20 (t, J = 9.3 Hz, 1H), 6.60-7.70 (m, 1H), 7.70-7.72
30 (m, 1H) ppm. MS (ESI): 391 (base, M+H).

EXAMPLE 338

4-[(8aS,12aR)-4,5,6,7,8a,9,10,11,12,12a-
decahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-2-yl]-3-
35 (trifluoromethyl)aniline

Step A:

Tert-butyl (8a*S*,12a*R*)-2-[4-[(*tert*-butoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.12 g, 84%) was prepared by the general method of Example 319, step A from *tert*-butyl (8a*S*,12a*R*)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.10 g, 0.25 mmol), 4-[(*tert*-butoxycarbonyl)amino]-2-(trifluoromethyl)phenylboronic acid (0.15 g, 0.50 mmol), Pd(PPh₃)₄ (12 mg, 0.010 mmol), and Ba(OH)₂ (0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS (ESI): 588 (base, M+H).

15

Step B:

The title compound (0.079 g, 98%) was prepared by the general method of Example 312, step B from *tert*-butyl (8a*S*,12a*R*)-2-[4-[(*tert*-butoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.12 g, 0.21 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 2H), 1.70-1.95 (m, 2H), 1.95-2.10 (m, 3H), 2.28-2.76 (m, 3H), 2.80-3.00 (m, 3H), 3.08 (dd, J = 6.3, 12.4 Hz, 1H), 3.10-3.40 (m, 3H), 3.84 (br, 2H), 6.77-6.90 (m, 3H), 7.01 (d, J = 2.6 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H) ppm. MS (ESI): 388 (lost two BOC groups) (base, M+H).

30

EXAMPLE 339

4-[(8a*S*,12a*R*)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indol-2-yl]-*N*-methyl-3-(trifluoromethyl)aniline

35 **Step A:**

Tert-butyl (8a*S*,12a*R*)-2-[4-[(*tert*-butoxycarbonyl)(methyl)amino]-2-(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.12 g, 81%)
5 was prepared by the general method of Example 319, step A from *tert*-butyl (8a*S*,12a*R*)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.10 g, 0.25 mmol), 4-[(*tert*-butoxycarbonyl)(methyl)amino]-2-
10 (trifluoromethyl)phenylboronic acid (0.16 g, 0.50 mmol), Pd(PPh₃)₄ (12 mg, 0.010 mmol), and Ba(OH)₂ (0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS (ESI): 602 (base, M+H).

Step B:

15 The title compound (0.081 g, 100%) was prepared by the general method of Example 312, step B from *tert*-butyl (8a*S*,12a*R*)-2-[4-[(*tert*-butoxycarbonyl)(methyl)amino]-2-(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-
20 carboxylate (0.12 g, 0.20 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 1H), 1.70-2.10 (m, 5H), 2.48-2.78 (m, 3H), 2.80-3.00 (m, 4H), 3.08 (dd, J = 6.3, 12.4 Hz, 1H), 3.10-3.40 (m, 3H), 3.91 (br, 1H), 6.74 (dd, J = 2, 6, 8.2 Hz, 1H), 6.86 (s, 1H), 6.87 (s, 1H), 6.91 (d, J = 2.6 Hz, 1H), 7.15 (d, J = 8.2 Hz, 1H) ppm. MS (ESI): 402 (lost two BOC groups) (base, M+H).

EXAMPLE 340

2-[(8a*S*,12a*R*)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indol-2-yl]benzaldehyde
30

Step A:

Tert-butyl (8a*S*,12a*R*)-2-(2-formylphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
35

hi]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.081 g, 38%) was prepared by the general method of Example 89, step C from *tert*-butyl (8a*S*,12a*R*)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-
5 carboxylate (0.20 g, 0.50 mmol), 2-formylphenylboronic acid (0.15 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 433 (base, M+H).

10 Step B:

The title compound (0.021 g, 91%) was prepared by the general method of Example 312, step B from *tert*-butyl (8a*S*,12a*R*)-2-(2-formylphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-
15 carboxylate (0.030 g, 0.070 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.88 (m, 3H), 1.90-2.12 (m, 4H), 2.52-2.80 (m, 3H), 2.87-3.04 (m, 3H), 3.08-3.20 (m, 1H), 3.24-3.38 (m, 2H), 3.38-3.44 (m, 1H), 6.93 (s, 1H), 6.97 (s, 1H), 7.38-7.46 (m, 2H), 7.66 (td, *J* = 7.5, 1.4 Hz, 1H),
20 7.99 (dd, *J* = 1.4, 8.0 Hz, 1H), 10.02 (s, 1H) ppm. MS (ESI): 333 (base, M+H).

EXAMPLE 341

{2-[(8a*S*,12a*R*)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indol-2-
25 yl]phenyl}methanol

Step A:

NaBH₄ (0.050 g, 1.3 mmol) was added in one portion to
30 a solution of *tert*-butyl (8a*S*,12a*R*)-2-(2-formylphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (0.051 g, 0.12 mmol) in MeOH (12 mL) at room temperature. The mixture was stirred at room temperature for 1 h, quenched with acetone
35 (5.0 mL) and concentrated in vacuo. Water (10 mL) was

added to the residue and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried, concentrated in vacuo and flash column chromatography (EtOAc:hexane / 1:4) gave tert-butyl (8aS,12aR)-2-[2-(hydroxymethyl)phenyl]-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.043, 84%) as
a white solid. MS (ESI): 435 (base, M+H).

Step B:

The title compound (0.033 g, 100%) was prepared by the general method of Example 312, step B from tert-butyl (8aS,12aR)-2-[2-(hydroxymethyl)phenyl]-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.043 g, 0.10
mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.95
(m, 3H), 1.95-2.10 (m, 3H), 2.44-2.80 (m, 3H), 2.80-3.00
(m, 3H), 3.00-3.10 (m, 1H), 3.10-3.40 (m, 3H), 4.65 (br,
2H), 6.92 (s, 1H), 6.95 (s, 1H), 7.22-7.38 (m, 3H), 7.50-
7.57 (m, 1H) ppm. MS (ESI): 335 (base, M+H).

EXAMPLE 342

2-[(8aS,12aR)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-2-yl]-5-methoxybenzaldehyde

Step A:

Tert-butyl (8aS,12aR)-2-(2-formyl-4-methoxyphenyl)-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.094 g, 41%)
was prepared by the general method of Example 89, step C from tert-butyl (8aS,12aR)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.20 g, 0.50 mmol), 2-formyl-4-methoxyphenylboronic acid (0.18 g, 1.0 mmol), Pd(PPh₃)₂Cl₂

(17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 463 (base, M+H).

Step B:

5 The title compound (0.060 g, 81%) was prepared by the general method of Example 312, step B from tert-butyl (8aS,12aR)-2-(2-formyl-4-methoxyphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.094 g, 0.20 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.50-1.70 (m, 1H), 1.70-1.90 (m, 2H), 1.90-2.10 (m, 4H), 2.50-2.76 (m, 3H), 2.85-3.08 (m, 3H), 3.08-3.20 (m, 1H), 3.25-3.42 (m, 3H), 3.47 (s, 1H), 3.88 (s, 3H), 6.88 (s, 1H), 6.91 (s, 1H), 7.16 (dd, J = 2.6, 8.4 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 2.6 Hz, 1H), 9.95 (s, 1H) ppm. MS (ESI): 363 (base, M+H).

EXAMPLE 343

{2-[(8aS,12aR)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-2-yl]-5-methoxyphenyl}methanol

Step A:

25 Tert-butyl (8aS,12aR)-2-[2-(hydroxymethyl)-4-methoxyphenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.54 g) was obtained as a byproduct of Example 342 as a white foam. MS (ESI): 465 (base, M+H).

30 **Step B:**

 The title compound (0.42 g, 100%) was prepared by the general method of Example 312, step B from tert-butyl (8aS,12aR)-2-[2-(hydroxymethyl)-4-methoxyphenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.054 g, 0.12

mmol) as a white foam. ^1H NMR (CDCl_3 , 300 MHz) δ 1.50-1.68 (m, 1H), 1.68-2.10 (m, 5H), 2.40-2.80 (m, 3H), 2.80-3.00 (m, 3H), 3.00-3.10 (m, 1H), 3.10-3.40 (m, 3H), 3.86 (s, 3H), 4.62 (br, 2H), 6.78-6.92 (m, 3H), 7.10 (d, $J = 3.0$ Hz, 1H), 7.19 (d, $J = 8.4$ Hz, 1H), ppm. MS (ESI): 365 (base, M+H).

EXAMPLE 344

4-[(8aS,12aR)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-2-yl]-3-methylbenzonitrile

Step A:

Tert-butyl (8aS,12aR)-2-(4-cyano-2-methylphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.095 g, 86%) was prepared by the general method of Example 319, step A from *tert-butyl* (8aS,12aR)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.10 g, 0.25 mmol), 4-cyano-2-methylphenylboronic acid (0.080 g, 0.50 mmol), $\text{Pd}(\text{PPh}_3)_4$ (12 mg, 0.010 mmol), and $\text{Ba}(\text{OH})_2$ (0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS (ESI): 444 (base, M+H).

Step B:

The title compound (0.074 g, 100%) was prepared by the general method of Example 312, step B from *tert-butyl* (8aS,12aR)-2-(4-cyano-2-methylphenyl)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.095 g, 0.21 mmol) as a white foam. ^1H NMR (CDCl_3 , 300 MHz) δ 1.50-1.70 (m, 1H), 1.70-2.10 (m, 5H), 2.32 (s, 3H), 2.85-3.00 (m, 3H), 3.08 (dd, $J = 6.3, 12.4$ Hz, 1H), 3.20-3.50 (m, 4H), 6.85 (s, 2H), 7.29 (d, $J = 7.9$ Hz, 1H), 7.47 (d, $J = 7.9$ Hz, 1H), 7.51 (s, 1H) ppm. MS (ESI): 344 (base, M+H).

EXAMPLE 345

1-{2-[(8aS,12aR)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-2-yl]-5-methoxyphenyl}ethanol

CH₃MgBr (1 M, 2.3 mL, 2.3 mmol) was added to a solution of 2-[(8aS,12aR)-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-2-yl]-5-methoxybenzaldehyde (0.080g, 0.23 mmol) in THF (5 mL) at 0°C. The mixture was stirred at room temperature for 18 h and quenched with water (5.0 mL). The mixture was extracted with CH₂Cl₂ (3 × 10 mL) and the organic layer was dried (Na₂SO₄) and concentrated in vacuo. Reverse phase HPLC (H₂O-CH₃CN-TFA (0.05%)) gave the title compound (2.0 mg, 4%). MS (ESI): 379 (base, M+H)

EXAMPLE 346

tert-butyl (7aS,11aR)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate

The title compound (7.73 g, 97%) was prepared by the method of Example 314 from tert-butyl (7aS,11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (6.40 g, 20 mmol) and NBS (3.63 g, 20 mmol) as a white solid.

EXAMPLE 347

(7aS,11aR)-2-(2,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

Step A:

Tert-butyl (7a*S*,11a*R*)-2-(2,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.15 g, 63%) was prepared by the method of
5 Example 315 from *tert-butyl* (7a*S*,11a*R*)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.20 g, 0.50 mmol), 2,4-dichlorophenylboronic acid (0.19 g, 1.0 mmol), Ba(OH)₂·8H₂O (0.32 g, 1.0 mmol),
10 Pd₂(dba)₃ (7.5 mg, 0.0075 mmol) and PPh₃ (5.24 mg, 0.02 mmol) as a white foam.

Step B:

The title compound (0.087 g, 77%) was prepared by the
15 general method of Example 312, step B from *tert-butyl* (7a*S*,11a*R*)-2-(2,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.15 g, 0.32 mmol) as a white foam.
¹H NMR (CDCl₃, 300 MHz) δ 1.75-2.00 (m, 2H), 2.08-2.30 (m,
20 3H), 2.60-2.80 (m, 4H), 2.80-2.92 (m, 2H), 3.07-3.15 (m, 2H), 3.28-3.35 (m, 1H), 3.38-3.48 (m, 1H), (s, 1H), 6.98 (s, 1H), 7.23 (d, J=1.9 Hz, 2H), 7.44 (t, J=1.3 Hz, 1H) ppm.

25

EXAMPLE 348

(7a*S*,11a*R*)-2-(3,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline

Step A:

30 *Tert-butyl* (7a*S*,11a*R*)-2-(3,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.085 g, 37%) was prepared by the general method of Example 89, step C from *tert-butyl* (7a*S*,11a*R*)-2-
35 bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-

pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7aH)-
carboxylate (0.20 g, 0.50 mmol), 3,4-dichlorophenylboronic
acid (0.19 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol),
Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI):
5 459 (base, M+H).

Step B:

The title compound (0.066 g, 100%) was prepared by the
general method of Example 312, step B from *tert*-butyl
10 (7a*S*,11a*R*)-2-(3,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-
octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-
10(7aH)-carboxylate (0.085 g, 0.19 mmol) as a white foam.
1H NMR (CDCl₃, 300 MHz) δ 1.80-2.05 (m, 2H), 2.05-2.20 (m,
2H), 2.55-2.80 (m, 4H), 2.82-2.98 (m, 2H), 3.07-3.20 (m,
15 2H), 3.20-3.38 (m, 1H), 3.38-3.48 (m, 1H), 3.64 (br, 1H),
7.01 (s, 1H), 7.11 (s, 1H), 7.34 (dd, J = 1.8, 8.4 Hz, 1H),
7.43 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 1.8 Hz, 1H) ppm. MS
(ESI): 359 (base, M+H).

20 **EXAMPLE 349**

(7a*S*,11a*R*)-2-(3,5-dichlorophenyl)-5,6,7a,8,9,10,11,11a-
octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline

Step A:

25 *Tert*-butyl (7a*S*,11a*R*)-2-(3,5-dichlorophenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4*H*-
pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7aH)-
carboxylate (0.045 g, 40%) was prepared by the general
method of Example 89, step C from *tert*-butyl (7a*S*,11a*R*)-2-
30 bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-
pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7aH)-
carboxylate (0.098 g, 0.25 mmol), 3,5-dichlorophenylboronic
acid (0.10 g, 0.5 mmol), Pd(PPh₃)₂Cl₂ (8.8 mg, 0.013 mmol),
Na₂CO₃ (2.0 M, 0.5 mL, 1.0 mmol) as a white foam. MS (ESI):
35 459 (base, M+H).

Step B:

The title compound (0.035 g, 100%) was prepared by the general method of Example 312, step B from *tert*-butyl (7a*S*,11a*R*)-2-(3,5-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.045 g, 0.10 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) • 1.80-2.05 (m, 2H), 2.05-2.20 (m, 2H), 2.55-2.80 (m, 4H), 2.88-2.96 (m, 3H), 3.07-3.20 (m, 2H), 3.23-3.36 (m, 1H), 3.38-3.48 (m, 1H), 7.08 (s, 1H), 7.10 (s, 1H), 7.21 (t, J=1.9 Hz, 1H), 7.37 (d, J=1.9 Hz, 2H) ppm. MS (ESI): 359 (base, M+H).

EXAMPLE 350

(7a*S*,11a*R*)-2-(2,5-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline

Step A:

Tert-butyl (7a*S*,11a*R*)-2-(2,5-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.080 g, 55%) was prepared by the general method of Example 319, step A from *tert*-butyl (7a*S*,11a*R*)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.13 g, 0.32 mmol), 2,5-dichlorophenylboronic acid (0.12 g, 0.64 mmol), Pd(PPh₃)₄ (14 mg, 0.012 mmol), and Ba(OH)₂ (0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS (ESI): 459 (base, M+H).

Step B:

The title compound (0.063 g, 100%) was prepared by the general method of Example 312, step B from *tert*-butyl (7a*S*,11a*R*)-2-(2,5-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-

10 (7aH)-carboxylate (0.080 g, 0.17 mmol) as a white foam.
1H NMR (CDCl₃, 300 MHz) δ 1.80-2.05 (m, 2H), 2.05-2.20 (m,
2H), 2.55-2.80 (m, 4H), 2.88-2.96 (m, 3H), 3.07-3.20 (m,
2H), 3.23-3.36 (m, 1H), 3.38-3.48 (m, 1H), 6.95 (s, 1H),
5 6.99 (s, 1H), 7.16 (dd, J=2.7, 8.4 Hz, 1H), 7.30 (d, J=2.7
Hz, 1H), 7.34 (d, J=8.4 Hz) ppm. MS (ESI): 359 (base,
M+H).

EXAMPLE 351

10 (7aS,11aR)-2-(2,6-dichlorophenyl)-5,6,7a,8,9,10,11,11a-
octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

Step A:

Tert-butyl (7aS,11aR)-2-(2,6-dichlorophenyl)-
15 5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.023 g, 19%) was prepared by the general
method of Example 320, step A from *tert-butyl* (8aS,11aR)-2-
bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-
20 hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.10 g, 0.26
mmol), 2,6-dichlorophenyl boronic acid (0.10 g, 0.52 mmol),
Pd(dppf)₂Cl₂ (10 mg, 0.012 mmol), TEA (1.0 mL, 7.2 mmol) as
a white foam.

25 Step B:

The title compound (0.018 g, 100%) was prepared by the
general method of Example 312, step B from *tert-butyl*
(7aS,11aR)-2-(2,6-dichlorophenyl)-5,6,7a,8,9,10,11,11a-
octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-
30 10(7aH)-carboxylate (0.023 g, 0.050 mmol) as a white foam.
1H NMR (CDCl₃, 300 MHz) δ 1.80-2.05 (m, 2H), 2.05-2.20 (m,
2H), 2.55-2.80 (m, 4H), 2.88-2.96 (m, 3H), 3.07-3.20 (m,
2H), 3.23-3.36 (m, 1H), 3.38-3.48 (m, 1H), 6.73 (s, 1H),
6.79 (s, 1H), 7.16 (t, J=8.0 Hz, 1H), 7.38 (d, J=8.0 Hz)
35 ppm. MS (ESI): 359 (base, M+H).

EXAMPLE 352

(7aS,11aR)-2-(2-chlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

5

Step A:

Tert-butyl (7aS,11aR)-2-(2-chlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.054 g, 51%) was prepared by the general method of Example 89, step C from *tert-butyl* (7aS,11aR)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.098 g, 0.25 mmol), 2-chlorophenylboronic acid (0.078 g, 0.5 mmol), Pd(PPh₃)₂Cl₂ (8.8 mg, 0.013 mmol), Na₂CO₃ (2.0 M, 0.5 mL, 1.0 mmol) as a white foam. MS (ESI): 425 (base, M+H).

Step B:

The title compound (0.040 g, 99%) was prepared by the general method of Example 312, step B from *tert-butyl* (7aS,11aR)-2-(2-chlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.054 g, 0.13 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.80-2.05 (m, 2H), 2.05-2.20 (m, 2H), 2.55-2.80 (m, 4H), 2.88-2.96 (m, 3H), 3.07-3.20 (m, 2H), 3.23-3.36 (m, 1H), 3.38-3.48 (m, 1H), 6.97 (s, 1H), 7.02 (s, 1H), 7.12-7.35 (m, 3H), 7.35-7.46 (m, 2H) ppm. MS (ESI): 325 (base, M+H).

30

EXAMPLE 353

(7aS,11aR)-2-(3-chlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

Step A:

35

Tert-butyl (7a*S*,11a*R*)-2-(3-chlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.060 g, 57%) was prepared by the general method of Example 89, step C from *tert*-butyl (7a*S*,11a*R*)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.098 g, 0.25 mmol), 3-chlorophenylboronic acid (0.078 g, 0.5 mmol), Pd(PPh₃)₂Cl₂ (8.8 mg, 0.013 mmol), Na₂CO₃ (2.0 M, 0.5 mL, 1.0 mmol) as a white foam. MS (ESI): 425 (base, M+H).

Step B:

The title compound (0.046 g, 100%) was prepared by the general method of Example 312, step B from *tert*-butyl (7a*S*,11a*R*)-2-(3-chlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.060 g, 0.14 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.80-2.05 (m, 2H), 2.05-2.20 (m, 2H), 2.55-2.80 (m, 4H), 2.88-2.96 (m, 3H), 3.07-3.20 (m, 2H), 3.23-3.36 (m, 1H), 3.38-3.48 (m, 1H), 7.11 (s, 1H), 7.12 (s, 1H), 7.20-7.40 (m, 3H), 7.48 (t, J=1.7 Hz, 1H) ppm. MS (ESI): 325 (base, M+H).

25

EXAMPLE 354

(7a*S*,11a*R*)-2-(4-chlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline

Step A:

Tert-butyl (7a*S*,11a*R*)-2-(4-chlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.045 g, 21%) was prepared by the general method of Example 89, step C from *tert*-butyl (7a*S*,11a*R*)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-

pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.20 g, 0.50 mmol), 4-chlorophenylboronic acid
(0.16 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃
(2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 425
5 (base, M+H).

Step B:

The title compound (0.033 g, 99%) was prepared by the
general method of Example 312, step B from tert-butyl
10 (7aS,11aR)-2-(4-chlorophenyl)-5,6,7a,8,9,10,11,11a-
octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-
10(7aH)-carboxylate (0.045 g, 0.11 mmol) as a white foam.
¹H NMR (CDCl₃, 300 MHz) δ 1.80-2.05 (m, 2H), 2.05-2.20 (m,
2H), 2.58-2.82 (m, 4H), 2.82-3.06 (m, 3H), 3.07-3.20 (m,
15 2H), 3.23-3.40 (m, 1H), 3.40-3.48 (m, 1H), 7.11 (s, 1H),
7.13 (s, 1H), 7.34 (d, J=8.4 Hz, 2H), 7.45 (d, J=8.4 Hz)
ppm. MS (ESI): 325 (base, M+H).

EXAMPLE 355

20 (7aS,11aR)-2-(2,6-difluorophenyl)-5,6,7a,8,9,10,11,11a-
octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

Step A:

Tert-butyl (7aS,11aR)-2-(2,6-difluorophenyl)-
25 5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.064 g, 15%) was prepared by the general
method of Example 320, step A from tert-butyl (8aS, 11aR)-
2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-
30 hi]pyrido[4,3-b]indole-11(8aH)-carboxylate (0.39 g, 1.0
mmol), 2,6-difluorophenylboronic acid (0.63 g, 4.0 mmol),
Pd(dppf)₂Cl₂ (48 mg, 0.06 mmol), TEA (3.0 mL, 22 mmol) as a
white foam.

Step B:

The title compound (0.029 g, 59%) was prepared by the general method of Example 312, step B from tert-butyl (7aS,11aR)-2-(2,6-difluorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10-(7aH)-carboxylate (0.064 g, 0.15 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.80-2.05 (m, 2H), 2.05-2.25 (m, 2H), 2.58-2.83 (m, 4H), 2.83-3.08 (m, 2H), 3.08-3.60 (m, 5H), 6.85-7.08 (m, 4H), 7.08-7.22 (m, 1H) ppm.

10

EXAMPLE 356

(7aS,11aR)-2-(2,6-difluorophenyl)-10-methyl-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

15

A mixture of (7aS,11aR)-2-(2,6-difluorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (0.050, 0.15 mmol), HCHO (0.20 mL, 2.9 mmol) and formic acid (1.0 mL, 2.9 mmol) was heated at 80 °C for 4 h and cooled to room temperature. Water (5.0 mL) was added and the solution was basified with saturated Na₂CO₃ until pH > 8. The mixture was extracted with CH₂Cl₂ (3 × 10 mL), dried (Na₂SO₄) and flash column chromatography (1-5% MeOH in CHCl₃) gave the title compound (0.032 g, 62%) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 2.00-2.20 (m, 5H), 2.20-2.50 (m, 4H), 2.55-2.68 (m, 1H), 2.68-2.82 (m, 3H), 2.86-2.98 (m, 1H), 3.28-3.42 (m, 3H), 6.90-7.08 (m, 4H), 7.14-7.25 (m, 1H) ppm. MS (ESI): 341 (base, M+H).

30

EXAMPLE 357

(7aS,11aR)-2-(2,3-difluorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

Step A:

Tert-butyl (7a*S*,11a*R*)-2-(2,3-difluorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.15 g, 70%) was prepared by the general method of Example 89, step C from *tert-butyl* (7a*S*,11a*R*)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.20 g, 0.50 mmol), 2,3-difluorophenyl boronic acid (0.16 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 427 (base, M+H).

Step B:

The title compound (0.10 g, 88%) was prepared by the general method of Example 312, step B from *tert-butyl* (7a*S*,11a*R*)-2-(2,3-difluorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.15 g, 0.35 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.75-2.00 (m, 2H), 2.05-2.30 (m, 3H), 2.60-2.80 (m, 4H), 2.80-2.90 (m, 2H), 3.02-3.16 (m, 2H), 3.24-3.38 (m, 1H), 3.38-3.48 (m, 1H), 6.94-7.20 (m, 5H) ppm. MS (ESI): 327 (base, M+H).

EXAMPLE 358

(7a*S*,11a*R*)-2-(3,4-difluorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline

Step A:

Tert-butyl (7a*S*,11a*R*)-2-(3,4-difluorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.077 g, 72%) was prepared by the general method of Example 319, step A from *tert-butyl* (7a*S*,11a*R*)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-

carboxylate (0.10 g, 0.25 mmol), 3,4-difluorophenyl boronic acid (0.080 g, 0.50 mmol), Pd(PPh₃)₄ (12 mg, 0.010 mmol), and Ba(OH)₂ (0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS (ESI): 427 (base, M+H).

5

Step B:

The title compound (0.054 g, 90%) was prepared by the general method of Example 312, step B from *tert*-butyl (7a*S*,11a*R*)-2-(3,4-difluorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.077 g, 0.18 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.70-2.00 (m, 4H), 2.10-2.50 (m, 3H), 2.50-2.70 (m, 1H), 2.79-2.85 (m, 2H), 3.10-3.60 (m, 5H), 7.06-7.35 (m, 5H) ppm. MS (ESI): 327 (base, M+H).

15

EXAMPLE 359

(7a*S*,11a*R*)-2-(3-fluorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline

20 **Step A:**

Tert-butyl (7a*S*,11a*R*)-2-(3-fluorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.055 g, 52%) was prepared by the general method of Example 319, step A from *tert*-butyl (7a*S*,11a*R*)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.10 g, 0.25 mmol), 3-fluorophenyl boronic acid (0.070 g, 0.50 mmol), Pd(PPh₃)₄ (12 mg, 0.010 mmol), and Ba(OH)₂ (0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS (ESI): 409 (base, M+H).

30 **Step B:**

The title compound (0.042 g, 100%) was prepared by the general method of Example 312, step B from *tert*-butyl

(7aS,11aR)-2-(3-fluorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.055 g, 0.13 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 2.05-2.22 (m, 4H), 2.55-2.68 (m, 1H), 2.68-2.80 (m, 3H), 3.00-3.20 (m, 2H), 3.2-3.48 (m, 4H), 5.00-5.50 (br, 1H), 6.85-7.00 (m, 1H), 7.08-7.40 (m, 5H) ppm. MS (ESI): 309 (base, M+H).

EXAMPLE 360

(7aS,11aR)-2-[2-chloro-4-methoxyphenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

Step A:

Tert-butyl (7aS,11aR)-2-[2-chloro-4-methoxyphenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.053 g, 23%) was prepared by the general method of Example 89, step C from *tert*-butyl (7aS,11aR)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.20 g, 0.50 mmol), 2-chloro-4-methoxyphenyl boronic acid (0.19 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam.

Step B:

The title compound (0.035 g, 85%) was prepared by the general method of Example 312, step B from *tert*-butyl (7aS,11aR)-2-[2-chloro-4-methoxyphenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.053 g, 0.12 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.80-2.05 (m, 2H), 2.05-2.20 (m, 3H), 2.58-2.68 (m, 1H), 2.68-2.80 (m, 2H), 2.85-3.05 (m, 3H), 3.07-3.20 (m, 2H), 3.23-3.36 (m, 1H), 3.38-3.48 (m, 1H),

6.95 (s, 1H), 6.99 (s, 1H), 7.16 (dd, J=2.7, 8.4 Hz, 1H),
7.30 (d, J=2.7 Hz, 1H), 7.34 (d, J=8.4 Hz, 1H) ppm.

EXAMPLE 361

5 (7aS,11aR)-2-[2-fluoro-4-methoxyphenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

Step A:

10 *Tert*-butyl (7aS,11aR)-2-[2-fluoro-4-methoxyphenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.15 g, 68%) was prepared by the general
method of Example 89, step C from *tert*-butyl (7aS,11aR)-2-
15 bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.20 g, 0.50 mmol), 2-fluoro-4-
methoxyphenylboronic acid (0.17 g, 1.0 mmol), Pd(PPh₃)₂Cl₂
(17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a
20 white foam. MS (ESI): 339 (base, M+H).

Step B:

The title compound (0.11 g, 94%) was prepared by the
general method of Example 312, step B from *tert*-butyl
25 (7aS,11aR)-2-[2-fluoro-4-methoxyphenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.15 g, 0.34 mmol) as a white foam. ¹H NMR
(CDCl₃, 300 MHz) δ 1.70-1.88 (m, 1H), 1.88-2.00 (m, 1H),
30 2.00-2.20 (m, 3H), 2.55-2.80 (m, 4H), 2.80-2.96 (m, 2H),
3.02-3.12 (m, 2H), 3.28-3.37 (m, 1H), 3.38-3.48 (m, 1H),
3.81 (s, 3H), 6.64-6.75 (m, 2H), 7.03 (s, 1H), 7.07 (s,
1H), 7.29 (t, J=8.8 Hz, 1H) ppm. MS (ESI): 339 (base,
M+H).

35

EXAMPLE 362

(7aS,11aR)-2-(4-methoxy-2-methylphenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

5

Step A:

Tert-butyl (7aS,11aR)-2-(4-methoxy-2-methylphenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
10 carboxylate (0.15 g, 68%) was prepared by the general
method of Example 89, step C from *tert*-butyl (7aS,11aR)-2-
bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.20 g, 0.50 mmol), 4-methoxy-2-
15 methylphenylboronic acid (0.17 g, 1.0 mmol), Pd(PPh₃)₂Cl₂
(17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a
white foam. MS (ESI): 449 (base, M+H).

Step B:

20 The title compound (0.095 g, 97%) was prepared by the
general method of Example 312, step B from *tert*-butyl
(7aS,11aR)-2-(4-methoxy-2-methylphenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
25 carboxylate (0.13 g, 0.29 mmol) as a white foam. ¹H NMR
(CDCl₃, 300 MHz) δ 1.74-1.88 (m, 1H), 1.88-2.00 (m, 1H),
2.05-2.28 (m, 3H), 2.28 (s, 3H), 2.55-2.80 (m, 4H), 2.80-
2.92 (m, 2H), 3.00-3.12 (m, 2H), 3.28-3.36 (m, 1H), 3.36-
3.45 (m, 1H), 3.82 (s, 3H), 6.70-6.82 (m, 3H), 6.84 (s,
30 1H), 7.14 (d, J=8.4 Hz, 1H) ppm. MS (ESI): 349 (base,
M+H).

EXAMPLE 363

(7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

5

Step A:

Tert-butyl (7aS,11aR)-2-[4-methoxy-2-
(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
10 carboxylate (3.02 g, 61%) was prepared by the general
method of Example 89, step C from *tert-butyl* (7aS,11aR)-2-
bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (3.93 g, 10 mmol), 4-methoxy-2-
15 (trifluoromethyl)phenylboronic acid (4.40 g, 20 mmol),
Pd(PPh₃)₂Cl₂ (0.35 g, 0.50 mmol), Na₂CO₃ (2.0 M, 20 mL, 40
mmol) as a white solid. MS (ESI): 489 (base, M+H).

Step B:

20 The title compound (2.38 g, 99%) was prepared by the
general method of Example 312, step B from *tert-butyl*
(7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
25 carboxylate (3.02 g, 6.1 mmol) as a white foam. ¹H NMR
(CDCl₃, 300 MHz) δ 1.80-2.05 (m, 2H), 2.08-2.10 (m, 3H),
2.60-2.80 (m, 4H), 2.80-2.96 (m, 2H), 3.04-3.15 (m, 2H),
3.32 (td, J=4.0, 10.0 Hz, 1H), 3.40-3.48 (m, 1H), 3.88 (s,
3H), 6.81 (s, 1H), 6.85 (s, 1H), 7.04 (dd, J=2.7, 8.4 Hz,
30 1H), 7.20-7.28 (m, 2H) ppm. MS (ESI): 389 (base, M+H).

EXAMPLE 364

2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,8,9,10,11-
hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

35

Step A:

Tert-butyl 2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,8,9,10,11-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10 (7aH)-carboxylate (0.78 g) was obtained as
5 a byproduct of Example 363 as a white solid.

Step B:

The title compound (0.60 g, 98%) was prepared by the general method of Example 312, step B from tert-butyl 2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,8,9,10,11-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10 (7aH)-carboxylate (0.78 g, 1.6 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 2.20-2.30 (m, 2H), 2.79 (t, J=5.4 Hz, 2H), 2.90-3.20 (m, 3H), 3.30 (t, J=5.8 Hz, 2H), 3.91 (s, 3H), 3.98 (t, J=5.8 Hz, 2H), 4.12 (s, 2H), 6.84 (s, 1H),
15 7.07 (dd, J=2.5, 8.4 Hz, 1H), 7.18 (s, 1H), 7.25-7.35 (m, 2H) ppm. MS (ESI): 428 (base, M+CH₃CN).

EXAMPLE 365

20 4-[(7aS,11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-2-yl]-3-(trifluoromethyl)phenol

BBr₃ in CH₂Cl₂ (0.91 M, 0.66 mL, 0.60 mmol) was added
25 dropwise to a solution of tert-butyl (7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10 (7aH)-carboxylate (0.049 g, 0.10 mmol) in CH₂Cl₂ (5.0 mL) at room temperature under N₂. The mixture was stirred for
30 18 h before quenched with water (5.0 mL). The mixture was basified with saturated NaHCO₃ until pH ~ 8 and extracted with CH₂Cl₂ (3 × 10 mL). The combined organic layer was dried (Na₂SO₄) and concentrated in vacuo. Reverse phase HPLC (H₂O-CH₃CN-TFA (0.05%)) gave the title compound (0.012

g, 32%) as a white solid. ^1H NMR (CDCl_3 , 300 MHz) δ 2.00-2.22 (m, 2H), 2.05-2.20 (m, 2H), 2.55-2.80 (m, 4H), 2.88-2.96 (m, 2H), 3.07-3.20 (m, 2H), 3.23-3.36 (m, 1H), 3.38-3.48 (m, 1H), 6.95 (s, 1H), 6.99 (s, 1H), 7.16 (dd, $J=2.7$, 8.4 Hz, 1H), 7.30 (d, $J=2.7$ Hz, 1H), 7.34 (d, $J=8.4$ Hz) ppm. MS (ESI): 375 (base, $\text{M}+\text{H}$).

EXAMPLE 366

(7a*S*,11a*R*)-2-[2-(trifluoromethyl)phenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4*H*-
pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline.

Step A:

Tert-butyl (7a*S*,11a*R*)-2-[2-(trifluoromethyl)phenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4*H*-
pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-
carboxylate (0.041 g, 18%) was prepared by the general
method of Example 89, step C from *tert*-butyl (7a*S*,11a*R*)-2-
bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-
pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-
carboxylate (0.20 g, 0.50 mmol), 2-(trifluoromethyl)phenyl
boronic acid (0.19 g, 1.0 mmol), $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (17 mg, 0.025
mmol), Na_2CO_3 (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS
(ESI): 459 (base, $\text{M}+\text{H}$).

Step B:

The title compound (0.030 g, 94%) was prepared by the
general method of Example 312, step B from *tert*-butyl
(7a*S*,11a*R*)-2-[2-(trifluoromethyl)phenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4*H*-
pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-
carboxylate (0.041 g, 0.090 mmol) as a white foam. ^1H NMR
(CDCl_3 , 300 MHz) δ 1.80-2.08 (m, 2H), 2.08-2.28 (m, 2H),
2.43 (br, 1H), 2.60-2.80 (m, 4H), 2.85-2.98 (m, 2H), 3.07-
3.20 (m, 2H), 3.25-3.40 (m, 1H), 3.40-3.48 (m, 1H), 6.84

(s, 1H), 6.88 (s, 1H), 7.34 (d, J=7.7 Hz, 1H), 7.40 (t, J=7.6 Hz, 1H), 7.51 (t, J=7.4 Hz, 1H), 7.71 (d, J=8.1 Hz, 1H) ppm. MS (ESI): 359 (base, M+H).

5

EXAMPLE 367

(7aS,11aR)-2-[4-isopropoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

10 **Step A:**

Tert-butyl (7aS,11aR)-2-[4-isopropoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.16 g, 61%) was prepared by the general method of Example 89, step C from tert-butyl (7aS,11aR)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.20 g, 0.50 mmol), 4-isopropoxy-2-(trifluoromethyl)phenylboronic acid (0.18 g, 0.73 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 517 (base, M+H).

Step B:

The title compound (0.13 g, 100%) was prepared by the general method of Example 312, step B from tert-butyl (7aS,11aR)-2-[4-isopropoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.16 g, 0.31 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.38 (d, J=6.0 Hz, 6H), 1.70-1.88 (m, 1H), 1.88-2.00 (m, 1H), 2.02-2.18 (m, 3H), 2.55-2.80 (m, 4H), 2.80-2.98 (m, 2H), 3.00-3.13 (m, 2H), 3.25-3.37 (m, 1H), 3.38-3.55 (m, 1H), 4.61, (p, J=6.0 Hz, 1H), 6.81 (s, 1H), 6.85 (s, 1H), 7.01 (dd, J=1.2, 8.6 Hz, 1H), 7.18-7.26 (m, 2H) ppm. MS (ESI): 417 (base, M+H).

EXAMPLE 368

(7aS,11aR)-2-[2,4-bis(trifluoromethyl)phenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
5 pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

Step A:

Tert-butyl (7aS,11aR)-2-[2,4-
bis(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-
10 4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.029 g, 11%) was prepared by the general
method of Example 89, step C from tert-butyl (7aS,11aR)-2-
bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
15 carboxylate (0.20 g, 0.50 mmol), 2,4-
bis(trifluoromethyl)phenylboronic acid (0.26 g, 1.0 mmol),
Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0
mmol) as a white foam. MS (ESI): 527 (base, M+H).

Step B:

The title compound (0.023 g, 100%) was prepared by the
general method of Example 312, step B from tert-butyl
(7aS,11aR)-2-[2,4-bis(trifluoromethyl)phenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
25 pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.029 g, 0.055 mmol) as a white foam. ¹H NMR
(CDCl₃, 300 MHz) δ 2.10-2.30 (m, 4H), 2.50-2.70 (m, 3H),
2.70-2.86 (m, 3H), 3.10-3.55 (m, 5H), 6.90 (s, 2H), 7.45
(d, J=7.8 Hz, 1H), 7.78 (d, J=7.8 Hz, 1H), 7.97 (s, 1H)
30 ppm. MS (ESI): 427 (base, M+H).

EXAMPLE 369

(7aS,11aR)-2-[4-fluoro-2-(trifluoromethyl)phenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
35 pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

Step A:

Tert-butyl (7aS,11aR)-2-[4-fluoro-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.093 g, 75%) was prepared by the general method of Example 319, step A from tert-butyl (7aS,11aR)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.10 g, 0.26 mmol), 4-fluoro-2-(trifluoromethyl)phenylboronic acid (0.11 g, 0.51 mmol), Pd(PPh₃)₄ (12 mg, 0.010 mmol), and Ba(OH)₂ (0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS (ESI): 477 (base, M+H).

Step B:

The title compound (0.071 g, 97%) was prepared by the general method of Example 312, step B from tert-butyl (7aS,11aR)-2-[4-fluoro-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.093 g, 0.19 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 2.08-2.12 (m, 4H), 2.58-2.85 (m, 4H), 3.02-3.24 (m, 2H), 3.28-3.50 (m, 5H), 7.11 (s, 1H), 7.12 (s, 1H), 7.21 (t, J=9.4 Hz, 1H), 7.58-7.68 (m, 1H), 7.68-7.75 (m, 1H) ppm. MS (ESI): 377 (base, M+H).

EXAMPLE 370

4-[(7aS,11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-2-yl]-3-(trifluoromethyl)aniline

Step A:

Tert-butyl (7aS,11aR)-2-[4-[(tert-butoxycarbonyl)amino]-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-

pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7aH)-
carboxylate (0.13 g, 93%) was prepared by the general
method of Example 319, step A from *tert*-butyl (7aS,11aR)-2-
bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-
5 pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7aH)-
carboxylate (0.10 g, 0.25 mmol), 4-[(*tert*-
butoxycarbonyl)amino]-2-(trifluoromethyl)phenylboronic acid
(0.15 g, 0.50 mmol), Pd(PPh₃)₄ (12 mg, 0.010 mmol), and
Ba(OH)₂ (0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS
10 (ESI): 574 (base, M+H).

Step B:

The title compound (0.079 g, 72%) was prepared by the
general method of Example 312, step B from *tert*-butyl
15 (7aS,11aR)-2-[4-[(*tert*-butoxycarbonyl)amino]-2-
(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7aH)-
carboxylate (0.13 g, 0.23 mmol) as a white foam. ¹H NMR
(CDCl₃, 300 MHz) δ 1.78-2.00 (m, 2H), 2.05-2.22 (m, 2H),
20 2.58-2.80 (m, 4H), 2.80-2.98 (m, 2H), 3.04-3.16 (m, 2H),
3.28-3.38 (m, 1H), 3.38-3.48 (m, 1H), 3.82 (br, 3H), 6.72-
6.88 (m, 3H), 7.00 (d, J=2.6 Hz, 1H), 7.11 (d, J=8.1 Hz,
1H) ppm. MS (ESI): 374 (base, M+H).

EXAMPLE 371

4-[(7aS,11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinolin-2-yl]-N-methyl-
3-(trifluoromethyl)aniline

Step A:

Tert-butyl (7aS,11aR)-2-[4-[(*tert*-
butoxycarbonyl)(methyl)amino]-2-(trifluoromethyl)phenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7aH)-
35 carboxylate (0.12 g, 82%) was prepared by the general

method of Example 319, step A from *tert*-butyl (7a*S*,11a*R*)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.10 g, 0.25 mmol), 4-[(*tert*-butoxycarbonyl)(methyl)amino]-2-(trifluoromethyl)phenylboronic acid (0.16 g, 0.50 mmol), Pd(PPh₃)₄ (12 mg, 0.010 mmol), and Ba(OH)₂ (0.17 M, 3.0 mL, 0.51 mmol) as a white foam. MS (ESI): 588 (base, M+H).

10 **Step B:**

The title compound (0.071g, 71%) was prepared by the general method of Example 312, step B from *tert*-butyl (7a*S*,11a*R*)-2-[4-[(*tert*-butoxycarbonyl)(methyl)amino]-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.12 g, 0.20 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.78-2.00 (m, 2H), 2.05-2.25 (m, 2H), 2.60-2.80 (m, 4H), 2.80-3.00 (m, 5H), 3.00-3.20 (m, 2H), 3.28-3.40 (m, 1H), 3.40-3.50 (m, 1H), 3.91 (br, 2H), 6.73 (dd, J=2.6, 8.3 Hz, 1H), 6.81 (s, 1H), 6.85 (s, 1H), 6.91 (d, J=2.6 Hz, 1H), 7.15 (d, J=8.3 Hz, 1H) ppm. MS (ESI): 388 (base, M+H).

EXAMPLE 372

25 4-[(7a*S*,11a*R*)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinolin-2-yl]-3-methylbenzonitrile

Step A:

30 *Tert*-butyl (7a*S*,11a*R*)-2-(4-cyano-2-methylphenyl)-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (0.073 g, 65%) was prepared by the general method of Example 319, step A from *tert*-butyl (7a*S*,11a*R*)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4*H*-

pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.10 g, 0.26 mmol), 4-cyano-2-
methylphenylboronic acid (0.088 g, 0.52 mmol), Pd(PPh₃)₄
(12 mg, 0.010 mmol), and Ba(OH)₂ (0.17 M, 3.0 mL, 0.51
5 mmol) as a white foam. MS (ESI): 430 (base, M+H).

Step B:

The title compound (0.050 g, 89%) was prepared by the
general method of Example 312, step B from tert-butyl
10 (7aS,11aR)-2-(4-cyano-2-methylphenyl)-5,6,7a,8,9,10,11,11a-
octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-
10(7aH)-carboxylate (0.073 g, 0.17 mmol) as a white foam.
1H NMR (CDCl₃, 300 MHz) δ 2.10-2.20 (m, 4H), 2.30 (s, 3H),
2.55-2.70 (m, 1H), 2.70-2.80 (m, 3H), 3.07-3.26 (m, 2H),
15 3.26-3.48 (m, 5H), 6.84 (s, 2H), 7.25 (d, J=7.7 Hz, 1H),
7.47 (d, J=7.7 Hz, 1H), 7.51 (s, 1H) ppm. MS (ESI): 330
(base, M+H).

EXAMPLE 373

20 2-[(7aS,11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-2-
yl]benzaldehyde

Step A:

25 Tert-butyl (7aS,11aR)-2-(2-formylphenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.091 g, 44%) was prepared by the general
method of Example 89, step C from tert-butyl (7aS,11aR)-2-
30 bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (0.20 g, 0.50 mmol), 2-formylphenylboronic acid
(0.15 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃
(2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 419
35 (base, M+H).

Step B:

The title compound (0.021 g, 91%) was prepared by the general method of Example 312, step B from tert-butyl (7aS,11aR)-2-(2-formylphenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.030 g, 0.070 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.94-2.24 (m, 4H), 2.59-2.82 (m, 5H), 3.00-3.24 (m, 2H), 3.28-3.42 (m, 3H), 3.44-3.52 (m, 1H), 6.90 (s, 1H), 6.97 (s, 1H), 7.38-7.46 (m, 2H), 7.66 (td, J=7.5, 1.4 Hz, 1H), 7.99 (dd, J=1.4, 8.0 Hz, 1H), 10.01 (s, 1H) ppm. MS (ESI): 319 (base, M+H).

EXAMPLE 374

{2-[(7aS,11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-2-yl]phenyl}methanol

Step A:

Tert-butyl (7aS,11aR)-2-[2-(hydroxymethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.42 g, 69%) was prepared by the method of Example 341 from tert-butyl (7aS,11aR)-2-(2-formylphenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.061 g, 0.15 mmol) and NaBH₄ (0.060 g, 1.6 mmol) as a white solid. MS (ESI): 421 (base, M+H).

Step B:

The title compound (0.032 g, 100%) was prepared by the general method of Example 312, step B from tert-butyl (7aS,11aR)-2-[2-(hydroxymethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-

carboxylate (0.042 g, 0.10 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.80-2.04 (m, 2H), 2.08-2.20 (m, 2H), 2.50-2.80 (m, 4H), 2.82-2.97 (m, 2H), 3.04-3.20 (m, 2H), 3.20-3.38 (m, 1H), 3.38-3.42 (m, 1H), 4.65 (s, 2H), 6.89 (s, 1H), 6.93 (s, 1H), 7.22-7.38 (m, 3H), 7.50-7.57 (m, 1H) ppm. MS (ESI): 321 (base, M+H).

EXAMPLE 375

2-[(7aS,11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-2-yl]-5-methoxybenzaldehyde

Step A:

Tert-butyl (7aS,11aR)-2-(2-formyl-4-methoxyphenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.084 g, 38%) was prepared by the general method of Example 89, step C from *tert*-butyl (7aS,11aR)-2-bromo-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.20 g, 0.50 mmol), 2-formyl-4-methoxyphenylboronic acid (0.18 g, 1.0 mmol), Pd(PPh₃)₂Cl₂ (17 mg, 0.025 mmol), Na₂CO₃ (2.0 M, 1.0 mL, 2.0 mmol) as a white foam. MS (ESI): 449 (base, M+H).

Step B:

The title compound (0.056 g, 86%) was prepared by the general method of Example 312, step B from *tert*-butyl (7aS,11aR)-2-(2-formyl-4-methoxyphenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.084 g, 0.19 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 2.00-2.10 (m, 2H), 2.10-2.25 (m, 2H), 2.59-2.82 (m, 4H), 2.98-3.20 (m, 2H), 3.20-3.40 (m, 3H), 3.42-3.52 (m, 2H), 3.92 (s, 3H), 6.86 (s, 1H), 6.92 (s,

1H), 7.18 (dd, J=8.4, 2.6 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 7.47 (d, J=2.6 Hz, 1H), 9.97 (s, 1H) ppm. MS (ESI): 349 (base, M+H).

5

EXAMPLE 376

{2-[(7aS,11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-2-yl]-5-methoxyphenyl}methanol

10 **Step A:**

Tert-butyl (7aS,11aR)-2-[2-(hydroxymethyl)-4-methoxyphenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.016 g) was obtained as a byproduct of
15 Example 375. MS (ESI): 451 (base, M+H).

Step B:

The title compound (0.010 g, 83%) was prepared by the general method of Example 312, step B from tert-butyl
20 (7aS,11aR)-2-[2-(hydroxymethyl)-4-methoxyphenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (0.016 g, 0.036 mmol) as a white foam. ¹H NMR (CDCl₃, 300 MHz) δ 1.70-2.02 (m, 2H), 2.08-2.20 (m, 2H),
25 2.50-2.80 (m, 4H), 2.80-2.95 (m, 2H), 3.00-3.14 (m, 2H), 3.28-3.38 (m, 1H), 3.38-3.46 (m, 1H), 3.87 (s, 3H), 4.65 (s, 2H), 6.80-6.90 (m, 3H), 7.10 (d, J=3.0 Hz, 1H), 7.19 (d, J=8.4 Hz, 1H) ppm. MS (ESI): 351 (base, M+H).

30

EXAMPLE 377

(8aS,12aR)-2-[4-ethoxy-2-(trifluoromethyl)phenyl]-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3b]indole

The title compound was afforded as a yellow oil (81 mg, 79%) according to the method of Example 319, step A followed by Example 312, step B from *tert*-butyl (8a*S*,12a*R*)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-
5 hi]pyrido[4,3b]indole-11(8*H*)-carboxylate (100 mg, 0.25 mmol) and 4-ethoxy-2-(trifluoromethyl)phenylboronic acid (83 mg, 0.5 mmol). ¹H NMR (CDCl₃) δ 1.37 (t, 3H, *J* = 7.0 Hz), 1.44-1.58 (m, 1H), 1.66-1.84 (m, 2H), 1.89-2.00 (m, 3H), 2.42-2.73 (m, 3H), 2.80-3.04 (m, 5H), 3.10-3.36 (m,
10 3H), 4.01 (q, 2H, *J* = 7.00 Hz), 6.77 (d, 2H, *J* = 5.2 Hz), 6.94 (dd, 1H, *J* = 2.5, 8.5 Hz), 7.13-7.19 (m, 2H) ppm. MS (ESI): 417 (base, *M* + *H*).

EXAMPLE 378

15 (7a*S*,11a*R*)-2-[4-ethoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline

The title compound was afforded as a yellow oil (56 mg, 56%) according to the method of Example 319, step A followed by Example 312, step B from *tert*-butyl (7a*S*,11a*R*)-2-bromo-5,6,8,9,11,11a-hexahydro-4*H*-pyrido[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-10(7a*H*)-carboxylate (100 mg, 0.25 mmol) and 4-methoxy-2-
25 (trifluoromethyl)phenylboronic acid (76 mg, 0.5 mmol). ¹H NMR (CDCl₃) δ 1.46 (t, 3H, *J* = 7.0 Hz), 1.86-2.03 (m, 2H), 2.10-2.21 (m, 2H), 2.62-2.80 (m, 5H), 2.84-2.96 (m, 2H), 3.09-3.19 (m, 2H), 3.33-3.39 (m, 1H), 3.42-3.47 (m, 1H), 4.10 (q, 2H, *J* = 7.0 Hz), 6.83 (d, 2H, *J* = 11.0 Hz), 7.02
30 (dd, 1H, *J* = 2.7, 8.3 Hz), 7.16-7.28 (m, 2H) ppm. MS (ESI): 403 (base, *M* + *H*).

EXAMPLE 379

(8aS,12aR)-2-[3-chloro-2-methylphenyl]-
4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3b]indole

5

The title compound was afforded as a yellow oil (49 mg, 53%) according to the method of Example 319, step A followed by Example 312, step B from tert-butyl (8aS,12aR)-2-bromo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3b]indole-11(8H)-carboxylate (100 mg, 0.24 mmol) and 3-chloro-2-methylphenylboronic acid (84 mg, 0.48 mmol). MS (ESI): 353 (base, M + H).

10

EXAMPLE 380

(7aS,11aR)-2-[3-chloro-2-methylphenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

15

The title compound was afforded as a yellow oil (55 mg, 65%) according to the method of Example 319, step A followed by Example 312, step B from tert-butyl (7aS,11aR)-2-bromo-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-carboxylate (100 mg, 0.24 mmol) and 3-chloro-2-methylphenylboronic acid (80 mg, 0.48 mmol). MS (ESI): 339 (base, M + H).

20

25

EXAMPLE 381

(7aS,11aR)-2-[5-fluoro-2-methylphenyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

30

The title compound was afforded as a yellow oil (29 mg, 91%) according to the method of Example 319, step A followed by Example 312, step B from tert-butyl (7aS,11aR)-2-bromo-5,6,8,9,11,11a-hexahydro-4H-

35

pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-10(7aH)-
carboxylate (50 mg, 0.13 mmol) and 5-fluoro-2-
methylphenylboronic acid (39 mg, 0.25 mmol). MS (ESI): 323
(base, M + H).

5

EXAMPLE 382

(±)-cis-2-(2,3-dichlorophenyl)-10-propyl-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

10

To a solution of (±)-cis-2-(2,3-dichlorophenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.083
mmol) in 1,4-dioxane (0.5 mL) and N,N-diisopropylethylamine
15 (108 mg, 0.83 mmol) were added 1-bromopropane (21 mg, 0.17
mmol) and KI (catalytic amount). The reaction mixture was
heated at 100 °C for 15h. The reaction mixture was cooled
to 20°C then concentrated in vacuo and chromatographed on a
silica gel column by elution with CHCl₃/MeOH (99/1) to give
20 the title compound (27 mg, 82%) as a yellow oil. ¹H NMR
(CDCl₃, 300 MHz) δ 0.92(t, J = 7.3 Hz, 3H), 1.58-1.75 (br,
2H), 2.03-2.23 (m, 5H), 2.42-2.55 (br, 2H), 2.58-2.67 (m,
1H), 2.75 (t, J = 7.4 Hz, 2H), 2.85-2.95 (br, 1H), 2.98-
3.12 (br, 1H), 3.31 (dt, J = 10.3, 3.6 Hz, 1H), 3.37-3.45
25 (br, 2H), 6.94 (s, 1H), 6.97 (s, 1H), 7.15-7.20 (m, 2H),
7.36-7.42 (m, 1H) ppm.

EXAMPLE 383

(7aS,11aR)-2-(2,3-dichlorophenyl)-10-propyl-
30 5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

The title compound was prepared by the method of
Example 382 as a yellow oil (22 mg, 66%) from (7aS,11aR)-2-
35 (2,3-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-

pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.083 mmol). The title compound was spectroscopically identical to Example 382. MS (CI, NH₃): 401.1 (base, M+H).

5

EXAMPLE 384

(±)-cis-10-butyl-2-(2,3-dichlorophenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

10

The title compound was prepared by the method of Example 382 as a yellow oil (28 mg, 82%) from (±)-cis-2-(2,3-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.083 mmol) and 1-bromobutane (23 mg, 0.17 mmol). ¹H NMR (CDCl₃,

15

300 MHz) δ 0.92 (t, J = 7.3 Hz, 3H), 1.32 (se, J = 7.3 Hz, 2H), 1.53-1.65 (br, 2H), 2.02-2.25 (m, 5H), 2.38-2.53 (br, 2H), 2.58-2.68 (m, 1H), 2.75 (t, J = 6.4 Hz, 2H), 2.80-2.92 (br, 1H), 2.95-3.07 (br, 1H), 3.31 (dt, J = 10.3, 3.6 Hz, 1H), 3.37-3.45 (br, 2H), 6.94 (s, 1H), 6.99 (s, 1H), 7.15-
20 7.21 (m, 2H), 7.35-7.40 (m, 1H) ppm.

EXAMPLE 385

(7aS,11aR)-10-butyl-2-(2,3-dichlorophenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4H-
25 pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

The title compound was prepared by the method of Example 382 as a yellow oil (23 mg, 62%) from (7aS,11aR)-2-(2,3-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-
30 pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.083 mmol). The title compound was spectroscopically identical to Example 384. MS (CI, NH₃): 415.1 (base, M+H).

EXAMPLE 386

(7aS,11aR)-2-(2,3-dichlorophenyl)-10-(4-pentenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

5

The title compound was prepared by the method of
Example 382 as a yellow oil (22 mg, 62%) from (7aS,11aR)-2-
(2,3-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.083
10 mmol) and 5-bromo-1-pentene (25 mg, 0.17 mmol). ¹H NMR
(CDCl₃, 300 MHz) δ 1.62-1.75 (br, 2H), 2.01-2.22 (m, 7H),
2.35-2.53 (br, 3H), 2.58-2.65 (m, 1H), 2.74 (t, J = 6.6 Hz,
2H), 2.75-2.85 (br, 1H), 2.88-3.05 (br, 1H), 3.28-3.41 (m,
3H), 4.97 (d, J = 13.5 Hz, 1H), 5.02 (dd, J = 17.6, 1.5 Hz,
15 1H), 5.73-5.83 (m, 1H), 6.93 (s, 1H), 6.98 (s, 1H), 7.15-
7.21 (m, 2H), 7.36-7.40 (m, 1H) ppm. MS (CI, NH₃): 427.1
(base, M+H).

EXAMPLE 387

20. (7aS,11aR)-2-(2,3-dichlorophenyl)-10-(3-methyl-2-butenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

The title compound was prepared by the method of
25 Example 382 as a yellow oil (27 mg, 76%) from (7aS,11aR)-2-
(2,3-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.083
mmol) and 4-bromo-2-methyl-2-butene (25 mg, 0.17 mmol). MS
(CI, NH₃): 427.1 (base, M+H).

30

EXAMPLE 388

(7aS,11aR)-2-(2,4-dichlorophenyl)-10-propyl-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

35

The title compound was prepared by the method of Example 382 as a yellow oil (21 mg, 65%) from (7aS,11aR)-2-(2,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.083 mmol) and 1-bromopropane (30 mg, 0.24 mmol). ¹H NMR (CDCl₃, 300 MHz) δ 0.92 (t, J = 7.3 Hz, 3H), 1.61-1.75 (m, 2H), 2.02-2.35 (m, 6H), 2.45-2.63 (m, 3H), 2.75 (t, J = 6.5 Hz, 2H), 2.87-2.98 (br, 1H), 3.00-3.08 (br, 1H), 3.30 (dt, J = 10.6, 4.0 Hz, 1H), 3.35-3.48 (m, 2H), 6.94 (s, 1H), 6.99 (s, 1H), 7.21-7.25 (m, 1H), 7.44 (d, J = 1.5 Hz, 1H) ppm. MS (CI, NH₃): 401.1 (base, M+H).

EXAMPLE 389

(7aS,11aR)-10-butyl-2-(2,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

The title compound was prepared by the method of Example 382 as a yellow oil (21 mg, 61%) from (7aS,11aR)-2-(2,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.083 mmol) and 1-bromobutane (23 mg, 0.17 mmol). MS (CI, NH₃): 415.1 (base, M+H).

EXAMPLE 390

(7aS,11aR)-2-(2,4-dichlorophenyl)-10-(4-pentenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

The title compound was prepared by the method of Example 382 as a yellow oil (23 mg, 67%) from (7aS,11aR)-2-(2,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.083 mmol) and 5-bromo-1-pentene (25 mg, 0.16 mmol). MS (CI, NH₃): 427.1 (base, M+H).

EXAMPLE 391

(7aS,11aR)-2-(2,4-dichlorophenyl)-10-(3-methyl-2-butenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4H-
5 pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

The title compound was prepared by the method of
Example 382 as a yellow oil (26 mg, 76%) from (7aS,11aR)-2-
(2,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-
10 pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.083
mmol) and 4-bromo-2-methyl-2-butene (25 mg, 0.16 mmol). ¹H
NMR (CDCl₃, 300 MHz) δ 1.68 (s, 3H), 1.81 (s, 3H), 2.12-
2.23 (m, 3H), 2.26-2.42 (m, 1H), 2.55-2.70 (m, 2H), 2.78
(t, J = 6.6 Hz, 2H), 3.10-3.45 (m, 6H), 3.63-3.77 (m, 2H),
15 5.42-5.55 (br, 1H), 6.99 (s, 1H), 7.03 (s, 1H), 7.24-
7.217.29 (m, 2H), 7.47 (d, J = 1.8 Hz, 1H) ppm. MS (CI,
NH₃): 427.1 (base, M+H).

EXAMPLE 392

20 (7aS,11aR)-10-(cyclobutylmethyl)-2-(2,3-dichlorophenyl)-
5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

The title compound was prepared by the method of
25 Example 382 as a yellow oil (22 mg, 58%) from (7aS,11aR)-2-
(2,4-dichlorophenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (32 mg, 0.089
mmol) and (bromomethyl)cyclobutane (27 mg, 0.18 mmol). MS
(CI, NH₃): 427.1 (base, M+H).

30

EXAMPLE 393

(7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-10-
methyl-5,6,7a,8,9,10,11,11a-octahydro-4H-
pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

35

The solution of (7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.077 mmol) in formaldehyde (37 wt % aqueous solution, 97 mg, 1.16 mmol) and formic acid (54 mg, 1.16 mmol) was heated at 80 °C for 2h. The reaction mixture was diluted with H₂O then basified with 1N NaOH to pH 12 and extract with CHCl₃. The combined organic solution was dried over MgSO₄, concentrated in vacuo, and the residue was chromatographed (silica gel; CHCl₃: MeOH 99:1-95:5) to give the title compound as a pale yellow oil (19 mg, 61%). MS (CI, NH₃): 403.1 (base, M+H).

EXAMPLE 394

(7aS,11aR)-10-ethyl-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

To a solution of (7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.077 mmol) in acetic acid (0.28 mL) was added NaBH₄ (30 mg, 0.80 mmol) in 2 portion in 10 min interval at 55 °C. The reaction mixture was stirred for 15 h at 55 °C then quenched by addition of H₂O. The aqueous solution was basified with 50 % NaOH then extracted with CHCl₃. The combined organic solution was dried over MgSO₄, concentrated in vacuo. The residue was chromatographed (silica gel; CHCl₃: MeOH 99:1-98:2) to give the title compound as a yellow oil (26 mg, 81%). ¹H NMR (CDCl₃, 300 MHz) δ 1.21-1.35 (m, 3H), 2.05-2.30 (m, 5H), 2.53-2.78 (m, 6H), 2.98-3.07 (br, 1H), 3.08-3.18 (br, 1H), 3.27-3.42 (m, 2H), 3.43-3.57 (br, 1H), 3.88 (s, 3H), 6.83 (s, 1H), 6.86

(s, 1H), 7.04 (dd, J = 8.8, 2.9 Hz, 1H), 7.20-7.26 (m, 2H) ppm. MS (CI, NH₃): 417.1 (base, M+H).

EXAMPLE 395

5 (7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-10-propyl-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

The title compound was prepared by the method of
10 Example 382 as a yellow oil (23 mg, 69%) from (7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.077 mmol) and 1-bromopropane (20 mg, 0.15 mmol).
1H NMR (CDCl₃, 300 MHz) δ 0.98 (t, J = 7.3 Hz, 3H), 1.78-
15 1.92 (br, 2H), 2.11-2.25 (m, 5H), 2.28-2.42 (m, 1H), 2.53-2.80 (m, 5H), 3.05-3.25 (br, 2H), 3.31 (dt, J = 10.2, 3.6 Hz, 1H), 3.37-3.45 (br, 1H), 3.60-3.72 (br, 1H), 3.89 (s, 3H), 6.85 (s, 1H), 6.87 (s, 1H), 7.05 (dd, J = 8.7, 2.6 Hz, 1H), 7.21-7.27 (m, 2H) ppm. MS (CI, NH₃): 431.2 (base,
20 M+H).

EXAMPLE 396

(7aS,11aR)-10-butyl-2-[4-methoxy-2-(trifluoromethyl)phenyl]-10-methyl-5,6,7a,8,9,10,11,11a-
25 octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

The title compound was prepared by the method of
Example 382 as a yellow oil (23 mg, 67%) from (7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-
30 octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.077 mmol) and 1-bromobutane (21 mg, 0.15 mmol).
1H NMR (CDCl₃, 300 MHz) δ 0.93 (t, J = 7.3 Hz, 3H), 1.34 (se, J = 7.3 Hz, 2H), 1.65-1.77 (br, 2H), 2.05-2.23 (m, 5H), 2.25-2.38 (br, 1H), 2.55-2.77 (m, 3H), 2.95-3.15 (br, 2H), 3.30 (dt, J = 10.2, 3.7 Hz, 1H), 3.32-3.40 (br, 1H),
35

3.42-3.55 (br, 1H), 3.86 (s, 3H), 6.82 (s, 1H), 6.85 (s, 1H), 7.03 (dd, J = 8.8, 2.6 Hz, 1H), 7.20-7.25 (m, 2H) ppm. MS (CI, NH₃): 445.2 (base, M+H).

5

EXAMPLE 397

(7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-10-(4-pentenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

10

The title compound was prepared by the method of Example 382 as a yellow oil (22 mg, 63%) from (7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.077 mmol) and 5-bromo-1-pentene (23 mg, 0.15

15

mmol). ¹H NMR (CDCl₃, 300 MHz) δ 1.68-1.79 (m, 2H), 2.01-2.26 (m, 7H), 2.43-2.62 (m, 4H), 2.71 (t, J = 6.3 Hz, 2H), 2.83-2.92 (br, 1H), 2.95-3.07 (br, 1H), 3.27-3.44 (m, 3H), 3.86 (s, 3H), 4.93-5.05 (m, 2H), 5.70-5.85 (m, 1H), 6.80 (s, 1H), 6.84 (s, 1H), 7.02 (dd, J = 8.1, 2.6 Hz, 1H),

20

7.18-7.24 (m, 2H) ppm. MS (CI, NH₃): 457.2 (base, M+H).

EXAMPLE 398

(7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-10-(3-methyl-2-butenyl)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

25

The title compound was prepared by the method of Example 382 as a yellow oil (25 mg, 71%) from (7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.077 mmol) and 4-bromo-2-methyl-2-butene (23 mg, 0.15 mmol). ¹H NMR (CDCl₃, 300 MHz) δ 1.65 (s, 3H), 1.79 (s, 3H), 2.12-2.22 (m, 3H), 2.24-2.40 (m, 1H), 2.57 (se, J = 7.7 Hz, 2H), 2.72 (t, J = 6.6 Hz, 2H), 2.74-2.84 (br, 1H), 3.05-3.45 (m, 6H), 3.59-3.77 (m, 1H), 3.86 (s, 3H),

35

5.42-5.55 (br, 1H), 6.83 (s, 1H), 6.85 (s, 1H), 7.03 (d, J = 8.8 Hz, 1H), 7.17-7.25 (m, 2H) ppm. MS (CI, NH₃): 457.2 (base, M+H).

5

EXAMPLE 399

(7aS,11aR)-10-(2-fluoroethyl)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

10

The title compound was prepared by the method of Example 382 as a yellow oil (32 mg, 96%) from (7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.077 mmol) and 1-bromo-2-fluoroethane (30 mg, 0.23 mmol). MS (CI, NH₃): 435.1 (base, M+H).

15

EXAMPLE 400

(7aS,11aR)-10-(2,2-difluoroethyl)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

20

The title compound was prepared by the method of Example 382 as a yellow oil (27 mg, 77%) from (7aS,11aR)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.077 mmol) and 2-bromo-1,1-difluoroethane (35 mg, 0.23 mmol). MS (CI, NH₃): 453.1 (base, M+H).

25

EXAMPLE 401

(7aS,11aR)-10-(cyclobutylmethyl)-2-[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

30

The title compound was prepared by the method of Example 382 as a yellow oil (32 mg, 96%) from (7aS,11aR)-2-

35

[4-methoxy-2-(trifluoromethyl)phenyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (30 mg, 0.077 mmol) and 1-bromo-2-fluoroethane (30 mg, 0.23 mmol). ¹H NMR (CDCl₃, 300 MHz) δ 1.70-1.82 (m, 4H), 1.85-1.98 (m, 1H), 2.02-2.30 (m, 7H), 2.53-2.63 (m, 1H), 2.68-2.88 (m, 5H), 2.92-3.15 (br, 2H), 3.25-3.38 (m, 2H), 3.52-3.62 (br, 1H), 3.87 (s, 3H), 6.82 (s, 1H), 6.84 (s, 1H), 7.03 (dd, J = 8.5, 2.5 Hz, 1H), 7.20-7.25 (m, 2H) ppm. MS (CI, NH₃): 457.2 (base, M+H). MS (CI, NH₃): 457.2 (base, M+H).

EXAMPLE 402

4-((7aS,11aR)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(7aH)-yl)-1-(4-fluorophenyl)-1-butanone

To a solution of (7aS,11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (0.21 g, 1.0 mmol) in 1,4-dioxane (7.0 mL) were added 4-chloro-4'-fluorobutyrophenone (0.40 g, 2.0 mmol), KI (catalytic amount) and K₂CO₃ (0.28 g, 2.0 mmol). The reaction mixture was heated at 100 °C for 48 h. The reaction mixture was cooled to 20 °C then diluted with CHCl₃. The solution was filtered to remove excess K₂CO₃ and the filtrate was concentrated in vacuo and chromatographed (silica gel, CHCl₃: MeOH 98:2) to give the title compound (0.22 g, 58%) as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 1.75-2.20 (m, 7H), 2.20-2.35 (m, 1H), 2.35-2.48 (m, 2H), 2.48-2.60 (m, 1H), 2.60-2.78 (m, 3H), 2.78-2.90 (m, 1H), 2.99 (t, J=7.2 Hz, 2H), 3.05-3.15 (m, 1H), 3.18-3.32 (m, 2H), 6.62 (t, J=7.3 Hz, 1H), 6.86 (d, J=7.3 Hz, 1H), 7.12 (t, J=8.6 Hz, 2H), 7.90-8.08 (m, 2H) ppm.

EXAMPLE 403

4-((7aR,11aS)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(7aH)-yl)-1-(4-fluorophenyl)-1-butanone

5

The title compound (0.16 g, 42%) was prepared by the general method of Example 402 from (7aR,11aS)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (0.21 g, 1.0 mmol), 4-chloro-4'-fluorobutyrophenone (0.40 g, 2.0 mmol), KI (catalytic) and K₂CO₃ (0.28 g, 2.0 mmol) after chromatographic purification as a white amorphous solid. The ¹H NMR was identical to that of Example 402, 4-((7aS,11aR)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(7aH)-yl)-1-(4-fluorophenyl)-1-butanone

10
15**EXAMPLE 404**

4-((7aS,11aR)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(7aH)-yl)-1-(2-aminophenyl)-1-butanone

20

The title compound (0.031 g, 16%) was prepared by the general method of Example 402 from (7aS,11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (0.11 g, 0.50 mmol), 4-chloro-2'-aminobutyrophenone (0.20 g, 1.0 mmol), KI (catalytic) and K₂CO₃ (0.14 g, 1.0 mmol) after chromatographic purification as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 1.80-2.20 (m, 7H), 2.20-2.60 (m, 3H), 2.82-2.95 (m, 1H), 2.98 (t, J=7.4 Hz, 2H), 3.05-3.20 (m, 2H), 3.20-3.38 (m, 2H), 3.64 (t, J=6.6 Hz, 1H), 3.68-3.80 (m, 1H), 3.81 (t, J=6.0 Hz, 1H), 6.26 (br, 2H), 6.58-6.68 (m, 2H), 6.80-6.92 (m, 2H), 7.10-7.30 (m, 2H), 7.52-

25
30

7.72 (m, 1H), 7.77 (dd, J=1.3, 8.4 Hz, 1H), 8.09 (td, J=1.6, 8.4 Hz, 1H) ppm.

EXAMPLE 405

5 4-((7aR,11aS)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(7aH)-yl)-1-(2-aminophenyl)-1-butanone

The title compound (0.080 g, 42%) was prepared by the
10 general method of Example 402 from (7aR,11aS)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (0.11 g, 0.50 mmol), 4-chloro-2'-aminobutyrophenone (0.20 g, 1.0 mmol), KI (catalytic) and K₂CO₃ (0.14 g, 1.0 mmol) after
15 chromatographic purification as a white amorphous solid. The ¹H NMR was identical to that of Example 404, 4-((7aS,11aR)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(7aH)-yl)-1-(2-aminophenyl)-1-butanone

20

EXAMPLE 406

(±)-cis-3-(5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(7aH)-yl)propyl 4-fluorophenyl ether

25

The title compound (0.14 g, 32%) was prepared by the general method of Example 402 from (±)-cis-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (0.25 g, 1.2
30 mmol), 1-(3-chloropropoxy)-4-fluorobenzene (0.37 g, 2.0 mmol), KI (catalytic) and K₂CO₃ (0.28 g, 2.0 mmol) after chromatographic purification as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 1.78-2.08 (m, 7H), 2.10-2.30 (m, 1H), 2.32-2.50 (m, 3H), 2.51-2.72 (m, 3H), 2.75-2.82 (m,

1H), 3.00-3.12 (m, 1H), 3.12-3.25 (m, 2H), 3.89 (t, J=6.3 Hz, 2H), 6.55 (t, J=7.5 Hz, 1H), 6.70-6.92 (m, 6H) ppm.

EXAMPLE 407

5 4-((±)-cis-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(7aH)-yl)-1-(4-pyridinyl)-1-butanone

The title compound (0.080 g, 18%) was prepared by the
10 general method of Example 402 from (±)-cis-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (0.25 g, 1.2 mmol), 4-chloro-1-(4-pyridinyl)-1-butanone (0.36 g, 2.0 mmol), KI (catalytic) and K₂CO₃ (0.28 g, 2.0 mmol) after
15 chromatographic purification as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 1.68-2.18 (m, 7H), 2.20-2.65 (m, 5H), 2.69 (t, J=6.4 Hz, 2H), 2.72-2.82 (m, 1H), 2.92-3.08 (m, 3H), 3.15-3.28 (m, 2H), 6.62 (t, J=7.5 Hz, 1H), 6.86 (d, J=7.6 Hz, 1H), 6.89 (d, J=7.4 Hz, 1H), 7.70-7.80 (m,
20 2H), 8.75-8.82 (m, 2H) ppm.

EXAMPLE 408

(±)-cis-10-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-
5,6,7a,8,9,10,11,11a-octahydro-4H-
25 pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

The title compound (0.15 g, 32%) was prepared by the
general method of Example 402 from (±)-cis-5,6,7a,8,9,10,11,11a-octahydro-4H-
30 pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (0.25 g, 1.2 mmol), 3-(3-chloropropyl)-6-fluoro-1,2-benzisoxazole (0.43 g, 2.0 mmol), KI (catalytic) and K₂CO₃ (0.28 g, 2.0 mmol) after chromatographic purification as a white amorphous
solid. ¹H NMR (CDCl₃, 300 MHz) δ 1.80-2.18 (m, 7H), 2.25
35 (td, J=11.5, 3.0 Hz, 1H), 2.35-2.68 (m, 4H), 2.70 (t, J=6.6

Hz, 2H), 2.75-2.88 (m, 1H), 3.01 (t, J=7.6 Hz, 2H), 3.05-3.15 (m, 1H), 3.20-3.30 (m, 2H), 6.62 (t, J=7.5 Hz, 1H), 6.86 (d, J=7.5 Hz, 1H), 6.92 (d, J=7.5 Hz, 1H), 7.06 (td, J=9.0, 2.1 Hz, 1H), 7.20-7.26 (m, 1H), 7.61 (dd, J=4.8, 8.7 Hz, 1H) ppm.

EXAMPLE 409

(7aS,11aR)-10-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

The title compound (0.31 g, 75%) was prepared by the general method of Example 402 from (7aS, 11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (0.21 g, 1.0 mmol), 3-(3-chloropropyl)-6-fluoro-1,2-benzisoxazole (0.43 g, 2.0 mmol), KI (catalytic) and K₂CO₃ (0.28 g, 2.0 mmol) after chromatographic purification as a white amorphous solid. The ¹H NMR was identical to that of Example 408, (±)-cis-10-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

EXAMPLE 410

1-(4-fluorophenyl)-4-(5,6,8,11-tetrahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(9H)-yl)-1-butanone

The title compound (0.060 g, 28%) was prepared by the general method of Example 402 from 5,6,8,11-tetrahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (0.12 g, 0.57 mmol), 4-chloro-4'-fluorobutyrophenone (0.40 g, 2.0 mmol), KI (catalytic) and K₂CO₃ (0.28 g, 2.0 mmol) after chromatographic purification as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) δ 1.80-2.15 (m, 2H), 2.15-2.30 (m,

2H), 2.71 (t, J=7.0 Hz, 2H), 2.82 (d, J=5.1 Hz, 2H), 2.90
(t, J=5.8 Hz, 2H), 2.97 (t, J=6.1 Hz, 2H), 3.02-3.20 (m,
2H), 3.73 (s, 2H), 3.98 (t, J=5.7 Hz, 2H), 6.84 (d, J=6.9
Hz, 1H), 6.97 (t, J=7.5 Hz, 1H), 7.02-7.20 (m, 2H), 7.25
5 (d, J=7.7 Hz, 1H), 7.20-7.25 (m, 1H), 7.95-8.20 (m, 2H)
ppm.

EXAMPLE 411

(±)-cis-4-(4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-
10 hi]pyrido[4,3-b]indol-11(8aH)-yl)-1-(4-fluorophenyl)-1-
butanone

The title compound (0.17 g, 74%) was prepared by the
general method of Example 402 from (±)-cis-
15 4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-
hi]pyrido[4,3-b]indole (0.14 g, 0.59 mmol), 4-chloro-4'-
fluorobutyrophenone (0.20 g, 1.0 mmol), KI (catalytic) and
K₂CO₃ (0.14 g, 1.0 mmol) after chromatographic purification
as a white amorphous solid. ¹H NMR (CDCl₃, 300 MHz) •
20 1.42-1.62 (m, 1H), 1.62-1.80 (m, 1H), 1.88-2.22 (m, 7H),
2.40-2.70 (m, 5H), 2.80-3.12 (m, 5H), 3.12-3.30 (m, 2H),
3.32-3.50 (m, 1H), 6.69 (t, J=7.5 Hz, 1H), 6.80-7.00 (m,
2H), 7.05-7.20 (m, 2H), 7.90-8.03 (m, 2H) ppm.

25 EXAMPLE 412

4-((8aS,12aR)-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-
hi]pyrido[4,3-b]indol-11(8aH)-yl)-1-(4-fluorophenyl)-1-
butanone

30 The title compound was prepared by preparative HPLC
separation of (±)-cis-4-(4,5,6,7,9,10,12,12a-
octahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-11(8aH)-yl)-1-
(4-fluorophenyl)-1-butanone on a CHIRALPAK® AD column
(CH₃CN/Ethanol/DEA = 85/15/0.05).

35

EXAMPLE 413

4-((8aR,12aS)-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-11(8aH)-yl)-1-(4-fluorophenyl)-1-butanone

5 The title compound was prepared by preparative HPLC separation of (±)-cis-4-(4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-11(8aH)-yl)-1-(4-fluorophenyl)-1-butanone on a CHIRALPAK® AD column (CH₃CN/Ethanol/DEA = 85/15/0.05).

10

EXAMPLE 414

4-((±)-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-11(8aH)-yl)-1-(2-amino-4-fluorophenyl)-1-butanone

15

 The title compound (0.16 g, 67%) was prepared by the general method of Example 402 from (±)-cis-4,5,6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indole (0.14 g, 0.59 mmol), 4-chloro-2'-amino-4'-fluorobutyrophenone (0.22 g, 1.0 mmol), KI (catalytic) and K₂CO₃ (0.14 g, 1.0 mmol) after chromatographic purification as a white amorphous solid.

¹H NMR (CDCl₃, 300 MHz) δ 1.45-1.62 (m, 2H), 1.62-2.10 (m, 8H), 2.20-2.52 (m, 4H), 2.52-2.72 (m, 2H), 2.72-2.84 (m, 1H), 2.84-3.00 (m, 2H), 3.12-3.30 (m, 3H), 6.20-6.60 (m, 4H), 6.67 (t, J=7.3 Hz, 1H), 6.91 (t, J=7.7 Hz, 2H), 7.77 (dd, J=6.4, 9.0 Hz, 1H) ppm.

25

EXAMPLE 415

30 4-((±)-cis-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(7aH)-yl)-1-(2-amino-4-fluorophenyl)-1-butanone

 The title compound was prepared by the method of Example 402 as a red oil (99 mg, 54%) from (±)-cis-

35

5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (100 mg, 0.47 mmol) and 1-(2-amino-4-fluorophenyl)-4-chloro-1-butanone (152 mg, 0.70 mmol). ¹H NMR (CDCl₃, 300 MHz) δ 1.95-2.15 (m, 7H), 2.37-2.57 (m, 5H), 2.67-2.85 (m, 3H), 2.90-3.05 (m, 3H), 3.24-3.33 (m, 2H), 6.27-6.39 (m, 2H), 6.41-6.50 (br, 2H), 6.64 (t, J = 7.3 Hz, 1H), 6.85-6.94 (m, 2H), 7.77 (dd, J = 9.2, 6.6 Hz, 1H) ppm.

10

EXAMPLE 416

4-((7aS,11aR)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(7aH)-yl)-1-(2-amino-4-fluorophenyl)-1-butanone

15

The title compound was prepared by the method of Example 402 as a yellow oil (35 mg, 20%) from (7aS,11aR)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (100 mg, 0.47 mmol) and 1-(2-amino-4-fluorophenyl)-4-chloro-1-butanone (202 mg, 0.93 mmol). The title compound was spectroscopically identical to Example 415.

20

EXAMPLE 417

4-((7aR,11aS)-5,6,8,9,11,11a-hexahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinolin-10(7aH)-yl)-1-(2-amino-4-fluorophenyl)-1-butanone

25

The title compound was prepared by the method of Example 402 as a yellow oil (95 mg, 34%) from (7aR,11aS)-5,6,7a,8,9,10,11,11a-octahydro-4H-pyrido[3',4':4,5]pyrrolo[3,2,1-ij]quinoline (150 mg, 0.70 mmol) and 1-(2-amino-4-fluorophenyl)-4-chloro-1-butanone (303 mg, 1.40 mmol). The title compound was spectroscopically identical to Example 415.

35

EXAMPLE 418

5,6,9,10,11,12-hexahydro-4*H*,8*H*-
azepino[4',5':4,5]pyrrolo[3,2,1-*ij*]quinoline

5 To a solution of 3,4-dihydro-1(2*H*)-quinolinamine (1.0 g, 14 mmol) and hexahydro-4*H*-azepin-4-one hydrochloride (1.0 g, 14 mmol) in EtOH (13 mL) was added concentrated HCl (1.2 mL). The reaction was stirred at reflux for 14 h, then cooled to 20 °C. A brown precipitate was filtered
10 from the reaction mixture, affording the title compound (800 mg, 45%) as a brown solid. ¹H NMR (CD₃OD, 300 MHz) δ 2.14-2.23 (m, 2H), 2.91 (t, 2H, *J* = 6.0 Hz), 3.16-3.21 (m, 2H), 3.27-3.33 (m, 2H), 3.39-3.50 (m, 4H), 4.04 (t, 2H, *J* = 5.7 Hz), 6.70 (d, 1H, *J* = 6.9 Hz), 6.87-6.93 (m, 1H), 7.22
15 (d, 1H, *J* = 8.0 Hz) ppm. MS (ESI): 227.2 (base, *M* + *H*).

EXAMPLE 419

(±)-5,6,8,9,10,11,12,12a-octahydro-4*H*,7a*H*-
azepino[4',5':4,5]pyrrolo[3,2,1-*ij*]quinoline

20

Step A:

To a solution of 5,6,9,10,11,12-hexahydro-4*H*,8*H*-
azepino[4',5':4,5]pyrrolo[3,2,1-*ij*]quinoline (150 mg, 0.65 mmol) in TFA (7.5 mL) was added NaCNBH₃ (123 mg, 1.95 mmol)
25 in small portions at 0 °C. The reaction mixture was stirred for 1 h. To the reaction mixture was added concentrated HCl (5 mL) and the reaction was heated at reflux for 10 m. The reaction mixture was concentrated *in vacuo* and basified to pH 14 with 50% NaOH. To this was
30 added 1,4-dioxane (14 mL), and to this solution was added di-*tert*-butyl dicarbonate (700 mg, 3.2 mmol). The solution was stirred at 20 °C for 16 h. Purification by column chromatography (hexanes:EtOAc 19:1) afforded *tert*-butyl
(±)-5,6,8,9,10,11,12,12a-octahydro-4*H*,7a*H*-

azepino[4',5':4,5]pyrrolo[3,2,1-ij]quinoline-10-carboxylate as a colorless oil.

Step B:

5 To a solution of tert-butyl (±)-5,6,8,9,10,11,12,12a-octahydro-4H,7aH-azepino[4',5':4,5]pyrrolo[3,2,1-ij]quinoline-10-carboxylate in CH₂Cl₂ (2.4 mL) was added TFA (0.6 mL). This was stirred at 20 °C for 3 h. The reaction mixture was diluted with CH₂Cl₂ (50 mL) and washed
10 with saturated NaHCO₃ (50 mL) and brine (50 mL), dried over MgSO₄ and concentrated in vacuo to afford the title compound as a yellow oil (87 mg, 59%). ¹H NMR (CDCl₃, 300 MHz) δ 1.77-2.13 (m, 7H), 2.56-2.79 (m, 5H), 2.83-2.93 (m, 1H), 3.00-3.16 (m, 2H), 3.33-3.41 (td, 1H, J = 3.7, 9.2
15 Hz), 3.60 (td, 1H, J = 4.4, 9.1 Hz), 6.50 (t, 1H, J = 7.3 Hz), 6.76 (t, 2H, 8.0 Hz) ppm.

EXAMPLE 420

4-[(±)-5,6,8,9,10,11,12,12a-octahydro-4H,7aH-azepino[4',5':4,5]pyrrolo [3,2,1-ij]quinolin-10-yl]-1-(4-fluorophenyl)-1-butanone
20

The title compound was isolated as a yellow oil (55 mg, 37%) according to the method of Example 402 from (±)-
25 5,6,8,9,10,11,12,12a-octahydro-4H,7aH-azepino[4',5':4,5]pyrrolo[3,2,1-ij]quinoline (87mg, 0.38 mmol) and 4-chloro-1-(4-fluorophenyl)-1-butanone (153 mg, 0.76 mmol). ¹H NMR (CDCl₃, 300 MHz) δ 2.04-2.36 (m, 6H), 2.65-2.89 (m, 6H), 2.93-3.39 (m, 8H), 3.50-3.59 (m, 1H),
30 3.71-3.80 (m, 1H), 6.65 (t, 1H, J = 7.3 Hz), 6.87 (t, 2H, J = 6.9 Hz), 7.09-7.17 (m, 2H), 7.94-8.01 (m, 2H) ppm.

EXAMPLE 421

4-[(±)-5,6,8,9,10,11,12,12a-octahydro-4*H*,7a*H*-
azepino[4',5':4,5]pyrrolo [3,2,1-*ij*]quinolin-10-yl]-1-(2-
amino-4-fluorophenyl)-1-butanone

5

The title compound was isolated as a yellow oil (23
mg, 12%) according to the method of Example 402 from (±)-
5,6,8,9,10,11,12,12a-octahydro-4*H*,7a*H*-
azepino[4',5':4,5]pyrrolo[3,2,1-*ij*]quinoline (111 mg, 0.49
10 mmol) and 4-chloro-1-(2-amino-4-fluorophenyl)-1-butanone
(210 mg, 0.97 mmol). ¹H NMR (CDCl₃, 300 MHz) δ 1.98-2.11
(m, 5H), 2.38-2.57 (m, 2H), 2.60-2.69 (m, 3H), 2.71-3.13
(m, 10H), 3.39-3.47 (m, 1H), 3.63-3.70 (m, 1H), 6.20-6.41
(m, 4H), 6.56 (t, 1H, *J* = 7.3 Hz), 6.79 (d, 2H, 7.7 Hz),
15 7.63-7.69 (m, 1H) ppm.

EXAMPLE 422

4,5,6,9,10,11,12,13-octahydro-9*H*-diazepino[4,5-*b*:3,2,1-
hi]indole

20

The title compound was prepared as a brown solid (287
mg, 65%) according to the method of Example 418 from
2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-amine (300 mg, 1.85
mmol) and hexahydro-4*H*-azepin-4-one hydrochloride (277 mg,
25 1.85 mmol). ¹H NMR (CD₃OD, 300 MHz) δ 1.99-2.16 (m, 4H),
3.04-3.12 (m, 5H), 3.16-3.21 (m, 2), 3.32-3.41 (m, 3H),
4.09-4.15 (m, 2H), 6.80-6.91 (m, 2H), 7.22 (d, 1H, *J* = 6.9
Hz) ppm.

30

EXAMPLE 423

(±)-4,5,6,7,9,10,11,12,13,13a-decahydro-8a*H*-diazepino[4,5-
b:3,2,1-*hi*]indole

The title compound was isolated as a yellow oil (38
35 mg, 25%) according to the procedure of Example 419, Steps A

and B from 4,5,6,9,10,11,12,13-octahydro-9H-diazepino[4,5-b:3,2,1-hi]indole (152 mg, 0.63 mmol). ¹H NMR (CDCl₃, 300 MHz) δ 1.37-1.55 (m, 1H), 1.64-1.80 (m, 1H), 1.85-2.09 (m, 4H), 2.11-2.23 (m, 2H), 2.56-2.97 (m, 6H), 3.12-3.23 (m, 2H), 3.57-3.71 (m, 2H), 6.68 (t, 1H, J = 7.4 Hz), 6.87-6.91 (m, 2H) ppm.

EXAMPLE 424

4-[(±)-4,5,6,7,9,10,11,12,13,13a-decahydro-11H-diazepino[4,5-b:3,2,1-hi]indol-11-yl]-1-(4-fluorophenyl)-1-butanone

The title compound was isolated as a yellow oil (20 mg, 60%) according to the method of Example 402 from (±)-4,5,6,7,9,10,11,12,13,13a-decahydro-8aH-diazepino[4,5-b:3,2,1-hi]indole (20 mg, 0.08 mmol) and 4-chloro-1-(4-fluorophenyl)-1-butanone (32 mg, 0.16 mmol). ¹H NMR (CDCl₃, 300 MHz) δ 1.37-1.45 (m, 1H), 1.59-1.77 (m, 1H), 1.91-2.04 (m, 6H), 2.13-2.22 (m, 2H), 2.55-2.71 (m, 6H), 2.85-3.19 (m, 6H), 3.53-3.67 (m, 2H), 6.68 (t, 1H, J = 7.3 Hz), 6.88 (d, 2H, J = 7.3 Hz), 7.08-7.16 (m, 2H), 7.97-8.03 (m, 2H) ppm.

EXAMPLE 425

4-[(±)-4,5,6,7,9,10,11,12,13,13a-decahydro-11H-diazepino[4,5-b:3,2,1-hi]indol-11-yl]-1-(2-amino-4-fluorophenyl)-1-butanone

The title compound was isolated as a yellow oil (23 mg, 66%) according to the method of Example 402 from (±)-4,5,6,7,9,10,11,12,13,13a-decahydro-8aH-diazepino[4,5-b:3,2,1-hi]indole (20 mg, 0.08 mmol) and 4-chloro-1-(2-amino-4-fluorophenyl)-1-butanone (53 mg, 0.25 mmol). ¹H NMR (CDCl₃, 300 MHz) δ 1.30-1.43 (m, 1H), 1.53-1.64 (m,

1H), 1.88-2.01 (m, 6H), 2.10-2.22 (m, 2H), 2.50-2.70 (m, 6H), 2.70-3.09 (m, 6H), 3.26-3.44 (m, 2H), 6.20-6.30 (m, 2H), 6.36 (br, 2H), 6.62 (t, 1H, $J = 7.4$ Hz), 6.79-6.85 (m, 2H), 7.65-7.70 (m, 1H) ppm.

5

EXAMPLE 426

(±)-cis-6,7,8a,9,10,11,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-4(5H)-one

10 Step A:

To a stirred solution of 1M BCl₃ in toluene (8.8 mL, 8.8 mmol) was added ethyl (±)-cis-1,3,4,4a,5,9b-hexahydro-2H-pyrido[4,3-b]indole-2-carboxylate (984 mg, 4.0 mmol) in benzene (32 mL) at 0°C. To the above solution was added 4-chlorobutanenitrile (0.39 mL, 4.4 mmol), and AlCl₃ (587mg, 4.4 mmol), the reaction mixture was stirred at r.t.. for 10 min., then was heated in a sealed tube for 18 h. After cooled down to r.t., was added 5N HCl (32mL) and heated at 80°C for 30 min. The reaction mixture was neutralized by 20 50% NaOH at 0°C, adjusted pH=14, extracted with CH₂Cl₂ (200mL), the organic layer was dried over MgSO₄, and concentrated in vacuo to afford after chromatographic purification ethyl (±)-cis-6-(4-chlorobutanoyl)-1,3,4,4a,5,9b-hexahydro-2H-pyrido[4,3-b]indole-2-carboxylate (413mg, 30%). 25

Step B:

To ethyl (±)-cis-6-(4-chlorobutanoyl)-1,3,4,4a,5,9b-hexahydro-2H-pyrido[4,3-b]indole-2-carboxylate (100mg, 0.29 mmol) in butanol (3 mL) was added KOH(50 mg) and heated at 30 109°C for 5hr.. After cooled down to r.t., KOH(50 mg) and KI(20 mg) were added. The reaction mixture was heated at 109°C in a sealed tube for 18 h. The reaction mixture was cooled down to r.t., extracted with CH₂Cl₂, dried over MgSO₄

to afford (\pm)-*cis*-6,7,8a,9,10,11,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indol-4(5*H*)-one (69 mg, 99%).

5 **Step C:**

To (\pm)-*cis*-6,7,8a,9,10,11,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indol-4(5*H*)-one (61mg, 0.25 mmol) in dioxane(1 mL) and 1N NaOH (1 mL) was added Boc₂O (60 mg, 0.27mmol), stirred at r.t. for 18 h.
10 After extracted with CH₂Cl₂, dried over MgSO₄, concentrated in vacuo to afford *tert*-butyl (\pm)-*cis*-4-oxo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate (40mg, 47%).

15 **Step D:**

The title compound was prepared by the method of Example 98 from *tert*-butyl (\pm)-*cis*-4-oxo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate to afford the title compound
20 (25mg, 88%). ¹H NMR (CD₃OD, 300 MHz) δ 7.86-7.89(m, 1H), 7.34(d, 1H, 6.9Hz), 6.73-6.78(m, 1H), 4.02-4.04(m, 1H), 3.37-3.39(m, 2H), 3.20-3.27(m, 2H), 2.82-2.92(m, 1H), 2.74-2.80(m, 1H), 2.10-2.14(m, 2H), 0.94-1.07(m, 5H) ppm. MS - ESI: 243 [MH]⁺.

25

EXAMPLE 427

tert-butyl (\pm)-*cis*-2-bromo-4-oxo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8a*H*)-carboxylate

30

The title compound was prepared by the method of Example 89 step B from *tert*-butyl (\pm)-*cis*-4-oxo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-

b]indole-11(8aH)-carboxylate (88mg, 0.26 mmol) to afford the title compound (110mg, 100%).

EXAMPLE 428

5 *tert*-butyl (±)-*cis*-2-(2,4-dichlorophenyl)-4-oxo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8aH)-carboxylate

The title compound was prepared by the method of
10 Example 89 step C from *tert*-butyl (±)-*cis*-2-bromo-4-oxo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8aH)-carboxylate (110mg, 0.26 mmol) and corresponding 2,4-dichlorophenylboronic acid (60mg, 0.31 mmol) to afford after chromatographic purification the
15 title compound (70mg, 55%).

EXAMPLE 429

(±)-*cis*-2-(2,4-dichlorophenyl)-6,7,8a,9,10,11,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indol-4(5H)-one
20

The title compound was prepared by the method of Example 98 from *tert*-butyl (±)-*cis*-2-(2,4-dichlorophenyl)-4-oxo-4,5,6,7,9,10,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indole-11(8aH)-carboxylate to afford the
25 title compound (50mg, 90%). ¹H NMR (CD₃OD, 300 MHz) δ 7.78(d, 1H, 1.4Hz), 7.48(d, 1H, 1.9Hz), 7.28-7.32(m, 2H), 7.01(s, 1H), 4.06-4.12(m, 1H), 2.59-3.22(m, 6H), 1.71-2.04(m, 3H), 0.95-1.28(m, 4H) ppm. MS - ApCI: 387 [M+H⁺].

EXAMPLE 430

(8aS, 12aR)-2-(2,4-dichlorophenyl)-6,7,8a,9,10,11,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indol-4(5H)-one

The resolution of 2-(2,4-dichlorophenyl)-
35 6,7,8a,9,10,11,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-

b]indol-4(5H)-one was carried out by High Performance Liquid Chromatography using a chiral column to afford the title compound.

5

EXAMPLE 431

(8aR, 12aS)-2-(2,4-dichlorophenyl)-6,7,8a,9,10,11,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-4(5H)-one

The resolution of 2-(2,4-dichlorophenyl)-
10 6,7,8a,9,10,11,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-4(5H)-one was carried out by High Performance Liquid Chromatography using a chiral column to afford the title compound.

15

EXAMPLE 432

(8aS, 12aR)-2-(2,4-dichlorophenyl)-6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-4-ol

To (8aS, 12aR)-2-(2,4-dichlorophenyl)-
20 6,7,8a,9,10,11,12,12a-octahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-4(5H)-one (12 mg, 0.03 mmol) in CH₃OH (1 mL) at RT was added NaBH₄ (5.4mg, 0.15 mmol) in three portions. The reaction mixture was stirred at RT for 2 h 2 drops of 1NHCl were added to the reaction mixture, concentrated in vacuo.
25 NH₄OH (1 mL) and water (2 mL) were added, extracted with CH₂Cl₂ (3 x 3 mL). The combined organic layer was dried over MgSO₄, concentrated to afford the title compound (8mg, 69%). MS - ESI: 389 [MH]⁺.

30

EXAMPLE 433

(8aR, 12aS)-2-(2,4-dichlorophenyl)-6,7,8a,9,10,11,12,12a-decahydroazepino[3,2,1-hi]pyrido[4,3-b]indol-4-ol

The title compound was prepared by the method of
35 Example 432 from (8aR, 12aS)-2-(2,4-dichlorophenyl)-

6,7,8a,9,10,11,12,12a-octahydroazepino[3,2,1-*hi*]pyrido[4,3-*b*]indol-4(5*H*)-one (14 mg, 0.04 mmol) to afford the title compound (12mg, 86%). MS - ESI: 389 [MH]⁺.

5

EXAMPLE 434

(±)-*cis*-5,6,8,9,10,11,12,12a-octahydro-4*H*,7a*H*-azepino[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline

Step A:

10 3,4-Dihydro-1(2*H*)-quinolinamine hydrochloride (5.0 g, 27 mmol) and 1,3-cyclohexanedione (3.1 g, 27 mmol) was mixed in AcOH (4.3 mL) and H₂O (4.3 mL). The mixture was heated at 40 °C for 10 min until dissolved completely. The mixture was then concentrated to dryness. The residue was
15 washed with acetonitrile then filtered to yield 3-(3,4-dihydro-1(2*H*)-quinolinylimino)-1-cyclohexen-1-ol hydrochloride (5.2 g, 69 %) as a yellow solid.

Step B:

20 3-(3,4-Dihydro-1(2*H*)-quinolinylimino)-1-cyclohexen-1-ol hydrochloride (4.78 g, 17 mmol) was mixed with AcOH (37 mL) and conc. HCl (6.1 mL). The reaction mixture was refluxed for 1h and cooled to RT. The reaction mixture was concentrated in vacuo then the residue was dissolved in
25 CH₂Cl₂. The organic solution was washed with H₂O and brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was chromatographed in silica gel (hex:EtOAc 1:1) to give 5,6,9,10-tetrahydro-4*H*-pyrido[3,2,1-*jk*]carbazol-11(8*H*)-one (1.25 g, 33%) as a light yellow solid.

30

Step C:

To a solution of 5,6,9,10-tetrahydro-4*H*-pyrido[3,2,1-*jk*]carbazol-11(8*H*)-one (820 mg, 3.6 mmol) in ethanol (7.5 mL) and H₂O (3.6 mL) was added hydroxylamine hydrochloride
35 (380 mg, 5.5 mmol) and sodium acetate (452 mg, 5.5 mmol).

The reaction mixture was refluxed for 15h then cooled to RT.

The precipitated solid was filtered and washed with H₂O. The solid was dried under vacuum to give 5,6,9,10-tetrahydro-4*H*-pyrido[3,2,1-*jk*]carbazol-11(8*H*)-one oxime (824 mg, 95%) as a gray powder.

Step D:

To a preheated polyphosphoric acid (25 g) was added 5,6,9,10-tetrahydro-4*H*-pyrido[3,2,1-*jk*]carbazol-11(8*H*)-one oxime (810 mg, 3.3 mmol) in one portion at 110 °C. The reaction mixture was stirred for 30 min at the same temperature then pour into ice water (100 mL) and triturated to complete the dissolution of the polyphosphoric acid. After 1h stirring at 20 °C, gummy solid was formed, and it was washed with H₂O and NH₄OH. The solid was crystallized in EtOAc to give 5,6,8,9,10,11-hexahydro-4*H*,12*H*-azepino[3',4':4,5]pyrrolo[3,2,1-*ij*]quinolin-12-one (320 mg, 40%) as a yellow solid.

Step E:

To a suspension of LiAlH₄ in 1,4-dioxane (26 mL) was added 5,6,8,9,10,11-hexahydro-4*H*,12*H*-azepino[3',4':4,5]pyrrolo[3,2,1-*ij*]quinolin-12-one (300 mg, 1.25 mmol) under N₂ at 20 °C. The reaction mixture was refluxed for 15 h. The reaction mixture was cooled in an ice bath and added successively with H₂O (0.3 mL), 15% NaOH (0.3 mL) and H₂O (0,8 mL). The mixture was stirred for 1h at 20°C then filtered. The filtrate was concentrated in vacuo. The residue was dissolved in dilute AcOH and washed with Et₂O. The aqueous solution was basified with 1N NaOH. A white solid was precipitated and filtered to yield 5,6,9,10,11,12-hexahydro-4*H*,8*H*-azepino[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline (270 mg, 95%).

Step F:

To a solution of 5,6,9,10,11,12-hexahydro-4H,8H-azepino[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline (240 mg, 1.06 mmol) in TFA (4.0 mL) was added Et₃SiH (2.0 mL). The mixture was stirred for 3 days then concentrated in vacuo. The residue was dissolved in dilute AcOH and washed with Et₂O. The aqueous solution was basified with 1N NaOH. A white solid was precipitated and filtered to yield the title compound as a pale yellow viscous oil (200 mg, 83%). MS (CI, NH₃): 229.4 (base, M+H).

EXAMPLE 435

tert-butyl (±)-*cis*-5,6,8,9,10,11,12,12a-octahydro-4H,7aH-azepino[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-11-carboxylate

The title compound (114 mg, 99%) was prepared by the method of Example 311 from (±)-*cis*-5,6,8,9,10,11,12,12a-octahydro-4H,7aH-azepino[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline (80 mg, 0.35 mmol) as a viscous colorless oil. MS (ESI): 329.4 (base, M+H).

EXAMPLE 436

tert-butyl (±)-*cis*-2-bromo-5,6,8,9,10,11,12,12a-octahydro-4H,7aH-azepino[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline-11-carboxylate

The title compound (120 mg, 81%) was prepared by the method of Example 314 from *tert*-butyl (±)-*cis*-5,6,8,9,10,11,12,12a-octahydro-4H,7aH-azepino[3',4':4,5]pyrrolo[3,2,1-*ij*]quinoline (114 mg, 0.35 mmol) as a viscous colorless oil.

EXAMPLE 437

(±)-cis-2-[4-methoxy-2-(trifluoromethyl)phenyl]-
5,6,8,9,10,11,12,12a-octahydro-4H,7aH-
azepino[3',4':4,5]pyrrolo[3,2,1-ij]quinoline

5

Step A:

Tert-butyl (±)-cis-2-[4-methoxy-2-
(trifluoromethyl)phenyl]-5,6,8,9,10,11,12,12a-octahydro-
4H,7aH-azepino[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-11-
10 carboxylate (56 mg, 91%) was prepared by the general method
of Example 319, step A from tert-butyl (±)-cis-2-bromo-
5,6,8,9,10,11,12,12a-octahydro-4H,7aH-
azepino[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-11-carboxylate
(50 mg, 0.12 mmol) and 4-methoxy-2-
15 (trifluoromethyl)phenylboronic acid (54 mg, 0.25 mmol) as a
white foam. MS (ESI): 503.6 (base, M+H).

Step B:

The title compound (44 mg, 99%) was prepared by the
20 general method of Example 312, step B from tert-Butyl (±)-
cis-2-[4-methoxy-2-(trifluoromethyl)phenyl]-
5,6,8,9,10,11,12,12a-octahydro-4H,7aH-
azepino[3',4':4,5]pyrrolo[3,2,1-ij]quinoline-11-carboxylate
(54 mg, 0.11 mmol) as a white foam. MS (CI): 403.4 (base,
25 M+H).

UTILITY

The compounds of the present invention have
therapeutic utility for illnesses or disorders involving
30 the neurotransmitter serotonin (5-hydroxy tryptamine or 5-
HT) and either agonism or antagonism of 5-HT₂ receptors, as
demonstrated by the assays described below. Therapeutic
utility for these illnesses or disorders could involve
numerous biological processes affected by serotonin
35 including, but not limited to, appetite, mood, sleep,

sexual activity, and arterial constriction. These biological processes may also be important to numerous central nervous system (CNS) disorders including those related to the affective disorders of depression, anxiety, psychosis, and schizophrenia, as well as, disorders of food intake such as anorexia, bulimia, and obesity. The compounds of the present invention potentially have therapeutic utility in other conditions in which serotonin has been implicated, such as migraine, attention deficit disorder or attention deficit hyperactivity disorder, addictive behavior, and obsessive-compulsive disorder, as well as, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility. Lastly, compounds of the present invention potentially have therapeutic utility in neurodegenerative diseases and traumatic conditions represented by the examples of Alzheimer's disease and brain/spinal cord trauma.

The pharmacological analysis of each compound for either antagonism or agonism of at 5-HT_{2A} and 5-HT_{2C} receptors consisted of in vitro and in vivo studies. In vitro analyses included K_i determinations at 5-HT_{2A} and 5-HT_{2C} receptors and an assessment of functional (i.e., agonism or antagonism) activity at each receptor class by IP₃ hydrolysis assays. Additional receptor assays were conducted to evaluate receptor specificity of 5-HT_{2A} and 5-HT_{2C} receptors over monoamine and nuisance receptors (e.g. histamine, dopamine, and muscarinic). A compound is considered active as a 5-HT_{2A} antagonist or a 5-HT_{2C} agonist if it has an IC₅₀ value or a K_i value of less than about 1 micromolar; preferably less than about 0.1 micromolar; more preferably less than about 0.01 micromolar. Compounds of the invention have been shown to have an IC₅₀ value of less than about 1 micromolar for 5-HT_{2A} antagonism or a 5-HT_{2C} agonism.

In vivo assays assessed compound activity in a variety of behavioral paradigms including quipazine head twitch, acute and chronic feeding models, anxiety and depression models (learned-helplessness, elevated plus maze, Geller-Siefter, conditioned taste aversion, taste reactivity, satiety sequence). In aggregate, these models reflect activity as a 5-HT_{2A} antagonist (quipazine head twitch, depression models) or 5-HT_{2C} agonist (feeding models, anxiety models, depression models) and provide some indication as to bioavailability, metabolism and pharmacokinetics.

Radioligand binding experiments were conducted on recombinant human 5-HT_{2A} and 5-HT_{2C} receptors expressed in HEK293E cells. The affinities of compounds of the present invention to bind at these receptors is determined by their capacity to compete for [¹²⁵I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane (DOI) binding at the 5-HT_{2A} or 5-HT_{2C}. General references for binding assays include 1) Lucaites VL, Nelson DL, Wainscott DB, Baez M (1996) Receptor subtype and density determine the coupling repertoire of the 5-HT₂ receptor subfamily. Life Sci., 59(13):1081-95. J Med Chem 1988 Jan;31(1):5-7; 2) Glennon RA, Seggel MR, Soine WH, Herrick-Davis K, Lyon RA, Titeler M (1988) [¹²⁵I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT₂ serotonin receptors. J Med. Chem. 31(1):5-7 and 3) Leonhardt S, Gorospe E, Hoffman BJ, Teitler M (1992) Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine_{1C} and 5-hydroxytryptamine₂ receptors. Mol Pharmacol.; 42(2):328-35.

The functional properties of compounds (efficacy and potency) were determined in whole cells expressing 5-HT_{2A} or 5-HT_{2C} receptors by assessing their ability to stimulate or inhibit receptor-mediated phosphoinositol hydrolysis. The procedures used are described below.

In Vitro Binding Assays

Stable expression of 5-HT_{2A} and 5-HT_{2C} receptors in 5 HEK293E cells.

Stable cell lines were generated by transfecting 293EBNA cells with plasmids containing human 5-HT_{2A}, 5-HT_{2B}, or 5-HT_{2C} (VNV edited isoform) cDNA using calcium phosphate. These plasmids also contained the
10 cytomegalovirus (CMV) immediate early promoter to drive receptor expression and EBV oriP for their maintenance as an extrachromosomal element, and the hph gene from E. Coli to yield hygromycin B resistance (Horlick et al., 1997). Transfected cells were maintained in Dulbecco's Modified
15 Eagle medium (DMEM) containing dialyzed 10% fetal bovine serum at 37°C in a humid environment (5% CO₂) for 10 days. The 5-HT_{2A} cells were adapted to spinner culture for bulk processing whereas it was necessary to maintain the other lines as adherent cultures. On the day of harvest, cells
20 were washed in phosphate-buffered saline (PBS), counted, and stored at -80 °C.

Membrane Preparation

On the day of assay, pellets of whole cells
25 (containing approximately 1 X 10⁸ cells) expressing the 5-HT_{2A} or 5-HT_{2C} receptor were thawed on ice and homogenized in 50 mM Tris HCl (pH 7.7) containing 1.0 mM EDTA using a Brinkman Polytron (PT-10, setting 6 for 10 sec). The homogenate was centrifuged at 48,000 x g for 10 min and the
30 resulting pellet washed twice by repeated homogenization and centrifugation steps. The final pellet was resuspended in tissue buffer and protein determinations were made by the bichichoninic acid (BCA) assay (Pierce Co., IL) using bovine serum albumin as the standard.

35

Radioligand binding assays for the 5-HT_{2A} and 5-HT_{2C} receptors.

Radioligand binding studies were conducted to determine the binding affinities (K_i values) of compounds for the human recombinant 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C} receptors (Fitzgerald et al., 1999). Assays were conducted in disposable polypropylene 96-well plates (Costar Corp., Cambridge, MA) and were initiated by the addition of 5-HT_{2A}, 5-HT_{2B}, or 5-HT_{2C} membrane homogenate in tissue buffer (10-30 (g/well) to assay buffer (50 mM Tris HCl, 0.5 mM EDTA, 10 mM pargyline, 10 mM MgSO₄, 0.05 % ascorbic acid, pH 7.5) containing [¹²⁵I]DOI for the 5-HT_{2A} and 5-HT_{2C} receptors (0.3-0.5 nM, final) or [³H]LSD (2-2.5 nM, final) for the 5-HT_{2B} receptor, with or without competing drug (i.e, newly synthesized chemical entity). For a typical competition experiment, a fixed concentration of radioligand was competed with duplicate concentrations of ligand (12 concentrations ranging from 10 picomolar to 10 micromolar). The reaction mixtures were incubated to equilibrium for 45 min at 37°C and terminated by rapid filtration (cell harvester; Inotech Biosystems Inc., Lansing, MI) over GFF glass-fiber filters that had been pre-soaked in 0.3% polyethyleneimine. Filters were washed in ice-cold 50 mM Tris HCl buffer (pH 7.5) and then counted in a gamma counter for the 5-HT_{2A} and 5-HT_{2C} assays, or by liquid scintillation spectroscopy for the 5-HT_{2B} assay.

Phosphoinositide hydrolysis studies.

The ability of newly synthesized compounds to stimulate phosphoinositide (PI) hydrolysis was monitored in whole cells using a variant (Egan et al., 1998) of a protocol described previously (Berridge et al., 1982). HEK293E cells expressing the human 5-HT_{2A}, 5-HT_{2B}, or 5-HT_{2C} receptor were lifted with 0.5 mM EDTA and plated at a density of 100,000/well onto poly-D-lysine-coated 24-well

plates (Biocoat; Becton Dickinson, Bedford, MA) in Dulbecco's modified Eagle's serum (DMEM; Gibco BRL) containing high glucose, 2mM glutamine, 10% dialyzed fetal calf serum, 250 (g/ml hygromycin B, and 250 (g/ml G418.

5 Following a 24-48 hr period, the growth media was removed and replaced with DMEM without fetal calf serum and inositol (Gibco BRL). The cells were then incubated with DMEM (without serum and inositol) containing a final concentration of 0.5 uCi/well myo-[³H]inositol for 16-18

10 hr. Following this incubation, the cells were washed with DMEM (without serum or inositol) containing 10 mM LiCl and 10 (M pargyline and then incubated for 30 min with the same media but now containing one of several test compounds. Reactions were terminated by aspirating the media and

15 lysing the cells by freeze-thaw. [³H]phosphoinositides were extracted with chloroform/methanol (1:2 v/v), separated by anion exchange chromatography (Bio-Rad AGI-X8 resin), and counted by liquid scintillation spectroscopy as described previously (Egan et al., 1998).

20

Data analyses

The equilibrium apparent dissociation constants (K_i's) from the competition experiments were calculated using an iterative nonlinear regression curve-fitting program

25 (GraphPad Prism; San Diego, CA). For the PI hydrolysis experiments, EC₅₀'s were calculated using a one-site 'pseudo' Hill model: $y = ((R_{max} - R_{min}) / (1 + R / EC_{50})^{nH}) + R_{min}$ where R= response (DeltaGraph, Monterey, CA). E_{max} (maximal response) was derived from the fitted curve maxima (net IP

30 stimulation) for each compound. Intrinsic activity (IA) was determined by expressing the E_{max} of a compound as a percentage of the E_{max} of 5-HT (IA=1.0).

In Vivo Experiments for Serotonergic Ligands.

35 Preclinical Efficacy, Potency, and Side Effect Liability.

a) Anti-Serotonin Efficacy.

Antagonism of Quipazine-Induced Head Twitch in Rat. Quipazine, an agonist at 5-HT receptors, produces a characteristic head twitch response in rats. 5-HT receptor antagonists effectively antagonize this 5-HT agonist-induced behavioral effect (Lucki et al., 1984). Accordingly, the quipazine-induced head twitch model in rat can function as an in vivo behavioral correlate to 5-HT receptor binding. Compounds are administered 30 minutes before behavioral testing (and 25 minutes before quipazine), and a dose-related antagonism of the quipazine response is determined.

b) Antipsychotic Efficacy.

Inhibition of the Conditioned Avoidance Response (CAR) in Rat. Rats are trained to consistently avoid (by climbing onto a pole suspended from the ceiling of the test chamber) an electric foot shock (0.75 mA) delivered to the grid floor of the testing chamber. All antipsychotic drugs effectively inhibit this conditioned avoidance response (Arnt, 1982). The ability of a compound to inhibit this response is used to determine the antipsychotic efficacy of potential drug candidates.

c) Extrapyramidal Side Effect Liability.

Induction of Catalepsy in Rat. Typical antipsychotic drugs produce extrapyramidal side effects (EPS) at clinically effective doses. The most widely accepted preclinical indicator of EPS liability in humans is a drug-induced catalepsy syndrome in rat (Costall and Naylor, 1975), a condition whereby the animal will remain immobile in an externally imposed posture (analogous to a catatonic stupor in humans). Rats are tested for induction of catalepsy in a dose-response test after oral administration of compounds.

d) CNS penetration: In vivo brain receptor occupancy.

In Vivo Binding. To determine the level of in vivo receptor occupancy, an in vivo receptor binding protocol is used. This procedure uses an appropriate radioligand to
5 label the receptor of interest. For example, to measure both Dopamine D2 and 5-HT2A receptors in vivo, one can use ³H-N-methyl spiperone (³H -NMSP), (Frost, et. al. 1987)
The procedure uses rats (or mice) fasted overnight. To measure the effects of compounds on the receptors of
10 interest, compounds are dosed, usually p.o. for example in 2 microliters/gram body weight in 0.25% Methocel suspension. The radiolabeled compound (in this example, ³H-NMSP) is administered by i.v. tail vein injection (10 microcuries label/200 gram rat). Time course experiments
15 are used to determine the optimal time of binding for both the radiolabeled and unlabeled compound. These optimal time frames are used for all subsequent dose-response experiments. After the appropriate time frame of compound/radioligand exposure, the animals are sacrificed
20 and the relevant brain regions dissected (frontal cortex for 5-HT2A and striatum for D2 receptors) and examined for their content of radioactivity. The level of non-specific binding is determined by examining a brain region known not to contain the receptor of interest (in this case the
25 cerebellum) or by administering an excess of compound known pharmacologically to interact with the receptor.

REFERENCES

- Arnt, J. Acta Pharmacol. et Toxicol. 1982: 51, 321-329.
30 Berridge M.J., Downes P.C. , Hanley M.R. (1982) Lithium amplifies agonist-dependent phosphatidylinositol response in brain and salivary glands. Biochem. J., 206, 587-595.
35 Costall, B and Naylor, R.J. Psychopharmacology. 1975: 43, 69-74.

- Egan C.T., Herrick-Davis K., Miller K., Glennon R.A., and Teitler M. (1998) Agonist activity of LSD and lisuride at cloned 5-HT_{2A} and 5-HT_{2C} receptors. *Psychopharmacology*, 136, 409-414.
- Fitzgerald LW, Conklin DS, Krause CM, Marshall AP, Patterson JP, Tran DP, Iyer G, Kostich WA, Largent BL, Hartig PR (1999) High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT_{2A} and 5-HT_{2C} receptors: evidence favoring the ternary complex and two-state models of agonist action. *J. Neurochem.*, 72, 2127-2134.
- Frost, J.J., Smith, A.C., Kuhar, M.J., Dannals, R.F., Wagner, H.N., 1987, In Vivo Binding of 3H-N-Methylspiperone to Dopamine and Serotonin Receptors. *Life Sciences*, 40:987-995.
- Horlick, R.A., Sperle, K., Breth, L.A., Reid, C.C., Shen, E.S., Robbids, A.K., Cooke, G.M., Largent, B.L. (1997) Rapid Generation of stable cell lines expressing corticotrophin-releasing hormone receptor for drug discovery. *Protein Expr. Purif.* 9, 301-308.
- Lucki, I, Nobler, M.S., Frazer, A., 1984, Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. *J. Pharmacol. Exp. Ther.* 228(1):133-139.

Dosage and Formulation

The serotonin agonist and serotonin antagonist compounds of this invention can be administered as treatment for the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep and sexual disorders,

migraine and other conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility by any means that produces contact of the active agent with the agent's site of action, i.e., 5-HT₂ receptors, in the body of a mammal. It can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as an individual therapeutic agent or in a combination of therapeutic agents. It can be administered alone, but preferably is administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts.

The dosage administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired. By way of general guidance, a daily dosage of active ingredient can be expected to be about 0.001 to about 1000 milligrams per kilogram of body weight, with the preferred dose being about 0.01 to about 100 mg/kg; with the more preferred dose being about 0.1 to about 30 mg/kg. Advantageously, compounds of the present invention may be administered in a single daily dose, or

the total daily dosage may be administered in divided doses of two, three, or four times daily.

Dosage forms of compositions suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition. The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets and powders, or in liquid dosage forms, such as elixirs, syrups and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.

Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts, and sodium EDTA. In addition, parenteral solutions

can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Suitable pharmaceutical carriers are described in *Remington's Pharmaceutical Sciences, supra*, a standard reference text
5 in this field.

Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

10 Capsules

A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg of lactose, 50 mg of cellulose, and 6 mg magnesium stearic.

15

Soft Gelatin Capsules

A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil can be prepared and injected by means of a positive displacement
20 pump into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules should then be washed and dried.

Tablets

25 A large number of tablets can be prepared by conventional procedures so that the dosage unit is 100 mg of active ingredient, 0.2 mg of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch and 98.8 mg of
30 lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

Suspension

An aqueous suspension can be prepared for oral
35 administration so that each 5 ml contain 25 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl

cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 mg of vanillin.


Injectable

5 A parenteral composition suitable for administration by injection can be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution is sterilized by commonly used techniques.

10

 The Tables below provide representative Examples, the synthesis of which are described above, of the compounds of Formula (I) of the present invention.

Table 1



Ex#	n	R7	R8	R9	b	R1
1	1	H	H	H	dbl	H
2	1	H	H	H	dbl	cycPropyl
3	1	H	H	H	sgl	H
16	2	H	H	H	dbl	H
17	2	H	H	H	sgl	H
37	1	H	H	H	sgl	-C(=O)cycPropyl
38	1	H	H	H	sgl	-C(=O)iPropyl
89	1	H	2-Cl-phenyl	H	sgl	-CO ₂ -tButyl
90	1	H	2,4-diCl-phenyl	H	sgl	-CO ₂ -tButyl
91	1	H	3,4-diCl-phenyl	H	sgl	-CO ₂ -tButyl
92	1	H	2,3-diCl-phenyl	H	sgl	-CO ₂ -tButyl
93	1	H	2-Cl-4-CF ₃ -phenyl	H	sgl	-CO ₂ -tButyl
94	1	H	2-Cl-4-MeO-phenyl	H	sgl	-CO ₂ -tButyl
95	1	H	2-MeO-4-iPr-phenyl	H	sgl	-CO ₂ -tButyl
96	1	H	3-F-phenyl	H	sgl	-CO ₂ -tButyl
97	1	H	2,4-diMeO-phenyl	H	sgl	-CO ₂ -tButyl
98	1	H	2-Cl-phenyl	H	sgl	H
99	1	H	2,4-diCl-phenyl	H	sgl	H
100	1	H	3,4-diCl-phenyl	H	sgl	H
101	1	H	2,3-diCl-phenyl	H	sgl	H
102	1	H	2-Cl-4-CF ₃ -phenyl	H	sgl	H
103	1	H	2-Cl-4-MeO-phenyl	H	sgl	H
104	1	H	2-MeO-4-iPr-phenyl	H	sgl	H
105	1	H	3-F-phenyl	H	sgl	H
106	1	H	2,4-diMeO-phenyl	H	sgl	H
107	2	H	H	H	sgl	-CO ₂ -tButyl
108	2	H	Br	H	sgl	-CO ₂ -tButyl
109	2	H	2,3-diCl-phenyl	H	sgl	-CO ₂ -tButyl

Table 1 cont.

Ex#	n	R7	R8	R9	b	R1
110	2	H	3,4-diCl-phenyl	H	sg1	-CO ₂ -tButyl
111	2	H	2-Cl-4-CF ₃ -phenyl	H	sg1	-CO ₂ -tButyl
112	2	H	2,3-diCl-phenyl	H	sg1	H
113	2	H	3,4-diCl-phenyl	H	sg1	H
114	2	H	2-Cl-4-CF ₃ -phenyl	H	sg1	H
189	1	H	2-Cl-phenyl	H	sg1	-(CH ₂) ₃ C(=O) (4-F-phenyl)
190	1	H	2,4-diCl-phenyl	H	sg1	-(CH ₂) ₃ C(=O) (4-F-phenyl)
191	2	H	H	H	sg1	-(CH ₂) ₃ C(=O) (4-F-phenyl)
265	1	H	H	H	sg1	-(CH ₂) ₃ C(=O) (4-F-phenyl)
274	1	H	2-F-4-MeO-phenyl	H	sg1	H
275	1	H	2-CF ₃ -4-EtO-phenyl	H	sg1	-CO ₂ -tButyl
276	1	H	2-CF ₃ -4-EtO-phenyl	H	sg1	H
277	1	H	2-F-4-Cl-phenyl	H	sg1	-CO ₂ -tButyl
278	1	H	2-F-4-Cl-phenyl	H	sg1	H
279	1	H	2-CF ₃ -4-iPrO-phenyl	H	sg1	-CO ₂ -tButyl
280	1	H	2-CF ₃ -4-iPrO-phenyl	H	sg1	H
281	1	H	2-CF ₃ -4-MeO-phenyl	H	sg1	-CO ₂ -tButyl
282	1	H	2-CF ₃ -4-MeO-phenyl	H	sg1	H
283	1	H	phenyl	H	sg1	-CO ₂ -tButyl
284	1	H	phenyl	H	sg1	H
285	1	H	2-Me-phenyl	H	sg1	-CO ₂ -tButyl
286	1	H	2-Me-phenyl	H	sg1	H
287	1	H	2-CF ₃ -phenyl	H	sg1	-CO ₂ -tButyl
288	1	H	2-CF ₃ -phenyl	H	sg1	H
289	1	H	3,4-diMeO-phenyl	H	sg1	-CO ₂ -tButyl
290	1	H	3,4-diMeO-phenyl	H	sg1	H
291	1	H	2,4-diCl-phenyl	H	sg1	-CO ₂ -tButyl
292	1	H	2,4-diCl-phenyl	H	sg1	H
293	1	H	3,5-diCl-phenyl	H	sg1	-CO ₂ -tButyl
294	1	H	3,5-diCl-phenyl	H	sg1	H

Table 1 cont.

Ex#	n	R7	R8	R9	b	R1
295	1	H	4-MeO-2-iPr-phenyl	H	sg1	-CO ₂ -tButyl
296	1	H	4-MeO-2-iPr-phenyl	H	sg1	H
297	1	H	5-F-4-MeO-2-Me-phenyl	H	sg1	-CO ₂ -tButyl
298	1	H	5-F-4-MeO-2-Me-phenyl	H	sg1	H
299	1	H	4-MeO-2-Me-phenyl	H	sg1	-CO ₂ -tButyl
300	1	H	4-MeO-2-Me-phenyl	H	sg1	H
301	1	H	2-Cl-4-MeO-phenyl	H	sg1	-CO ₂ -tButyl
302	1	H	2-Cl-4-MeO-phenyl	H	sg1	H
303	1	H	4-Cl-2-Me-phenyl	H	sg1	-CO ₂ -tButyl
304	1	H	4-Cl-2-Me-phenyl	H	sg1	H
305	1	H	2-CHO-4-MeO-phenyl	H	sg1	H
306	1	H	2,6-diCl-phenyl	H	sg1	H
307	1	H	2-CF ₃ -4-MeNH-phenyl	H	sg1	H
308	1	H	2-CF ₃ -4-NH ₂ -phenyl	H	sg1	H
309	1	H	4-MeO-2-CH ₃ CH(OH)-phenyl	H	sg1	H
310	3	H	H	H	sg1	H
311	3	H	H	H	sg1	-CO ₂ -tButyl
312	3	H	H	H	sg1	H
313	3	H	H	H	sg1	H
314	3	H	H	H	sg1	-CO ₂ -tButyl
315	3	H	2,4-diCl-phenyl	H	sg1	H
316	3	H	2,3-diCl-phenyl	H	sg1	H
317	3	H	3,4-diCl-phenyl	H	sg1	H
318	3	H	3,5-diCl-phenyl	H	sg1	H
319	3	H	2,5-diCl-phenyl	H	sg1	H
320	3	H	2,6-diCl-phenyl	H	sg1	H
321	3	H	2-Cl-phenyl	H	sg1	H
322	3	H	3-Cl-phenyl	H	sg1	H
323	3	H	4-Cl-phenyl	H	sg1	H
324	3	H	2,6-diF-phenyl	H	sg1	H
325	3	H	2,6-diF-phenyl	H	sg1	H
326	3	H	2,3-diF-phenyl	H	sg1	H
327	3	H	3,4-diF-phenyl	H	sg1	H

Table 1 cont.

Ex#	n	R7	R8	R9	b	R1
328	3	H	3-F-phenyl	H	sgl	H
329	3	H	2-Cl-4-CF ₃ -phenyl	H	sgl	H
330	3	H	2-Cl-4-MeO-phenyl	H	sgl	H
331	3	H	2-F-4-MeO-phenyl	H	sgl	H
332	3	H	4-MeO-2-Me-phenyl	H	sgl	H
333	3	H	2-CF ₃ -4-MeO-phenyl	H	sgl	H
334	3	H	2-CF ₃ -phenyl	H	sgl	H
335	3	H	2-CF ₃ -4-iPrO-phenyl	H	sgl	H
336	3	H	2,4-diCF ₃ -phenyl	H	sgl	H
337	3	H	2-F-2-CF ₃ -phenyl	H	sgl	H
338	3	H	2-CF ₃ -4-NH ₂ -phenyl	H	sgl	H
339	3	H	2-CF ₃ -4-MeNH-phenyl	H	sgl	H
340	3	H	2-CHO-phenyl	H	sgl	H
341	3	H	2-CH ₂ (OH)-phenyl	H	sgl	H
342	3	H	4-MeO-2-CHO-phenyl	H	sgl	H
343	3	H	4-MeO-2-CH ₂ (OH)- phenyl	H	sgl	H
344	3	H	4-CN-2-Me-phenyl	H	sgl	H
345	3	H	4-MeO-2-CH ₃ CH(OH)- phenyl	H	sgl	H
346	2	H	Br	H	sgl	-CO ₂ -tButyl
347	2	H	2,4-diCl-phenyl	H	sgl	H
348	2	H	3,4-diCl-phenyl	H	sgl	H
349	2	H	3,5-diCl-phenyl	H	sgl	H
350	2	H	2,5-diCl-phenyl	H	sgl	H
351	2	H	2,6-diCl-phenyl	H	sgl	H
352	2	H	2-Cl-phenyl	H	sgl	H
353	2	H	3-Cl-phenyl	H	sgl	H
354	2	H	4-Cl-phenyl	H	sgl	H
355	2	H	2,6-diF-phenyl	H	sgl	H
356	2	H	2,6-diF-phenyl	H	sgl	Me
357	2	H	2,3-diF-phenyl	H	sgl	H
358	2	H	3,4-diF-phenyl	H	sgl	H
359	2	H	3-F-phenyl	H	sgl	H
360	2	H	2-Cl-4-MeO-phenyl	H	sgl	H

Table 1 cont.

Ex#	n	R7	R8	R9	b	R1
361	2	H	2-F-4-MeO-phenyl	H	sgl	H
362	2	H	4-MeO-2-Me-phenyl	H	sgl	H
363	2	H	2-CF ₃ -4-MeO-phenyl	H	sgl	H
364	2	H	2-CF ₃ -4-MeO-phenyl	H	dbl	H
365	2	H	2-CF ₃ -4-OH-phenyl	H	sgl	H
366	2	H	2-CF ₃ -phenyl	H	sgl	H
367	2	H	2-CF ₃ -4-iPrO-phenyl	H	sgl	H
368	2	H	2,4-diCF ₃ -phenyl	H	sgl	H
369	2	H	2-CF ₃ -4-F-phenyl	H	sgl	H
370	2	H	2-CF ₃ -4-NH ₂ -phenyl	H	sgl	H
371	2	H	2-CF ₃ -4-MeNH-phenyl	H	sgl	H
372	2	H	4-CN-2-Me-phenyl	H	sgl	H
373	2	H	2-CHO-phenyl	H	sgl	H
374	2	H	2-CH ₂ (OH)-phenyl	H	sgl	H
375	2	H	4-MeO-2-CHO-phenyl	H	sgl	H
376	2	H	4-MeO-2-CH ₃ CH(OH)-phenyl	H	sgl	H
377	3	H	2-CF ₃ -4-EtO-phenyl	H	sgl	H
378	2	H	2-CF ₃ -4-EtO-phenyl	H	sgl	H
379	3	H	3-Cl-2-Me-phenyl	H	sgl	H
380	2	H	3-Cl-2-Me-phenyl	H	sgl	H
381	2	H	5-F-2-Me-phenyl	H	sgl	H
382	2	H	2,3-diCl-phenyl	H	sgl	Pr
383	2	H	2,3-diCl-phenyl	H	sgl	Pr
384	2	H	2,3-diCl-phenyl	H	sgl	Bu
385	2	H	2,3-diCl-phenyl	H	sgl	Bu
386	2	H	2,3-diCl-phenyl	H	sgl	4-pentenyl
387	2	H	2,3-diCl-phenyl	H	sgl	3-Me-2-butenyl
388	2	H	2,4-diCl-phenyl	H	sgl	Pr
389	2	H	2,4-diCl-phenyl	H	sgl	Bu
390	2	H	2,4-diCl-phenyl	H	sgl	4-pentenyl
391	2	H	2,4-diCl-phenyl	H	sgl	3-Me-2-butenyl
392	2	H	2,4-diCl-phenyl	H	sgl	cyclobutylmethyl
393	2	H	2-CF ₃ -4-MeO-phenyl	H	sgl	Me
394	2	H	2-CF ₃ -4-MeO-phenyl	H	sgl	Et

Table 1 cont.





Ex#	n	R7	R8	R9	b	R1
395	2	H	2-CF ₃ -4-MeO-phenyl	H	sgl	Pr
396	2	H	2-CF ₃ -4-MeO-phenyl	H	sgl	Bu
397	2	H	2-CF ₃ -4-MeO-phenyl	H	sgl	4-pentenyl
398	2	H	2-CF ₃ -4-MeO-phenyl	H	sgl	3-Me-2-butenyl
399	2	H	2-CF ₃ -4-MeO-phenyl	H	sgl	2-F-ethyl
400	2	H	2-CF ₃ -4-MeO-phenyl	H	sgl	2,2-diF-ethyl
401	2	H	2-CF ₃ -4-MeO-phenyl	H	sgl	cyclobutylmethyl
402	2	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
403	2	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
403	2	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
404	2	H	H	H	sgl	-(CH ₂) ₃ C(=O) (2-NH ₂ -phenyl)
405	2	H	H	H	sgl	-(CH ₂) ₃ C(=O) (2-NH ₂ -phenyl)
406	2	H	H	H	sgl	-(CH ₂) ₃ O (4-F-phenyl)
407	2	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-pyridyl)
408	2	H	H	H	sgl	
409	2	H	H	H	sgl	
410	2	H	H	H	dbl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
411	3	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
412	3	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)

Table 1 cont.

Ex#	n	R7	R8	R9	b	R1
413	3	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})$ (4-F-phenyl)
414	3	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})$ (4-F-2-NH ₂ -phenyl)
415	2	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})$ (4-F-2-NH ₂ -phenyl)
416	2	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})$ (4-F-2-NH ₂ -phenyl)
417	2	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})$ (4-F-2-NH ₂ -phenyl)


Table 2

Ex#	n	k	R7	R8	R9	b	R1
418	2	2	H	H	H	dbl	H
419	2	2	H	H	H	sgl	H
420	2	2	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
421	2	2	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-2-NH ₂ -phenyl)
422	3	2	H	H	H	dbl	H
423	3	2	H	H	H	sgl	H
424	3	2	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
425	3	2	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-2-NH ₂ -phenyl)
434	2	1	H	H	H	sgl	H
435	2	1	H	H	H	sgl	-CO ₂ -tButyl
436	2	1	H	Br	H	sgl	-CO ₂ -tButyl
437	2	1	H	2-CF ₃ -4-MeO-phenyl	H	sgl	H

Table 3

Ex#	X	R7	R8	R9	b	R1
426	C=O	H	H	H	sg1	H
427	C=O	H	H	H	sg1	-CO ₂ -tButyl
428	C=O	H	2,4-diCl-phenyl	H	sg1	-CO ₂ -tButyl
429	C=O	H	2,4-diCl-phenyl	H	sg1	H
430	C=O	H	2,4-diCl-phenyl	H	sg1	H
431	C=O	H	2,4-diCl-phenyl	H	sg1	H
432	CH(OH)	H	2,4-diCl-phenyl	H	sg1	H
433	CH(OH)	H	2,4-diCl-phenyl	H	sg1	H

Table 4




Ex#	X	n	k	R7	R8	R9	b	R1
196	NHCO	1	1	H	H	H	db1	$-(CH_2)_3C(=O)$ (4-F-phenyl)
210	NMe	2	1	H	H	H	sg1	$-(CH_2)_3C(=O)$ (4-pyridyl)
211	NH	2	1	H	H	H	sg1	H
212	NH	2	1	H	H	H	sg1	$-(CH_2)_3C(=O)$ (4-F-phenyl)
217	NMe	2	1	H	H	H	sg1	
218	NMe	2	1	H	H	H	sg1	
255	NMe	2	1	H	H	H	sg1	H
256	NEt	2	1	H	H	H	sg1	H
257	NPr	2	1	H	H	H	sg1	H
258	N(i-Pr)	2	1	H	H	H	sg1	H
259	N(n-Bu)	2	1	H	H	H	sg1	H
260	N(CH ₂ Ph)	2	1	H	H	H	sg1	H
261	NMe	2	1	H	H	H	sg1	$-(CH_2)_3C(=O)$ (4-F-phenyl)
262	NEt	2	1	H	H	H	sg1	$-(CH_2)_3C(=O)$ (4-F-phenyl)
263	N(i-Pr)	2	1	H	H	H	sg1	$-(CH_2)_3C(=O)$ (4-F-phenyl)
264	N(CH ₂ Ph)	2	1	H	H	H	sg1	$-(CH_2)_3C(=O)$ (4-F-phenyl)
269	NMe	2	1	H	H	H	sg1	$-(CH_2)_3O$ (4-F-phenyl)
N274	NMe	2	1	H	2,4-diCl-phenyl	H	sg1	H
N275	NH	2	1	H	2,4-diCl-phenyl	H	sg1	H
N276	NMe	2	1	H	Br	H	sg1	$-(CH_2)_3C(=O)$ (4-F-phenyl)
N277	NMe	2	1	H	MeO	H	sg1	$-(CH_2)_3C(=O)$ (4-F-phenyl)
N278	NMe	2	1	H	2,4-diCl-phenyl	H	sg1	H

Table 4 cont.

Ex#	X	n	k	R7	R8	R9	b	R1
N279	NH	3	1	H	4-MeO-2-Me-phenyl	H	sg1	H
N280	NHCO	2	1	H	2,4-diCl-pehnyl	H	sg1	H
N281	NMe	2	2	H	H	H	sg1	H
N282	NMe	2	2	H	H	H	sg1	-(CH ₂) ₃ C(=O)(4-F-phenyl)
N283	NHCH(Me)	1	1	H	2,4-diCl-phenyl	H	sg1	H

Table 5



Ex#	R7	R8	R9	b	R1
4	H	H	F	dbl	-CO ₂ Et
5	H	H	F	dbl	H
6	H	H	Me	dbl	H
7	H	H	Me	dbl	-CO ₂ -tBu
8	H	H	Me	sgl	H
9	H	H	H	sgl	H
10	H	H	NO ₂	dbl	H
11	H	H	NO ₂	sgl	H
12	Cl	H	H	dbl	H
13	Cl	H	H	sgl	H
14	Me	H	H	dbl	H
15	Me	H	H	sgl	H
18	H	H	Br	dbl	H
19	H	H	Br	sgl	H
25	H	H	H	sgl	-C(=O) (3,4-diMeO-phenyl)
26	H	H	H	sgl	-C(=O) (2,5-diMeO-phenyl)
27	H	H	H	sgl	-C(=O) (3,5-diMeO-phenyl)
28	H	H	H	sgl	2,6-diMeO-benzyl
29	H	H	H	sgl	2,4-diMeO-benzyl
30	H	H	H	sgl	2,4,6-triMeO-benzyl
31	H	H	H	sgl	2,3-diMeO-benzyl
32	H	H	H	sgl	2,4,5-triMeO-benzyl
33	H	H	H	sgl	cyclohexylmethyl
34	H	H	H	sgl	2,3,4-triMeO-benzyl
35	H	H	H	sgl	3,4-diMeO-benzyl
36	H	H	H	sgl	3,4,5-triMeO-benzyl
39	H	H	H	sgl	-CO ₂ Et
40	H	-C(=O)CH ₃	H	sgl	-CO ₂ Et
41	H	-NHC(=O)CH ₃	H	sgl	-CO ₂ Et

Table 5 cont.

Ex#	R7	R8	R9	b	R1
42	H	H	H	sgl	-CH ₂ CH ₂ (4-F-phenyl)
43	H	H	H	sgl	Et
44	H	H	H	sgl	Pr
45	H	H	H	sgl	butyl
46	H	H	H	sgl	pentyl
47	H	H	H	sgl	hexyl
48	H	H	H	sgl	2-propyl
49	H	H	H	sgl	2-butyl
50	H	H	H	sgl	2-pentyl
51	H	H	H	sgl	2-hexyl
52	H	H	H	sgl	2-Me-propyl
53	H	H	H	sgl	2-Me-butyl
54	H	H	H	sgl	2-Me-pentyl
55	H	H	H	sgl	2-Et-butyl
56	H	H	H	sgl	3-Me-pentyl
57	H	H	H	sgl	3-Me-butyl
58	H	H	H	sgl	4-Me-pentyl
59	H	H	H	sgl	cyclopropylmethyl
60	H	H	H	sgl	cyclobutylmethyl
61	H	H	H	sgl	cyclohexylmethyl
62	H	H	H	sgl	2-propenyl
63	H	H	H	sgl	2-Me-2-propenyl
64	H	H	H	sgl	trans-2-butenyl
65	H	H	H	sgl	3-Me-butenyl
66	H	H	H	sgl	3-butenyl
67	H	H	H	sgl	trans-2-pentenyl
68	H	H	H	sgl	cis-2-pentenyl
69	H	H	H	sgl	4-pentenyl
70	H	H	H	sgl	4-Me-3-pentenyl
71	H	H	H	sgl	3,3-diCl-2-propenyl
72	H	H	H	sgl	benzyl
73	H	H	H	sgl	2-Me-benzyl
74	H	H	H	sgl	3-Me-benzyl
75	H	H	H	sgl	4-Me-benzyl
76	H	H	H	sgl	2,5-diMe-benzyl
77	H	H	H	sgl	2,4-diMe-benzyl
78	H	H	H	sgl	3,5-diMe-benzyl
79	H	H	H	sgl	2,4,6-triMe-benzyl

Table 5 cont.

Ex#	R7	R8	R9	b	R1
80	H	H	H	sgl	3-MeO-benzyl
81	H	H	H	sgl	3,5-diMeO-benzyl
82	H	H	H	sgl	pentafluorobenzyl
83	H	H	H	sgl	2-phenylethyl
84	H	H	H	sgl	1-phenyl-2-propyl
85	H	H	H	sgl	trans-3-phenyl-2-propenyl
86	H	H	H	sgl	4-phenylbutyl
87	H	H	H	sgl	4-phenylbenzyl
88	H	H	H	sgl	2-phenylbenzyl

Table 5 cont.

5

Ex#	R7	R8	R9	b	R1
169	H	Me	H	sgl	H
170	H	CN	H	sgl	H
171	H	Et	H	sgl	H
175	H	H	H	dbl	Me
176	H	H	H	sgl	Me
177	H	H	H	sgl	H
178	Cl	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
179	Me	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
180	H	H	H	sgl	-(CH ₂) ₃ S(3-F-phenyl)
181	H	H	H	sgl	-(CH ₂) ₃ CH(OH) (4-F-phenyl)
186	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
187	H	MeO	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
192	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-Br-phenyl)
193	H	H	H	sgl	-(CH ₂) ₃ SO ₂ (3-F-phenyl)
194	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-(3,4-diCl-phenyl)phenyl)
197	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-Me-phenyl)
198	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
199	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-MeO-phenyl)
200	H	H	H	sgl	-(CH ₂) ₂ C(=O) (4-F-phenyl)

Table 5 cont.




Ex#	R7	R8	R9	b	R1
201	H	H	H	sgl	$-(CH_2)_3SO_2(4-F-phenyl)$
202	H	H	H	sgl	$-(CH_2)_3S(=O)(4-F-phenyl)$
203	H	H	H	sgl	$-(CH_2)_3O(4-F-phenyl)$
204	H	H	H	sgl	$-(CH_2)_3O(phenyl)$
205	H	H	H	sgl	$-(CH_2)_3S(4-F-phenyl)$
206	H	H	H	sgl	$-(CH_2)_3NH(4-F-phenyl)$
207	H	H	H	sgl	$-(CH_2)_3N(CH_3)(4-F-phenyl)$
208	H	H	H	sgl	$-(CH_2)_3C(=O)(4-pyridyl)$
209	H	H	H	sgl	$-(CH_2)_3C(=O)(3-pyridyl)$
214	H	H	H	sgl	
215	H	H	H	sgl	
219	H	H	H	sgl	$-(CH_2)_3CO_2Et$
220	H	H	H	sgl	$-(CH_2)_4CO_2Et$
221	H	H	H	sgl	$-(CH_2)_3C(=O)N(CH_3)(OCH_3)$
222	H	H	H	sgl	$-(CH_2)_4C(=O)N(CH_3)(OCH_3)$
223	H	H	H	sgl	$-(CH_2)_3C(=O)(3-Me-4-F-phenyl)$
224	H	H	H	sgl	$-(CH_2)_3C(=O)(phenyl)$
225	H	H	H	sgl	$-(CH_2)_3C(=O)(4-Cl-phenyl)$
226	H	H	H	sgl	$-(CH_2)_3C(=O)(3-Me-phenyl)$
227	H	H	H	sgl	$-(CH_2)_3C(=O)(4-tBu-phenyl)$
228	H	H	H	sgl	$-(CH_2)_3C(=O)(3,4-diF-phenyl)$
229	H	H	H	sgl	$-(CH_2)_3C(=O)(2-MeO-5-F-phenyl)$
230	H	H	H	sgl	$-(CH_2)_4C(=O)(phenyl)$
231	H	H	H	sgl	$-(CH_2)_3C(=O)(4-F-1-naphthyl)$
232	H	H	H	sgl	$-(CH_2)_3C(=O)(benzyl)$
233	H	H	H	sgl	$-(CH_2)_2C(=O)NH(4-F-phenyl)$
234	H	H	H	sgl	$-(CH_2)_3C(=O)NH(4-F-phenyl)$

Table 5 cont.

Ex#	R7	R8	R9	b	R1
235	H	H	H	sgl	$-(CH_2)_3CH(OH)(4-F-phenyl)$
236	H	H	H	sgl	$-(CH_2)_3CH(OH)(4-pyridyl)$
237	H	H	H	sgl	$-(CH_2)_3CH(OH)(2,3-diMeO-phenyl)$
238	H	H	H	sgl	$-(CH_2)_3C(=O)(2,3-diMeO-phenyl)$
239	H	H	H	sgl	$-(CH_2)_4(cyclohexyl)$
240	H	H	H	sgl	$-(CH_2)_3CH(phenyl)_2$
241	H	H	H	sgl	$-CH_2CH_2CH=C(phenyl)_2$
242	H	H	H	sgl	$-(CH_2)_3CH(4-F-phenyl)_2$
243	H	H	H	sgl	$-CH_2CH_2CH=C(4-F-phenyl)_2$
244	H	H	H	sgl	$-(CH_2)_2NHC(=O)(phenyl)$
245	H	H	H	sgl	$-(CH_2)_2NHC(=O)(2-F-phenyl)$
246	H	H	H	sgl	$-(CH_2)_2NHC(=O)(4-F-phenyl)$
247	H	H	H	sgl	$-(CH_2)_3(3-indolyl)$
248	H	H	H	sgl	$-(CH_2)_3(1-Me-3-indolyl)$
249	H	H	H	sgl	$-CH_2CH_2(3-indolyl)$
250	H	H	H	sgl	$-(CH_2)_3(1-indolyl)$
251	H	H	H	sgl	$-(CH_2)_3(1-indolynyl)$
252	H	H	H	sgl	$-(CH_2)_3(1-benzimidazolyl)$
253	H	H	H	sgl	



254 H H H sgl




Table 5 cont.

Ex#	R7	R8	R9	b	R1
268	H	F	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
271	H	H	H	sgl	H
273	H	F	H	sgl	H
S274	Br	H	H	sgl	H
S275	2,6-diF-phenyl	H	H	sgl	H
S276	2-Me-4-MeO-phenyl	H	H	sgl	H
S277	4-CF ₃ -phenyl	H	H	sgl	H
S278	2,3-diCl-phenyl	H	H	sgl	H
S279	2,4-diCl-phenyl	H	H	sgl	H
S280	2-Cl-4-CF ₃ -phenyl	H	H	sgl	H
S281	CN	H	H	sgl	H
S282	CN	Br	H	sgl	H
S283	benzyl	H	H	sgl	H
S284	CHO	H	H	sgl	H
S285	CO ₂ H	H	H	sgl	H
S286	H	H	H	sgl	-(CH ₂) ₂ NHC(=O) (2,4-diF-phenyl)
S287	H	H	H	sgl	-(CH ₂) ₂ NMeC(=O)-phenyl
S288	H	H	H	sgl	-(CH ₂) ₂ NMeC(=O) (2-F-phenyl)
S289	H	H	H	sgl	-(CH ₂) ₂ NMeC(=O) (2,4-diF-phenyl)
S290	H	H	H	sgl	-(CH ₂) ₂ NMeC(=O) (4-F-phenyl)
S291	H	H	H	sgl	-(CH ₂) ₃ (1H-1,2,3-benzotriazol-1-yl)
S292	H	H	H	sgl	-(CH ₂) ₃ (1H-1,2,3-benzotriazol-2-yl)

Table 5 cont.





Ex#	R7	R8	R9	b	R1
S293	H	H	H	sgl	
S294	H	H	H	sgl	
S295	H	H	H	sgl	
S296	H	H	H	sgl	$-(\text{CH}_2)_2(1\text{H}-1,2,3\text{-benzotriazol-1-yl})$
S297	H	H	H	sgl	
S298	H	H	H	sgl	$-(\text{CH}_2)_2(1\text{H}-1,2,3\text{-benzotriazol-2-yl})$
S299	H	H	H	sgl	$-(\text{CH}_2)_3(3,4\text{-dihydro-1(2H)-quinolinyl})$

Table 5 cont.

Ex#	R7	R8	R9	b	R1
S300	H	H	H	sgl	-CH ₂ CH ₂ CH=CMe(4-F-phenyl)
S301	H	H	H	sgl	-(CH ₂) ₂ (2,3-dihydro-1H-inden-2-yl)
S302	H	H	H	sgl	-(CH ₂) ₃ C(=O)(2-NH ₂ -phenyl)
S303	H	H	H	sgl	-(CH ₂) ₃ C(=O)(2-NH ₂ -phenyl)
S304	H	H	H	sgl	-(CH ₂) ₃ C(=O)(2-NH ₂ -5-F-phenyl)
S305	H	H	H	sgl	-(CH ₂) ₃ C(=O)(2-NH ₂ -3-F-phenyl)
S306	H	H	H	sgl	-(CH ₂) ₃ C(=O)(2-NH ₂ -4-Cl-phenyl)
S307	H	H	H	sgl	-(CH ₂) ₃ C(=O)(2-NH ₂ -4-OH-phenyl)
S308	H	H	H	sgl	-(CH ₂) ₃ C(=O)(2-NH ₂ -4-Br-phenyl)
S309	H	H	H	sgl	-(CH ₂) ₃ (1H-indazol-3-yl)
S310	H	H	H	sgl	-(CH ₂) ₃ (5-F-1H-indazol-3-yl)
S311	H	H	H	sgl	-(CH ₂) ₃ (7-F-1H-indazol-3-yl)

Table 5 cont.


Ex#	R7	R8	R9	b	R1
S312	H	H	H	sgl	-(CH ₂) ₃ (6-Cl-1H-indazol-3-yl)
S313	H	H	H	sgl	-(CH ₂) ₃ (6-Br-1H-indazol-3-yl)
S314	H	H	H	sgl	-(CH ₂) ₃ C(=O)(2-NHMe-phenyl)
S315	H	H	H	sgl	-(CH ₂) ₃ (1-benzothien-3-yl)
S355	H	H	H	sgl	
S356	H	H	H	sgl	-(CH ₂) ₃ (6-F-1H-indol-1-yl)
S357	H	H	H	sgl	-(CH ₂) ₃ (5-F-1H-indol-1-yl)
S358	H	H	H	sgl	-(CH ₂) ₃ (6-F-2,3-dihydro-1H-indol-1-yl)
S359	H	H	H	sgl	-(CH ₂) ₃ (5-F-2,3-dihydro-1H-indol-1-yl)
S360	H	H	H	sgl	-(CH ₂) ₃ (6-F-1H-indol-3-yl)
S361	H	H	H	sgl	-(CH ₂) ₃ (6-F-1H-indol-3-yl)

Table 5 cont.


Ex#	R7	R8	R9	b	R1
S362	H	H	H	sgl	$-(\text{CH}_2)_3(5\text{-F-1H-indol-3-yl})$
S363	H	H	H	sgl	$-(\text{CH}_2)_3(5\text{-F-1H-indol-3-yl})$
S364	H	H	H	sgl	$-(\text{CH}_2)_3(9\text{H-purin-9-yl})$
S365	H	H	H	sgl	$-(\text{CH}_2)_3(7\text{H-purin-7-yl})$
S366	H	H	H	sgl	
S367	H	H	H	sgl	$-(\text{CH}_2)_3(6\text{-F-1H-indazol-3-yl})$
S368	H	H	H	sgl	$-(\text{CH}_2)_3(6\text{-F-1H-indazol-3-yl})$
S369	H	H	H	sgl	$-(\text{CH}_2)_3(6\text{-F-1H-indazol-3-yl})$
S370	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})(2\text{-NH}_2\text{-4-F-phenyl})$
S371	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})(2\text{-NH}_2\text{-4-F-phenyl})$
S372	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})(2\text{-NHSO}_2\text{Me-4-F-phenyl})$


Table 5 cont.

Ex#	R7	R8	R9	b	R1
S373	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O}) (2\text{-NHC}(=\text{O})\text{Me-4-F-phenyl})$
S374	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O}) (2\text{-NHC}(=\text{O})\text{Me-4-F-phenyl})$
S375	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O}) (2\text{-NHCO}_2\text{Et-4-F-phenyl})$
S376	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O}) (2\text{-NHC}(=\text{O})\text{NHEt-4-F-phenyl})$
S377	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O}) (2\text{-NHCHO-4-F-phenyl})$
S378	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O}) (2\text{-OH-4-F-phenyl})$
S379	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O}) (2\text{-MeS-4-F-phenyl})$
442	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O}) (2\text{-NHSO}_2\text{Me-4-F-phenyl})$
485	H	H	H	sgl	$-(\text{CH}_2)_2\text{C}(\text{Me})\text{CO}_2\text{Me}$
486	H	H	H	sgl	$-(\text{CH}_2)_2\text{C}(\text{Me})\text{C}(\text{OH}) (4\text{-F-phenyl})_2$
487	H	H	H	sgl	$-(\text{CH}_2)_2\text{C}(\text{Me})\text{C}(\text{OH}) (4\text{-Cl-phenyl})_2$
489	H	H	H	sgl	$-(\text{CH}_2)_2\text{C}(\text{Me})\text{C}(=\text{O}) (4\text{-F-phenyl})$

Table 5 cont.

Ex#	R7	R8	R9	b	R1
490	H	H	H	sgl	$-(\text{CH}_2)_2\text{C}(\text{Me})\text{C}(=\text{O})$ (2-MeO-4-F-phenyl)
491	H	H	H	sgl	$-(\text{CH}_2)_2\text{C}(\text{Me})\text{C}(=\text{O})$ (3-Me-4-F-phenyl)
492	H	H	H	sgl	$-(\text{CH}_2)_2\text{C}(\text{Me})\text{C}(=\text{O})$ (2-Me-phenyl)
493	H	H	H	sgl	$-(\text{CH}_2)_2\text{C}(\text{Me})\text{C}(=\text{O})$ phenyl
591	Cl	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})$ (2-NH ₂ -4-F-phenyl)

Table 5A



Ex#	R7	R8	R9	b	R1
115	H	H	Br	dbl	-CO ₂ -tBu
116	H	H	2,3-diCl-phenyl	dbl	-CO ₂ -tBu
117	H	H	3,4-diCl-phenyl	dbl	-CO ₂ -tBu
118	H	H	2-Cl-4-CF ₃ -phenyl	dbl	-CO ₂ -tBu
119	H	H	2,3-diCl-phenyl	dbl	H
120	H	H	3,4-diCl-phenyl	dbl	H
121	H	H	2-Cl-4-CF ₃ -phenyl	dbl	H
122	H	H	2,3-diCl-phenyl	sgl	H
123	H	H	3,4-diCl-phenyl	sgl	H
124	H	H	2-Cl-4-CF ₃ -phenyl	sgl	H
125	H	H	Br	sgl	-CO ₂ -tBu
126	H	H	2,6-diF-phenyl	sgl	-CO ₂ -tBu
127	H	H	2,6-diF-phenyl	sgl	H
128	H	2,4-diCl-phenyl	H	sgl	H
129	H	phenyl	H	sgl	H
130	H	4-F-phenyl	H	sgl	H
131	H	4-Cl-phenyl	H	sgl	H
132	H	2-Cl-phenyl	H	sgl	H
133	H	2-MeO-phenyl	H	sgl	H
134	H	2-Cl-4-CF ₃ -phenyl	H	sgl	H
135	H	2,4-diMe-phenyl	H	sgl	H
136	H	2-Cl-4-MeO-phenyl	H	sgl	H
137	H	4-iPr-phenyl	H	sgl	H
138	H	4-Bu-phenyl	H	sgl	H
139	H	2-Me-4-MeO-5-F-phenyl	H	sgl	H
140	H	2-Me-4-MeO-phenyl	H	sgl	H
141	H	2-Cl-4-CF ₃ O-phenyl	H	sgl	H

Table 5A cont.

Ex#	R7	R8	R9	b	R1
142	H	2,4,5-triMe-phenyl	H	sgl	H
143	H	3-Cl-phenyl	H	sgl	H
144	H	4-Me-phenyl	H	sgl	H
145	H	2-Me-4-Cl-phenyl	H	sgl	H
146	H	2,5-diCl-phenyl	H	sgl	H
147	H	2-MeO-4-iPr-phenyl	H	sgl	H
148	H	2,6-diCl-phenyl	H	sgl	H
149	H	2,6-diF-phenyl	H	sgl	H
150	H	2-CF ₃ -4-MeO-phenyl	H	sgl	H
151	H	2-CF ₃ -phenyl	H	sgl	H
152	H	4-pyridyl	H	sgl	H
153	H	2-furanyl	H	sgl	H
154	H	2-thiophenyl	H	sgl	H
155	H	4-F-phenyl	H	sgl	H
156	H	2,3-diCl-phenyl	H	sgl	H
157	H	4-Et-phenyl	H	sgl	H
158	H	2,4-diMeO-phenyl	H	sgl	H
159	H	2-F-3-Cl-phenyl	H	sgl	H
160	H	4-MeO-phenyl	H	sgl	H
161	H	4-MeS-phenyl	H	sgl	H
162	H	4-CN-phenyl	H	sgl	H
163	H	3-CF ₃ -phenyl	H	sgl	H
164	H	2-MeO-phenyl	H	sgl	H
165	H	2-naphthyl	H	sgl	H
166	H	4-acetylphenyl	H	sgl	H
167	H	3-acetamidophenyl	H	sgl	H
168	H	2,4-diCl-phenyl	H	sgl	Me
S316	H	2,3-diMe-phenyl	H	sgl	H
S317	H	2-Me-5-F-phenyl	H	sgl	H
S318	H	2-F-5-Me-phenyl	H	sgl	H
S319	H	2-MeO-5-F-phenyl	H	sgl	H
S320	H	2-Me-3-Cl-phenyl	H	sgl	H
S321	H	3-NO ₂ -phenyl	H	sgl	H
S322	H	2-NO ₂ -phenyl	H	sgl	H
S323	H	2-Cl-3-Me-phenyl	H	sgl	H
S324	H	2-MeO-phenyl	H	sgl	H
S325	H	2,3-diCl-phenyl	H	sgl	H

Table 5A cont.

Ex#	R7	R8	R9	b	R1
S326	H	2-Cl-4-CF ₃ -phenyl	H	sgl	H
S327	H	2-Me-4-EtO-phenyl	H	sgl	H
S328	H	2-Me-4-F-phenyl	H	sgl	H
S329	H	4-Bu-phenyl	H	sgl	H
S330	H	2-CF ₃ -phenyl	H	sgl	H
S331	H	2-Cl-6-F-phenyl	H	sgl	H
S332	H	2-Cl-4-(CHF ₂)O-phenyl	H	sgl	H
S333	H	4-CF ₃ -phenyl	H	sgl	H
S334	H	4-Me-phenyl	H	sgl	H
S335	H	4-CF ₃ O-phenyl	H	sgl	H
S336	H	2,4-diMeO-6-F-phenyl	H	sgl	H
S337	H	2-Me-phenyl	H	sgl	H
S338	H	2-CF ₃ -6-F-phenyl	H	sgl	H
S339	H	2-MeS-phenyl	H	sgl	H
S340	H	2,4,6-triF-phenyl	H	sgl	H
S341	H	2,4,6-triCl-phenyl	H	sgl	H
S342	H	2,6-diCl-4-MeO-phenyl	H	sgl	H
S343	H	2,3,4-triF-phenyl	H	sgl	H
S344	H	2,6-diF-4-Cl-phenyl	H	sgl	H
S345	H	2,3,4,6-tetraF-phenyl	H	sgl	H
S346	H	2,3,4,5,6-pentaF-phenyl	H	sgl	H
S347	H	2,6-diCF ₃ -phenyl	H	sgl	H
S348	H	2-CF ₃ O-phenyl	H	sgl	H
S349	H	2-CF ₃ -4-EtO-phenyl	H	sgl	H

Table 5A cont.

Ex#	R7	R8	R9	b	R1
S350	H	2-CF ₃ -4-iPrO-phenyl	H	sgl	H
S351	H	2-naphtyl	H	sgl	H
S352	H	2-CF ₃ -4-Cl-phenyl	H	sgl	H
S353	H	2-CF ₃ -4-F-phenyl	H	sgl	H
S354	H	2,4-diF-phenyl	H	sgl	Me
S380	H	2-Cl-4-EtO-phenyl	H	sgl	H
S381	H	2-Cl-4-iPrO-phenyl	H	sgl	H
S382	H	2-Et-4-MeO-phenyl	H	sgl	H
S383	H	2-CHO-4-MeO-phenyl	H	sgl	H
S384	H	2-CH(OH)Me-4-MeO-phenyl	H	sgl	H
S385	H	2-CH(OMe)Me-4-MeO-phenyl	H	sgl	H
S386	H	2-C(=O)Me-4-MeO-phenyl	H	sgl	H
S387	H	2-CH ₂ (OH)-4-MeO-phenyl	H	sgl	H
S388	H	2-CH ₂ (OMe)-4-MeO-phenyl	H	sgl	H
S389	H	2-CH(OH)Et-4-MeO-phenyl	H	sgl	H
S390	H	2-C(=O)Et-4-MeO-phenyl	H	sgl	H
S391	H	(Z)-2-CH=CHCO ₂ Me-4-MeO-phenyl	H	sgl	H
S392	H	2-CH ₂ CH ₂ CO ₂ Me-4-MeO-phenyl	H	sgl	H

Table 5A cont.

Ex#	R7	R8	R9	b	R1
S393	H	(Z)-2-CH=CHCH ₂ (OH)- 4-MeO-phenyl	H	sgl	H
S394	H	(E)-2-CH=CHCO ₂ Me-4- MeO-phenyl	H	sgl	H
S395	H	(E)-2-CH=CHCH ₂ (OH)- 4-MeO-phenyl	H	sgl	H
S396	H	2-CH ₂ CH ₂ OMe-4-MeO- phenyl	H	sgl	H
S397	H	2-F-4-MeO-phenyl	H	sgl	H
S403	H	2-Cl-4-F-phenyl	H	sgl	H
S405	H	(2-Cl-phenyl)- CH=CH-	H	sgl	H
S406	H	(3-Cl-phenyl)- CH=CH-	H	sgl	H
S407	H	(2,6-diF-phenyl)- CH=CH-	H	sgl	H
S410	H	cyclohexyl	H	sgl	H
S411	H	cyclopentyl	H	sgl	H
S412	H	cyclohexylmethyl	H	sgl	H
S413	H	-CH ₂ CH ₂ CO ₂ Et	H	sgl	H
S414	H	-(CH ₂) ₃ CO ₂ Et	H	sgl	H
S415	H	-(CH ₂) ₄ CO ₂ Et	H	sgl	H
S416	H	-CH ₂ CH=CH ₂	H	sgl	H
S417	H	Pr	H	sgl	H
S418	H	benzyl	H	sgl	H
S419	H	2-F-benzyl	H	sgl	H
S420	H	3-F-benzyl	H	sgl	H
S421	H	4-F-benzyl	H	sgl	H
S422	H	3-MeO-benzyl	H	sgl	H


Table 5A cont.

Ex#	R7	R8	R9	b	R1
S423	H	3-OH-benzyl	H	sgl	H
S424	H	2-MeO-benzyl	H	sgl	H
S425	H	2-OH-benzyl	H	sgl	H
S426	H	2-CO ₂ Me-3-MeO- phenyl	H	sgl	H
S427	H	2,6-diF-phenyl	H	sgl	H
S428	H	phenyl-CH=CH-	H	sgl	H
S429	H	(2-Me-4-MeO- phenyl)-CH=CH-	H	sgl	H
S430	H	-NMe ₂	H	sgl	H
S431	H	1-pyrrolidinyl	H	sgl	H
S432	H	-NTs ₂	H	sgl	H
S433	H	MeO	H	sgl	H
445	H	2-Me-4-MeO-phenyl	Me	sgl	H
446	H	2-CF ₃ -4-MeO-phenyl	Me	sgl	H
458	Me	2-CF ₃ -4-MeO-phenyl	H	sgl	H
459	Me	2,4-diCl-phenyl	H	sgl	H
460	H	3-CN-phenyl	H	sgl	H
461	H	2-Me-4-CN-phenyl	H	sgl	H
462	H	2-Me-3-CN-phenyl	H	sgl	H
463	H	2-CN-phenyl	H	sgl	H
464	H	2-CF ₃ -4-CN-phenyl	Me	sgl	H
465	H	3-CHO-phenyl	Me	sgl	H
466	H	3-CH ₂ (OH)-phenyl	Me	sgl	H
467	H	3-CH ₂ (OMe)-phenyl	Me	sgl	H
468	H	3-CH ₂ (NMe ₂)-phenyl	Me	sgl	H
469	H	3-CN-4-F-phenyl	Me	sgl	H
470	H	3-CONH ₂ -4-F-phenyl	Me	sgl	H

Table 5A cont.


Ex#	R7	R8	R9	b	R1
580	NH ₂	H	H	sgl	H
581	H	phenyl-NH-	H	sgl	H
582	phenyl-NH-	H	H	sgl	H
583	H	(4-F-phenyl)-NH-	H	sgl	H
584	H	(2,4-diCl-phenyl)-NH-	H	sgl	H
585	H	phenyl-C(=O)NH-	H	sgl	H
586	H	benzyl-NH-	H	sgl	H
587	H	phenyl-S-	H	sgl	H
588	MeO	H	H	sgl	H
589	H	2-CH ₂ (NH ₂)-4-MeO-phenyl-	H	sgl	H
590	H	2-Me-4-MeO-phenyl-	H	sgl	H
592	H	(2-Me-4-MeO-phenyl)-NH-	H	sgl	H
593	H	(2-F-4-MeO-phenyl)-NH-	H	sgl	H
595	H	(2-Me-4-F-phenyl)-NH-	H	sgl	H

Table 6




Ex#	n	k	m	R7	R8	R9	b	R1
471	2	2	1	H	H	H	sgl	H
472	2	2	1	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
473	2	2	1	H	H	H	sgl	-(CH ₂) ₃ O(4-F-phenyl)
474	2	2	1	H	H	H	sgl	-(CH ₂) ₃ (6-F-benzisoxazol-3-yl)
475	2	2	1	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-pyridyl)
476	2	3	0	H	H	H	sgl	H
477	2	3	0	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
478	2	3	0	H	H	H	sgl	-(CH ₂) ₂ (6-F-benzisoxazol-3-yl)
483	2	2	1	H	Br	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
484	2	2	1	H	Br	H	sgl	-(CH ₂) ₃ O(4-F-phenyl)
488	1	2	1	H	Br	H	sgl	-CO ₂ -tBu

Table 6A



Ex#	n	k	m	R7	R8	R9	b	R1
479	2	2	1	H	2,4-diCl-phenyl	H	sgl	H
480	2	2	1	H	2-Cl-4-MeO-phenyl	H	sgl	H
481	2	2	1	H	2-Me-4-MeO-phenyl	H	sgl	H
482	2	2	1	H	Br	H	sgl	H
497	1	1	1	H	2-Cl-phenyl	H	sgl	H
498	1	1	1	H	3-Cl-phenyl	H	sgl	H
499	1	1	1	H	3-F-phenyl	H	sgl	H
500	1	1	1	H	4-Cl-phenyl	H	sgl	H
501	1	1	1	H	4-F-phenyl	H	sgl	H
502	1	1	1	H	2,3-diCl-phenyl	H	sgl	H
503	1	1	1	H	2,3-diF-phenyl	H	sgl	H
504	1	1	1	H	3,5-diCl-phenyl	H	sgl	H
505	1	1	1	H	3,5-diF-phenyl	H	sgl	H
506	1	1	1	H	3,4-diCl-phenyl	H	sgl	H
507	1	1	1	H	3,4-diF-phenyl	H	sgl	H
508	1	1	1	H	3-Cl-4-F-phenyl	H	sgl	H
509	1	1	1	H	2-F-4-Cl-phenyl	H	sgl	H

Table 7



Ex#	n	k	m	R7	R8	R9	b	R1
172	2	1	1	H	H	H	sgl	H
173	1	1	1	H	2,4-diCl-phenyl	H	sgl	H
174	1	1	1	H	2-Cl-4-MeO-phenyl	H	sgl	H
436	1	1	1	H	2-Cl-phenyl	H	sgl	H
497	1	1	1	H	2-Cl-phenyl	H	sgl	H
498	1	1	1	H	3-Cl-phenyl	H	sgl	H
499	1	1	1	H	3-F-phenyl	H	sgl	H
500	1	1	1	H	4-Cl-phenyl	H	sgl	H
501	1	1	1	H	4-F-phenyl	H	sgl	H
502	1	1	1	H	2,3-diCl-phenyl	H	sgl	H
503	1	1	1	H	2,3-diF-phenyl	H	sgl	H
504	1	1	1	H	3,5-diCl-phenyl	H	sgl	H
505	1	1	1	H	3,5-diF-phenyl	H	sgl	H
506	1	1	1	H	3,4-diCl-phenyl	H	sgl	H
507	1	1	1	H	3,4-diF-phenyl	H	sgl	H
508	1	1	1	H	3-Cl-4-F-phenyl	H	sgl	H
509	1	1	1	H	2-F-4-Cl-phenyl	H	sgl	H
510	1	1	1	H	2-Cl-4-F-phenyl	H	sgl	H
511	1	1	1	H	2,5-diCl-phenyl	H	sgl	H
512	1	1	1	H	2,6-diCl-phenyl	H	sgl	H
513	1	1	1	H	2-CF ₃ -phenyl	H	sgl	H
514	1	1	1	H	4-CF ₃ -phenyl	H	sgl	H
515	1	1	1	H	2,4-diCF ₃ -phenyl	H	sgl	H
516	1	1	1	H	2-Cl-4-CF ₃ -phenyl	H	sgl	H
517	1	1	1	H	2-MeO-phenyl	H	sgl	H
518	1	1	1	H	2,4-diMeO-phenyl	H	sgl	H
519	1	1	1	H	2-MeO-5-iPr-phenyl	H	sgl	H
520	1	1	1	H	3-NO ₂ -phenyl	H	sgl	H
521	1	1	1	H	2-CHO-phenyl	H	sgl	H


Table 7 cont.

Ex#	n	k	m	R7	R8	R9	b	R1
522	1	1	1	H	2-CH(Me) (OH)- phenyl	H	sgl	H
523	1	1	1	H	2-CH ₂ (OH)-phenyl	H	sgl	H
524	1	1	1	H	2-CHO-4-MeO-phenyl	H	sgl	H
525	1	1	1	H	2-OH-phenyl	H	sgl	H
526	1	1	1	H	2-CF ₃ -4-EtO-phenyl	H	sgl	H
527	1	1	1	H	2-CF ₃ -4-iPrO- phenyl	H	sgl	H
532	1	1	1	H	2-Me-4-MeO-phenyl	H	sgl	H
533	1	1	1	H	2-CF ₃ -4-MeO-phenyl	H	sgl	H
534	1	2	1	H	3,4,5-triMeO- phenyl	H	sgl	H
535	1	2	1	H	1-naphthyl	H	sgl	H
536	1	2	1	H	3-MeO-phenyl	H	sgl	H
537	1	2	1	H	2,4-diCl-phenyl	H	sgl	H
538	1	1	2	H	H	H	sgl	H
541	2	1	1	H	H	H	db1	H
542	2	1	1	H	H	H	sgl	H
543	2	1	1	H	2,6-diF-phenyl	H	sgl	H
545	1	2	1	H	H	H	sgl	H
547	2	1	1	H	2-CF ₃ -4-MeO-phenyl	H	sgl	H
548	2	1	1	H	2-Me-4-MeO-phenyl	H	sgl	H
549	2	1	1	H	2-Cl-4-CF ₃ -phenyl	H	sgl	H
550	2	1	1	H	2,3-diCl-phenyl	H	sgl	H
551	2	1	1	H	2,4-diMeO-phenyl	H	sgl	H
552	2	1	1	H	3,4-diMeO-phenyl	H	sgl	H
553	2	1	1	H	2,4-diCl-phenyl	H	sgl	H
554	2	1	1	H	3,4-diCl-phenyl	H	sgl	H
555	2	1	1	H	2,5-diCl-phenyl	H	sgl	H
556	2	1	1	H	2-CF ₃ -phenyl	H	sgl	H
557	2	1	1	H	2-Me-phenyl	H	sgl	H
558	2	1	1	H	2-Cl-phenyl	H	sgl	H
559	2	1	1	H	3-F-phenyl	H	sgl	H
560	2	1	1	H	phenyl	H	sgl	H

Table 7 cont.

Ex#	n	k	m	R7	R8	R9	b	R1
561	2	1	1	H	2-CF ₃ -4-EtO-phenyl	H	sgl	H
562	2	1	1	H	2-CF ₃ -4-iPrO-phenyl	H	sgl	H
563	2	1	1	H	2-MeO-4-iPr-phenyl	H	sgl	H
564	2	1	1	H	2-F-4-Cl-phenyl	H	sgl	H
565	2	1	1	H	2-Cl-4-MeO-phenyl	H	sgl	H
566	2	1	1	H	2-CHO-phenyl	H	sgl	H
567	2	1	1	H	2-CHO-4-MeO-phenyl	H	sgl	H
568	2	1	1	H	2-CH ₂ (OH)-4-MeO-phenyl	H	sgl	H
569	2	1	1	H	2-CH ₂ (OH)-phenyl	H	sgl	H
570	2	1	1	H	2-CF ₃ -4-NHMe-phenyl	H	sgl	H
571	2	1	1	H	2-CF ₃ -4-NH ₂ -phenyl	H	sgl	H
572	2	1	1	H	2-C(=O)Me-phenyl	H	sgl	H
573	2	1	1	H	2-C(=O)Me-4-MeO-phenyl	H	sgl	H
574	2	1	1	H	2-CH(Me)(OH)-phenyl	H	sgl	H
575	2	1	1	H	2-CH(Me)(OH)-4-MeO-phenyl	H	sgl	H
576	2	1	1	H	2-CF ₃ -4-OH-phenyl	H	sgl	H
577	2	1	1	H	2-CF ₃ -4-O(C=O)Me-phenyl	H	sgl	H


Table 7A



Ex#	n	k	m	R7	R8	R9	b	R1
182	1	1	1	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
266	1	1	1	H	H	Me	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
270	1	1	1	H	H	H	sgl	-(CH ₂) ₃ O (4-F-phenyl)
272	1	1	1	H	H	H	sgl	H
494	1	1	1	H	H	H	sgl	-(CH ₂) ₃ C(=O) (2-NH ₂ -phenyl)
495	1	1	1	H	H	H	sgl	-(CH ₂) ₃ C(=O) (2-NH ₂ -phenyl)
496	1	1	1	H	H	H	sgl	-(CH ₂) ₃ (1H-indazol-3-yl)
528	1	1	1	H	H	H	sgl	-(CH ₂) ₃ (6-F-1H-indazol-3-yl)
529	1	1	1	H	H	H	sgl	-(CH ₂) ₃ C(=O) (2-NH ₂ -4-F-phenyl)


Table 7A cont.

Ex#	n	k	m	R7	R8	R9	b	R1
530	1	1	1	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})$ (2-NH ₂ - 4-F-phenyl)
531	1	1	1	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})$ (2-OH- 4-F-phenyl)
539	1	2	1	H	H	H	sgl	$-(\text{CH}_2)_3\text{O}$ (4-F- phenyl)
540	1	2	1	H	H	H	sgl	$-(\text{CH}_2)_3$ (6-F-1,2- benzisoxazol-3-yl)
544	2	1	1	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})$ (4-F- phenyl)
546	1	2	1	H	H	H	sgl	$-(\text{CH}_2)_3\text{C}(=\text{O})$ (4-F- phenyl)

Table 8


5

Ex#	R7	R8	R9	b	R1
183	H	H	CF ₃	dbl	-(CH ₂) ₃ CH(OH) (4-F-phenyl)
184	H	H	CF ₃	dbl	-(CH ₂) ₃ C(OCH ₂ CH ₂ O) (4-F-phenyl)
185	H	H	CF ₃	sgl	-(CH ₂) ₄ (4-F-phenyl)
188	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
195	H	H	CF ₃	dbl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
213	H	CH ₃	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
438	H	H	H	sgl	-(CH ₂) ₃ C(=O) (2-NH ₂ -phenyl)
439	H	H	H	sgl	-(CH ₂) ₃ C(=O) (2-NH ₂ -phenyl)
440	H	H	H	sgl	-(CH ₂) ₃ C(=O) (2-NH ₂ -4-F-phenyl)
441	H	H	H	sgl	-(CH ₂) ₃ C(=O) (2-NH ₂ -4-F-phenyl)
456	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)
457	H	H	H	sgl	-(CH ₂) ₃ C(=O) (4-F-phenyl)

Table 8A

Ex#	R7	R8	R9	b	R1
443	2,3-diCl-phenyl	H	H	sgl	H
444	2,3-diF-phenyl	H	H	sgl	H
447	2,6-diCl-phenyl	H	H	sgl	H
452	2-Me-4-MeO-phenyl	H	H	sgl	H
453	2-Cl-6-F-phenyl	H	H	sgl	H
454	2,6-diF-phenyl	H	H	sgl	H
455	2,4-diCl-phenyl	H	H	sgl	H

Table 9




Ex#	X	n	R7	R8	R9	b	R1
S398	SO ₂	2	H	2,4-diCl-phenyl	H	sgl	H
S399	SO ₂	2	H	2,6-diF-phenyl	H	sgl	H
S400	SO ₂	2	H	2-Cl-phenyl	H	sgl	H
S401	SO ₂	2	H	2-F-4-MeO-phenyl	H	sgl	H
S402	SO ₂	2	H	2-Me-4-MeO-phenyl	H	sgl	H
S404	SO	2	H	2-Cl-4-F-phenyl	H	sgl	H
S434	SO	2	H	2,4-diCl-phenyl	H	sgl	H
S435	SO	2	H	2-Me-4-MeO-phenyl	H	sgl	H
448	SO ₂	1	H	H	H	sgl	H
449	SO	1	H	H	H	sgl	H
450	SO ₂	1	H	2-CF ₃ -4-MeO-phenyl	H	sgl	H
451	SO ₂	1	H	2,4-diCl-phenyl	H	sgl	H

CLAIMS

What is claimed is:

- 5 1. A compound of the formula (I):



(I)

or stereoisomers or pharmaceutically acceptable salt forms
10 thereof, wherein:

b is a single bond or a double bond;

X is -CHR¹⁰- or -C(=O)-;

15 R¹ is selected from

H,

C(=O)R²,

C(=O)OR²,

20 C₁₋₈ alkyl,

C₂₋₈ alkenyl,

C₂₋₈ alkynyl,

C₃₋₇ cycloalkyl,

C₁₋₆ alkyl substituted with Z,

25 C₂₋₆ alkenyl substituted with Z,

C₂₋₆ alkynyl substituted with Z,

C₃₋₆ cycloalkyl substituted with Z,

aryl substituted with Z,

5-6 membered heterocyclic ring system containing at

30 least one heteroatom selected from the group

consisting of N, O, and S, said heterocyclic ring
system substituted with Z;
C₁₋₃ alkyl substituted with Y,
C₂₋₃ alkenyl substituted with Y,
5 C₂₋₃ alkynyl substituted with Y,
C₁₋₆ alkyl substituted with 0-2 R²,
C₂₋₆ alkenyl substituted with 0-2 R²,
C₂₋₆ alkynyl substituted with 0-2 R²,
aryl substituted with 0-2 R², and
10 5-6 membered heterocyclic ring system containing at
least one heteroatom selected from the group
consisting of N, O, and S, said heterocyclic ring
system substituted with 0-2 R²;

15 Y is selected from

C₃₋₆ cycloalkyl substituted with Z,
aryl substituted with Z,
5-6 membered heterocyclic ring system containing at
least one heteroatom selected from the group
20 consisting of N, O, and S, said heterocyclic ring
system substituted with Z;
C₃₋₆ cycloalkyl substituted with -(C₁₋₃ alkyl)-Z,
aryl substituted with -(C₁₋₃ alkyl)-Z, and
5-6 membered heterocyclic ring system containing at
25 least one heteroatom selected from the group
consisting of N, O, and S, said heterocyclic ring
system substituted with -(C₁₋₃ alkyl)-Z;

Z is selected from H,
30 -CH(OH)R²,
-C(ethylenedioxy)R²,
-OR²,
-SR²,
-NR²R³,

-C(O)R²,
-C(O)NR²R³,
-NR³C(O)R²,
-C(O)OR²,
5 -OC(O)R²,
-CH(=NR⁴)NR²R³,
-NHC(=NR⁴)NR²R³,
-S(O)R²,
-S(O)₂R²,
10 -S(O)₂NR²R³, and -NR³S(O)₂R²;

R², at each occurrence, is independently selected from
halo,
C₁₋₃ haloalkyl,
15 C₁₋₄ alkyl,
C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
aryl substituted with 0-5 R⁴²;
20 C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;

25 R³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and
C₁₋₄ alkoxy;

30 alternatively, R² and R³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R⁴)-;

R⁴, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

R⁵ is H or C₁₋₄ alkyl;

5

R^{6a} and R^{6b}, at each occurrence, are independently selected from

H, -OH, -NR⁴⁶R⁴⁷, -CF₃, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, and
10 aryl substituted with 0-3 R⁴⁴;

R⁷ and R⁹, at each occurrence, are independently selected from

15 H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl, C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy, C₃₋₁₀ cycloalkyl substituted with 0-2 R³³, C₁₋₄ alkyl substituted with 0-2 R¹¹,
20 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, aryl substituted with 0-5 R³³, 5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3
25 R³¹;

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³, NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹², CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
30 S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹², NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and NR¹²C(O)NHR¹⁵;

R⁸ is selected from

- H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂,
C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy,
5 C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
C₁₋₄ alkyl substituted with 0-2 R¹¹,
C₂₋₄ alkenyl substituted with 0-2 R¹¹,
C₂₋₄ alkynyl substituted with 0-1 R¹¹,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
10 aryl substituted with 0-5 R³³,
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;
15
OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,
20 NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and
NR¹²C(O)NHR¹⁵;

R¹⁰ is selected from H, -OH,

- C₁₋₆ alkyl substituted with 0-1 R^{10B},
25 C₂₋₆ alkenyl substituted with 0-1 R^{10B},
C₂₋₆ alkynyl substituted with 0-1 R^{10B}, and
C₁₋₆ alkoxy;

R^{10B} is selected from

- 30 C₁₋₄ alkoxy,
C₃₋₆ cycloalkyl,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
phenyl substituted with 0-3 R³³, and

5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-2
R⁴⁴;

5

R¹¹ is selected from

H, halo, -CF₃, -CN, -NO₂,

C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,

C₁₋₈ alkoxy, C₃₋₁₀ cycloalkyl,

10 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,

aryl substituted with 0-5 R³³,

5-10 membered heterocyclic ring system containing from

1-4 heteroatoms selected from the group

consisting of N, O, and S substituted with 0-3

15

R³¹;

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,

NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,

CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,

20 S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,

NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and

NR¹²C(O)NHR¹⁵;

R¹², at each occurrence, is independently selected from

25 C₁₋₄ alkyl substituted with 0-1 R^{12a},

C₂₋₄ alkenyl substituted with 0-1 R^{12a},

C₂₋₄ alkynyl substituted with 0-1 R^{12a},

C₃₋₆ cycloalkyl substituted with 0-3 R³³,

phenyl substituted with 0-5 R³³;

30 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and

5-10 membered heterocyclic ring system containing from

1-4 heteroatoms selected from the group

consisting of N, O, and S substituted with 0-3
R³¹;

5 R^{12a}, at each occurrence, is independently selected from
phenyl substituted with 0-5 R³³;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
10 R³¹;

R¹³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

15 alternatively, R¹² and R¹³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R¹⁴)-;

alternatively, R¹² and R¹³ when attached to N may be
combined to form a 9- or 10-membered bicyclic
20 heterocyclic ring system containing from 1-3
heteroatoms selected from the group consisting of N,
O, and S, wherein said bicyclic heterocyclic ring
system is unsaturated or partially saturated, wherein
said bicyclic heterocyclic ring system is substituted
25 with 0-3 R¹⁶;

R¹⁴, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

30 R¹⁵, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

R¹⁶, at each occurrence, is independently selected from
H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,

C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,
C₁₋₃ haloalkyl-oxy-, and C₁₋₃ alkyloxy-;

5 R³¹, at each occurrence, is independently selected from
H, OH, halo, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, and C₁₋₄ alkyl;

R³³, at each occurrence, is independently selected from
H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,
C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,
10 C₃₋₆ cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyl-oxy-,
C₁₋₄ alkyloxy-,
C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, C₁₋₄ alkyl-C(=O)NH-,
C₁₋₄ alkyl-OC(=O)-,
C₁₋₄ alkyl-C(=O)O-, C₃₋₆ cycloalkyl-oxy-, C₃₋₆
15 cycloalkylmethyl-oxy-;
C₁₋₆ alkyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy; and
C₂₋₆ alkenyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy;

20 R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, =O;
C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl
C₁₋₄ alkyl substituted with 0-1 R⁴³,
25 aryl substituted with 0-3 R⁴², and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;

30 R⁴², at each occurrence, is independently selected from

H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, SOR⁴⁵, SR⁴⁵, NR⁴⁶SO₂R⁴⁵,
NR⁴⁶COR⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, CH(=NH)NH₂,
NHC(=NH)NH₂,
C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
5 C₃₋₆ cycloalkyl,
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴⁴, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
10 consisting of N, O, and S substituted with 0-3
R⁴⁴;

R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;

15 R⁴⁴, at each occurrence, is independently selected from H,
halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂,
C₁₋₄ alkyl, and C₁₋₄ alkoxy;

R⁴⁵ is C₁₋₄ alkyl;

20

R⁴⁶, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

R⁴⁷, at each occurrence, is independently selected from H,
25 C₁₋₄ alkyl, -C(=O)NH(C₁₋₄ alkyl), -SO₂(C₁₋₄ alkyl),
-C(=O)O(C₁₋₄ alkyl), -C(=O)(C₁₋₄ alkyl), and -C(=O)H;

k is 1 or 2;

m is 0, 1, or 2;

30 n is 0, 1, 2, or 3;

provided when m is 0 or 1 then k is 1 or 2;

provided when m is 2 then k is 1;

provided that when b is a double bond; n is 0 or 1; m is 1; k is 1; X is -CH₂-; and R¹ is hydrogen, C₁₋₆ alkyl or benzyl; then one of R⁷, R⁸, and R⁹, must be other than hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy or trifluoromethyl;

5

provided that when R⁶ or R^{6a} is NH₂, then X is not -CH(R¹⁰); and

provided that when n=0, then R⁶ or R^{6a} is not NH₂ or -OH.

10

2. A compound of Claim 1 wherein:

X is -CHR¹⁰- or -C(=O)-;

15 R¹ is selected from

H,

C(=O)R²,C(=O)OR²,C₁₋₈ alkyl,

20

C₂₋₈ alkenyl,C₂₋₈ alkynyl,C₃₋₇ cycloalkyl,C₁₋₆ alkyl substituted with 0-2 R²,C₂₋₆ alkenyl substituted with 0-2 R²,

25

C₂₋₆ alkynyl substituted with 0-2 R²,aryl substituted with 0-2 R², and

5-6 membered heterocyclic ring system containing at least one heteroatom selected from the group consisting of N, O, and S, said heterocyclic ring

30

system substituted with 0-2 R²;

R², at each occurrence, is independently selected from

F, Cl, CH₂F, CHF₂, CF₃,C₁₋₄ alkyl,

- C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
phenyl substituted with 0-5 R⁴²;
- 5 C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;
- 10 R⁵ is H, methyl, ethyl, propyl, or butyl;
- R^{6a} is selected from
H, -OH, -NR⁴⁶R⁴⁷, -CF₃,
- 15 C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, and
aryl substituted with 0-3 R⁴⁴;
- R^{6b} is H;
- 20 R⁷ and R⁹, at each occurrence, are independently selected
from
H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷,
C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy,
- 25 C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
C₁₋₄ alkyl substituted with 0-2 R¹¹,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5-10 membered heterocyclic ring system containing from
- 30 1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

OR^{12} , SR^{12} , $NR^{12}R^{13}$, $C(O)H$, $C(O)R^{12}$, $C(O)NR^{12}R^{13}$,
 $NR^{14}C(O)R^{12}$, $C(O)OR^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$,
 $CH(=NR^{14})NR^{12}R^{13}$, $NHC(=NR^{14})NR^{12}R^{13}$, $S(O)R^{12}$, $S(O)_2R^{12}$,
 $S(O)NR^{12}R^{13}$, $S(O)_2NR^{12}R^{13}$, $NR^{14}S(O)R^{12}$, $NR^{14}S(O)_2R^{12}$,
5 $NR^{12}C(O)R^{15}$, $NR^{12}C(O)OR^{15}$, $NR^{12}S(O)_2R^{15}$, and
 $NR^{12}C(O)NHR^{15}$;

R^8 is selected from

H , halo, $-CF_3$, $-OCF_3$, $-OH$, $-CN$, $-NO_2$,
10 C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-4} haloalkyl,
 C_{1-8} alkoxy, $(C_{1-4}$ haloalkyl)oxy,
 C_{3-10} cycloalkyl substituted with 0-2 R^{33} ,
 C_{1-4} alkyl substituted with 0-2 R^{11} ,
 C_{2-4} alkenyl substituted with 0-2 R^{11} ,
15 C_{2-4} alkynyl substituted with 0-1 R^{11} ,
 C_{3-10} carbocyclic residue substituted with 0-3 R^{33} ,
aryl substituted with 0-5 R^{33} ,
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
20 consisting of N, O, and S substituted with 0-3
 R^{31} ;

OR^{12} , SR^{12} , $NR^{12}R^{13}$, $C(O)H$, $C(O)R^{12}$, $C(O)NR^{12}R^{13}$,
 $NR^{14}C(O)R^{12}$, $C(O)OR^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$,
25 $CH(=NR^{14})NR^{12}R^{13}$, $NHC(=NR^{14})NR^{12}R^{13}$, $S(O)R^{12}$, $S(O)_2R^{12}$,
 $S(O)NR^{12}R^{13}$, $S(O)_2NR^{12}R^{13}$, $NR^{14}S(O)R^{12}$, $NR^{14}S(O)_2R^{12}$,
 $NR^{12}C(O)R^{15}$, $NR^{12}C(O)OR^{15}$, $NR^{12}S(O)_2R^{15}$, and
 $NR^{12}C(O)NHR^{15}$;

30 R^{10} is selected from H , $-OH$,

C_{1-6} alkyl substituted with 0-1 R^{10B} ,
 C_{2-6} alkenyl substituted with 0-1 R^{10B} ,
 C_{2-6} alkynyl substituted with 0-1 R^{10B} , and

C₁₋₆ alkoxy;

R^{10B} is selected from

- 5 C₁₋₄ alkoxy,
C₃₋₆ cycloalkyl,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
phenyl substituted with 0-3 R³³, and
5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
10 consisting of N, O, and S substituted with 0-2
R⁴⁴;

R¹¹ is selected from

- H, halo, -CF₃, -CN, -NO₂,
15 C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
C₁₋₈ alkoxy, C₃₋₁₀ cycloalkyl,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5-10 membered heterocyclic ring system containing from
20 1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

- OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
25 NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,
NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵; NR¹²S(O)₂R¹⁵, and
NR¹²C(O)NHR¹⁵;

30

R¹², at each occurrence, is independently selected from

- C₁₋₄ alkyl substituted with 0-1 R^{12a},
C₂₋₄ alkenyl substituted with 0-1 R^{12a},

- C₂₋₄ alkynyl substituted with 0-1 R^{12a},
C₃₋₆ cycloalkyl substituted with 0-3 R³³,
phenyl substituted with 0-5 R³³;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;
- 10 R^{12a}, at each occurrence, is independently selected from
phenyl substituted with 0-5 R³³;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
15 consisting of N, O, and S substituted with 0-3
R³¹;
- R¹³, at each occurrence, is independently selected from
20 H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;
- alternatively, R¹² and R¹³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R¹⁴)-;
- 25 alternatively, R¹² and R¹³ when attached to N may be
combined to form a 9- or 10-membered bicyclic
heterocyclic ring system containing from 1-3
heteroatoms selected from the group consisting of N,
O, and S, wherein said bicyclic heterocyclic ring
30 system is unsaturated or partially saturated, wherein
said bicyclic heterocyclic ring system is substituted
with 0-3 R¹⁶;

- R¹⁴, at each occurrence, is independently selected from H and C₁₋₄ alkyl;
- 5 R¹⁵, at each occurrence, is independently selected from H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;
- 10 R¹⁶, at each occurrence, is independently selected from H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ haloalkyl-oxy-, and C₁₋₃ alkyloxy-;
- 15 R³¹, at each occurrence, is independently selected from H, OH, halo, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, and C₁₋₄ alkyl;
- 20 R³³, at each occurrence, is independently selected from H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyl-oxy-, C₁₋₄ alkyloxy-, C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, C₁₋₄ alkyl-C(=O)NH-, C₁₋₄ alkyl-OC(=O)-, C₁₋₄ alkyl-C(=O)O-, C₃₋₆ cycloalkyl-oxy-, C₃₋₆ cycloalkylmethyl-oxy-, C₁₋₆ alkyl substituted with OH, methoxy, ethoxy, propoxy, or butoxy; and
- 25 C₂₋₆ alkenyl substituted with OH, methoxy, ethoxy, propoxy, or butoxy;
- 30 R⁴¹, at each occurrence, is independently selected from H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN; C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ alkyl substituted with 0-1 R⁴³, aryl substituted with 0-3 R⁴², and

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;

5

R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,

CH(=NH)NH₂, NHC(=NH)NH₂,

C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,

10

C₃₋₆ cycloalkyl,

C₁₋₄ alkyl substituted with 0-1 R⁴³,

aryl substituted with 0-3 R⁴⁴, and

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group

15

consisting of N, O, and S substituted with 0-3
R⁴⁴;

R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;

20 R⁴⁴, at each occurrence, is independently selected from H,
halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂,
C₁₋₄ alkyl, and C₁₋₄ alkoxy;

R⁴⁵ is C₁₋₄ alkyl;

25

R⁴⁶, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

R⁴⁷, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;

30

k is 1 or 2;

m is 0, 1, or 2; and

n is 0, 1, 2, or 3.

3. A compound of Claim 2 wherein:

5

X is $-\text{CHR}^{10}-$;

R^1 is selected from

- H,
10 $\text{C}(=\text{O})\text{R}^2$,
 $\text{C}(=\text{O})\text{OR}^2$,
 C_{1-6} alkyl,
 C_{2-6} alkenyl,
 C_{2-6} alkynyl,
15 C_{3-6} cycloalkyl,
 C_{1-4} alkyl substituted with 0-2 R^2 ,
 C_{2-4} alkenyl substituted with 0-2 R^2 , and
 C_{2-4} alkynyl substituted with 0-2 R^2 ;

- 20 R^2 , at each occurrence, is independently selected from
 C_{1-4} alkyl,
 C_{2-4} alkenyl,
 C_{2-4} alkynyl,
 C_{3-6} cycloalkyl,
25 phenyl substituted with 0-5 R^{42} ;
 C_{3-10} carbocyclic residue substituted with 0-3 R^{41} , and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
30 R^{41} ;

R^5 is H, methyl, ethyl, propyl, or butyl;

R^{6a} is selected independently from

H, -OH, -NR⁴⁶R⁴⁷, -CF₃, C₁₋₃ alkyl, and C₁₋₃ alkoxy;

R^{6b} is H;

5 R⁷ and R⁹, at each occurrence, are independently selected from

H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷,
C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,
C₁₋₆ alkoxy, (C₁₋₄ haloalkyl)oxy,

10 C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
C₁₋₄ alkyl substituted with 0-2 R¹¹,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5-10 membered heterocyclic ring system containing from
15 1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
20 NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹²,
S(O)₂R¹², S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹²,
and NR¹⁴S(O)₂R¹²;

25 R⁸ is selected from

H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂,
C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,
C₁₋₆ alkoxy, (C₁₋₄ haloalkyl)oxy,

C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
30 C₁₋₄ alkyl substituted with 0-2 R¹¹,
C₂₋₄ alkenyl substituted with 0-2 R¹¹,
C₂₋₄ alkynyl substituted with 0-1 R¹¹,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,

aryl substituted with 0-5 R³³,
 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 5 R³¹;

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
 NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
 CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
 10 S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,
 NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and
 NR¹²C(O)NHR¹⁵;

R¹⁰ is selected from H, -OH,
 15 C₁₋₆ alkyl substituted with 0-1 R^{10B},
 C₂₋₆ alkenyl substituted with 0-1 R^{10B},
 C₂₋₆ alkynyl substituted with 0-1 R^{10B}, and
 C₁₋₆ alkoxy;

20 R^{10B} is selected from
 C₁₋₄ alkoxy,
 C₃₋₆ cycloalkyl,
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
 phenyl substituted with 0-3 R³³, and
 25 5-6 membered heterocyclic ring system containing 1, 2,
 or 3 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-2
 R⁴⁴;

30 R¹¹ is selected from
 H, halo, -CF₃, -CN, -NO₂, C₁₋₆ alkyl,
 C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₆ alkoxy,
 C₃₋₁₀ cycloalkyl,

- C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
5 consisting of N, O, and S substituted with 0-3
R³¹;
- OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
10 CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹²,
S(O)₂R¹², S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹²,
and NR¹⁴S(O)₂R¹²;
- R¹², at each occurrence, is independently selected from
15 C₁₋₄ alkyl substituted with 0-1 R^{12a},
C₂₋₄ alkenyl substituted with 0-1 R^{12a},
C₂₋₄ alkynyl substituted with 0-1 R^{12a},
C₃₋₆ cycloalkyl substituted with 0-3 R³³,
phenyl substituted with 0-5 R³³,
20 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;
- 25 R^{12a}, at each occurrence, is independently selected from
phenyl substituted with 0-5 R³³;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5-10 membered heterocyclic ring system containing from
30 1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

R¹³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

alternatively, R¹² and R¹³ join to form a 5- or 6-membered
5 ring optionally substituted with -O- or -N(R¹⁴)-;

alternatively, R¹² and R¹³ when attached to N may be
combined to form a 9- or 10-membered bicyclic
heterocyclic ring system containing from 1-3
10 heteroatoms selected from the group consisting of N,
O, and S, wherein said bicyclic heterocyclic ring
system is unsaturated or partially saturated, wherein
said bicyclic heterocyclic ring system is substituted
with 0-3 R¹⁶;

15

R¹⁴, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

R¹⁵, at each occurrence, is independently selected from
20 H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

R¹⁶, at each occurrence, is independently selected from
H, OH, F, Cl, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,
methyl, ethyl, methoxy, ethoxy, trifluoromethyl, and
25 trifluoromethoxy;

R³¹, at each occurrence, is independently selected from
H, OH, halo, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, and C₁₋₄ alkyl;

30 R³³, at each occurrence, is independently selected from
H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,
C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,
C₃₋₆ cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyl-oxy-,
C₁₋₄ alkyloxy-,

- C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, C₁₋₄ alkyl-C(=O)NH-,
C₁₋₄ alkyl-OC(=O)-,
C₁₋₄ alkyl-C(=O)O-, C₃₋₆ cycloalkyl-oxy-, C₃₋₆
cycloalkylmethyl-oxy-;
- 5 C₁₋₆ alkyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy; and
C₂₋₆ alkenyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy;
- 10 R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴², and
- 15 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;
- 20 R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
CH(=NH)NH₂, NHC(=NH)NH₂,
C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
C₃₋₆ cycloalkyl,
- 25 C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴⁴, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
- 30 R⁴⁴;

R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;

R⁴⁴, at each occurrence, is independently selected from H, halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂, C₁₋₄ alkyl, and C₁₋₄ alkoxy;

5 R⁴⁵ is C₁₋₄ alkyl;

R⁴⁶, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

10 R⁴⁷, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

k is 1 or 2;

15 m is 0 or 1; and

n is 0, 1 or 2.

4. A compound of Claim 2 wherein:

20

X is -CH₂-;

R¹ is selected from

25 H,
C₁₋₄ alkyl,
C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₄ cycloalkyl,
C₁₋₃ alkyl substituted with 0-1 R²,
30 C₂₋₃ alkenyl substituted with 0-1 R², and
C₂₋₃ alkynyl substituted with 0-1 R²;

R², at each occurrence, is independently selected from C₁₋₄ alkyl,

- C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
phenyl substituted with 0-5 R⁴²;
5 C₃₋₆ carbocyclic residue substituted with 0-3 R⁴¹, and
5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;
10
R⁵ is H, methyl, ethyl, propyl, or butyl;

R^{6a} is H, methyl, ethyl, methoxy, -OH, or -CF₃;

15 R^{6b} is H;

R⁷ and R⁹, at each occurrence, are independently selected
from
H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷,
20 C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,
C₁₋₄ alkoxy, (C₁₋₄ haloalkyl)oxy,
C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
C₁₋₄ alkyl substituted with 0-2 R¹¹,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
25 aryl substituted with 0-5 R³³, and
5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;
30
R⁸ is selected from
H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂,
C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,
C₁₋₄ alkoxy, (C₁₋₄ haloalkyl)oxy,

C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
C₁₋₄ alkyl substituted with 0-2 R¹¹,
C₂₋₄ alkenyl substituted with 0-2 R¹¹,
C₂₋₄ alkynyl substituted with 0-1 R¹¹,
5 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
10 R³¹;
OR¹², SR¹², NR¹²R¹³, NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵,
NR¹²S(O)₂R¹⁵, and NR¹²C(O)NHR¹⁵;

R¹¹ is selected from
15 H, halo, -CF₃, -CN, -NO₂,
C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,
C₁₋₄ alkoxy, (C₁₋₄ haloalkyl)oxy,
C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
20 aryl substituted with 0-5 R³³, and
5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

25
R¹², at each occurrence, is independently selected from
C₁₋₄ alkyl substituted with 0-1 R^{12a},
C₂₋₄ alkenyl substituted with 0-1 R^{12a},
C₂₋₄ alkynyl substituted with 0-1 R^{12a},
30 C₃₋₆ cycloalkyl substituted with 0-3 R³³,
phenyl substituted with 0-5 R³³,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

5

R^{12a}, at each occurrence, is independently selected from
phenyl substituted with 0-5 R³³;

C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

10

R¹³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

15

alternatively, R¹² and R¹³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R¹⁴)-;

alternatively, R¹² and R¹³ when attached to N may be
combined to form a 9- or 10-membered bicyclic
heterocyclic ring system containing from 1-3
heteroatoms selected from the group consisting of one
N, two N, three N, one N one O, and one N one S;
wherein said bicyclic heterocyclic ring system is
unsaturated or partially saturated, wherein said
bicyclic heterocyclic ring system is substituted with
0-2 R¹⁶;

20

25

R¹⁴, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

30

R¹⁵, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

35

- R^{16} , at each occurrence, is independently selected from
H, OH, F, Cl, CN, NO₂, methyl, ethyl, methoxy, ethoxy,
trifluoromethyl, and trifluoromethoxy;
- 5 R^{31} , at each occurrence, is independently selected from
H, OH, halo, CF₃, methyl, ethyl, and propyl;
- R^{33} , at each occurrence, is independently selected from
H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,
10 C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,
C₃₋₆ cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyl-oxy-,
C₁₋₄ alkyloxy-,
C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, C₁₋₄ alkyl-C(=O)NH-,
C₁₋₄ alkyl-OC(=O)-,
15 C₁₋₄ alkyl-C(=O)O-, C₃₋₆ cycloalkyl-oxy-, C₃₋₆
cycloalkylmethyl-oxy-;
C₁₋₆ alkyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy; and
C₂₋₆ alkenyl substituted with OH, methoxy, ethoxy,
20 propoxy, or butoxy;
- R^{41} , at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₃ alkoxy, C₁₋₃ haloalkyl,
25 and C₁₋₃ alkyl;
- R^{42} , at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
CH(=NH)NH₂, NHC(=NH)NH₂,
30 C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₃ alkoxy, C₁₋₃ haloalkyl,
C₃₋₆ cycloalkyl, and C₁₋₃ alkyl;

R⁴³ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, or pyridyl, each substituted with 0-3 R⁴⁴;

5 R⁴⁴, at each occurrence, is independently selected from H, halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, and butoxy;

10 R⁴⁵ is methyl, ethyl, propyl, or butyl;

R⁴⁶, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;

15 R⁴⁷, at each occurrence, is independently selected from from H, methyl, ethyl, propyl, and butyl;

k is 1;

20 m is 1; and

n is 0, 1 or 2.

5. A compound of Claim 2 wherein:

25 X is -CH₂-;

R¹ is selected from
H,
C₁₋₄ alkyl,
30 C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₄ cycloalkyl,
C₁₋₃ alkyl substituted with 0-1 R²,
C₂₋₃ alkenyl substituted with 0-1 R², and

C₂₋₃ alkynyl substituted with 0-1 R²;

R², at each occurrence, is independently selected from

C₁₋₄ alkyl,

5 C₂₋₄ alkenyl,

C₂₋₄ alkynyl,

C₃₋₆ cycloalkyl,

phenyl substituted with 0-5 R⁴²;

C₃₋₆ carbocyclic residue substituted with 0-3 R⁴¹, and

10 5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴¹;

15 R⁵ is H, methyl, ethyl, propyl, or butyl;

R^{6a} is H, methyl, ethyl, methoxy, -OH, or -CF₃;

R^{6b} is H;

20

R⁷ and R⁹, at each occurrence, are independently selected
from

H, F, Cl, -CH₃, -OCH₃, -CF₃, -OCF₃, -CN, and -NO₂,

25 R⁸ is selected from

H, F, Cl, Br, -CF₃, -OCF₃, -OH, -CN, -NO₂,

C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,

C₁₋₄ alkoxy, (C₁₋₄ haloalkyl)oxy,

C₃₋₁₀ cycloalkyl substituted with 0-2 R³³,

30 C₁₋₄ alkyl substituted with 0-2 R¹¹,

C₂₋₄ alkenyl substituted with 0-2 R¹¹,

C₂₋₄ alkynyl substituted with 0-1 R¹¹,

C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,

aryl substituted with 0-5 R^{33} ,
5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
5 R^{31} ;
 OR^{12} , SR^{12} , $NR^{12}R^{13}$, $NR^{12}C(O)R^{15}$, $NR^{12}C(O)OR^{15}$,
 $NR^{12}S(O)_2R^{15}$, and $NR^{12}C(O)NHR^{15}$;

R^{11} is selected from
10 H, halo, $-CF_3$, $-CN$, $-NO_2$,
 C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl,
 C_{1-4} alkoxy, $(C_{1-4}$ haloalkyl)oxy,
 C_{3-10} cycloalkyl substituted with 0-2 R^{33} ,
 C_{3-10} carbocyclic residue substituted with 0-3 R^{33} ,
15 aryl substituted with 0-5 R^{33} , and
5-6 membered heterocyclic ring system containing 1, 2,
or 3 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
 R^{31} ;

20 R^{12} , at each occurrence, is independently selected from
 C_{1-4} alkyl substituted with 0-1 R^{12a} ,
 C_{2-4} alkenyl substituted with 0-1 R^{12a} ,
 C_{2-4} alkynyl substituted with 0-1 R^{12a} ,
25 C_{3-6} cycloalkyl substituted with 0-3 R^{33} ,
phenyl substituted with 0-5 R^{33} ;
 C_{3-10} carbocyclic residue substituted with 0-3 R^{33} , and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
30 consisting of N, O, and S substituted with 0-3
 R^{31} ;

R^{12a} , at each occurrence, is independently selected from

phenyl substituted with 0-5 R^{33} ;
C₃₋₁₀ carbocyclic residue substituted with 0-3 R^{33} , and
5 5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

R¹³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

10

alternatively, R¹² and R¹³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R¹⁴)-;

alternatively, R¹² and R¹³ when attached to N may be
15 combined to form a 9- or 10-membered bicyclic
heterocyclic ring system containing from 1-3
heteroatoms selected from the group consisting of N,
O, and S; wherein said bicyclic heterocyclic ring
system is selected from indolyl, indolinyl, indazolyl,
20 benzimidazolyl, benzimidazolinyl, benztriazolyl,
benzoxazolyl, benzoxazolinyl, benzthiazolyl, and
dioxobenzthiazolyl; wherein said bicyclic heterocyclic
ring system is substituted with 0-1 R¹⁶;

25 R¹⁴, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

R¹⁵, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

30

R¹⁶, at each occurrence, is independently selected from
H, OH, F, Cl, CN, NO₂, methyl, ethyl, methoxy, ethoxy,
trifluoromethyl, and trifluoromethoxy;

35 R³¹, at each occurrence, is independently selected from

H, OH, halo, CF₃, methyl, ethyl, and propyl;

R³³, at each occurrence, is independently selected from
H; OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, -C(=O)H,
5 C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,
C₃₋₆ cycloalkyl, C₁₋₄ haloalkyl, C₁₋₄ haloalkyl-oxy-,
C₁₋₄ alkyloxy-,
C₁₋₄ alkylthio-, C₁₋₄ alkyl-C(=O)-, C₁₋₄ alkyl-C(=O)NH-,
C₁₋₄ alkyl-OC(=O)-,
10 C₁₋₄ alkyl-C(=O)O-, C₃₋₆ cycloalkyl-oxy-, C₃₋₆
cycloalkylmethyl-oxy-;
C₁₋₆ alkyl substituted with OH, methoxy, ethoxy,
propoxy, or butoxy; and
C₂₋₆ alkenyl substituted with OH, methoxy, ethoxy,
15 propoxy, or butoxy;

R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₃ alkoxy, C₁₋₃ haloalkyl,
20 and C₁₋₃ alkyl;

R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN,
CH(=NH)NH₂, NHC(=NH)NH₂,
25 C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₃ alkoxy, C₁₋₃ haloalkyl,
C₃₋₆ cycloalkyl, and C₁₋₃ alkyl;

R⁴³ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
phenyl, or pyridyl, each substituted with 0-3 R⁴⁴;
30

R⁴⁴, at each occurrence, is independently selected from H,
halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂,

methyl, ethyl, propyl, butyl, methoxy, ethoxy,
propoxy, and butoxy;

R⁴⁵ is methyl, ethyl, propyl, or butyl;

5

R⁴⁶, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

R⁴⁷, at each occurrence, is independently selected from
10 from H, methyl, ethyl, propyl, and butyl;

k is 1;

m is 1; and

15

n is 0, 1 or 2.

6. A compound of Claim 2 wherein:

20 X is -CH₂-;

R¹ is selected from H,

C₁₋₅ alkyl substituted with 0-1 R²,

C₂₋₅ alkenyl substituted with 0-1 R², and

25 C₂₋₃ alkynyl substituted with 0-1 R²;

R² is C₃₋₆ cycloalkyl;

R⁵ is H, methyl, ethyl, or propyl;

30

R^{6a} is H, methyl, or ethyl;

R^{6b} is H;

R⁷ and R⁹, at each occurrence, are independently selected from

H, F, Cl, -CH₃, -OCH₃, -CF₃, -OCF₃, -CN, and -NO₂,

5 R⁸ is selected from

methyl substituted with R¹¹;

ethenyl substituted with R¹¹;

OR¹², SR¹², NR¹²R¹³, NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵,

NR¹²S(O)₂R¹⁵, and NR¹²C(O)NHR¹⁵;

10

R¹¹ is selected from

phenyl- substituted with 0-5 fluoro;

2-(H₃CCH₂C(=O))-phenyl- substituted with R³³;

2-(H₃CC(=O))-phenyl- substituted with R³³;

15 2-(HC(=O))-phenyl- substituted with R³³;

2-(H₃CCH(OH))-phenyl- substituted with R³³;

2-(H₃CCH₂CH(OH))-phenyl- substituted with R³³;

2-(HOCH₂)-phenyl- substituted with R³³;

2-(HOCH₂CH₂)-phenyl- substituted with R³³;

20 2-(H₃COCH₂)-phenyl- substituted with R³³;

2-(H₃COCH₂CH₂)-phenyl- substituted with R³³;

2-(H₃CCH(OMe))-phenyl- substituted with R³³;

2-(H₃COC(=O))-phenyl- substituted with R³³;

2-(HOCH₂CH=CH)-phenyl- substituted with R³³;

25 2-((MeOC(=O)CH=CH)-phenyl- substituted with R³³;

2-(methyl)-phenyl- substituted with R³³;

2-(ethyl)-phenyl- substituted with R³³;

2-(i-propyl)-phenyl- substituted with R³³;

2-(F₃C)-phenyl- substituted with R³³;

30 2-(NC)-phenyl- substituted with R³³;

2-(H₃CO)-phenyl- substituted with R³³;

2-(fluoro)-phenyl- substituted with R³³;

- 2-(chloro)-phenyl- substituted with R^{33} ;
3-(NC)-phenyl- substituted with R^{33} ;
3-(H₃CO)-phenyl- substituted with R^{33} ;
3-(fluoro)-phenyl- substituted with R^{33} ;
5 3-(chloro)-phenyl- substituted with R^{33} ;
4-(NC)-phenyl- substituted with R^{33} ;
4-(fluoro)-phenyl- substituted with R^{33} ;
4-(chloro)-phenyl- substituted with R^{33} ;
4-(H₃CS)-phenyl- substituted with R^{33} ;
10 4-(H₃CO)-phenyl- substituted with R^{33} ;
4-(ethoxy)-phenyl- substituted with R^{33} ;
4-(i-propoxy)-phenyl- substituted with R^{33} ;
4-(i-butoxy)-phenyl- substituted with R^{33} ;
4-(H₃CCH₂CH₂C(=O))-phenyl- substituted with R^{33} ;
15 4-((H₃C)₂CHC(=O))-phenyl- substituted with R^{33} ;
4-(H₃CCH₂C(=O))-phenyl- substituted with R^{33} ;
4-(H₃CC(=O))-phenyl- substituted with R^{33} ;
4-(H₃CCH₂CH₂CH(OH))-phenyl- substituted with R^{33} ;
4-((H₃C)₂CHCH(OH))-phenyl- substituted with R^{33} ;
20 4-(H₃CCH₂CH(OH))-phenyl- substituted with R^{33} ;
4-(H₃CCH(OH))-phenyl- substituted with R^{33} ;
4-(cyclopropyloxy)-phenyl- substituted with R^{33} ;
4-(cyclobutyloxy)-phenyl- substituted with R^{33} ; and
4-(cyclopentyloxy)-phenyl- substituted with R^{33} ;

25

R^{12} is selected from

- phenyl- substituted with 0-5 fluoro;
2-(H₃CCH₂C(=O))-phenyl- substituted with R^{33} ;
2-(H₃CC(=O))-phenyl- substituted with R^{33} ;
30 2-(HC(=O))-phenyl- substituted with R^{33} ;
2-(H₃CCH(OH))-phenyl- substituted with R^{33} ;
2-(H₃CCH₂CH(OH))-phenyl- substituted with R^{33} ;

- 2-(HOCH₂)-phenyl- substituted with R³³;
2-(HOCH₂CH₂)-phenyl- substituted with R³³;
2-(H₃COCH₂)-phenyl- substituted with R³³;
2-(H₃COCH₂CH₂)-phenyl- substituted with R³³;
5 2-(H₃CCH(OMe))-phenyl- substituted with R³³;
2-(H₃COC(=O))-phenyl- substituted with R³³;
2-(HOCH₂CH=CH)-phenyl- substituted with R³³;
2-((MeOC=O)CH=CH)-phenyl- substituted with R³³;
2-(methyl)-phenyl- substituted with R³³;
10 2-(ethyl)-phenyl- substituted with R³³;
2-(i-propyl)-phenyl- substituted with R³³;
2-(F₃C)-phenyl- substituted with R³³;
2-(NC)-phenyl- substituted with R³³;
2-(H₃CO)-phenyl- substituted with R³³;
15 2-(fluoro)-phenyl- substituted with R³³;
2-(chloro)-phenyl- substituted with R³³;
3-(NC)-phenyl- substituted with R³³;
3-(H₃CO)-phenyl- substituted with R³³;
3-(fluoro)-phenyl- substituted with R³³;
20 3-(chloro)-phenyl- substituted with R³³;
4-(NC)-phenyl- substituted with R³³;
4-(fluoro)-phenyl- substituted with R³³;
4-(chloro)-phenyl- substituted with R³³;
4-(H₃CS)-phenyl- substituted with R³³;
25 4-(H₃CO)-phenyl- substituted with R³³;
4-(ethoxy)-phenyl- substituted with R³³;
4-(i-propoxy)-phenyl- substituted with R³³;
4-(i-butoxy)-phenyl- substituted with R³³;
4-(H₃CCH₂CH₂C(=O))-phenyl- substituted with R³³;
30 4-((H₃C)₂CHC(=O))-phenyl- substituted with R³³;
4-(H₃CCH₂C(=O))-phenyl- substituted with R³³;
4-(H₃CC(=O))-phenyl- substituted with R³³;

- 4-(H₃CCH₂CH₂CH(OH))-phenyl- substituted with R³³;
4-((H₃C)₂CHCH(OH))-phenyl- substituted with R³³;
4-(H₃CCH₂CH(OH))-phenyl- substituted with R³³;
4-(H₃CCH(OH))-phenyl- substituted with R³³;
5 4-(cyclopropyloxy)-phenyl- substituted with R³³;
4-(cyclobutyloxy)-phenyl- substituted with R³³; and
4-(cyclopentyloxy)-phenyl- substituted with R³³;

R¹³ is H, methyl, or ethyl;

10

alternatively, R¹² and R¹³ join to form a 5- or 6-membered ring selected from pyrrolyl, pyrrolidinyl, imidazolyl, piperidinyl, piperiziny, methylpiperiziny, and morpholinyl;

15

alternatively, R¹² and R¹³ when attached to N may be combined to form a 9- or 10-membered bicyclic heterocyclic ring system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S; wherein said bicyclic heterocyclic ring system is selected from indolyl, indolinyl, indazolyl, benzimidazolyl, benzimidazolinyl, benztriazolyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, and dioxobenzthiazolyl; wherein said bicyclic heterocyclic ring system is substituted with 0-1 R¹⁶;

20

25

R¹⁵ is H, methyl, ethyl, propyl, or butyl;

30

R¹⁶, at each occurrence, is independently selected from H, OH, F, Cl, CN, NO₂, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, and trifluoromethoxy;

R³³, at each occurrence, is independently selected from


H, F, Cl, -CH₃, -OCH₃, -CF₃, -OCF₃, -CN, and -NO₂;

k is 1;

m is 1; and

5 n is 1 or 2.

7. A compound of Claim 2 of Formula (I-a)



(I-a)

wherein:

b is a single bond or a double bond;

15 X is -CH₂-, -CH(OH)-, or -C(=O)-;

R¹ is selected from

hydrogen, methyl, ethyl, n-propyl, n-butyl, s-butyl,
20 t-butyl, n-pentyl, n-hexyl, 2-propyl, 2-butyl, 2-pentyl,
2-hexyl, 2-methylpropyl, 2-methylbutyl, 2-methylpentyl,
2-ethylbutyl, 3-methylpentyl, 3-methylbutyl,
4-methylpentyl, 2-fluoroethyl, 2,2-difluoroethyl,
2,2,2-trifluoroethyl,

25 2-propenyl, 2-methyl-2-propenyl, trans-2-butenyl,
3-methyl-butenyl, 3-butenyl, trans-2-pentenyl,
cis-2-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl,
3,3-dichloro-2-propenyl, trans-3-phenyl-2-propenyl,

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl,
cyclohexylmethyl,

- 5 benzyl, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl,
2,5-dimethylbenzyl, 2,4-dimethylbenzyl, 3,5-
dimethylbenzyl,
2,4,6-trimethylbenzyl, 3-methoxybenzyl, 3,5-dimethoxy-
benzyl, pentafluorobenzyl, 2-phenylethyl, 1-phenyl-2-
10 propyl, 4-phenylbutyl, 4-phenylbenzyl, 2-phenylbenzyl,

(2,3-dimethoxy-phenyl)C(=O)-, (2,5-dimethoxy-
phenyl)C(=O)-, (3,4-dimethoxy-phenyl)C(=O)-,
(3,5-dimethoxy-phenyl)C(=O)-, cyclopropyl-C(=O)-,
15 isopropyl-C(=O)-, ethyl-CO₂-, propyl-CO₂-, t-butyl-CO₂-,
2,6-dimethoxybenzyl, 2,4-dimethoxybenzyl,
2,4,6-trimethoxybenzyl, 2,3-dimethoxybenzyl,
2,4,5-trimethoxybenzyl, 2,3,4-trimethoxybenzyl,
3,4-dimethoxybenzyl, 3,4,5-trimethoxybenzyl,
20 (4-fluoro-phenyl)ethyl,

-CH=CH₂, -CH₂-CH=CH₂, -CH=CH-CH₃, -C≡CH, -C≡C-CH₃, and
-CH₂-C≡CH;

- 25 R⁷, R⁸, and R⁹, at each occurrence, are independently
selected from
hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl,
propyl, isopropyl, butyl, t-butyl, nitro,
trifluoromethyl, methoxy, ethoxy, isopropoxy,
30 trifluoromethoxy, phenyl,

methylC(=O)-, ethylC(=O)-, propylC(=O)-, isopropylC(=O)-,
butylC(=O)-, phenylC(=O)-,

methylCO₂-, ethylCO₂-, propylCO₂-, isopropylCO₂-,
butylCO₂-, phenylCO₂-,

5 dimethylamino-S(=O)-, diethylamino-S(=O)-,
dipropylamino-S(=O)-, di-isopropylamino-S(=O)-,
dibutylamino-S(=O)-, diphenylamino-S(=O)-,

10 dimethylamino-SO₂-, diethylamino-SO₂-, dipropylamino-SO₂-
, di-isopropylamino-SO₂-, dibutylamino-SO₂-,
diphenylamino-SO₂-,

15 dimethylamino-C(=O)-, diethylamino-C(=O)-,
dipropylamino-C(=O)-, di-isopropylamino-C(=O)-,
dibutylamino-C(=O)-, diphenylamino-C(=O)-,

2-chlorophenyl, 2-fluorophenyl, 2-bromophenyl, 2-
cyanophenyl, 2-methylphenyl, 2-trifluoromethylphenyl,
2-methoxyphenyl, 2-trifluoromethoxyphenyl,

20 3-chlorophenyl, 3-fluorophenyl, 3-bromophenyl,
3-cyanophenyl, 3-methylphenyl, 3-ethylphenyl,
3-propylphenyl, 3-isopropylphenyl, 3-butylphenyl,
3-trifluoromethylphenyl, 3-methoxyphenyl,
3-isopropoxyphenyl, 3-trifluoromethoxyphenyl,
25 3-thiomethoxyphenyl,

4-chlorophenyl, 4-fluorophenyl, 4-bromophenyl,
4-cyanophenyl, 4-methylphenyl, 4-ethylphenyl,
4-propylphenyl, 4-isopropylphenyl, 4-butylphenyl,
30 4-trifluoromethylphenyl, 4-methoxyphenyl,
4-isopropoxyphenyl, 4-trifluoromethoxyphenyl,
4-thiomethoxyphenyl,

35 2,3-dichlorophenyl, 2,3-difluorophenyl, 2,3-
dimethylphenyl,

- 2,3-ditrifluoromethylphenyl, 2,3-dimethoxyphenyl,
2,3-ditrifluoromethoxyphenyl,
- 5 2,4-dichlorophenyl, 2,4-difluorophenyl, 2,4-
dimethylphenyl,
2,4-ditrifluoromethylphenyl, 2,4-dimethoxyphenyl,
2,4-ditrifluoromethoxyphenyl,
- 10 2,5-dichlorophenyl, 2,5-difluorophenyl, 2,5-
dimethylphenyl,
2,5-ditrifluoromethylphenyl, 2,5-dimethoxyphenyl,
2,5-ditrifluoromethoxyphenyl,
- 15 2,6-dichlorophenyl, 2,6-difluorophenyl, 2,6-
dimethylphenyl,
2,6-ditrifluoromethylphenyl, 2,6-dimethoxyphenyl,
2,6-ditrifluoromethoxyphenyl,
- 20 3,4-dichlorophenyl, 3,4-difluorophenyl, 3,4-
dimethylphenyl,
3,4-ditrifluoromethylphenyl, 3,4-dimethoxyphenyl,
3,4-ditrifluoromethoxyphenyl,
- 25 2,4,6-trichlorophenyl, 2,4,6-trifluorophenyl,
2,4,6-trimethylphenyl, 2,4,6-tritrifluoromethylphenyl,
2,4,6-trimethoxyphenyl, 2,4,6-tritrifluoromethoxyphenyl,
- 30 2-chloro-4-CF₃-phenyl, 2-fluoro-3-chloro-phenyl,
2-chloro-4-CF₃-phenyl, 2-chloro-4-methoxy-phenyl,
2-methoxy-4-isopropyl-phenyl, 2-CF₃-4-methoxy-phenyl,
2-methyl-4-methoxy-5-fluoro-phenyl,
2-methyl-4-methoxy-phenyl, 2-chloro-4-CF₃O-phenyl,
2,4,5-trimethyl-phenyl, 2-methyl-4-chloro-phenyl,
- 35 methyl-C(=O)NH-, ethyl-C(=O)NH-, propyl-C(=O)NH-,

- isopropyl-C(=O)NH-, butyl-C(=O)NH-, phenyl-C(=O)NH-,
- 4-acetylphenyl, 3-acetamidophenyl, 4-pyridyl, 2-furanyl,
2-thiophenyl, 2-naphthyl;
- 5 2-Me-5-F-phenyl, 2-F-5-Me-phenyl, 2-MeO-5-F-phenyl,
2-Me-3-Cl-phenyl, 3-NO₂-phenyl, 2-NO₂-phenyl,
2-Cl-3-Me-phenyl, 2-Me-4-EtO-phenyl, 2-Me-4-F-phenyl,
2-Cl-6-F-phenyl, 2-Cl-4-(CHF₂)O-phenyl,
- 10 2,4-diMeO-6-F-phenyl, 2-CF₃-6-F-phenyl,
2-MeS-phenyl, 2,6-diCl-4-MeO-phenyl,
2,3,4-triF-phenyl, 2,6-diF-4-Cl-phenyl,
2,3,4,6-tetraF-phenyl, 2,3,4,5,6-pentaF-phenyl,
2-CF₃-4-EtO-phenyl, 2-CF₃-4-iPrO-phenyl,
- 15 2-CF₃-4-Cl-phenyl, 2-CF₃-4-F-phenyl, 2-Cl-4-EtO-phenyl,
2-Cl-4-iPrO-phenyl, 2-Et-4-MeO-phenyl,
2-CHO-4-MeO-phenyl, 2-CH(OH)Me-4-MeO-phenyl,
2-CH(OMe)Me-4-MeO-phenyl, 2-C(=O)Me-4-MeO-phenyl,
2-CH₂(OH)-4-MeO-phenyl, 2-CH₂(OMe)-4-MeO-phenyl,
- 20 2-CH(OH)Et-4-MeO-phenyl, 2-C(=O)Et-4-MeO-phenyl,
(Z)-2-CH=CHCO₂Me-4-MeO-phenyl,
2-CH₂CH₂CO₂Me-4-MeO-phenyl,
(Z)-2-CH=CHCH₂(OH)-4-MeO-phenyl,
(E)-2-CH=CHCO₂Me-4-MeO-phenyl,
- 25 (E)-2-CH=CHCH₂(OH)-4-MeO-phenyl,
2-CH₂CH₂OMe-4-MeO-phenyl,
2-F-4-MeO-phenyl, 2-Cl-4-F-phenyl,
(2-Cl-phenyl)-CH=CH-, (3-Cl-phenyl)-CH=CH-,
(2,6-diF-phenyl)-CH=CH-, -CH₂CH=CH₂,
- 30 phenyl-CH=CH-, (2-Me-4-MeO-phenyl)-CH=CH-,
cyclohexyl, cyclopentyl, cyclohexylmethyl,
-CH₂CH₂CO₂Et, -(CH₂)₃CO₂Et, -(CH₂)₄CO₂Et,
benzyl, 2-F-benzyl, 3-F-benzyl, 4-F-benzyl,
3-MeO-benzyl, 3-OH-benzyl, 2-MeO-benzyl,


2-OH-benzyl, 2-CO₂Me-3-MeO-phenyl,
 2-Me-4-CN-phenyl, 2-Me-3-CN-phenyl, 2-CF₃-4-CN-phenyl,
 3-CHO-phenyl, 3-CH₂(OH)-phenyl, 3-CH₂(OMe)-phenyl,
 3-CH₂(NMe₂)-phenyl, 3-CN-4-F-phenyl,
 5 3-CONH₂-4-F-phenyl, 2-CH₂(NH₂)-4-MeO-phenyl-,
 phenyl-NH-, (4-F-phenyl)-NH-, (2,4-diCl-phenyl)-NH-,
 phenyl-C(=O)NH-, benzyl-NH-, (2-Me-4-MeO-phenyl)-NH-,
 (2-F-4-MeO-phenyl)-NH-, (2-Me-4-F-phenyl)-NH-,
 phenyl-S-, -NMe₂, 1-pyrrolidinyl, and
 10 -N(tosylate)₂,

provided that two of R⁷, R⁸, and R⁹, are independently
 selected from hydrogen, fluoro, chloro, bromo, cyano,
 methyl, ethyl, propyl, isopropyl, butyl, t-butyl, nitro,
 15 trifluoromethyl, methoxy, ethoxy, isopropoxy, and
 trifluoromethoxy;

m is 1; and

20 n is 0, 1 or 2.

8. A compound of Claim 7. of Formula (V)



(V)

wherein:

b is a single bond, wherein the bridge hydrogens are in a
 cis position;

R¹ is selected from

hydrogen, methyl, ethyl, n-propyl, n-butyl, s-butyl,
 t-butyl, n-pentyl, n-hexyl, 2-propyl, 2-butyl, 2-pentyl,
 2-hexyl, 2-methylpropyl, 2-methylbutyl, 2-methylpentyl,
 5 2-ethylbutyl, 3-methylpentyl, 3-methylbutyl,
 4-methylpentyl, 2-fluoroethyl, 2,2-difluoroethyl,
 2,2,2-trifluoroethyl, 2-propenyl, 2-methyl-2-propenyl,
 trans-2-butenyl, 3-methyl-butenyl, 3-butenyl,
 trans-2-pentenyl, cis-2-pentenyl, 4-pentenyl,
 10 4-methyl-3-pentenyl, 3,3-dichloro-2-propenyl,
 trans-3-phenyl-2-propenyl, cyclopropyl, cyclobutyl,
 cyclopentyl, cyclohexyl, cyclopropylmethyl,
 cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl,
 -CH=CH₂, -CH₂-CH=CH₂, -CH=CH-CH₃, -C≡CH, -C≡C-CH₃,
 15 and -CH₂-C≡CH;

R⁷ and R⁹, at each occurrence, are independently selected
 from hydrogen, fluoro, methyl, trifluoromethyl, and
 methoxy;

20

R⁸ is selected from

hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl,
 propyl, isopropyl, butyl, t-butyl, nitro,
 trifluoromethyl, methoxy, ethoxy, isopropoxy,
 25 trifluoromethoxy, phenyl,

methylC(=O)-, ethylC(=O)-, propylC(=O)-, isopropylC(=O)-,
 butylC(=O)-, phenylC(=O)-,

30 methylCO₂-, ethylCO₂-, propylCO₂-, isopropylCO₂-,
 butylCO₂-, phenylCO₂-,

dimethylamino-S(=O)-, diethylamino-S(=O)-,
 dipropylamino-S(=O)-, di-isopropylamino-S(=O)-,
 35 dibutylamino-S(=O)-, diphenylamino-S(=O)-,

- dimethylamino-SO₂-, diethylamino-SO₂-, dipropylamino-SO₂-
, di-isopropylamino-SO₂-, dibutylamino-SO₂-,
diphenylamino-SO₂-,
5
dimethylamino-C(=O)-, diethylamino-C(=O)-,
dipropylamino-C(=O)-, di-isopropylamino-C(=O)-,
dibutylamino-C(=O)-, diphenylamino-C(=O)-,
10 2-chlorophenyl, 2-fluorophenyl, 2-bromophenyl, 2-
cyanophenyl, 2-methylphenyl, 2-trifluoromethylphenyl,
2-methoxyphenyl, 2-trifluoromethoxyphenyl,
3-chlorophenyl, 3-fluorophenyl, 3-bromophenyl,
15 3-cyanophenyl, 3-methylphenyl, 3-ethylphenyl,
3-propylphenyl, 3-isopropylphenyl, 3-butylphenyl,
3-trifluoromethylphenyl, 3-methoxyphenyl,
3-isopropoxyphenyl, 3-trifluoromethoxyphenyl,
3-thiomethoxyphenyl,
20 4-chlorophenyl, 4-fluorophenyl, 4-bromophenyl,
4-cyanophenyl, 4-methylphenyl, 4-ethylphenyl,
4-propylphenyl, 4-isopropylphenyl, 4-butylphenyl,
4-trifluoromethylphenyl, 4-methoxyphenyl,
25 4-isopropoxyphenyl, 4-trifluoromethoxyphenyl,
4-thiomethoxyphenyl,
2,3-dichlorophenyl, 2,3-difluorophenyl, 2,3-
dimethylphenyl,
30 2,3-ditrifluoromethylphenyl, 2,3-dimethoxyphenyl,
2,3-ditrifluoromethoxyphenyl,
2,4-dichlorophenyl, 2,4-difluorophenyl, 2,4-
dimethylphenyl,
35 2,4-ditrifluoromethylphenyl, 2,4-dimethoxyphenyl,

- 2,4-ditrifluoromethoxyphenyl,
- 2,5-dichlorophenyl, 2,5-difluorophenyl, 2,5-dimethylphenyl,
- 5 2,5-ditrifluoromethylphenyl, 2,5-dimethoxyphenyl,
2,5-ditrifluoromethoxyphenyl,
- 2,6-dichlorophenyl, 2,6-difluorophenyl, 2,6-dimethylphenyl,
- 10 2,6-ditrifluoromethylphenyl, 2,6-dimethoxyphenyl,
2,6-ditrifluoromethoxyphenyl,
- 3,4-dichlorophenyl, 3,4-difluorophenyl, 3,4-dimethylphenyl,
- 15 3,4-ditrifluoromethylphenyl, 3,4-dimethoxyphenyl,
3,4-ditrifluoromethoxyphenyl,
- 2,4,6-trichlorophenyl, 2,4,6-trifluorophenyl,
2,4,6-trimethylphenyl, 2,4,6-tritrifluoromethylphenyl,
- 20 2,4,6-trimethoxyphenyl, 2,4,6-tritrifluoromethoxyphenyl,
- 2-chloro-4-CF₃-phenyl, 2-fluoro-3-chloro-phenyl,
2-chloro-4-CF₃-phenyl, 2-chloro-4-methoxy-phenyl,
2-methoxy-4-isopropyl-phenyl, 2-CF₃-4-methoxy-phenyl,
- 25 2-methyl-4-methoxy-5-fluoro-phenyl,
2-methyl-4-methoxy-phenyl, 2-chloro-4-CF₃O-phenyl,
2,4,5-trimethyl-phenyl, 2-methyl-4-chloro-phenyl,
- methyl-C(=O)NH-, ethyl-C(=O)NH-, propyl-C(=O)NH-,
30 isopropyl-C(=O)NH-, butyl-C(=O)NH-, phenyl-C(=O)NH-,
- 4-acetylphenyl, 3-acetamidophenyl, 4-pyridyl, 2-furanyl,
2-thiophenyl, 2-naphthyl;
- 35 2-Me-5-F-phenyl, 2-F-5-Me-phenyl, 2-MeO-5-F-phenyl,

- 2-Me-3-Cl-phenyl, 3-NO₂-phenyl, 2-NO₂-phenyl,
 2-Cl-3-Me-phenyl, 2-Me-4-EtO-phenyl, 2-Me-4-F-phenyl,
 2-Cl-6-F-phenyl, 2-Cl-4-(CHF₂)O-phenyl,
 2,4-diMeO-6-F-phenyl, 2-CF₃-6-F-phenyl,
 5 2-MeS-phenyl, 2,6-diCl-4-MeO-phenyl,
 2,3,4-triF-phenyl, 2,6-diF-4-Cl-phenyl,
 2,3,4,6-tetraF-phenyl, 2,3,4,5,6-pentaF-phenyl,
 2-CF₃-4-EtO-phenyl, 2-CF₃-4-iPrO-phenyl,
 2-CF₃-4-Cl-phenyl, 2-CF₃-4-F-phenyl, 2-Cl-4-EtO-phenyl,
 10 2-Cl-4-iPrO-phenyl, 2-Et-4-MeO-phenyl,
 2-CHO-4-MeO-phenyl, 2-CH(OH)Me-4-MeO-phenyl,
 2-CH(OMe)Me-4-MeO-phenyl, 2-C(=O)Me-4-MeO-phenyl,
 2-CH₂(OH)-4-MeO-phenyl, 2-CH₂(OMe)-4-MeO-phenyl,
 2-CH(OH)Et-4-MeO-phenyl, 2-C(=O)Et-4-MeO-phenyl,
 15 (Z)-2-CH=CHCO₂Me-4-MeO-phenyl,
 2-CH₂CH₂CO₂Me-4-MeO-phenyl,
 (Z)-2-CH=CHCH₂(OH)-4-MeO-phenyl,
 (E)-2-CH=CHCO₂Me-4-MeO-phenyl,
 (E)-2-CH=CHCH₂(OH)-4-MeO-phenyl,
 20 2-CH₂CH₂OMe-4-MeO-phenyl,
 2-F-4-MeO-phenyl, 2-Cl-4-F-phenyl,
 (2-Cl-phenyl)-CH=CH-, (3-Cl-phenyl)-CH=CH-,
 (2,6-diF-phenyl)-CH=CH-, -CH₂CH=CH₂,
 phenyl-CH=CH-, (2-Me-4-MeO-phenyl)-CH=CH-,
 25 cyclohexyl, cyclopentyl, cyclohexylmethyl,
 -CH₂CH₂CO₂Et, -(CH₂)₃CO₂Et, -(CH₂)₄CO₂Et,
 benzyl, 2-F-benzyl, 3-F-benzyl, 4-F-benzyl,
 3-MeO-benzyl, 3-OH-benzyl, 2-MeO-benzyl,
 2-OH-benzyl, 2-CO₂Me-3-MeO-phenyl,
 30 2-Me-4-CN-phenyl, 2-Me-3-CN-phenyl, 2-CF₃-4-CN-phenyl,
 3-CHO-phenyl, 3-CH₂(OH)-phenyl, 3-CH₂(OMe)-phenyl,
 3-CH₂(NMe₂)-phenyl, 3-CN-4-F-phenyl,
 3-CONH₂-4-F-phenyl, 2-CH₂(NH₂)-4-MeO-phenyl-,
 phenyl-NH-, (4-F-phenyl)-NH-, (2,4-diCl-phenyl)-NH-,

phenyl-C(=O)NH-, benzyl-NH-, (2-Me-4-MeO-phenyl)-NH-,
(2-F-4-MeO-phenyl)-NH-, (2-Me-4-F-phenyl)-NH-,
phenyl-S-, -NMe₂, 1-pyrrolidinyl, and
-N(tosylate)₂; and

5

n is 0, 1 or 2.

9. A compound of Claim 1 wherein:

10 X is -CHR¹⁰- or -C(=O)-;

R¹ is selected from

- C₁₋₆ alkyl substituted with Z,
- C₂₋₆ alkenyl substituted with Z,
- 15 C₂₋₆ alkynyl substituted with Z,
- C₃₋₆ cycloalkyl substituted with Z,
- aryl substituted with Z,
- 5-6 membered heterocyclic ring system containing at
least one heteroatom selected from the group
consisting of N, O, and S, said heterocyclic ring
20 system substituted with Z;
- C₁₋₆ alkyl substituted with 0-2 R²,
- C₂₋₆ alkenyl substituted with 0-2 R²,
- C₂₋₆ alkynyl substituted with 0-2 R²,
- 25 aryl substituted with 0-2 R², and
- 5-6 membered heterocyclic ring system containing at
least one heteroatom selected from the group
consisting of N, O, and S, said heterocyclic ring
system substituted with 0-2 R²;

30

Z is selected from H,

- CH(OH)R²,
- C(ethylenedioxy)R²,
- OR²,

- SR²,
- NR²R³,
- C(O)R²,
- C(O)NR²R³,
- 5 -NR³C(O)R²,
- C(O)OR²,
- OC(O)R²,
- CH(=NR⁴)NR²R³,
- NHC(=NR⁴)NR²R³,
- 10 -S(O)R²,
- S(O)₂R²,
- S(O)₂NR²R³, and -NR³S(O)₂R²;

- R², at each occurrence, is independently selected from
- 15 C₁₋₄ alkyl,
 - C₂₋₄ alkenyl,
 - C₂₋₄ alkynyl,
 - C₃₋₆ cycloalkyl,
 - aryl substituted with 0-5 R⁴²;
 - 20 C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
 - 5-10 membered heterocyclic ring system containing from
 - 1-4 heteroatoms selected from the group
 - consisting of N, O, and S substituted with 0-3
 - R⁴¹;

- 25 R³, at each occurrence, is independently selected from
- H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and
 - C₁₋₄ alkoxy;

- 30 alternatively, R² and R³ join to form a 5- or 6-membered
- ring optionally substituted with -O- or -N(R⁴)-;

- R⁴, at each occurrence, is independently selected from H,
- methyl, ethyl, propyl, and butyl;

R⁵ is H, methyl, ethyl, propyl, or butyl;

R^{6a} is selected from

- 5 H, -OH, -NR⁴⁶R⁴⁷, -CF₃,
 C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₄
 haloalkyl, C₃₋₆ cycloalkyl, and
 aryl substituted with 0-3 R⁴⁴;

- 10 R^{6b} is H;

R⁷, R⁸, and R⁹, at each occurrence, are independently
selected from

- H, halo, -CF₃, -OCF₃, -OH, -CN, -NO₂, -NR⁴⁶R⁴⁷,
15 C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
 C₁₋₈ alkoxy, (C₁₋₄ haloalkyl)oxy,
 C₁₋₄ alkyl substituted with 0-2 R¹¹,
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
 aryl substituted with 0-5 R³³,
20 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 R³¹;

25 OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
 NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
 CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹²,
 S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹²,
 NR¹²C(O)R¹⁵, NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and
30 NR¹²C(O)NHR¹⁵;

R¹⁰ is selected from H, -OH,

 C₁₋₆ alkyl substituted with 0-1 R^{10B},

C₂₋₆ alkenyl substituted with 0-1 R^{10B},
 C₂₋₆ alkynyl substituted with 0-1 R^{10B}, and
 C₁₋₆ alkoxy;

- 5 R^{10B} is selected from
 C₁₋₄ alkoxy,
 C₃₋₆ cycloalkyl,
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
 phenyl substituted with 0-3 R³³, and
 10 5-6 membered heterocyclic ring system containing 1, 2,
 or 3 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-2
 R⁴⁴;
- 15 R¹¹ is selected from
 H, halo, -CF₃, -CN, -NO₂,
 C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ haloalkyl,
 C₁₋₈ alkoxy, C₃₋₁₀ cycloalkyl,
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
 20 aryl substituted with 0-5 R³³,
 5-10 membered heterocyclic ring system containing from
 1-4 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 R³¹;
- 25
 OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
 NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², OC(O)OR¹²,
 CH(=NR¹⁴)NR¹²R¹³, NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹²,
 S(O)₂R¹², S(O)NR¹²R¹³, S(O)₂NR¹²R¹³, NR¹⁴S(O)R¹²,
 30 and NR¹⁴S(O)₂R¹²;

R¹², at each occurrence, is independently selected from
 C₁₋₄ alkyl,

- C₂₋₄ alkenyl,
C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
phenyl substituted with 0-5 R³³;
5 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;
10 R¹³, at each occurrence, is independently selected from
H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;
alternatively, R¹² and R¹³ join to form a 5- or 6-membered
15 ring optionally substituted with -O- or -N(R¹⁴)-;
R¹⁴, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;
20 R³¹, at each occurrence, is independently selected from
H, OH, halo, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷, methyl, ethyl, and
propyl;
R³³, at each occurrence, is independently selected from
25 H, OH, halo, CN, NO₂, CF₃, SO₂R⁴⁵, NR⁴⁶R⁴⁷,
C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, C₃₋₅ cycloalkyl,
C₁₋₃ haloalkyl, C₁₋₃ haloalkyl-oxy-, C₁₋₃ alkyloxy-
, C₁₋₃ alkylthio-, C₁₋₃ alkyl-C(=O)-, and C₁₋₃
alkyl-C(=O)NH-;
30 R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, =O,
C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl
C₁₋₄ alkyl substituted with 0-1 R⁴³,

- aryl substituted with 0-3 R⁴², and
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
5 R⁴⁴;
- R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, SR⁴⁵, NR⁴⁶R⁴⁷, OR⁴⁸,
NO₂, CN, CH(=NH)NH₂, NHC(=NH)NH₂,
10 C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
C₃₋₆ cycloalkyl,
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴⁴, and
5-10 membered heterocyclic ring system containing from
15 1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;
- R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;
20
- R⁴⁴, at each occurrence, is independently selected from H,
halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂,
C₁₋₄ alkyl, and C₁₋₄ alkoxy;
- 25 R⁴⁵ is C₁₋₄ alkyl;
- R⁴⁶, at each occurrence, is independently selected from H
and C₁₋₄ alkyl;
- 30 R⁴⁷, at each occurrence, is independently selected from H,
C₁₋₄ alkyl, -C(=O)NH(C₁₋₄ alkyl), -SO₂(C₁₋₄ alkyl),
-SO₂(phenyl), -C(=O)O(C₁₋₄ alkyl), -C(=O)(C₁₋₄ alkyl),
and -C(=O)H;

R⁴⁸, at each occurrence, is independently selected from H, C₁₋₄ alkyl, -C(=O)NH(C₁₋₄ alkyl), -C(=O)O(C₁₋₄ alkyl), -C(=O)(C₁₋₄ alkyl), and -C(=O)H;

5 k is 1 or 2;

m is 0, 1, or 2; and

n is 0, 1 or 2.

10

10. A compound of Claim 9 wherein:

X is -CHR¹⁰- or -C(=O)-;

15 R¹ is selected from

C₂₋₅ alkyl substituted with Z,

C₂₋₅ alkenyl substituted with Z;

C₂₋₅ alkynyl substituted with Z,

C₃₋₆ cycloalkyl substituted with Z,

20

aryl substituted with Z,

5-6 membered heterocyclic ring system containing at least one heteroatom selected from the group consisting of N, O, and S, said heterocyclic ring system substituted with Z;

25

C₁₋₅ alkyl substituted with 0-2 R²,

C₂₋₅ alkenyl substituted with 0-2 R², and

C₂₋₅ alkynyl substituted with 0-2 R²;

Z is selected from H,

30

-CH(OH)R²,

-C(ethylenedioxy)R²,

-OR²,

-SR²,

-NR²R³,

-C(O)R²,
 -C(O)NR²R³,
 -NR³C(O)R²,
 -C(O)OR²,
 5 -OC(O)R²,
 -CH(=NR⁴)NR²R³,
 -NHC(=NR⁴)NR²R³,
 -S(O)R²,
 -S(O)₂R²,
 10 -S(O)₂NR²R³, and -NR³S(O)₂R²;

R², at each occurrence, is independently selected from
 C₁₋₄ alkyl,
 C₂₋₄ alkenyl,
 15 C₂₋₄ alkynyl,
 C₃₋₆ cycloalkyl,
 aryl substituted with 0-5 R⁴²,
 C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
 5-10 membered heterocyclic ring system containing from
 20 1-4 heteroatoms selected from the group
 consisting of N, O, and S substituted with 0-3
 R⁴¹;

R³, at each occurrence, is independently selected from
 25 H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and
 C₁₋₄ alkoxy;

alternatively, R² and R³ join to form a 5- or 6-membered
 ring optionally substituted with -O- or -N(R⁴)-;

30 R⁴, at each occurrence, is independently selected from H,
 methyl, ethyl, propyl, and butyl;

R⁵ is H, methyl, or ethyl;

R^{6a} is selected from

H, -OH, -NR⁴⁶R⁴⁷, -CF₃,

C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₄
haloalkyl, and C₃₋₆ cycloalkyl;

R^{6b} is H;

R⁷, R⁸, and R⁹, at each occurrence, are independently

selected from

H, halo, -CF₃, -OCF₃, -OH, -OCH₃, -CN, -NO₂, -NR⁴⁶R⁴⁷,

C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl,
C₁₋₆ alkoxy, (C₁₋₄ haloalkyl)oxy,

C₁₋₄ alkyl substituted with 0-2 R¹¹,

C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,

aryl substituted with 0-5 R³³,

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,

NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², CH(=NR¹⁴)NR¹²R¹³,

NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹², S(O)₂NR¹²R¹³,

NR¹⁴S(O)₂R¹², NR¹⁴S(O)R¹², NR¹⁴S(O)₂R¹², NR¹²C(O)R¹⁵,

NR¹²C(O)OR¹⁵, NR¹²S(O)₂R¹⁵, and NR¹²C(O)NHR¹⁵;

R¹⁰ is selected from H, -OH, C₁₋₆ alkyl, C₁₋₄ alkoxy, and

C₁₋₂ alkyl substituted with 0-1 R^{10B};

R^{10B} is C₃₋₆ cycloalkyl or

phenyl substituted with 0-3 R³³;

R¹¹ is selected from

- H, halo, -CF₃, -OCF₃, -OH, -OCH₃, -CN, -NO₂, -NR⁴⁶R⁴⁷,
C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl,
C₁₋₆ alkoxy, (C₁₋₄ haloalkyl)oxy,
5 C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³,
aryl substituted with 0-5 R³³,
5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
10 R³¹;

OR¹², SR¹², NR¹²R¹³, C(O)H, C(O)R¹², C(O)NR¹²R¹³,
NR¹⁴C(O)R¹², C(O)OR¹², OC(O)R¹², CH(=NR¹⁴)NR¹²R¹³,
NHC(=NR¹⁴)NR¹²R¹³, S(O)R¹², S(O)₂R¹², S(O)₂NR¹²R¹³,
15 and NR¹⁴S(O)₂R¹²;

- R¹², at each occurrence, is independently selected from
C₁₋₄ alkyl,
C₂₋₄ alkenyl,
20 C₂₋₄ alkynyl,
C₃₋₆ cycloalkyl,
phenyl substituted with 0-5 R³³,
C₃₋₁₀ carbocyclic residue substituted with 0-3 R³³, and
5-10 membered heterocyclic ring system containing from
25 1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R³¹;

- R¹³, at each occurrence, is independently selected from
30 H, C₁₋₄ alkyl, C₂₋₄ alkenyl, and C₂₋₄ alkynyl;

alternatively, R¹² and R¹³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R¹⁴)-;

- R¹⁴, at each occurrence, is independently selected from H and C₁₋₄ alkyl;
- 5 R³¹, at each occurrence, is independently selected from H, OH, halo, CF₃, methyl, and ethyl;
- R³³, at each occurrence, is independently selected from H, OH, halo, CN, NO₂, CF₃, methyl, and ethyl;
- 10 R⁴¹, at each occurrence, is independently selected from H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, =O, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ alkyl substituted with 0-1 R⁴³, aryl substituted with 0-3 R⁴², and
- 15 5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R⁴⁴;
- 20 R⁴², at each occurrence, is independently selected from H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, SR⁴⁵, NR⁴⁶R⁴⁷, OR⁴⁸, NO₂, CN, CH(=NH)NH₂, NHC(=NH)NH₂, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl,
- 25 C₁₋₄ alkyl substituted with 0-1 R⁴³, aryl substituted with 0-3 R⁴⁴, and 5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3
- 30 R⁴⁴;
- R⁴³ is C₃₋₆ cycloalkyl or aryl substituted with 0-3 R⁴⁴;

R⁴⁴, at each occurrence, is independently selected from H, halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂, C₁₋₄ alkyl, and C₁₋₄ alkoxy;

5 R⁴⁵ is C₁₋₄ alkyl;

R⁴⁶, at each occurrence, is independently selected from H and C₁₋₃ alkyl;

10 R⁴⁷, at each occurrence, is independently selected from H, C₁₋₄ alkyl, -C(=O)NH(C₁₋₄ alkyl), -SO₂(C₁₋₄ alkyl), -SO₂(phenyl), -C(=O)O(C₁₋₄ alkyl), -C(=O)(C₁₋₄ alkyl), and -C(=O)H;

15 R⁴⁸, at each occurrence, is independently selected from H, C₁₋₄ alkyl, -C(=O)NH(C₁₋₄ alkyl), -C(=O)O(C₁₋₄ alkyl), -C(=O)(C₁₋₄ alkyl), and -C(=O)H;

k is 1 or 2;

20

m is 0, 1, 2; and

n is 0, 1 or 2.

25 11. A compound of Claim 9 wherein:

X is -CH₂-;

R¹ is selected from

30

C₂₋₄ alkyl substituted with Z,
C₂₋₄ alkenyl substituted with Z,
C₂₋₄ alkynyl substituted with Z,
C₃₋₆ cycloalkyl substituted with Z,
aryl substituted with Z,

5-6 membered heterocyclic ring system containing at least one heteroatom selected from the group consisting of N, O, and S, said heterocyclic ring system substituted with Z;

5 C₂₋₄ alkyl substituted with 0-2 R², and
C₂₋₄ alkenyl substituted with 0-2 R²;

Z is selected from H,

-CH(OH)R²,
10 -C(ethylenedioxy)R²,
-OR²,
-SR²,
-NR²R³,
-C(O)R²,
15 -C(O)NR²R³,
-NR³C(O)R²,
-C(O)OR²,
-S(O)R²,
-S(O)₂R²,
20 -S(O)₂NR²R³, and -NR³S(O)₂R²;

R², at each occurrence, is independently selected from phenyl substituted with 0-5 R⁴²;

C₃₋₁₀ carbocyclic residue substituted with 0-3 R⁴¹, and
25 5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R⁴¹;

30 R³, at each occurrence, is independently selected from H, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and C₁₋₄ alkoxy;

alternatively, R² and R³ join to form a 5- or 6-membered
ring optionally substituted with -O- or -N(R⁴)-;

5 R⁴, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

R⁵ is H;

10 R^{6a} is selected from H, -OH, -CF₃, methyl, ethyl, propyl,
butyl, methoxy, and, ethoxy;

R^{6b} is H;

15 R⁷, R⁸, and R⁹, at each occurrence, are independently
selected from
H, halo, -CF₃, -OCF₃, -OH, -OCH₃, -CN, -NO₂,
C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, (C₁₋₃
haloalkyl)oxy, and
C₁₋₄ alkyl substituted with 0-2 R¹¹;

20

R¹¹ is selected from
H, halo, -CF₃, -OCF₃, -OH, -OCH₃, -CN, -NO₂,
C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, and (C₁₋₃
haloalkyl)oxy;

25

R³³, at each occurrence, is independently selected from
H, OH, halo, CF₃, and methyl;

30 R⁴¹, at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, NR⁴⁶R⁴⁷, NO₂, CN, =O,
C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,
C₁₋₄ alkyl substituted with 0-1 R⁴³,
aryl substituted with 0-3 R⁴², and

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group
consisting of N, O, and S substituted with 0-3
R⁴⁴;

5

R⁴², at each occurrence, is independently selected from
H, CF₃, halo, OH, CO₂H, SO₂R⁴⁵, SR⁴⁵, NR⁴⁶R⁴⁷, OR⁴⁸,

NO₂, CN, CH(=NH)NH₂, NHC(=NH)NH₂,

C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,

10

C₃₋₆ cycloalkyl,

C₁₋₄ alkyl substituted with 0-1 R⁴³,

aryl substituted with 0-3 R⁴⁴, and

5-10 membered heterocyclic ring system containing from
1-4 heteroatoms selected from the group

15

consisting of N, O, and S substituted with 0-3

R⁴⁴;

R⁴³ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
phenyl, or pyridyl, each substituted with 0-3 R⁴⁴;

20

R⁴⁴, at each occurrence, is independently selected from H,
halo, -OH, NR⁴⁶R⁴⁷, CO₂H, SO₂R⁴⁵, -CF₃, -OCF₃, -CN, -NO₂,
methyl, ethyl, propyl, butyl, methoxy, ethoxy,
propoxy, and butoxy;

25

R⁴⁵ is methyl, ethyl, propyl, or butyl;

R⁴⁶, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

30

R⁴⁷, at each occurrence, is independently selected from
H, methyl, ethyl, n-propyl, i-propyl, n-butyl,
i-butyl, -C(=O)NH(methyl), -C(=O)NH(ethyl),
-SO₂(methyl), -SO₂(ethyl), -SO₂(phenyl),

-C(=O)O(methyl), -C(=O)O(ethyl), -C(=O)(methyl),
-C(=O)(ethyl), and -C(=O)H;

5 R⁴⁸, at each occurrence, is independently selected from
H, methyl, ethyl, n-propyl, i-propyl, -
C(=O)NH(methyl), -C(=O)NH(ethyl), -C(=O)O(methyl), -
C(=O)O(ethyl), -C(=O)(methyl), -C(=O)(ethyl), and -
C(=O)H;

10 k is 1;

m is 0, 1, or 2; and

n is 0, 1 or 2.

15

12. A compound of Claim 9 wherein:

X is -CH₂-;

20 R¹ is selected from
ethyl substituted with Z,
propyl substituted with Z,
butyl substituted with Z,
propenyl substituted with Z,
25 butenyl substituted with Z,
ethyl substituted with R²,
propyl substituted with R²,
butyl substituted with R²,
propenyl substituted with R², and
30 butenyl substituted with R²;

Z is selected from H,

-CH(OH)R²,

-OR²,

35 -SR²,

-NR²R³,
-C(O)R²,
-C(O)NR²R³,
-NR³C(O)R²,
5 -C(O)OR²,
-S(O)R²,
-S(O)₂R²,
-S(O)₂NR²R³, and -NR³S(O)₂R²;

10 R², at each occurrence, is independently selected from
phenyl substituted with 0-3 R⁴²;
naphthyl substituted with 0-3 R⁴²;
cyclopropyl substituted with 0-3 R⁴¹;
cyclobutyl substituted with 0-3 R⁴¹;
15 cyclopentyl substituted with 0-3 R⁴¹;
cyclohexyl substituted with 0-3 R⁴¹;
pyridyl substituted with 0-3 R⁴¹;
indolyl substituted with 0-3 R⁴¹;
indolinyl substituted with 0-3 R⁴¹;
20 benzimidazolyl substituted with 0-3 R⁴¹;
benzotriazolyl substituted with 0-3 R⁴¹;
benzothienyl substituted with 0-3 R⁴¹;
benzofuranyl substituted with 0-3 R⁴¹;
phthalimid-1-yl substituted with 0-3 R⁴¹;
25 inden-2-yl substituted with 0-3 R⁴¹;
2,3-dihydro-1H-inden-2-yl substituted with 0-3 R⁴¹;
indazolyl substituted with 0-3 R⁴¹;
tetrahydroquinolinyl substituted with 0-3 R⁴¹; and
tetrahydro-isoquinolinyl substituted with 0-3 R⁴¹;

30

R³, at each occurrence, is independently selected from
H, methyl, and ethyl;

R⁵ is H;

R^{6a} is selected from H, -OH, methyl, and methoxy;

5

R^{6b} is H;

R⁷, R⁸, and R⁹, at each occurrence, are independently
selected from H, F, Cl, methyl, ethyl, methoxy, -CF₃,
and -OCF₃;

10

R⁴¹, at each occurrence, is independently selected from
H, F, Cl, Br, OH, CF₃, NO₂, CN, =O, methyl, ethyl,
propyl, butyl, methoxy, and ethoxy;

15

R⁴², at each occurrence, is independently selected from
H, F, Cl, Br, OH, CF₃, SO₂R⁴⁵, SR⁴⁵, NR⁴⁶R⁴⁷, OR⁴⁸, NO₂,
CN, =O, methyl, ethyl, propyl, butyl, methoxy, and
ethoxy;

20

R⁴⁵ is methyl, ethyl, propyl, or butyl;

R⁴⁶, at each occurrence, is independently selected from H,
methyl, ethyl, propyl, and butyl;

25

R⁴⁷, at each occurrence, is independently selected from
H, methyl, ethyl, n-propyl, i-propyl, n-butyl,
i-butyl, -C(=O)NH(methyl), -C(=O)NH(ethyl),
-SO₂(methyl), -SO₂(ethyl), -SO₂(phenyl),
-C(=O)O(methyl), -C(=O)O(ethyl), -C(=O)(methyl),
-C(=O)(ethyl), and -C(=O)H;

30

R⁴⁸, at each occurrence, is independently selected from

H, methyl, ethyl, n-propyl, i-propyl, -
 C(=O)NH(methyl), -C(=O)NH(ethyl), -C(=O)O(methyl), -
 C(=O)O(ethyl), -C(=O)(methyl), -C(=O)(ethyl), and -
 C(=O)H;


5

k is 1;

m is 0, 1, or 2; and

10 n is 0, 1 or 2.

13. A compound of Claim 9 of Formula (I-a)



(I-a)

15

wherein:

b is a single bond or a double bond;

20

X is -CH₂-, CH(OH)-, or -C(=O)-

R¹ is selected from

- (CH₂)₃C(=O) (4-fluoro-phenyl),
- 25 - (CH₂)₃C(=O) (4-bromo-phenyl),
- (CH₂)₃C(=O) (4-methyl-phenyl),
- (CH₂)₃C(=O) (4-methoxy-phenyl),
- (CH₂)₃C(=O) (4-(3,4-dichloro-phenyl)phenyl),
- (CH₂)₃C(=O) (3-methyl-4-fluoro-phenyl),
- 30 - (CH₂)₃C(=O) (2,3-dimethoxy-phenyl),
- (CH₂)₃C(=O) (phenyl),


- (CH₂)₃C(=O) (4-chloro-phenyl),
- (CH₂)₃C(=O) (3-methyl-phenyl),
- (CH₂)₃C(=O) (4-t-butyl-phenyl),
- (CH₂)₃C(=O) (3,4-difluoro-phenyl),
- 5 - (CH₂)₃C(=O) (2-methoxy-5-fluoro-phenyl),
- (CH₂)₃C(=O) (4-fluoro-1-naphthyl),
- (CH₂)₃C(=O) (benzyl),
- (CH₂)₃C(=O) (4-pyridyl),
- (CH₂)₃C(=O) (3-pyridyl),
- 10 - (CH₂)₃CH(OH) (4-fluoro-phenyl),
- (CH₂)₃CH(OH) (4-pyridyl),
- (CH₂)₃CH(OH) (2,3-dimethoxy-phenyl),
- (CH₂)₃S (3-fluoro-phenyl),
- (CH₂)₃S (4-fluoro-phenyl),
- 15 - (CH₂)₃S(=O) (4-fluoro-phenyl),
- (CH₂)₃SO₂ (3-fluoro-phenyl),
- (CH₂)₃SO₂ (4-fluoro-phenyl),
- (CH₂)₃O (4-fluoro-phenyl),
- (CH₂)₃O (phenyl),
- 20 - (CH₂)₃O (3-pyridyl),
- (CH₂)₃O (4-pyridyl),
- (CH₂)₃O (2-NH₂-phenyl),
- (CH₂)₃O (2-NH₂-5-F-phenyl),
- (CH₂)₃O (2-NH₂-4-F-phenyl),
- 25 - (CH₂)₃O (2-NH₂-3-F-phenyl),
- (CH₂)₃O (2-NH₂-4-Cl-phenyl),
- (CH₂)₃O (2-NH₂-4-OH-phenyl),
- (CH₂)₃O (2-NH₂-4-Br-phenyl),
- (CH₂)₃O (2-NHC(=O)Me-4-F-phenyl),
- 30 - (CH₂)₃O (2-NHC(=O)Me-phenyl),
- (CH₂)₃NH (4-fluoro-phenyl),
- (CH₂)₃N (methyl) (4-fluoro-phenyl),
- (CH₂)₃CO₂ (ethyl),

- (CH₂)₃C(=O)N(methyl)(methoxy),
- (CH₂)₃C(=O)NH(4-fluoro-phenyl),
- (CH₂)₂NHC(=O)(phenyl),
- (CH₂)₂NMeC(=O)(phenyl),
- 5 - (CH₂)₂NHC(=O)(2-fluoro-phenyl),
- (CH₂)₂NMeC(=O)(2-fluoro-phenyl),
- (CH₂)₂NHC(=O)(4-fluoro-phenyl),
- (CH₂)₂NMeC(=O)(4-fluoro-phenyl),
- (CH₂)₂NHC(=O)(2,4-difluoro-phenyl),
- 10 - (CH₂)₂NMeC(=O)(2,4-difluoro-phenyl),
- (CH₂)₃(3-indolyl),
- (CH₂)₃(1-methyl-3-indolyl),
- (CH₂)₃(1-indolyl),
- (CH₂)₃(1-indolinyl),
- 15 - (CH₂)₃(1-benzimidazolyl),
- (CH₂)₃(1H-1,2,3-benzotriazol-1-yl),
- (CH₂)₃(1H-1,2,3-benzotriazol-2-yl),
- (CH₂)₂(1H-1,2,3-benzotriazol-1-yl),
- (CH₂)₂(1H-1,2,3-benzotriazol-2-yl),
- 20 - (CH₂)₃(3,4 dihydro-1(2H)-quinolinyl),
- (CH₂)₂C(=O)(4-fluoro-phenyl),
- (CH₂)₂C(=O)NH(4-fluoro-phenyl),
- CH₂CH₂(3-indolyl),
- CH₂CH₂(1-phthalimidyl),
- 25 - (CH₂)₄C(=O)N(methyl)(methoxy),
- (CH₂)₄CO₂(ethyl),
- (CH₂)₄C(=O)(phenyl),
- (CH₂)₄(cyclohexyl),
- (CH₂)₃CH(phenyl)₂,
- 30 -CH₂CH₂CH=C(phenyl)₂,
- CH₂CH₂CH=CMe(4-F-phenyl),
- (CH₂)₃CH(4-fluoro-phenyl)₂,
- CH₂CH₂CH=C(4-fluoro-phenyl)₂,


- (CH₂)₂ (2,3-dihydro-1H-inden-2-yl),
- (CH₂)₃C(=O) (2-NH₂-phenyl),
- (CH₂)₃C(=O) (2-NH₂-5-F-phenyl),
- (CH₂)₃C(=O) (2-NH₂-4-F-phenyl),
- 5 -(CH₂)₃C(=O) (2-NH₂-3-F-phenyl),
- (CH₂)₃C(=O) (2-NH₂-4-Cl-phenyl),
- (CH₂)₃C(=O) (2-NH₂-4-OH-phenyl),
- (CH₂)₃C(=O) (2-NH₂-4-Br-phenyl),
- (CH₂)₃ (1H-indazol-3-yl),
- 10 -(CH₂)₃ (5-F-1H-indazol-3-yl),
- (CH₂)₃ (7-F-1H-indazol-3-yl),
- (CH₂)₃ (6-Cl-1H-indazol-3-yl),
- (CH₂)₃ (6-Br-1H-indazol-3-yl),
- (CH₂)₃C(=O) (2-NHMe-phenyl),
- 15 -(CH₂)₃ (1-benzothien-3-yl),
- (CH₂)₃ (6-F-1H-indol-1-yl),
- (CH₂)₃ (5-F-1H-indol-1-yl),
- (CH₂)₃ (6-F-2,3-dihydro-1H-indol-1-yl),
- (CH₂)₃ (5-F-2,3-dihydro-1H-indol-1-yl),
- 20 -(CH₂)₃ (6-F-1H-indol-3-yl),
- (CH₂)₃ (5-F-1H-indol-3-yl),
- (CH₂)₃ (5-F-1H-indol-3-yl),
- (CH₂)₃ (9H-purin-9-yl),
- (CH₂)₃ (7H-purin-7-yl),
- 25 -(CH₂)₃ (6-F-1H-indazol-3-yl),
- (CH₂)₃C(=O) (2-NHSO₂Me-4-F-phenyl),
- (CH₂)₃C(=O) (2-NHC(=O)Me-4-F-phenyl),
- (CH₂)₃C(=O) (2-NHC(=O)Me-phenyl),
- (CH₂)₃C(=O) (2-NHCO₂Et-4-F-phenyl),
- 30 -(CH₂)₃C(=O) (2-NHC(=O)NH₂Et-4-F-phenyl),
- (CH₂)₃C(=O) (2-NHCHO-4-F-phenyl),
- (CH₂)₃C(=O) (2-OH-4-F-phenyl),
- (CH₂)₃C(=O) (2-MeS-4-F-phenyl),

- (CH₂)₃C(=O) (2-NHSO₂Me-4-F-phenyl) ,
 - (CH₂)₂C(Me)CO₂Me ,
 - (CH₂)₂C(Me)CH(OH) (4-F-phenyl)₂ ,
 - (CH₂)₂C(Me)CH(OH) (4-Cl-phenyl)₂ ,
 5 - (CH₂)₂C(Me)C(=O) (4-F-phenyl) ,
 - (CH₂)₂C(Me)C(=O) (2-MeO-4-F-phenyl) ,
 - (CH₂)₂C(Me)C(=O) (3-Me-4-F-phenyl) ,
 - (CH₂)₂C(Me)C(=O) (2-Me-phenyl) ,
 - (CH₂)₂C(Me)C(=O)phenyl ,

10



15



R⁷, R⁸, and R⁹, at each occurrence, are independently selected from

- hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl,
 20 propyl, isopropyl, butyl, t-butyl, nitro,
 trifluoromethyl, methoxy, ethoxy, isopropoxy,
 trifluoromethoxy, phenyl, benzyl,

- HC(=O)-, methylC(=O)-, ethylC(=O)-, propylC(=O)-,
 25 isopropylC(=O)-, n-butylC(=O)-, isobutylC(=O)-,
 secbutylC(=O)-, tertbutylC(=O)-, phenylC(=O)-,

methylC(=O)NH-, ethylC(=O)NH -, propylC(=O)NH-,
isopropylC(=O)NH-, n-butylC(=O)NH-, isobutylC(=O)NH-,
secbutylC(=O)NH-, tertbutylC(=O)NH-, phenylC(=O)NH-,


5 methylamino-, ethylamino-, propylamino-, isopropylamino-,
n-butylamino-, isobutylamino-, secbutylamino-,
tertbutylamino-, phenylamino-,

provided that two of substituents R⁷, R⁸, and R⁹, are
10 independently selected from hydrogen, fluoro, chloro,
bromo, cyano, methyl, ethyl, propyl, isopropyl, butyl, t-
butyl, nitro, trifluoromethyl, methoxy, ethoxy,
isopropoxy, and trifluoromethoxy;

15 k is 1 or 2;
m is 1 or 2; and
n is 0, 1 or 2.

14. A compound of Claim 13 of Formula (V-a)

20



wherein:

25

b is a single bond, wherein the bridge hydrogens are in a
cis position;

R¹ is selected from

30 - (CH₂)₃C(=O) (4-fluoro-phenyl),
- (CH₂)₃C(=O) (4-bromo-phenyl),
- (CH₂)₃C(=O) (4-methyl-phenyl),



- (CH₂)₃C(=O) (4-methoxy-phenyl) ,
- (CH₂)₃C(=O) (4- (3, 4-dichloro-phenyl)phenyl) ,
- (CH₂)₃C(=O) (3-methyl-4-fluoro-phenyl) ,
- (CH₂)₃C(=O) (2, 3-dimethoxy-phenyl) ,
- 5 - (CH₂)₃C(=O) (phenyl) ,
- (CH₂)₃C(=O) (4-chloro-phenyl) ,
- (CH₂)₃C(=O) (3-methyl-phenyl) ,
- (CH₂)₃C(=O) (4-t-butyl-phenyl) ,
- (CH₂)₃C(=O) (3, 4-difluoro-phenyl) ,
- 10 - (CH₂)₃C(=O) (2-methoxy-5-fluoro-phenyl) ,
- (CH₂)₃C(=O) (4-fluoro-1-naphthyl) ,
- (CH₂)₃C(=O) (benzyl) ,
- (CH₂)₃C(=O) (4-pyridyl) ,
- (CH₂)₃C(=O) (3-pyridyl) ,
- 15 - (CH₂)₃CH(OH) (4-fluoro-phenyl) ,
- (CH₂)₃CH(OH) (4-pyridyl) ,
- (CH₂)₃CH(OH) (2, 3-dimethoxy-phenyl) ,
- (CH₂)₃S(3-fluoro-phenyl) ,
- (CH₂)₃S(4-fluoro-phenyl) ,
- 20 - (CH₂)₃S(=O) (4-fluoro-phenyl) ,
- (CH₂)₃SO₂ (3-fluoro-phenyl) ,
- (CH₂)₃SO₂ (4-fluoro-phenyl) ,
- (CH₂)₃O(4-fluoro-phenyl) ,
- (CH₂)₃O(phenyl) ,
- 25 - (CH₂)₃NH(4-fluoro-phenyl) ,
- (CH₂)₃N(methyl) (4-fluoro-phenyl) ,
- (CH₂)₃CO₂ (ethyl) ,
- (CH₂)₃C(=O)N(methyl) (methoxy) ,
- (CH₂)₃C(=O)NH(4-fluoro-phenyl) ,
- 30 - (CH₂)₂NHC(=O) (phenyl) ,
- (CH₂)₂NMeC(=O) (phenyl) ,
- (CH₂)₂NHC(=O) (2-fluoro-phenyl) ,
- (CH₂)₂NMeC(=O) (2-fluoro-phenyl) ,

- (CH₂)₂NHC(=O) (4-fluoro-phenyl) ,
- (CH₂)₂NMeC(=O) (4-fluoro-phenyl) ,
- (CH₂)₂NHC(=O) (2,4-difluoro-phenyl) ,
- (CH₂)₂NMeC(=O) (2,4-difluoro-phenyl) ,
- 5 - (CH₂)₃ (3-indolyl) ,
- (CH₂)₃ (1-methyl-3-indolyl) ,
- (CH₂)₃ (1-indolyl) ,
- (CH₂)₃ (1-indoliny) ,
- (CH₂)₃ (1-benzimidazolyl) ,
- 10 - (CH₂)₃ (1H-1,2,3-benzotriazol-1-yl) ,
- (CH₂)₃ (1H-1,2,3-benzotriazol-2-yl) ,
- (CH₂)₂ (1H-1,2,3-benzotriazol-1-yl) ,
- (CH₂)₂ (1H-1,2,3-benzotriazol-2-yl) ,
- (CH₂)₃ (3,4 dihydro-1(2H)-quinolinyl) ,
- 15 - (CH₂)₂C(=O) (4-fluoro-phenyl) ,
- (CH₂)₂C(=O)NH (4-fluoro-phenyl) ,
- CH₂CH₂ (3-indolyl) ,
- CH₂CH₂ (1-phthalimidyl) ,
- (CH₂)₄C(=O)N(methyl) (methoxy) ,
- 20 - (CH₂)₄CO₂ (ethyl) ,
- (CH₂)₄C(=O) (phenyl) ,
- (CH₂)₄ (cyclohexyl) ,
- (CH₂)₃CH (phenyl)₂ ,
- CH₂CH₂CH=C (phenyl)₂ ,
- 25 -CH₂CH₂CH=CMe (4-F-phenyl) ,
- (CH₂)₃CH (4-fluoro-phenyl)₂ ,
- CH₂CH₂CH=C (4-fluoro-phenyl)₂ ,
- (CH₂)₂ (2,3-dihydro-1H-inden-2-yl) ,
- (CH₂)₃C(=O) (2-NH₂-phenyl) ,
- 30 - (CH₂)₃C(=O) (2-NH₂-5-F-phenyl) ,
- (CH₂)₃C(=O) (2-NH₂-4-F-phenyl) ,
- (CH₂)₃C(=O) (2-NH₂-3-F-phenyl) ,
- (CH₂)₃C(=O) (2-NH₂-4-Cl-phenyl) ,


- (CH₂)₃C(=O) (2-NH₂-4-OH-phenyl),
- (CH₂)₃C(=O) (2-NH₂-4-Br-phenyl),
- (CH₂)₃ (1H-indazol-3-yl),
- (CH₂)₃ (5-F-1H-indazol-3-yl),
- 5 - (CH₂)₃ (7-F-1H-indazol-3-yl),
- (CH₂)₃ (6-Cl-1H-indazol-3-yl),
- (CH₂)₃ (6-Br-1H-indazol-3-yl),
- (CH₂)₃C(=O) (2-NHMe-phenyl),
- (CH₂)₃ (1-benzothien-3-yl),
- 10 - (CH₂)₃ (6-F-1H-indol-1-yl),
- (CH₂)₃ (5-F-1H-indol-1-yl),
- (CH₂)₃ (6-F-2,3-dihydro-1H-indol-1-yl),
- (CH₂)₃ (5-F-2,3-dihydro-1H-indol-1-yl),
- (CH₂)₃ (6-F-1H-indol-3-yl),
- 15 - (CH₂)₃ (5-F-1H-indol-3-yl),
- (CH₂)₃ (5-F-1H-indol-3-yl),
- (CH₂)₃ (9H-purin-9-yl),
- (CH₂)₃ (7H-purin-7-yl),
- (CH₂)₃ (6-F-1H-indazol-3-yl),
- 20 - (CH₂)₃C(=O) (2-NHSO₂Me-4-F-phenyl),
- (CH₂)₃C(=O) (2-NHC(=O)Me-4-F-phenyl),
- (CH₂)₃C(=O) (2-NHC(=O)Me-4-F-phenyl),
- (CH₂)₃C(=O) (2-NHCO₂Et-4-F-phenyl),
- (CH₂)₃C(=O) (2-NHC(=O)NH₂Et-4-F-phenyl),
- 25 - (CH₂)₃C(=O) (2-NHCHO-4-F-phenyl),
- (CH₂)₃C(=O) (2-OH-4-F-phenyl),
- (CH₂)₃C(=O) (2-MeS-4-F-phenyl),
- (CH₂)₃C(=O) (2-NHSO₂Me-4-F-phenyl),
- (CH₂)₂C(Me)CO₂Me,
- 30 - (CH₂)₂C(Me)CH(OH) (4-F-phenyl)₂,
- (CH₂)₂C(Me)CH(OH) (4-Cl-phenyl)₂,
- (CH₂)₂C(Me)C(=O) (4-F-phenyl),
- (CH₂)₂C(Me)C(=O) (2-MeO-4-F-phenyl),

- (CH₂)₂C(Me)C(=O) (3-Me-4-F-phenyl),
- (CH₂)₂C(Me)C(=O) (2-Me-phenyl),
- (CH₂)₂C(Me)C(=O)phenyl,

5



, and



10

R⁷, R⁸, and R⁹, at each occurrence, are independently selected from hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, nitro, trifluoromethyl, methoxy, ethoxy, isopropoxy, trifluoromethoxy, methylC(=O)-, ethylC(=O)-, propylC(=O)-, isopropylC(=O)-, methylC(=O)NH-, ethylC(=O)NH-, propylC(=O)NH-, isopropylC(=O)NH-, methylamino-, ethylamino-, propylamino-, and isopropylamino-,

20

provided that two of substituents R⁷, R⁸, and R⁹, are independently selected from hydrogen, fluoro, chloro, methyl, trifluoromethyl, methoxy, and trifluoromethoxy;

25 m is 1 or 2; and

n is 0, 1 or 2.

15. A compound of Claim 1 selected from the group consisting of compounds disclosed in Table 1.
16. A compound of Claim 1 selected from the group
5 consisting of compounds disclosed in Table 2.
17. A compound of Claim 1 selected from the group consisting of compounds disclosed in Table 3.
- 10 18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to one of Claims 1-17, or a pharmaceutically acceptable salt thereof.
- 15 19. A method for treating a human suffering from a disorder associated with 5HT2C receptor modulation comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to one of Claims 1-8, or a pharmaceutically acceptable salt
20 thereof.
20. A method of Claim 19 for treating a human suffering from a disorder associated with 5HT2C receptor modulation wherein the compound is a 5HT2C agonist.
- 25 21. A method for treating a human suffering from a disorder associated with 5HT2A receptor modulation comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to one of Claims 1 or 9-14, or a pharmaceutically acceptable
30 salt thereof.
22. A method of Claim 21 for treating a human suffering from a disorder associated with 5HT2A receptor modulation
35 wherein the compound is a 5HT2A antagonist.

23. A method for treating obesity comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to one of Claims 1-17, or a pharmaceutically acceptable salt thereof.

5

24. A method for treating schizophrenia comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to one of Claims 1-17, or a pharmaceutically acceptable salt thereof.

10

25. A method for treating depression comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to one of Claims 1-17, or a pharmaceutically acceptable salt thereof.

15

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/16375

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/16 A61K31/437 A61K31/55 A61K31/407 A61P25/00
C07D487/16 //(C07D471/16,221:00,209:00,209:00),(C07D471/16,
221:00,221:00,209:00),(C07D471/16,223:00,221:00,209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 299 078 A (PACHTER, I.J.) 17 January 1967 (1967-01-17) column 1, line 14 - line 17; claim 1; examples 1,10-2 -----	1,18

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

28 November 2000

Date of mailing of the international search report

06/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 00/16375

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3299078	A	17-01-1967	NONE